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ABSTRACT 
Background 
Escherichia coli is the most common gram-negative bacteria to cause human infection. The pathological 
manifestations range from minor disease to severe life threatening sepsis. Urinary tract infection, most often 
caused by E. coli, is also the most common bacterial infection in humans.  Since the inception of 
antimicrobial therapy in the early 20th century, E. coli has systematically developed resistance to almost all 
known antimicrobials, posing a challenge for the treatment of such infections. 
From a global perspective, the first decade of the 21st century heralded a change in the epidemiology and 
tempo of resistance amongst E. coli. Previously, resistance to third generation cephalosporins (3GC) was 
primarily associated with current or previous healthcare exposure. In the past decade however, expanded-
spectrum cephalosporin resistant E. coli (ESC-R-EC), usually mediated by Extended Spectrum beta-
lactamase (ESBL) genes has spread widely within the communities of many regions, independent of 
healthcare associated acquisition. 
The latter half of this decade has led to the delineation of two further challenges amongst resistant E. coli. 
The first is the identification of Sequence Type 131 E. coli (ST131), a global ‘pandemic’	  clone fine-tuned for 
resistance and virulence. This clone is now implicated in a significant proportion of community ESBL E. coli 
infections globally. The second challenge is the emergence of E. coli harbouring carbapenemase genes, 
conferring resistance to carbapenem antimicrobials used to treat severe ESBL producing E. coli infection. 
Methods 
Through several studies we have aimed to better define global and local aspects of antimicrobial resistant E. 
coli, in particular ESC-R-EC. The studies have included clinical and laboratory based research.  
Clinical research included a multi-centre case-control study of community onset ESC-R-EC infection in 
Australia and New Zealand, and a national survey of health services’	  infection control practices pertaining to 
multi-resistant gram-negative bacilli and patients at risk of harbouring these. 
Laboratory research included molecular epidemiological investigation of E. coli from two sources. The first 
was isolates from the 182 participants in the case-control study, comprising a broad sample of community 
onset 3GC resistant and susceptible E. coli from Australia and New Zealand. The second was a collection of 
isolates from a previously conducted study on carriage of resistant E. coli in overseas travellers returning to 
Australia.  
Results 182 patients (91 cases and 91 controls) were recruited across six tertiary hospitals in Australia and 
New Zealand for the case-control study.  Multivariate logistic regression identified risk factors for 3GCR-EC 
III 
including birth on the Indian subcontinent (OR=11.13, 2.17-56.98, p=0.003), urinary tract infection in the 
past year (per infection OR=1.430, 1.13-1.82, p=0.003), travel to South East Asia, China, Indian 
subcontinent, Africa and the Middle East (OR=3.089, 1.29-7.38, p=0.011), prior exposure to trimethoprim+/-
sulfamethoxazole &/or extended spectrum cephalosporins (OR=3.665, 1.30-10.35, p=0.014) and healthcare 
exposure in the previous six months (OR=3.16, 1.54-6.46, p=0.02).  
Molecular epidemiological analysis of isolates demonstrated a predominance of CTX-M type ESBL’s, as 
now reported in most other regions of the world. From a global perspective, a unique distribution of ST131 
E. coli was demonstrated, with a very low prevalence of ST131 amongst 3GC susceptible isolates compared
with resistant isolates (7% vs. 45%). Susceptible isolates showed diversity with six MLST defined clusters of
isolates. Amongst 3GCR isolates, ST131 dominated, comprising 40/89 isolates, with 88% (35/40) of ST131
being of the recently defined fimH 30 sub-clone variant. Whilst patients with ST131 were significantly more
likely to have an upper rather than lower urinary tract infection (relative risk 1.8, p=0.040), they were
otherwise relatively epidemiologically homogenous with other 3GCR-EC.
Analysis of isolates from returned travellers gave insight into the dynamics of carriage of antimicrobial 
resistant E. coli in the bowel flora and supported a number of findings from the case control study. The risk 
of prolonged carriage after travel was lower for 3GC-resistant than ciprofloxacin or gentamicin resistant 
isolates and the duration of carriage was also longer for the latter resistance phenotypes (75th quartile 8 vs. 
62 and 63 days respectively). In multivariate analysis, risks of prolonged carriage included antimicrobial use 
whilst travelling (RR 3.3, 1.3–8.4) and phylogenetic group B2 (RR 9.3, 3.4–25.6) and D (RR 3.8, 1.6–8.8). 
Clonality amongst longitudinal isolates from the same participant was demonstrated in 92% of participants 
and most marked amongst 3GC resistant isolates. ST131 was surprisingly infrequent amongst participants 
(3% of participants).  
Conclusion 
Within this thesis, study of a variety of aspects of antimicrobial resistant E. coli in Australia and New 
Zealand has revealed unique insights into this pathogen locally and globally.  These insights include the 
delineation of risks within the community, temporality of risk and a unique molecular epidemiology. 
Furthermore studies completed within this thesis highlight several key future directions of research including 
clinical studies to investigate risk-factor modification and optimal therapy, economic impact analyses of 
resistant E. coli infection, and further in-depth genetic studies. 
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CHAPTER 1. ESCHERICHIA COLI AND ANTIMICROBIAL 
RESISTANCE 
INTRODUCTION 
Humans and the Enterobacteriaceae E. coli have an intimate relationship. The gastrointestinal tract 
(GIT) harbours vast numbers of commensal or non-pathogenic E. coli. They comprise the most 
common facultative anaerobe in the human GIT.[1] In contrast, pathogenic E. coli strains are able to 
cause a broad range of human disease. The spectrum of pathology ranges from minor to life 
threatening. It is the most common cause of community onset bacteraemia and urinary tract 
infections (UTI) in adults and children.[2-4] In addition, it causes a range of infections including 
diarrhoeal disease, meningitis and health care associated infection, in critically unwell patients and 
those with immunocompromise. Infections have been classically divided into three broad 
syndromes: urinary tract infection, meningitis & sepsis, and diarrhoeal disease.[5] This distinction 
was made on the basis of differences in susceptible population groups and differing ‘pathotypes’ of 
E. coli causing such infections, although further molecular insight into bacteria has led to a simpler 
two-group stratification. 
E. coli causing extra-intestinal infection have been broadly described as ‘ExPEC’ or extra-intestinal 
pathogenic E. coli. This descriptive group evolved from the recognition that phenotypic and 
genotypic distinction between the E. coli causing a variety of extra-intestinal infections, is not 
exact.[6] Infections include UTI, neonatal meningitis, nosocomial pneumonia, GIT and biliary 
infections, osteomyelitis and septic arthritis.[1] A simplified schema of infection requires 
colonisation of non-sterile sites such as the GIT or genital tract, then invasion of a sterile site. 
Colonisation without infection is also a frequent occurrence with up to 20% people harbouring 
ExPEC strains as their predominant GIT coloniser.[7] In addition, non-pathogenic commensal 
strains of E. coli are implicated in infection where regular host defences are compromised, such as 
catheter associated UTIs, peritonitis or host immunocompromise.[5, 6] 
In contrast to commensals and ExPEC strains, E. coli causing gastrointestinal infection are 
described as obligate pathogens. They are rarely found in the gastrointestinal tract of the healthy 
host.[6] Six pathotypes have been described and members of these groups are diverse. They may be 
divided by genetic and phenotypic characteristics but are ultimately defined by their mechanism of 
interaction with eukaryotic cells (invasion, toxicity, aggregation etc.).[5] These E. coli are relatively 
genetically and epidemiologically distinct from those causing extra-intestinal infection and will not 
be explored further in this research.[6] 
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The clinical manifestations and environmental niches of E. coli are protean and thus its genome is 
highly diverse. Each organism carries approximately 5000 genes, with only 2200 estimated to be 
common amongst all E. coli. The E. coli pan-genome may contain up to 13,000 different genes 
shared across the whole species.[8] Such diversity has most likely driven the marked mobility of the 
E. coli genome.  Frequent recombination by conjugation with exchange of genetic material between 
bacteria, described by some authors as ‘bacterial sex’, is a common occurrence.[9] 
At a more immediate level, the genes encoding much of the emerging antimicrobial resistance 
amongst E. coli do not reside within the E. coli genome. Instead, they reside on highly mobile, 
independently replicating, circular plasmids within the bacteria. Such plasmids have constituted one 
of the foci of attempts at understanding the spread of resistance through bacterial species.[10] 
EXTRA-INTESTINAL E. COLI INFECTION 
Urinary tract infection and bacteraemia are the two most common presentations of extra-intestinal 
E. coli infection. 
URINARY TRACT INFECTION  
UTI is one of the most common human bacterial infections, with E. coli the most frequent 
pathogen.[11] E. coli causes 85-95% of all uncomplicated cystitis and 75-95% of 
pyelonephritis.[12, 13] 
Incidence studies in many population groups confirm that UTI is a frequent occurrence. In a study, 
the self-reported incidence amongst females >18 years was 10.8% in the previous 12 months.[14] In 
sexually active young females, the incidence of symptomatic UTI has been more rigorously 
estimated at 0.5-0.7/person year.[15] A population based study of pyelonephritis suggested that the 
highest incidence was in women aged 15-34 at an annual rate of approximately 20 per 10,000 with 
approximately 1 in 6 patients requiring hospitalisation.[16] 
In 2003 the economic burden of community acquired urinary tract infection in North America was 
estimated with direct costs of over 1 billion United States dollars per year and with significantly 
higher secondary costs due to lost productivity.[12] More recent data arising from the use of a 
different methodology places the costs even higher at 2.14 billion USD per year for acute 
pyelonephritis alone.[17]  
Morbidity and mortality from urinary tract infection vary greatly depending upon the clinical 
setting. Few studies of uncomplicated cystitis and pyelonephritis in adults demonstrate mortality or 
morbidity. Whilst there is a presumption of minimal long-term consequences, few longitudinal 
studies have been conducted to confirm this.[17] 
7 
Increasing age and male gender were identified as risk factors for mortality in a large study of data 
from North America of in-patients with E. coli pyelonephritis. In this group, mortality was not 
insignificant at 7.3/1000 and 16.5/1000 hospitalised patients for females and males respectively.[18] 
Predictors of poor outcome in other studies of E. coli UTI have included bedridden status of 
patients before infection, previous antibiotic therapy and septic shock at presentation.[19] 
BACTERAEMIA 
In large bacteraemia series, E. coli accounts for typically 20-30% of all episodes, with the majority 
community acquired and of community onset. Frequently, the only comparable organism, by 
incidence, is the gram-positive Staphylococcus aureus.[2-4, 20, 21] Two recent studies have 
suggested an overall annual population incidence of E. coli bacteraemia approximately 30/100,000 
people/year.[22, 23] 
Clinical and demographic features of E. coli bacteraemia are relatively homogenous across several 
contemporary studies.[22, 24, 25] Cheong, in a large study of community onset E. coli bacteraemia 
found a mean age of 62 and a female predominance (62.4%). A urinary source was most common 
(47%) followed by hepatobiliary origin (27%). A minority of infections (23.8%) were healthcare 
associated.[24] These findings are also reflected in recent data from the European Antimicrobial 
Resistance Surveillance Network (EARS-NET), showing 64% of patients with invasive E. coli 
infection were 65 years or older.[26] 
Whilst the mortality from uncomplicated UTI is relatively low, patients with E. coli bacteraemia 
incur significant morbidity and mortality. Historical studies indicate a mortality of up to 30% with 
this presentation.[20] More recently, mortality in two contemporary studies is lower, although still 
significant (11% and 13.6%).[22, 24] Predictors of mortality included increased age and co-
morbidities and increased severity of the bacteraemic illness. A non-urinary source of infection has 
also been shown to have a poorer outcome.[22, 24] The healthcare burden of bacteraemia is high, 
with a mean hospital length-of-stay in the range of 7-12 days.[25, 27] 
ANTIMICROBIAL RESISTANT E. COLI 
Since the mid-20th century, the emergence and spread of E. coli resistance to single antimicrobial 
classes or agents has been repeatedly noted. This includes sulphur-based agents, fluoroquinolones 
and narrow-spectrum beta-lactams.[28, 29] A number of outbreaks of antimicrobial resistance have 
been associated with clonal strains.[30] 
THE EMERGENCE OF COMMUNITY ONSET ESBL E. COLI 
The emergence of multi-drug resistant ESBL harbouring E. coli (ESBL-EC) as a community 
pathogen has led to a marked change in the epidemiology of multi-resistant gram-negative bacteria 
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in the past two decades. Before this time, multi-resistant gram-negative infection was almost 
entirely nosocomial. Although the organisms implicated included E. coli, other species such as 
Klebsiella pneumoniae and Enterobacter cloacae dominated. The ESBL genes involved were 
usually from the blaTEM or blaSHV classes.[31, 32] 
In a comprehensive review of the topic, Pitout et al identified a 1998 publication describing an 
elderly patient from Ireland, as the first described case of community acquired ESBL-EC 
infection.[33, 34] In the following years, a number of publications reported low but increasing 
prevalence of community onset ESBL infection in European countries, including Spain and France. 
These infections consisted of a mix of healthcare associated and truly community acquired 
infection.[35-37] 
By 2005 the literature contained a variety of publications, originating from multiple continents 
describing community onset, community acquired ESBL-EC.[34] Noteworthy amongst these were 
two articles: one providing the description of an E. coli ‘epidemic clone,’ harbouring the previously 
infrequent blaCTX-M beta-lactamase, spread throughout many regions of the UK;[38] and the second, 
providing Canadian data demonstrating blaCTX-M as the predominant ESBL in the Calgary 
region.[39] 
NOMENCLATURE USED TO DESCRIBE ESBL-EC WITHIN THIS THESIS 
Within literature on ESBL-EC nomenclature can be somewhat confusing as descriptors may refer to 
the bacterial strain and/or the resistance genes harboured within this strain. 
Nomenclature referring to bacterial strains 
Sequence Type (ST) is used to describe bacterial strains classified by multi-locus sequence typing  
(MLST) of seven conserved housekeeping genes spread across the bacterial chromosome. It is 
based on a standardised schema so globally comparable.[9] 
fimH typing is another form of genetic sequence based typing. It classifies bacteria based on 
polymorphisms in the fimH gene. Unlike the housekeeping genes of MLST, the fimH gene is a 
functional component of bacterial virulence. It is also based on a standardised schema.[40] 
Nomenclature referring to resistance mechanisms 
Beta-lactamase resistance mechanisms are described with a standardised scientific nomenclature. 
The terminology varies depending on whether the description is of the gene or the enzyme. In 
description of a gene e.g. blaCTX-M-15, the prefix of ‘bla’ refers to the gene function (beta-lactamase). 
The following sub-text e.g. ‘CTX-M-15’ refers to the sub-family ‘CTX-M’ and the specific variant ‘15’. 
Where the beta-lactamase is referred to as simply ‘CTX-M-15’ this is a reference to the enzyme 
rather than the gene. 
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The sub-family naming comes from various original scientific descriptions. Within beta-lactamases 
it is a common practice to designate the sub-family based on the hydrolysis substrate of the enzyme 
and the geographical location where the gene was first identified. For instance CTX-M is a 
‘cefotaximase’ from ‘Munich’. Newly identified variants of the gene are submitted to a centralised 
repository for numerical classification e.g CTX-M-13, CTX-M-14 or CTX-M-15.[41] 
EXTENDED SPECTRUM BETA-LACTAMASE HARBOURING E. COLI IN AUSTRALIAN AND NEW 
ZEALAND 
The Australian and New Zealand epidemiology of ESBL-EC is beginning to be characterised. 
Whilst there is no unified national surveillance program, the Australian Group on Antimicrobial 
Resistance has undertaken three point-prevalence surveys amongst hospital-based laboratories over 
the last decade. In a 2004 nationwide survey, the rate of ceftriaxone resistance amongst 596 E. coli 
isolates ranged by region from 1.1 to 2%. Most isolates were from blood and originated from a mix 
of in-patients and outpatients.[42] A follow-up 2009 survey of 1746 E. coli isolates from 
hospitalised patients (92% urinary isolates) showed a national rate of 7.7% third-generation 
cephalosporin (3GC) resistance amongst E. coli.[43] The 2010 survey of 2092 isolates originating 
from out-patient urine samples from the same group of institutions, showed a lower rate of 3GC 
resistance amongst E. coli at 3.4%. This ranged by region from 0.7% (Tasmania) to 5.5% 
(Victoria).[44] 
A number of publications have also reported rates and trends from specific locations and population 
groups. In a study of E. coli bacteraemia during 2000-2004, in Canberra, ACT, Australia a 0.4% 
rate of cefotaxime resistance was identified.[23] In a survey indicative of current trends, over the 
years 2003-2007, a Melbourne hospital identified a statistically significant rise in the rates of ESBL 
harbouring isolates amongst urine E. coli (0.4 to 1.8%). Furthermore, by 2007, 63% of infections 
were community acquired.[45] In a 2009-2011 study of a selected population (women of child-
bearing age, with UTI), in a single region of NSW, Australia, a rate of 5% and 9% ESBL expression 
was identified amongst E. coli causing cystitis and pyelonephritis respectively.[46] 
Rates of gastrointestinal carriage of ESBL E. coli, have been less frequently studied in the Asia 
Pacific region. A survey of travellers departing from Canberra between 2008-2009, showed a 2% 
ESBL E. coli rate pre-travel.[47] A similarly low rate (1%) was demonstrated in NSW, amongst 
healthy family members of those individuals who took part in the study above mentioned study.[46] 
In contrast to these low rates, a 2010 point-prevalence survey of selected long term care facilities 
(LTCFs) in Melbourne, Victoria, detected ESBL-EC GIT carriage in 12% of residents, although this 
was highly variable between LTCFs ranging from 0% to 27% across facilities.[48] 
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As in overseas reports blaCTX-M ESBLs are now the dominant mechanism of multi-resistance in 
Australia.[44, 49] No contemporary Australian studies have examined local risk factors for ESBL-
EC infection. 
In New Zealand data from a number of research studies show close similarity to Australian data. In 
a point prevalence survey in 2006, ESBLs accounted for 0.7% (55/8707) of E. coli from urinary 
tract infections across the nation.[50] Although low, this was a considerably higher rate than 
identified in a 2000 survey, which reported a prevalence of 0.1%.[51] Isolates in the later study 
were almost exclusively blaCTX-M ESBLs. A limited 2009-2010 sample of 20 isolates from the 
industry-sponsored ‘SMART’ surveillance program showed a higher rate, at 5% ESBL production 
amongst ‘upper’ UTI in New Zealand, although these isolates were not stratified by community and 
hospital onset.[52]  
Risk factors for ESBL-EC have been investigated in several small New Zealand studies. Older data 
identified residence in long-term care and airways disease (potentially representing frequent 
antimicrobial exposure) as risk factors for ESBL infection.[53] More recent data has identified a 
strong correlation between overseas travel and community acquired ESBL E. coli infection.[54] 
Further analysis of this patient group also revealed that the sub-type of blaCTX-M ESBL enzyme 
detected, was highly associated with the ethnicity of the patient.[55] A case-control study of 21 
patients with ESBL-EC bacteraemia between 2003-2007, identified fluoroquinolone exposure, first 
generation cephalosporin exposure, and previously known colonisation with ESBL-EC, as 
independent risks for bacteraemia.[56] A 2009 survey of stool samples in a single region identified 
a 4.2% ESBL-EC carriage rate and an overall 5.1% carriage rate for ESBL harbouring 
Enterobacteriaceae, amongst 1691 patients. A limited multivariate analysis identified male sex and 
residence in a long term care facility as independent risks for carriage.[57]  
CARBAPENEM RESISTANT ENTEROBACTERIACEAE IN AUSTRALIA AND NEW ZEALAND 
Carbapenem resistant E. coli, and more generally carbapenem resistant Enterobacteriaceae (CRE), 
pose an emerging threat on a global scale. Although they comprise only a small subset of 3GC 
resistant E. coli in our region, they pose a disproportionate threat with regard to the impact of 
possible dissemination. 
At present, with the exception of endemic blaIMP-4 producing isolates, the majority of carbapenem 
resistant E. coli reported are associated with direct importation from overseas. However, one recent 
report has described local spread of an imported carbapenemase[58], and unpublished reports 
suggest possible broader local transmission of other carbapenemases, as outlined below. 
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Enterobacteriaceae harbouring the blaIMP-4 metallo-beta-lactamase (MBL) gene were first identified 
in Australia in 2004.[59, 60] Since this time they have been implicated in a number of outbreaks of 
CRE[61, 62]. Currently they are considered to have low-level endemicity in a number of Intensive 
Care Units (ICUs) along the east coast of Australia.[63] Fortunately, this resistance mechanism has 
not been reported outside of healthcare settings in Australia. 
Newer carbapenemase mechanisms are increasingly being reported in Australia and New Zealand in 
a variety of settings. Importation of the New Delhi MBL into Australia was identified very soon 
after initial reports of its dissemination in India and the United Kingdom.[64, 65] Since this time, a 
number of other importations in a variety of Enterobacteriaceae have been reported in the literature, 
associated with healthcare contact or community acquisition on the Indian subcontinent.[66-69] 
Thus far, local acquisition and transmission have not been described. 
The blaOXA-48 and blaOXA-48-like Ambler class D carbapenemase have also been reported in Australia 
and New Zealand in patients with overseas healthcare contact. Thus far, they have been exclusively 
described in Klebsiella pneumoniae.[58, 70, 71] In one reported importation, secondary spread 
within a NSW hospital resulted in four new acquisitions and three deaths were directly attributed to 
the pathogen.[58] 
E. coli and K. pneumoniae harbouring the Ambler class A Klebsiella pneumoniae carbapenemase 
(KPC) have been imported into the region in a similar manner to other classes.[72, 73] Of concern, 
a number of groups have informally reported isolates harbouring KPC’s from patients without 
overseas travel, possibly indicating local transmission. (Unpublished - Ingram PI and Iredell J, 
reported on OZBUG, Australian infectious diseases email bulletin, 2012) 
IMPACT OF ANTIMICROBIAL RESISTANCE 
Antimicrobial resistance, such as 3GCR-EC, can impact on many facets of patient care. These 
include increased morbidity, mortality and cost of care. In addition, changes in pathogenicity of 
resistant bacteria have also been speculated.  
Inadequate therapy and increased morbidity and mortality 
The presence of unsuspected antimicrobial resistance in bacterial infection may render 
antimicrobial therapy ineffective. This risk of inappropriate therapy is dependent on two variables: 
the background incidence of resistant bacteria and the choice of empirical antimicrobial therapy. 
Marschall et al, in a large study examining all non-ICU gram-negative bacteraemia at a single site, 
identified a rate of 32% inadequate empirical therapy. However, in this institution the relatively low 
rates of antimicrobial resistant E. coli led to a statistically significant lower rate of inadequate 
empirical therapy (12.7%) in E. coli compared to other organisms.[74] In contrast, when a cohort of 
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patients with 3GC resistant isolates is studied, rates of inadequate therapy are frequently higher than 
those for susceptible isolates. In a meta-analysis of the impact of bacterial infection when 
Enterobacteriaceae harbour ESBL enzymes, an odds ratio (OR) of 5.56 for delay in effective 
therapy was identified.[75] Another comparison of ESBL and non-ESBL E. coli infections 
demonstrated 78% compared with 18%, rates of ‘one or more day delay’ in appropriate therapy.[25]  
A significant delay in effective therapy, for any reason, is strongly associated with increased 
mortality in sepsis presentations.[76] Several studies have demonstrated this effect specifically with 
antimicrobial resistant E. coli.[24, 25, 77] Inappropriate empirical therapy was a significant 
predictor of mortality (OR 4.2) in community associate E. coli bacteraemia on multivariate analysis 
by Cheong et al.[24] Another study identified an OR of 3.6 for mortality with ESBL-EC infection, 
which the authors attributed to delayed therapy.[25] 
Recent modelling of population estimates from the American Centres for Disease Control (CDC) 
provides insight into the scale of morbidity. For healthcare associated disease, in North America, 
ESBL producing E. coli lead to 9000 infections and 600 deaths per year. Estimates for carbapenem 
resistant E. coli indicate 1400 infections and 90 deaths per year.[78] 
Economic cost 
The economic cost of antimicrobial resistance is high. A recent study of ESBL E. coli blood stream 
infection (BSI) directly calculated a significantly higher cost of care per patient (€5026.00 
increase/1.5 fold increase) when compared to susceptible isolates causing BSI. This burden 
increased further if inadequate empirical therapy was used due to a prolonged of length of stay and 
other complications.[79] Quite a number of older studies on a variety of ESBL infections have 
drawn similar conclusions through varied methodology.[80] Recent modelling by the CDC of cost 
of infection indicates an additional $40,000 USD per infection for healthcare associated ESBL 
producing Enterobacteriaceae infection.[78] 
The economic impact of community ESBL-EC urinary tract infection compared to susceptible 
infection is yet to be rigorously compared. One small observational study (n=47), which may give 
some indication of relevant comparisons, analyses the differing cost of two treatment strategies for 
ESBL-EC. In this study the cost of treatment with oral fosfomycin therapy was considerably lower 
(less than 1/50th) of the cost of parenteral carbapenem therapy, whilst outcomes were equivalent 
between the groups.[81]  
Virulence 
The issue of potentially increased virulence of antimicrobial resistant E. coli has been examined 
from a clinical perspective by several authors.[46, 82] To date, studies looking at differences in 
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survival have been hampered by the difficulty in adjusting for differences in other characteristics 
and treatment of the two groups involved.[75] Other authors have studied virulence from a 
laboratory perspective and found little difference between blaCTX-M producing E. coli compared 
with non-ESBLs and other groups, including older ESBL mechanisms.[25] Once recent 
development has been the indication of increased ‘clinical’ virulence amongst ST131 E. coli, when 
compared with other strains. This has been demonstrated through a propensity for the clone to cause 
upper-tract infections relative to other isolates.[46, 83] Somewhat paradoxically, in-vitro studies 
have frequently failed to show significantly heightened virulence of this clone, possibly indicating 
limitations of the in-vitro techniques available.[84, 85] 
INFECTION CONTROL MANAGEMENT OF ANTIMICROBIAL RESISTANT E. COLI 
Contemporary infection control guidelines offer recommendations on the management of patients 
with multi-resistant E. coli and other antimicrobial resistant Enterobacteriaceae. They frequently 
pertain to bacteria harbouring an ESBL gene and/or those with carbapenem resistance. The 
Australian NHMRC guidelines and the American CDC guidelines recommend the use of 
transmission-based precautions for ESBL-EC.[86, 87] Measures recommended include the use of a 
single room, gowning and gloving when in contact with the patient. 
However, due to the relatively recent epidemiological expansion of 3GCR-EC and CRE, many of 
the recommendations in these guidelines have been derived from research based on other 
pathogens, including Acinetobacter species and gram-positives such as MRSA. They were also 
formulated at a time when these pathogens had a lower prevalence and a more traditional 
healthcare-associated epidemiology. Furthermore, there are considerable differences in the physical 
characteristics of Enterobacteriaceae, particularly E. coli, which may reduce its persistence on 
hospital surfaces and the likelihood patient-to patient transmission compared with other 
organisms.[88]  
Recently, a number of publications have offered further insight into the infection control 
requirements for antimicrobial resistant Enterobacteriacea.  They have used contemporary 
molecular epidemiology to investigate transmission within hospital settings in a quantitative 
manner. The first of these studies was a 3-year observational study of ESBL-EC transmission 
amongst patients in an intensive care unit. Over this time only three episodes, most likely 
representing direct transmission of ESBL-EC between patients, were identified from the 74 
admissions with known ESBL E. coli colonization, and 23 new hospital acquisitions.[89] In 
contrast, a parallel on K. pneumoniae identified 27 acquisitions with over half (52%) matched by 
pulse-field gel electrophoresis (PFGE) and clinical epidemiology.[90]  
	  
 
14 
Two other studies from the same time period provide data on the transmission of antimicrobial 
resistant Enterobacteriaceae within the hospital system. Over an 18-month period, a prospective 
study at a large Dutch hospital characterised all ‘highly resistant’ gram-negatives (those harbouring 
an ESBL gene, or resistant to ciprofloxacin and gentamicin) within the hospital.. Transmission 
based precautions were used for all patients with this resistance. Over the study three 
epidemiologically linked clusters, totalling four transmission events, were identified amongst 96 E. 
coli isolates meeting the resistance definition.[91] In a follow-up study, over six months at 18 
different hospital sites, the authors were able to determine a ‘transmission index’ for highly resistant 
gram-negatives, greater than 50% of which were E. coli. They identified 22 linked clusters of up to 
six people. Half of these involved ICUs. In total, approximately 7% of isolates were thought to be 
due to secondary transmission.[92] 
Whilst the above studies demonstrated relatively low transmission with the use of transmission 
based precautions, more recent studies have provided data without these potentially burdensome 
measures. Two recent Swiss studies investigated transmission of ESBL Enterobacteriaceae in 
clinical settings without transmission based precautions. In one study of ESBL harbouring 
Enterobacteriaceae (75% E. coli), investigators studied patients who were roomed with an ESBL 
Enterobacteriaceae harbouring index patient before contact precautions were instituted. From 220 
contacts originating from 93 index patients, only two episodes of transmission were identified 
(1.5%).[93] 
A second study looked at transmission of ESBL harbouring Enterobacteriacea within hospital and 
also within households after discharge from care. Only 22% of the patients harbouring E. coli were 
managed with transmission based precautions in hospital compared with 75% of patients with K. 
pneumoniae. For E. coli, within hospital transmission was detected in 4 of 88 patients exposed to 40 
index patients (overall 5.6 new cases per 1000 exposure days). For K. pneumoniae the rate was 
significantly higher at 13.8 cases per 1000 exposure days.[94]  
The investigation of subsequent household contacts identified transmission in almost one quarter of 
this group.[94] Further support for the higher incidence of transmission in a setting of prolonged co-
habitation comes from a recent study of a rehabilitation ward in Israel. In the rehabilitation ward, 
transmission was responsible for 54% of new ESBL-EC acquisitions.[95] 
GLOBAL MOVEMENT AND THE SPREAD OF ANTIMICROBIAL RESISTANCE 
The literature on CRE in Australia and New Zealand highlights the spread of new mechanisms of 
antimicrobial resistance, or highly pathogenic clones, by direct movement of patients. In the 
published paper ‘Country-to-Country Transfer of Patients and the risk of multi-resistant bacterial 
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infection’ this paradigm is reviewed.[96] This paper outlines demographics, characteristics and 
clinical features of patients who may move country. An extensive literature review searched for 
examples of multi-resistant gram-negative bacteria spread in this manner, and expanded this review 
to illustrative examples from gram-positive bacteria. In addition the publication provides some 
recommendations for mitigating this risk when managing patients with recent overseas healthcare 
contact in a clinical setting. 
 
RESEARCH PROGRAM WITHIN THIS THESIS 
 
Dissemination of antimicrobial resistant E. coli and the infections it causes encompass broad 
ranging issues. Considerations span from the intricate genetics of E. coli and its resistance elements 
to the sociological aspects of global population movements. Likewise, the management of patients 
with infection caused by such resistant bacteria is multifaceted. In addition to determining effective 
antimicrobial therapy other considerations include infection control management of patients within 
hospital and community settings. 
The research program presented in this thesis aims to explore various interlinking aspects of 
antimicrobial resistant E. coli focusing on the Australian region. Chapter 2 presents a detailed 
review of ST131 E. coli, a newly described world-wide pandemic clone, which is currently one of 
the greatest global drivers of fluoroquinolone and ESC resistance spread. This review was a spring-
board for the molecular epidemiological research in Chapter 4 and offers a global context in which 
to assess findings from our region presented in Chapters 3 and 4. 
Chapter 3 presents an observational epidemiological study of risks for carriage of ESC-R-EC. This 
‘classical’ research study identifies risk factors for harbouring resistant isolates, relevant to the  
clinician. It provides pragmatic data for healthcare workers and offers a foundation on which to 
build more in-depth research. The in-depth molecular epidemiological study in Chapter 4 builds on 
the observational study (Chapter 3) from which the bacterial isolates were derived. It provides some 
validation to the risks identified in the observational study, allows comparison with global data on 
molecular epidemiology and demonstrates findings unique to our region. 
The investigation of carriage of resistance in returned travelers (Chapter 5) offers in-depth 
exploration of a particular aspect of introduction of ESC-R-EC delineated in Chapters 3 and 4, 
enhancing our understanding of this phenomenon and how it translates to the risk identified in the 
preceding chapters The survey of infection control practice presented in Chapter 6 investigates the 
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in-hospital management of patients with antimicrobial resistant E. coli. This research was 
undertaken in response to data collected as part of the observational study in Chapter 3. It informs 
an often over-looked aspect of patient care. 
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ABSTRACT 
Management of patients with a history of health-care contact in multiple countries is now a reality 
for many clinicians. Leisure tourism, the burgeoning industry of medical tourism, military conflict, 
disasters and changing patterns of human migration may all contribute to this emerging 
epidemiological trend. Such individuals may be both a vector and victim of healthcare-associated 
infection with multi-resistant bacteria.  
Current literature describes inter-country transfer of multi-resistant Acinetobacter spp. and 
Klebsiella pneumoniae (including Klebsiella pneumoniae carbapenemase and New Delhi beta-
lactamase producing strains), methicillin-resistant Staphylococcus aureus, vancomycin-resistant 
Enterococci, and hyper-virulent Clostridium difficile. Introduction of such organisms to new 
locations has led to their dissemination within hospitals. 
Healthcare institutions should have sound infection prevention strategies to mitigate the risk of 
dissemination of multi-resistant organisms from patients who have been admitted to hospitals in 
other countries. Clinicians may also need to individualize empiric prescribing patterns to reflect the 
risk of multi-resistant organisms in these patients.  
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INTRODUCTION 
Although the world may not be truly getting smaller, the increasing use of air transport could give 
this impression.  The exponential growth of international air travel means almost 1 billion 
passengers are projected to take an international flight during 2011[97]. An intercontinental journey 
now takes a matter of hours, rather than the weeks or months of old. Any medical practitioner could 
be faced with a person who may have been in hospital in any part of the world in preceding days. 
Confounding this, practitioners are increasingly managing patients who have travelled vast 
distances primarily for the purpose of seeking medical or surgical treatment for an illness. This 
emerging and diverse category of patient has previously been described in various relevant 
contexts[98-101]. Collectively we term members of this group the ‘inter-country patient’. It 
includes the military and civilian aeromedical evacuee, the ‘medical tourist’ who travels specifically 
to seek medical treatment internationally and a larger, less well defined group of informal medical 
tourists; those whose medical care is divided between countries for a variety of social, familial or 
financial reasons. 
Diseases such as malaria and arbovirus infection are classically described in returned travellers. The 
acquisition of blood borne viruses such as HIV, Hepatitis B & C has been associated with medical 
care in some developing health care systems[102]. The inter-country patient is also at high risk of 
the more prosaic, however. Health care associated multi-resistant bacterial infection is greatly 
heterogeneous, and not necessarily divided along lines of economic development and 
industrialisation. Even ubiquitous nosocomial pathogens such as Staphylococcus aureus and 
Klebsiella pneumoniae will harbour vastly differing antimicrobial resistance patterns depending on 
the location of acquisition[103, 104]. Unsuspected resistance has implications on many levels. At an 
individual level, inadequate empirical antimicrobial therapy of severe bacterial infection, is now 
clearly linked to decreased survival.[76] At an institutional level, such patients may be the index 
case for nosocomial outbreaks of new pathogens. At a community level, inadvertent human carriage 
has been associated with the global spread of antimicrobial resistance in community 
pathogens[101]. 
This review categorises patients at risk of transferring multi-resistant bacterial pathogens from 
healthcare facilities in one country to another. We outline known examples of country to country 
transfer of specific multi-resistant bacterial pathogens of emerging and contemporary importance. 
Data was identified from a systematic search of the Medline and Ovid databases, the reference lists 
of published works and web-based resources identified in these works. 
PATIENTS AT RISK 
Aeromedical evacuation of civilians  
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Aeromedical evacuation, defined as international patient transfer to a medical facility by long 
distance air flight, is increasingly common. It is noteworthy that people with an increasing burden 
of co-morbid disease are now travelling internationally and may have been hospitalized 
overseas[105]. Collated statistics on civilian aeromedical evacuation are not readily available, 
although anecdotal reports indicate rising numbers[106]. A French insurer reported over 400 
evacuations and repatriations in a single year[107].  The indications for transfer from a foreign 
hospital include a broad spectrum of medical and surgical conditions, occurring in both the military 
and civilian domains. Recently, mass mobilisation of civilian evacuation services has been utilised 
in the settings of a natural disaster such as the South East Asian Tsunami in 2004 and of an 
unnatural disaster such as the ‘Bali Bombing’ terrorist attacks in 2002[108, 109].  In both disasters, 
there were reports of transfer of multi-resistant gram-negative bacilli to institutions with low 
background rates of these organisms[100, 110]. 
There are factors in the dynamics of aeromedical evacuation that may increase the risk that such 
patients harbour multi-resistant bacterial pathogens (Table 1). Two European studies have 
investigated rates of carriage of multi-resistant organisms (MROs) in patients repatriated via air-
transfer. Although one study showed rates of MRSA and multi-resistant gram-negative bacilli 
colonization in patients undergoing aeromedical evacuation to be similar to rates at their receiving 
institutions[111], a second study showed far higher rates[112]. The risk of MRSA was found to be 
highest in those with a prolonged ICU stay prior to transfer[111] while risk of multi-resistant gram-
negative bacilli was found to be highest in patients transferred from Asia and Eastern Europe[112].  
 
Aeromedical evacuation of military personnel  
Military patient movements are frequent, with the United States Air Force Aeromedical evacuation 
system reporting over 40,000 patient movements globally during an 18 month period[113]. Recent 
military operations reveal a contemporary view of evacuees from the theatre of war. High rates of 
infection caused by multi-resistant gram-negative bacilli have been reported in injured military 
personnel evacuated from Iraq and Afghanistan[114, 115]. Some studies estimate bacterial infection 
complicating 15 to 25% of admissions[116, 117]. Etiological investigation of infections has 
implicated both environmental contamination of field hospitals and frequent nosocomial 
transmission within the military health system[118, 119]. Risk factors for infection during 
evacuation included abdominal injuries, soft tissue injuries and a high overall injury severity score. 
Additionally, the occurrence of such infection increased the likelihood of the evacuee requiring 
intensive care unit management[117]. At receiving institutions in North America, increasing MRO 
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infection has led to a marked escalation in the use of broader spectrum and higher cost 
antimicrobials in the military healthcare system[114].  
Medical Tourists 
Medical tourism has been defined as “organised travel outside one’s natural health care jurisdiction 
for the enhancement or restoration of the individual’s health through medical intervention”[120]. 
With increasing globalisation, such travel is now increasingly common[121]. For many years, 
patients have travelled internationally to access new and advanced treatment, unobtainable in their 
home country. Patients are now increasingly travelling outbound from developed countries to 
centres in South & Central America, South Africa and Asia where treatment may be obtained at a 
lower cost, without the delay incurred by publicly funded health systems in their home location; or 
with a greater privacy for cosmetic and other procedures[122, 123]. Destinations for medical 
tourists now encompass most corners of the globe. Patients travel internationally for procedures 
ranging from cosmetic surgery through to fertility treatment, major joint replacement and even 
lifesaving cardiac surgery and organ transplant. The utilisation of overseas medical care in order to 
defray cost is now employed by some health insurers in North America[121]. The American 
Medical Association and the American College of Surgeons have recently issued position 
statements pertaining to medical tourism[124, 125]. The exact numbers of ‘medical tourists’ of all 
types has not been documented. Recent estimates suggest that by 2012, 1.6 million patients per year 
will travel ‘outbound’ from North America to receive health care in another country[121-123]. 
Thailand, Hungary, India and Singapore are all expected to have one million or more in-bound 
medical tourists by 2012[126]. 
Certain aspects of medical tourism may increase the risk of acquisition and complicate the 
management of MRO infection (Table 1). There have been no prospective studies of the infections 
associated with medical tourism, most likely due to the difficulty in prospectively capturing this 
group. Available data comes from retrospective case series and surveys of patient and physician 
experience[127]. The largest published experiences arise from solid organ transplantation owing to 
the obligate need for medical contact in the recipient’s home country[128-131]. Illustrating the 
difficulty of such studies, a single centre experience from North America found fewer bacterial 
infections in those who received transplants overseas when compared to local recipients. The 
authors felt this was significantly confounded by the inability to measure the incidence of early 
transplant infection in the overseas recipients[128]. Few series have specified the infecting bacterial 
pathogens. A Canadian experience reported eight of 20 patients with bacterial infection after renal 
transplant overseas, although the location of the transplant procedure was not specified. Four of 
	  
 
21 
these patients suffered infection with bacteria likely producing an extended spectrum ß-lactamase 
(ESBL)[131]. 
 
Care Shared Across Countries 
Similar in nature to the above groups are a broader group of informal ‘medical tourists’; patients for 
whom care of an acute or chronic condition is spread across multiple nations. Factors influencing 
the country of care may include the proximity to friends and family, financial factors and access to 
advanced facilities. The term “diaspora” has been used in reference to large permanent expatriate 
populations from many nations. Recently this term as been applied to thriving expatriate Indian and 
Pakistani communities, which likely number more than 24 million and 7 million individuals, 
respectively.[132, 133] A nation’s “diaspora” may maintain strong familial and cultural links to 
their nation of origin, including frequent return travel and potentially medical treatment for acute 
and chronic conditions spread across multiple nations.[65, 67, 134]  This group is likely more 
numerous than that of medical tourists or that of aeromedical evacuees. 
INFECTIONS OF CURRENT CONCERN 
Gram-Negative Bacilli 
ACINETOBACTER SPECIES 
In a large outbreak of carbapenem resistant A. baumannii in a Belgian hospital, the two index 
patients were evacuated from a Greek ICU after road trauma. Despite increased infection prevention 
precautions, 17 subsequent cases of a clonal isolate were identified over the next six months[135]. 
Also secondary to evacuees from Greece, a smaller outbreak was also described in northern 
Italy[136]. 
A widespread carbapenem-resistant Acinetobacter outbreak in medical facilities involved in the 
treatment of aeromedical evacuees from military operations in Iraq and Afghanistan has been 
reported[115, 137]. Over 100 cases of bacteraemia over an 18 month period occurred within 
military hospitals in the United States and Germany[137]. Although Acinetobacter is associated 
with traumatic injury in many settings, molecular and clinical studies demonstrate the majority of 
infection in this outbreak was due to nosocomial acquisition[118, 119]. The UK has also reported 
the introduction of new strains of Acinetobacter from evacuees from Iraq[115]. In the setting of 
traumatic burns and blast injuries after the 2002 “Bali bombing” terrorist attacks, frequent 
Acinetobacter infection was noted in patients evacuated to Australia. Subsequent nosocomial spread 
in receiving hospitals was again reported[110]. 
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BACTERIA HARBOURING KPC & NDM CARBAPENEM RESISTANCE GENES 
Epidemiological investigation suggests that introduction of the KPC gene into several regions has 
been due to carriage by the inter-country patient. Israel was the first nation outside of the United 
States to report a large outbreak of KPC-harbouring K. pneumoniae. Widespread healthcare 
associated transmission occurred of a strain identified as of North American origin[138]. Greece has 
identified widespread clonal KPC producing K. pneumoniae indistinguishable from contemporary 
Israeli clones[139]. In neither case was a single point of introduction identified. The likely index 
case in a single centre outbreak in Germany was a patient who had previously been hospitalised in 
Greece[140]. Many further countries, including the United Kingdom and France, have reported 
episodes of colonisation or infection of patients transferred from endemic countries (Figure 1)[141, 
142]. 
The New Delhi metallo-ß-lactamase gene (NDM-1) also confers almost complete ß-lactam 
resistance. NDM-1 has been identified in a broad range of gram-negative bacteria including K. 
pneumoniae, E. coli and Citrobacter freundii. Almost all isolates are also resistant to 
aminoglycosides, fluoroquinolones and other classes of antimicrobials. Of concern, some isolates 
have exhibited resistance to the agents of last resort, tigecycline and colistin[64]. The NDM-1 gene 
was first described in Sweden[143] and the United Kingdom[144], and was strongly associated with 
health care received on the Indian Sub-continent. In the UK, 9 of 19 patients had had recent 
hospitalisation in India or Pakistan for treatment ranging from solid organ transplantation to plastic 
surgery. Subsequently, imported cases associated with healthcare contact in India and Bangladesh 
have been reported in other regions, including the United States, Australia, Canada, Japan and 
several Europe nations[65, 145, 146].  Cases have also been identified amongst patients repatriated 
to locations in Western Europe from hospitals in Balkan nations and a cluster of cases identified in 
Kenya[147, 148]. These epidemiological observations require further elucidation (Figure 1).  
BACTERIA HARBOURING ESBL ENZYMES 
Carriage of bacteria harbouring ESBL enzymes by the inter-country patient is long standing, and 
still remains a significant risk[149]. Early reports include intercontinental transfer of common 
nosocomial ESBL-producing bacteria such as K. pneumoniae[150]. Current literature reflects the 
emergence of E. coli harbouring CTX-M ESBLs, with healthcare associated acquisition responsible 
for approximately 15% of travel related infections due to ESBL producers in some studies.[54, 151] 
Gram-Positive Organisms 
METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS 
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Almost fifty years after its emergence, the spread of MRSA by the inter-country patient still poses a 
threat to institutions that have maintained low MRSA prevalence. The prevalence amongst hospital 
acquired S. aureus isolates in the Netherlands and Scandinavia remains <1%, contrasting with 
levels in other European nations and North America (6-63%)[103]. Two outbreaks in the 
Netherlands were directly linked to the transfer of patients from institutions in France and Turkey 
where MRSA is endemic[152]. A study in Sweden demonstrated one quarter of 1,733 MRSA cases 
reported between 2000 and 2003 were likely acquired abroad; over half of these were healthcare 
associated[153]. The potential inter-country spread of MRSA via healthcare workers, rather than 
patients, is illustrated by the report of a Swiss physician found to have new nasopharyngeal 
colonisation with a North American clone of MRSA after returning from a clinical fellowship in 
North America[154]. 
Vancomycin Resistant Enterococci 
Reports of inter-country spread of VRE come primarily from molecular epidemiologic assessments. 
VRE clonal complex-17 (CC-17), a group consisting of a number of closely related VRE sequence 
types, has been responsible for VRE dissemination in countries including the UK, Australia and 
North America[155]. Investigators linked a sharp rise in the rate of VRE in south-west Germany to 
the likely importation of CC-17 VRE to their hospital system[156]. An outbreak due to CC-17 has 
also been reported in Turkey[157]. Neither report identified a single point of introduction. 
Clinical reports of VRE transfer between nations have been prevalent in Europe.[158] Low 
incidence Nordic countries (where VRE accounts for <1% of enterococcal isolates) have had 
sporadic importation and outbreaks from other nations since the early 1990s[158]. Molecular 
studies were strongly suggestive of inter-country spread of a distinctive VRE clone from North 
America to Norway and also to Ireland[159]. In a prospective study from the Netherlands, VRE was 
identified in approximately 3% of patients repatriated from a number of countries, with Asian origin 
being a significant risk[112].  
HYPER VIRULENT CLOSTRIDIUM DIFFICILE 
Since the initial description of hypervirulent ribotype O27, there have been repeated descriptions of 
transfer of the strain with the inter-country patient[160, 161]. A retrospective study in 2007 
identified the transfer of a patient infected with the hypervirulent strain from the UK to Ireland very 
soon after the initial descriptions in 2005; fortunately no outbreak occurred[160]. Introduction of 
the strain into France in 2006, which now has sustained transmission, was speculated to be due to 
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transfer with patients from neighbouring Belgium[162]. Australia has reported a single case of 
importation in a patient recently hospitalized in North America[161].  
 
APPROACH TO THE PATIENT 
All hospitals should have a pre-defined approach to management of the patients transferred from 
other institutions, including those in other countries (Table 2). Pre-emptive contact isolation may be 
considered when there is a risk of introduction of an MRO not currently found in the institution 
receiving the patient. In institutions with few or no endemic MROs, there will likely be a greater 
willingness to institute pre-emptive contact isolation. In some institutions, there may already be a 
high prevalence of MROs and it may seem to matter little that a patient has come from another 
institution which also has endemic MROs. However, introduction of new mechanisms of antibiotic 
resistance or new “hospital adapted” bacterial strains may pose risks of amplifying antibiotic 
resistance. An example may be the receipt of a patient in a hospital in the United States with 
endemic KPC producers of a patient from a hospital in India or Pakistan where NDM producers are 
endemic.  
In the setting of management of an individual patient with suspected bacterial infection, the authors 
suggest a considered approach to the use of empirical therapy (table 3). 
Healthcare staff must adopt a pragmatic and non-judgemental approach to the management of the 
inter-country patient who has acquired an MRO infection. This may be challenging in the setting of 
a patient who has sought a healthcare intervention believed inappropriate or unethical by the home 
treating clinician, such as commercial organ transplantation, experimental or cosmetic procedures. 
This attitude is crucial in order to avoid the patient feeling stigmatised and to facilitate open 
communication of information between the patient, family and clinician. International institutions 
may operate with constraints and resource limitations that are not present in the patient’s home-
nation. Furthermore, the patient may have felt they had no option but to utilize the facilities 
available in a foreign country due to the urgency of care required or the financial cost of care at 
home. 
Local, national and international regulations may pertain to the notification, transit and control of 
patients harbouring MROs[163]. This is a complex and evolving area that varies between 
jurisdictions.  
Conclusion 
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Management of patients transferred from other institutions is a daily reality for almost all health 
care practitioners. The patient with international healthcare contact may present to healthcare 
institutions in a variety of forms, ranging from the overt (e.g. aeromedical evacuee) to the 
unsuspected (e.g. elective surgical day case). In some settings, ready identification of a patient’s 
origin in overseas hospitals is difficult and requires specific questioning. Similarly, a multitude of 
communication barriers may lead to difficulty obtaining information pertaining to a patient’s 
medical care in another country. 
Contemporary molecular epidemiological techniques have allowed us considerable insight into the 
origins and movement of healthcare-associated MROs. The range of potential MROs acquired by 
the inter-country patient is broad. The authors have outlined a small number with current 
significance. A key concept is the dynamic nature of such outbreaks. These may emerge and 
disseminate before reaching the general medical literature. At times, outbreaks may go undetected 
in their country of origin until exported with the inter-country patient[64, 139].  
Furthermore, emerging data now suggests that the risk of acquisition of some MROs may extend to 
those without healthcare contact during travel to countries of high endemicity[47, 164]. Given the 
very large pool of international travellers, this area requires further exploration to better define risk 
factors and the potential magnitude of this problem. 
For an individual patient, the significance of an MRO infection will largely depend on their current 
medical condition and may range from an incidental finding to a life threatening infection. For an 
institution, the significance of importation of MROs depends on the pre-existing milieu of MROs 
and the likelihood of spread, determined by infection prevention practices.  
In conclusion, there are many factors that may complicate the identification and management of 
infections with MROs in the inter-country patient.  Clinical vigilance in the form of sensitive and 
thorough questioning coupled with a high standard of baseline infection prevention practice in all 
patients must be the first line of defence. 
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FIGURES AND TABLES 
Table 1 
Factors predisposing to increased risk of infection and carriage of multi-resistant bacterial 
organisms in aeromedical evacuees and medical tourists 
FACILITIES 
Hospital accreditation varies vastly between nations, providing variable levels of 
oversight for institutional infection control and antimicrobial use. 
Medical tourists may have procedures undertaken in unlicensed settings occasionally 
using unproven & experimental techniques. 
Evacuees may transit through multiple health facilities in a short space of time during 
the process of evacuation. For example, contemporary US military evacuees averaged 
4 facilities in 7 days[118].  
Confined spaces and limited facilities of transport vehicles used for evacuation may 
make some regular infection control practices impossible.  
Barriers including language and differing clinical practice may limit the scope of 
information transferred with a patient. 
PATIENTS 
Common scenarios for evacuation such as road trauma & combat injuries have high 
background rates of secondary infection[117]. 
High acuity of illness in transferred patients means they may be transferred directly 
from Intensive care units which traditionally have high rates of MROs.  
Medical tourists undergoing solid organ transplant or cancer therapy acquire the 
additional risk factor of immunosuppression whilst overseas. 
Medical tourism packages are frequently combined with a vacation which risks 
exposure to a broader range of community pathogens.  
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Table 2 
Recommendations for the management of patients who have been hospitalized internationally 
Maintain vigilance. 
Ask specifically about healthcare contact whenever a patient reports international 
travel within the previous 12 months. 
Pre-emptive isolation and screening should be used in patients with a history of 
hospitalization internationally and who have a high risk of carriage of multiresistant 
organisms  
Isolate patients who have had direct hospital to hospital transfer or recent international 
hospitalization involving prolonged hospital stay, intensive care or critical care 
admission, major trauma, burns or receipt of chemotherapy or immunosuppression 
e.g. solid organ or stem-cell transplant
Screening needs to be customized to the receiving institution: Focus screening on 
organisms that are not already endemic at your site.  
Basic screening may include axillary, inguinal and nose/throat swabs PLUS rectal 
swab or stool sample PLUS clinical specimens including catheter urine, surgical drain 
or wound discharges –Screen for MRSA, VRE & ESBL producing or carbapenem 
resistant GNBs.  
Only screen for C. difficile if diarrhoea is present 
Receive transferred patients in an area of the hospital equipped to manage isolation 
for MROs 
Patients may initially require management in an area of higher acuity than required 
for their medical care e.g. patients for rehabilitation may need to go to an acute ward 
until screened 
All receiving institutions should have a readily accessible infection prevention policy 
defining at-risk patients, screening procedures and pre-emptive isolation criteria.  
If your institution frequently receives patients from a particular location, a customised 
protocol should be developed and maintained for this location: Including an outline of 
the current pathogens of concern and empirical therapy recommended in the case of 
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infection. 
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Table 3  
Approach to suspected bacterial sepsis in the patient previously hospitalized in another country. 
Ensure appropriate microbiology samples for the clinical presentation e.g. blood 
cultures, urine culture, respiratory tract cultures if required 
Notify the microbiology laboratory of the patient origin. They may broaden their 
testing beyond their normal scope, e.g., detection of NDM-1 beta-lactamase, C. 
difficile ribotype etc 
If screening has identified MROs: These bacteria must be targeted in empirical 
therapy. 
If susceptibilities are available, use these to guide antimicrobial selection. If 
susceptibilities are not available, empirical therapy may include agents such as 
Linezolid or Daptomycin (for VRE and MRSA) and Polymyxin B, Colistin or 
Amikacin for MDR gram negative bacilli.  If available, consultation with an 
Infectious Disease physician or clinical microbiologist may be helpful in selecting the 
optimal agent for identified pathogens.  
If no screening results are available: Therapy must target the prevalent pathogens at 
the transferring institution. 
When possible, ascertain these by direct discussion with this institution as recent 
outbreaks may not be publicized. See suggestions above for empirical therapy. 
If screening does not detect an MRO: Treat as per local guidelines. However, 
screening is not 100% sensitive. 
 If the patient fails to improve on empirical therapy, then re-assess for occult sites of 
infection and re-culture as extensively as possible. Consider empirical therapy for 
organisms prevalent at the transferring institution as above. 
MDR=multidrug resistant 
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Figure 1. 
Schematic representation of epicentres (black) and reported/potential importations of NDM-1 (panel 
A) and KPC (panel B) ß-lactamase producing organisms (grey).[65, 138-142, 145-148]
Panel A – NDM-1 
Panel B - KPC 

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CHAPTER 2. THE ESCHERICHIA COLI ST131 PANDEMIC CLONE 
INTRODUCTION 
The recently emerged worldwide pandemic E. coli clone, multi-locus sequence type (MLST) 131 is 
a significant global actor in the spread of 3GC and fluoroquinolone resistant E. coli.  Aspects of this 
clone, including its origins, epidemiology and antimicrobial resistance were extensively reviewed in 
the 2010 published paper ‘Escherichia coli O25b-ST131: a pandemic, multi-resistant, community-
associated strain’, summarised in the abstract below.[165]  
Escherichia coli sequence type 131 (ST131) is a worldwide pandemic clone of E. coli, causing 
predominantly community-onset antimicrobial-resistant infection. Its pandemic spread was 
identified in 2008 by utilising multi-locus sequence typing (MLST) of CTX-M-15 extended-spectrum 
beta-lactamase (ESBL)-producing E. coli from three continents. Subsequent research has 
confirmed the worldwide prevalence of ST131 harbouring a broad range of virulence and 
resistance genes on a transferable plasmid. A high prevalence of the clone (approximately 30-60%) 
has been identified amongst fluoroquinolone-resistant E. coli. In addition, it potentially harbours a 
variety of beta-lactamase genes, including most often CTX-M family beta-lactamases, and less 
frequently TEM, SHV and CMY beta-lactamases. Our knowledge of ST131’s geographical 
distribution is incomplete. A broad distribution has been demonstrated amongst antimicrobial-
resistant E. coli from human infection in Europe (particularly the UK), North America, Canada, 
Japan and Korea. High rates are suggested from limited data in Asia, the Middle East and Africa. 
The clone has also been detected in companion animals, non-companion animals and foods. The 
clinical spectrum of disease described is similar to other E. coli, with urinary tract infection 
predominant. This can range from cystitis to life threatening sepsis. Infection occurs in humans of 
all ages. Therapy must be tailored to the antimicrobial resistance phenotype of the infecting isolate 
and the site of infection. Phenotypic detection of the ST131 clone is not possible and DNA-based 
techniques including MLST and PCR to identify known single nucleotide polymorphisms and 
repetitive sequence PCR are described.  
Since 2010 a number of publications have further delineated and tracked changes in the 
epidemiology of ST131. Many of these studies suggest increasing rates of ST131 amongst 
fluoroquinolone resistant and/or ESC-R-EC, including a number of regions now reporting that more 
than half of all ESBL-EC are ST131. Additionally, ST131 has now been found to carry 
carbapenemases encoding genes, a finding which multiplies the risk created by this successful clone 
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INTRODUCTION 
Escherichia coli is a finely tuned, ubiquitous human pathogen. It is a common cause of urinary tract 
infection (UTI) and bacteraemia in humans of all ages. In addition, it is a frequent cause of varied 
organ infections ranging from the biliary system to the central nervous system. The spectrum of 
pathology can range from a spontaneously resolving cystitis to life threatening sepsis syndrome.[1] 
Not confined to the community, E. coli infection is also a common hospital acquired pathogen.[166] 
Over the past five decades the medical community has witnessed increasing antimicrobial resistance 
in E. coli in the community setting. Initially, resistance was described to particular agents, such as 
ampicillin, trimethoprim, sulphur-based antimicrobials or tetracyclines.[28] More recently the 
horizon of resistance has broadened with the emergence of broad resistance to large families of 
agents. In particular, plasmid-mediated extended-spectrum beta-lactamases (ESBLs) have become 
prominent in community-onset E. coli infection.[31, 34] In addition to the resulting resistance to 
most beta-lactam antibiotics, ESBL producers are frequently also resistant to aminoglycosides and 
fluoroquinolones.  
There are a variety of reasons for the increase in prevalence of antibiotic-resistant E. coli. E. coli is 
an organism known for its mobile genome and propensity to exchange genetic material.[9] 
However, the dissemination of ‘clonal’ organisms harbouring resistance is also well documented. 
Clonal outbreaks of E. coli clinical infection previously described include ‘Clonal Group A’ (CGA) 
in North America7 and O15:K52:H1 in multiple nations.[30, 167] It is estimated that 10-20% of all 
E. coli UTIs may be caused by a small set of clonal groups.[168] In 2008, two research groups
analysing the population biology of ESBL-producing E. coli, almost simultaneously described
‘serogroup O25b, sequence type 131 (ST131)’ occurring in multiple countries on three continents.
This previously unremarkable molecular clone harboured a CTX-M ESBL gene and larger
armamentarium of virulence genes.[169, 170] Since this discovery in 2008, research has
retrospectively documented a ‘pandemic’ emergence amongst ESBL-producing and other
antimicrobial-resistant clinical isolates in the middle of this decade. Previous to this, only sporadic
isolates of this clone can be identified in multi-locus sequence typing (MLST) databases and
published series. The rapid and apparently boundless rise of the ST131 E. coli clone is the subject
of this review.
EPIDEMIOLOGY 
Human infection and colonisation  
Published research detailing the geographical distribution and antimicrobial resistance of human 
infection and colonisation by E. coli ST131 is summarized in Table 1. 
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EUROPE 
ST131 E. coli is widely disseminated amongst ‘antibiotic-resistant’ community and hospital-onset 
E. coli in the UK. Originally identified as the ‘CTX-M ESBL-producing UK epidemic strains A-
E’,12 between 2003 and 2004, these strains have subsequently been confirmed as ST131.[38, 171] In
one UK region ST131 comprised 64% of community-acquired and 84% of hospital-acquired
cefpodoxime-resistant E. coli infections.[172] A UK national study of fluoroquinolone-resistant,
non-ESBL-producing E. coli bacteraemia isolates illustrates the rapid emergence of this strain with
isolates first identified only in 2004.[173] High rates of asymptomatic carriage of fluoroquinolone-
resistant ST131 strains have been demonstrated in Northern Ireland nursing home patients.[174] In
the Republic of Ireland, ST131 was also widely disseminated amongst CTX-M ESBL-producing E.
coli.[175] No data exist on ST131 among relatively antibiotic ‘susceptible’ strains.
The epidemiology of the clone throughout mainland Europe is less well characterised. Current data 
suggest a heterogeneous distribution of infection and carriage, with prominence of the clone 
amongst antibiotic-resistant isolates. A collection of fluoroquinolone-resistant E. coli from eight 
European countries showed ST131 comprised 24% of this entire group. However, the number of 
isolates varied markedly between countries with Spain and Italy most prominent.[176] Spanish 
ESBL-producing E. coli data from 2004 revealed 9% of isolates were ST131.18 A follow-up 
national study in 2006 demonstrated that 13% of ESBL-producing E. coli were ST131 and that they 
had a nationwide distribution.[177, 178] More recent data from a single region in Spain found that 
22% of similar isolates from 2006-2008 were ST131 - 50% originated from nursing home 
patients.[179]. A study of a single region in Italy found that 61% of isolates selected from a 
collection with fluoroquinolone resistance and harbouring ESBL genes, were ST131.[180] French 
data demonstrate the emergence of this clone primarily amongst resistant isolates. ST131 was first 
identified in France in 2001 and rose to comprise 46% of ESBL-producing E. coli from 2006-2007 
in one series.[181, 182] Nationwide data from community-onset ESBL-producing E. coli infections 
identified that 25% were ST131, although only one of 40 patients was felt to have ‘true community-
acquired’ infection.[183] Data on non-ESBL-producing E. coli from UTIs from 2002-2003 revealed 
that only 3% were ST131, with the authors calculating an overall rate of 1.5% of UTIs caused by 
the clone.[181] Similarly, carriage of ST131 without CTX-M ESBLs has been identified in a 7% of 
healthy volunteer stool in France.[184] In Norway 20% of all national CTX-M-producing E. coli in 
2003 were ST131.[185] Belgian data from 2006-2007 demonstrate a high prevalence of the clone in 
community-acquired ESBL-producing isolates. All CTX-M-15-carrying E. coli assayed, comprising 
62% of all isolates, were ST131.[186] 
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The epidemiology of other European nations can only be inferred from case reports and smaller 
studies. Primarily hospital-based outbreaks have been described in Croatia,[187] Portugal11 and 
Germany.[188] The clone has also been identified in Austria, Germany, Hungary, Russia, 
Switzerland and Turkey.[169, 176, 189] 
THE AMERICAS 
The epidemiology of ST131 is well characterised in Canada, with low rates in susceptible E. coli 
and high rates in resistant isolates. Two studies comprising UTI isolates, with little antimicrobial 
resistance, from the years 2005-2007, have demonstrated rates of ST131 in isolate collections of 
<3% and 1%.[168, 190] In contrast, in ambulatory patient isolates selected for fluoroquinolone or 
trimethoprim-sulfamethoxazole resistance from 2002-2004, ST131 comprised 23% of all isolates 
and 44% of fluoroquinolone-resistant isolates.[191] Blood culture isolates of ESBL-producing E. 
coli from a single region mirror the UK experience, with emergence of the strain in 2003 and a 
rapid rise to comprise 41% of isolates from 2004-2007. An overall rise in the incidence of ESBL-
producing E. coli bacteraemia was also attributed to the emergence of the clone.[3] 
Recent data from North America suggests ST131 as “the major cause of significantly antimicrobial-
resistant E. coli infections in the United States”.[192] A geographically widespread selection of 
isolates primarily from blood stream infections suggested that ST131 comprised 67-69% of isolates 
resistant to fluoroquinolone or extended-spectrum cephalosporins. In this study, no susceptible 
samples were ST131.[192] Recent studies from Chicago and Pittsburgh also identified high rates 
amongst resistant isolates. ST131 comprised 53% of CTX-M-ESBL-producing E. coli in Chicago 
and 30% of ESBL-producing E. coli in Pittsburgh, with a range of accompanying ESBL genes.[193, 
194] ST131 E. coli has also been identified in renal transplant recipients and haematology patients
in Texas, both groups with high background antimicrobial use.[195, 196]
A single report has identified ST131 in South America. The clone comprised 8% of 28 ESBL-
producing E. coli hospital associated isolates from Rio De Janeiro, Brazil.[197] 
ASIA AND THE MIDDLE EAST 
ST131 has been frequently identified among antimicrobial-resistant isolates in Japan and Korea. A 
national survey in Japan identified the clone in 21% of ESBL-producing E. coli from 2002-2003. 
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Interestingly a greater genetic diversity within the clone and a greater variety of accompanying 
CTX-M ESBL genes was found in this region than elsewhere.[198] The clone comprised 33-63% of 
fluoroquinolone-resistant isolates from various Japanese regions.[199] Amongst community-onset 
infection ciprofloxacin-resistant isolates in Korea, the clone comprised 25% of isolates, only 19% 
of which harboured an ESBL gene[200]  
In a small Cambodian sample, ST131 clones comprised 27% of community-onset UTIs due to 
ESBL-producing E. coli during 2004-2005.[181] Infrequent isolates have been detected among 
larger collections of clinical isolates in China[199] and the Philippines.[201] Faecal carriage was 
identified in a small number of hospital patients with ESBL-producing E. coli in stool in 
Lebanon.[169] The epidemiology in other Asian countries has been inferred from studies of 
returned travellers and from the high proportion of ESBL-producing E. coli ST131 isolates from 
India, Pakistan, Iran and Lebanon.[151] Supporting these data, the SMART study showed 
remarkably high background rates of 79% ESBL production amongst E. coli isolated from intra-
abdominal infections in India.[202]  
AUSTRALIA 
Two studies from a single region of Australia recently confirmed the presence of the ST131 clone in 
this country. In one study of E. coli selected for fluoroquinolone or cephalosporin resistance, 31% 
of isolates were ST131. Less than half were CTX-M-producing.[203] In a second study 35% of 
fluoroquinolone-resistant isolates from a mix of hospital and community clinics were ST 131.[204] 
AFRICA 
Little data exist on the presence of the clone in Africa. Two small samples have suggested high 
rates amongst ESBL-producing E. coli. In Cape Town, South Africa, 43% of 23 such isolates were 
ST131 and expressed either CTX-M-14 or CTX-M-15 enzymes.[205] In the Central African 
Republic, 50% of CTX-M-15-producing E. coli were ST131.[181] A high proportion of ST131 
have also been identified in a small number of travel-related ESBL-producing E. coli infections 
from Africa.[151] 
Non-human carriage and infection 
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ST131 is represented amongst resistant isolates in companion and non-companion animals, 
although the extent is unclear thus far. A collection from eight European countries confirmed the 
presence of ST131, comprising 6% of ESBL-producing E. coli isolates recovered from companion 
animals.[206] Australian data show a surprisingly low incidence amongst fluoroquinolone-resistant 
isolates from companion animals (7.2% were ST131) compared with humans (35% were 
ST131).[204] Johnson et al. demonstrated intra-household sharing of the clone between 
domesticated animals; however transmission from companion animals to humans has not been 
confirmed.[207] 
In non-companion animals, ST131 has been identified among ESBL-producing isolates in 
seagulls49 and rats,50 both of which have close contact with human populations. Two Spanish 
studies have suggested a low prevalence of the clone amongst poultry and pig farms in that 
nation.[208, 209] Mora found that the clone comprised 1.5% of E. coli strains recovered from 
Spanish poultry between 2007 and 2009. Surprisingly, in this study, the prevalence amongst E. coli 
recovered from retail chicken meat was considerably higher, comprising 7% of strains. In addition, 
a cluster of poultry and human strains was identified by PFGE, all of which carried the CTX-M-9 
gene and a similar virulence profile, suggesting recent crossover between human and avian 
hosts.[209] The high similarity of an isolate from raw chicken and two human infections in the 
same geographical region in Canada was suggestive of transmission from foodstuff to humans.[190] 
Although these links are tantalising, there remains to be found a solid molecular epidemiologic 
connection between human infection and prior consumption of food containing ST131 E. coli. 
Molecular epidemiological observations 
Thus far, there are 48 entries of ST131 voluntarily submitted to the largest publicly accessible E. 
coli MLST database, with isolation dates ranging from 1992 to 2009. Notably, only a handful of 
other STs have a greater number of entries. This may equally reflect the current interest in ST131 
and/or the ubiquity of this ST amongst E. coli. The majority of the isolates originate from human 
infection, primarily UTIs. In addition, ST131 E. coli from domesticated and farm animals, bird and 
food produce are also recorded in this database.[210] 
Utilising the discriminating power of PFGE to analyse MLST-defined ST131 isolates has given 
considerable insight into the origin of the clone. Collections from focal outbreaks, and those 
selected for suspected clonality, have confirmed genetic similarity in excess of 85% on PGFE.[169, 
179] In contrast, collections with a less highly-selected sample from human or animal origin have
shown ST131 isolates with considerable diversity (<65% similarity by PFGE), at times unrelated by
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traditional definitions. Even in such broad collections, small groups of identical or very closely 
related isolates are identified, often at distant locations.[171, 206] This pattern likely reflects the 
dual phenomenon of recent divergence of the clone from a common ancestor together with ongoing 
transmission of the clone.[169] Clinical reports support this hypothesis. There is convincing 
description of direct transmission between humans[211, 212], between animals and in contrast, 
surprising diversity amongst isolates from closely associated patient groups.[195] The ancestry and 
significance of occasional widely divergent or unrelated ST131 isolates remains unclear.[206]  
Elucidating the worldwide distribution, transmission and reservoirs of ST131 is of importance in 
understanding the potential mechanisms of its dissemination and control. To date, this 
epidemiology has not been clearly defined. Since the initial descriptions in 2008, research has 
focused on identifying this strain in particular groups or collections selected for antimicrobial 
resistance phenotype or epidemiological clustering. There have been fewer opportunities to study 
this strain in unselected collections of pathogenic and non-pathogenic isolates. 
Reservoirs of ST131 
Potential reservoirs of ST131 including food or water sources, and travel from nations with a high 
prevalence of the clone, have been proposed in order to explaining the rapid emergence of the clone 
on multiple continents.[80] To date, reservoirs have been detected only at a local level, with high 
carriage and infection rates in nursing home residents in several nations.[174, 179] Investigations 
have only found sporadic isolates of ST131 amongst commercial animals and food-sources, 
although studies are limited.[190, 209]  The potential spread of ST131 after introduction from 
international travellers has only been demonstrated indirectly. Pitout found the highest proportion of 
ST131 clones amongst travellers with ESBL-producing infections in those returning from the 
Indian Subcontinent and the Middle East.[151] Freeman and colleagues demonstrated a strong 
relationship between travel to India and community-onset CTX-M-15-producing E. coli infection in 
New Zealand.[54] Countries implicated in these reports, such as India and Pakistan, have known 
high rates of ESBL-producing E. coli infection but no data on the prevalence of the ST131 clone as 
yet.[202]  
ANTIBIOTIC RESISTANCE 
The ST131 ‘pandemic’ was initially described amongst E. coli harbouring the CTX-M-15 ESBL 
gene on a relatively homogenous plasmid.[169, 170] Subsequent investigation identified a high 
incidence of the clone amongst fluoroquinolone resistant non-ESBL-producing isolates and a low 
incidence amongst collections of susceptible E. coli isolates.[173, 176, 191, 195, 199] With further 
work, many authors have now confirmed surprising diversity amongst key transferable resistance 
elements including ESBL genes, fluoroquinolone resistance genes and the plasmid scaffold 
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harbouring them.[188, 200, 213] This diversity amongst a ‘clonal’ E. coli offers insight into the 
evolution of the clone and resistance. Lee et al. suggested the acquisition of transferable resistance 
elements as independent events from ST131 dissemination.[200] However, the timing and sequence 
of resistance acquisition remains unclear. Potential explanations offered include the spread of 
ciprofloxacin-resistant isolates, which then acquire a CTX-M gene, or possibly the simultaneous 
spread of clonal organisms and genes.[177, 199, 200] Johnson et al., analysing North American 
isolates, demonstrated both vertical and horizontal transfer of the blaCTX-M-15 genes. The gene was 
found in isolates closely related by PFGE – however, even within these clusters there was blaCTX-M-
15 discordance, suggesting horizontal gene transfer or potentially gene loss.[192] Given the clone’s 
propensity for acquisition of resistance, a fine-tuning or evolutionary convergence between the 
clone, plasmids and acquisition of ESBL genes is likely.[170] 
ESBL and AmpC enzymes 
Resistance to β-lactam antibiotics in ST131 can be mediated by β-lactam-hydrolysing enzymes 
from two Ambler classes (A and C) and four distinct families. Among the ESBLs, CTX-M is the 
most prevalent in ST131, while SHV and TEM have been infrequently detected.39, 25, 47Of the 
AmpC β-lactamases, CMY has been most frequently reported.[180, 185, 194, 203, 214] Carriage of 
the genes encoding these β-lactamases is usually on a large plasmid (64 – 160 kb) frequently 
carrying genes encoding additional non-extended-spectrum β-lactamases, blaTEM-1 and blaOXA-1, and 
the aminoglycoside-modifying enzyme AAC(6’)-1b-cr.[3, 169, 170, 215] 
CTX-M-15, the enzyme most closely associated with ST131, was first identified in India in 
1999.[216-218] It is now the most widely distributed CTX-M worldwide.[219] The enzyme is 
responsible for resistance to the penicillins, cephalosporins (excluding the cephamycins) and 
monobactams. CTX-M takes its name from the enzyme’s propensity to confer a higher level of 
resistance to cefotaxime than to ceftazidime (the M refers to its discovery in Munich).[220] Other 
CTX-M-type β-lactamases reported in association with the clone include CTX-M-2, CTX-M-3, 
CTX-M-9, CTX-M-14, CTX-M-27, CTX-M-32, CTX-M-61[181, 198, 209] A chromosomal rather 
than plasmid location of CTX-M-15 amongst ST131 isolates had also been reported, and could 
potentially be a contributing factor in the clonal spread of CTX-M-15-producing ST131 E. coli[170, 
180]. SHV and TEM variants described in ST131 include SHV-12, SHV-5, SHV-7; TEM-24 and 
TEM-116[180, 181, 194, 206]. Isolates expressing these ESBLs may be susceptible to cefoxitin, β-
lactamase inhibitors (clavulanic acid, sulbactam and tazobactam) and carbapenems. However, the 
co-production of ESBLs with inhibitor-resistant β-lactamases (most prominently OXA-1) renders 
these strains resistant to commonly used β-lactamase inhibitors like clavulanic acid. AmpC β-
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lactamases (such as CMY) are also resistant to β-lactamase inhibitors, as well as to cephamycins 
such as cefoxitin. Spanish data demonstrated 6% of AmpC-producing E. coli as ST131. The 
remainder had mutations leading to increased expression of chromosomally located AmpC 
genes.[214] The range and prevalence of ESBL and AmpC genes associated with ST131 is 
summarised in Table 2. 
Resistance to other antibiotics 
Fluoroquinolone resistance is found to be common amongst ST131 in most studies[180, 191, 195]. 
Johnson found that fluoroquinolone resistance and also trimethoprim-sulphamethoxazole resistance 
were significant markers of ST131 E. coli in Canada.[191, 192] This finding is not consistent 
through all regions, however.[203] The mechanism of fluoroquinolone resistance in ST131 isolates 
varies depending on the level of resistance. Amongst E. coli, low-level fluoroquinolone resistance is 
usually due to a single mutation in genes encoding fluoroquinolone targets.[221] The presence of 
plasmid-mediated quinolone resistance (PMQR) genes including qnrA, qnrS and qnrB may also 
contribute to low-level resistance, although they are infrequently described in the ST131 clone.[3, 
193, 200, 222] Less common variations including qnrB1 and qnrB2 have also been reported 
associated with ST131.[180, 223] The ‘dual substrate’ aminoglycoside modifying enzyme 
AAC(6’)-1b-cr also contributes to quinolone resistance via acetylation of selected 
fluoroquinolones.[224, 225] The effect of these plasmid-mediated genes on fluoroquinolone MICs 
is greater in combination than in isolation.[225]  
When present, high level fluoroquinolone resistance in ST131 is generally due to chromosomal 
mutations of genes coding the fluoroquinolone targets gyrA, gyrB, parC and parE, as described in 
other E. coli.[221, 226] Studies of a ciprofloxacin-resistant clone (MIC90 ≥32 mg/L) showed 
multiple mutations in gyrA at codons Ser83 and Asp87, generating Asp-87→ Asn, Asp-87→ Gly or 
Asn-87 → Try amino acid changes and further single or double mutations of parC at Ser-80 and/or 
Glu-84 codons (Ser-80 → Ile and Glu-84 → Val or Glu-84 →Gly).[180] 
The aminoglycoside-modifying enzyme AAC(6’)-1b-cr is frequently associated with ST131.[3, 
169, 170, 215]. (Table 2) Other aminoglycoside resistance enzymes have been detected less 
frequently and sometimes in combination.[227] Resistance to aminoglycosides remains variable 
despite the presence of this gene. In one study where 69% of 96 ST131 E. coli isolates possessed 
this enzyme, 35%, 49% and 35% of isolates were resistant to gentamicin, tobramycin and amikacin, 
respectively.[222] 
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Plasmids 
The initial descriptions of ST131 demonstrated the IncFII group of plasmids harbouring CTX-M-
15.[170] IncFII plasmids may also encode other types of β-lactamases found in ST131 E. coli 
including SHV-12 and CMY-2.[180, 185, 206] Greater clonal complexity among plasmids 
encoding CTX-M-15 is now apparent, with the multireplicons FIA, FIB and FII having been 
described in CTX-M-15-carrying plasmids of ST131 E. coli.[170, 185, 193, 228] In a Norwegian 
study of 23 ST131 strains, the CTX-M-15 gene was related to IncFII, FIB and FIA (87%, 44% and 
42%, respectively).[185] 
The full sequences of two CTX-M-15-carrying plasmids of representative ST131 E. coli have been 
characterised and shown to demonstrate extensive resistance gene profiles. The plasmid of one 
isolate, pEK499 (strain A: 117,536bp), a fusion of type FII and FIA replicons, harboured resistance 
genes for 10 antibiotics from 8 classes; blaCTX-M-15, blaOXA-1, blaTEM-1, aac6’-Ib-cr, mph (A), catB4, 
tet(A) and the integron borne dfrA7, aadA5 and sulI genes. These were responsible for 
cephalosporin, β-lactamase inhibitor, aminoglycoside, chloramphenicol, tetracycline and 
trimethoprim-sulfamethoxazole resistance.[227] 
DETECTION OF O25B-ST131 
The three major characteristics of O25b-ST131 E. coli are its serogroup O25b, phylogenetic group 
B2 and sequence type 131. Each of these characteristics has been used to aid detection. Of note, a 
variety of molecular techniques have been used to determine clonality in previously described 
clones. The ST131 ‘pandemic’ is amongst the first examples where MLST has been the defining 
technique in defining a widespread bacterial strain. The power of this technique is demonstrated in 
several studies where re-analysis by MLST of previously defined PFGE groups has confirmed a 
much broader clonality than originally suspected.[171, 191] This increased resolution does 
complicate comparison of the scope of ST131 to previous outbreaks, however. 
MLST 
MLST first delineated the pandemic clone and remains the ‘gold standard’ for identification. This 
requires the sequencing of pre-specified regions of highly conserved housekeeping genes, allowing 
comparison of nucleotide sequence with publically accessible databases. Hitherto, two separate 
schemas for sequencing and classification are available. That of Achtman et al.[9] defined and 
continues to maintain the database most frequently utilized in ST131 studies 
(http://mlst.ucc.ie/mlst/dbs/Ecoli).[168, 169, 172, 194, 203, 229] This scheme is based on the allele 
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of seven housekeeping genes, adk (adenylate kinase), fumC (fumarate hydratase), gryB (DNA 
gyrase), icd (isocitrate dehydrogenase), mdh (malate dehydrogenase), purA (adenylosuccinate 
synthetase) and recA (ATP/GTP binding motif). An alternative E. coli MLST scheme also using 7 
housekeeping genes operated by Michigan State University, USA (http://www.shigatox.net/mlst) 
has been used.[3, 151] All but one of the housekeeping genes used in this scheme differ from the 
method proposed by Achtman et al..[9]   
PCR based rapid detection methods 
Rapid detection methods have been developed to overcome the labour intensity of MLST. Rapid 
detection of ST131 using a single-nucleotide polymorphism (SNP) method based on only two 
housekeeping genes from the Atchman MLST schema (mdh and gryB) has been developed. The 
O25b variants showed the SNP on C288T and C525T for mdh; and C621T, C729T and T735C for 
gyrB.[191] This method has shown 100% sensitivity. When verified on a broader sample, it is likely 
that this method can be used as an alternative option to full MLST. 
PCR-based methods to detect the phylogenetic[230] and O25 type,[229] followed by the 
confirmation of selected samples using MLST, have also been used.[169, 185, 189, 195, 229] This 
technique for detecting the O serotype O25b, is based on a method originally used to type important 
E. coli causing septicaemia.[231] This O25b typing uses the specific primers rfb1bis.f (5’-
ATACCGACGACGCCGATCTG-3’) and rfbO25b.r (5’-TGCTATTCATTATGCGCAGC-
3’).[229] A more accurate duplex PCR-based method to detect this clone was developed by the
same group. This duplex PCR-based detection method for O25b-ST131 uses allele-specific PCR for
the pabB gene unique to phylogenetic group B2 subgroup I isolates of O type 25b.[181] This duplex
PCR has been successfully used as a rapid screening method for O25b-ST131 E. coli in many
countries.[181, 193, 203, 232] A PCR method on a real-time platform has recently been described.
This assay utilises amplicon melt curve analysis of two regions of the pabB gene. A third amplicon
based on the group 1 CTX-M gene can be used to simultaneously detect the presence of blaCTX-M-
15.[233]
A third technique using triplex PCR to specifically detect CTX-M-15-producing O25b-ST131 E. 
coli is also described, based on the detection of the operon afa FM955459, rfbO25b and the 3’ end 
of blaCTX-M-15.[179] 
REPETITIVE SEQUENCE PCR 
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Semi-automated repetitive sequence based PCR typing technique (Diversilab®, bioMerieux) has 
been found to reliably identify the pandemic clone.[203, 222, 234, 235] Although ≥ 95 % similarity 
to a known ST131 strain was used to define presumed ST131 by Diversilab in a Canadian 
study,[222, 235] other authors have shown that ST131 strains may have similarities as low as 
92%.[203, 234] 
PFGE 
PFGE has been used to determine relationships amongst the ST131 complex rather than identify the 
clone in broader collections. The similarity of ST131 on PGFE depends on the origin of the 
collection. The majority of ST131 strains have similarities ≥ 80% by PFGE, corresponding to 4-6 
bands difference.[236] However a minority of isolates show quite a diverse PFGE pattern. For 
example, the similarities of ST131 E. coli from the UK, Chicago and Japan were only 73%,[171] 
67%[193] and 70%,[198] respectively.  
VIRULENCE
E. coli ST131 is primarily an extra-intestinal pathogenic E. coli (ExPEC) harbouring virulence
genes required for successful pathogenic invasion of a human or animal host. These virulence genes
allow the clone to attach, to avoid and/or subvert host defence mechanisms within extra-intestinal
sites, to scavenge limiting nutrients such as iron from the host; and to incite a noxious host
inflammatory response, cumulatively leading to extra-intestinal diseases. The putative virulence
genes possessed by extra-intestinal pathogenic E. coli can be classified into at least five categories
based on their function: adhesins, toxins, protectins (capsule synthesis), siderophores and other
additional virulence genes. There are ten commonly described virulence genes in ST131 E. coli.
They include iha and fimH (encoding the adhesion-siderophore receptor and type I fimbriae,
respectively), sat (secreted auto transporter, a type of toxin), kpsM (encoding protectin II involved
in group II capsular polysaccharide synthesis), fyuA and iutA (encoding siderophores involved in
synthesis and uptake of ferric yersiniabactin and aerobactin, respectively), usp (uropathogenic-
specific protein), traT (surface exclusion, serum resistance associated), ompT (outer membrane
protease) and malX (pathogenicity island marker).[169, 191] The adhesins, iha and fimH were
identified in 91-100% of O25b-ST131.[169] In addition to iha, Canadian O25b-ST131 E. coli
isolates possessed the P fimbria subunit F10 allele (98%).[191] Unlike the other typical ExPEC E.
coli including CGA and O15:K52:H1 E. coli; O25b-ST131 E. coli did not possess typical fimbriae
and pilus tip adhesion molecules for pyelonephritis such as papA, P fimbriae structural subunit F16
allele and papG II.[191] In Korean isolates however, the papG III allele was identified in all ST131
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studied.[200] The sat gene was present in 95–100% of O25b-ST131 E. coli.[169, 191] This is also a 
common toxin possessed by the other two types of E. coli (CGA and O15:K52:H1 E. coli).[191] 
The fyuA and iutA genes encoding the two siderophore virulence factors were present in 95–100% 
of O25b-ST131 E. coli.[169, 191] The kpsM II gene was detected in 94% of O25b-ST131 CTX-M-
15-producing E. coli.[169] In contrast, this gene appeared less frequently (54%) amongst O25b-
ST131 E. coli in Canada that were mostly non-ESBL producers but fluoroquinolone-resistant[191].
The other common E. coli virulence genes usp, traT, ompT and malX also appeared in nearly all 
ST131 E. coli.[169, 191] A clinical report of septic shock and emphysematous pyelonephritis in a 
previously healthy individual with CTX-M-15-producing ST131, described the presence of these 10 
virulence genes plus afa and dra (central region of Dr antigen-specific fimbria, associated with 
binding and invasion in the mammalian urinary tract[7]).[211] These latter two virulence genes 
occurred in approximately 20% of ST131 isolates tested.[169] 
The ibeA gene, encoding an invasion determinant associated with neonatal meningitis, has been 
detected in 34% of non-ESBL-producing ST131 E. coli blood culture isolates from north-west 
Spain.[209] This gene has only been infrequently reported in other collections.[191, 200] 
The ST131 clone has also been identified amongst adherent-invasive E. coli (AIEC) from intestinal 
and extra-intestinal disease. This pathovar, distinguished from other ExPEC strains by a unique 
phenotype of adhesion and invasion properties, is associated with inflammatory bowel disease.[237] 
The intestinal AIEC phenotype ST131 carried multiple virulence genes infrequently described in 
the clone, including papC, hlyA and cnf1.[209, 238] 
Clermont has demonstrated in vitro and in vivo virulence of the ST 131 clone. Bio-film formation 
identified in vitro is a potential contributor to the long-term persistence of the clone in various 
environments and its resistance to host immune defences. High virulence in a ‘mouse lethality’ 
model of extra-intestinal virulence, was speculated to be due to unspecified virulence genes 
harboured by the clone.[229] 
HUMAN INFECTION 
The spectrum of clinical infection caused by the ST131 clone appears broadly similar to that of 
other E. coli. UTI, representing the most common site of human infection with E. coli, is 
predominant. Description ranges from uncomplicated cystitis to severe infection complicated by 
bacteraemia, renal abscess and emphysematous pyelonephritis.[190, 211] Pitout et al. identified a 
propensity for urinary sepsis above other sites of infection when comparing ST131 and non-ST131 
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E. coli bacteraemia.[3] Johnson et al., studying urinary tract origin isolates, found no clear
correlation between ST131 and any particular clinical syndrome of renal tract infection.[195]
Other sites of infection have included the respiratory tract, ascitic fluid, intra-abdominal abscess, 
bones/joints and bacteraemia without a clinically apparent focus.[198, 212, 239]  
ST131 has also been reported as a prominent cause of E. coli neonatal sepsis.[212] An exception to 
the usual spectrum of E. coli infection has been the description of E. coli ST131 pyomyositis 
amongst patients with haematological malignancy.[196] 
Two reports illustrate direct transmission or the sharing of an identical ST131 clone between 
humans. Transmission of ST131 E. coli from an elderly father with pyelonephritis to his adult 
daughter after brief contact, caused her to suffer a similar illness.[211] Similarly, an identical isolate 
was recovered from an osteoarticluar infection in a young child and a faecal sample from her 
mother.[212] 
Treatment 
As mentioned above, the ST131 clone can harbour a diverse range of antimicrobial resistance 
mechanisms. Few descriptions of infections with the clone include details of antimicrobial therapy. 
Isolates harbouring CTX-M genes have been successfully treated with carbapenems alone or in 
combination with amikacin.[196, 211] For the clinician, even with identification and susceptibilities 
of a pathogenic E. coli, the sequence type of the isolate is unlikely to be known. Hence, comment 
on therapy is based on the commonly encountered antibiotic resistance phenotypes of ST131, which 
would be expected to respond in a similar manner to other sequence types with the same 
antimicrobial phenotype. 
NON-ESBL-PRODUCING, FLUOROQUINOLONE-RESISTANT ISOLATES 
Fluoroquinolone resistance is a hallmark of ST131 in many series. Although not harbouring an 
ESBL gene, such clones frequently carry resistance to other antibiotics. Among UTI isolates, the 
incidence of co-resistance to trimethoprim-sulfamethoxazole was 42% in Canada[191], 47% in 
Korea[200] and 70% in a European collection (including other STs)[176]. Carriage of non-
extended-spectrum β-lactamase enzymes confers resistance to narrow-spectrum β-lactams, with 
ampicillin resistance rates ranging from 90-94%.[176, 191, 200] Fortunately, almost all isolates not 
producing ESBLs or AmpC remain susceptible to the third-generation cephalosporins such as 
ceftriaxone and cefotaxime.[195, 200] In severe infection with a strain not producing ESBLs or 
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AmpC, these would be potentially reliable treatment options. Oral therapy with an agent such as 
amoxicillin-clavulanate or trimethoprim-sulfamethoxazole if susceptibility is confirmed, could also 
be used in less severe infection such as uncomplicated UTI. 
ESBL-PRODUCING ISOLATES 
Parenteral therapy 
Using older breakpoints, ESBL-producing E. coli isolates may test within the susceptible MIC 
range to some third-generation cephalosporins. In this circumstance many regions’ laboratory 
standards suggest reporting resistance to these agents due to uncertainty about their efficacy in this 
setting.[240] Concern arises from studies suggesting poorer outcomes with third and fourth-
generation cephalosporin therapy against ESBL-producers.[241, 242] Some authors suggest that β-
lactam/β-lactamase inhibitor combinations may be effective where in vitro susceptibility of the 
isolate is demonstrated.[243, 244] The parenteral combination piperacillin-tazobactam has been 
used for UTIs and other infections including bacteraemia, skin structure infection and pneumonia, 
although published experience is limited.[243, 244] 
Amongst ST131 clones, including those not producing ESBLs, concurrent aminoglycoside 
resistance is frequent. Reported rates of gentamicin resistance range from 44% amongst non-ESBL-
producing isolates in Korea[200] to 86% resistance in CTX-M ESBL-producing isolates.[3] 
Amikacin resistance is less well characterised but also present in high rates amongst ESBL-
producing isolates.[169] Even in the setting of in vitro susceptibility, uncertainty remains about 
therapeutic efficacy in severe infection such as blood stream infection.[245] 
Carbapenems are the treatment of choice in serious ESBL-producing infection.[246] Several studies 
demonstrate successful therapy of UTI and non-urinary tract serious infection with meropenem or 
imipenem/cilastatin.[247] [248] Ertapenem, a newer narrower spectrum agent, has a limited body of 
experience, which also suggests successful therapy with ESBL-producing E. coli infection.[249, 
250] There is a report of the emergence of carbapenem resistance in E. coli whilst a patient was
ertapenem therapy.[251]
Tigecycline is a glycylcyline derived from minocycline with good in vitro activity against ESBL-
producing E. coli.[252] There is some uncertainty about its potential drug concentrations achieved 
in the urinary tract.[253] However, a case report has documented successful outcomes in UTI 
caused by ESBL-producing E. coli and other highly resistant Enterobacteriaciae.[254] Temocillin, a 
derivative of ticarcillin with stability to β-lactamase hydrolysis and in vitro activity against the 
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majority of ESBL-producing Enterobacteriaceae, is a potential therapeutic option in this setting. 
There is limited published experience in treatment of a variety of ESBL-producing infections.[255] 
Oral therapy 
The oral combination amoxicillin-clavulanate has been used effectively in uncomplicated ESBL-
producing E. coli cystitis when in vitro susceptibility is confirmed.[256] Of note, ESBL strains co-
producing the non-extended-spectrum beta-lactamase OXA-1 may be resistant to b-lactamase 
inhibitor combinations.[257]  
Fosfomycin is an oral antimicrobial that inhibits cell wall biosynthesis. It has been used for the 
treatment of ESBL-producing E. coli cystitis with a high success rate.[256] Of concern, a recent 
report demonstrates a rapid rise in resistance rates amongst ESBL-producing ST131 clones to 22% 
in Spain, closely tied to increasing use of fosfomycin.[258] 
Nitrofurantoin is a synthetic nitrofuran antimicrobial with a long history of use in uncomplicated 
UTI.[259] No papers directly describe susceptibility of ST131 isolates. Amongst a European 
collection of fluoroquinolone resistant non-ESBL-producing isolates including ST131, 86% were 
susceptible to this agent.[176] Amongst Spanish ESBL-producing E. coli, 87% were 
susceptible.[178] It must be noted that nitrofurantoin is only useful in cystitis, not in renal infection 
per se. 
CONCLUSION 
Emerging from ‘molecular obscurity’ in the first decade of this century, ST131 E. coli is now a 
worldwide pathogen causing potentially severe antimicrobial-resistant infection. The dissemination 
of this clone has increased resistance to many low-cost and easily available antimicrobials 
commonly used to treat E. coli infection. Due to the rapid evolution of this worldwide pandemic, 
relatively little is known about this foe.  
Molecular epidemiological study is increasingly describing the clone’s widespread but 
heterogeneous distribution amongst humans and animals. The vast majority of these data emanate 
from the developed world. Little is known about the distribution of ST131 in many parts of the 
developing world, areas suspected of having high rates of infection and which have even been 
postulated as reservoirs of the pathogen.[80] These areas, in addition, have a population particularly 
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vulnerable to morbidity and mortality from resistant infection due to the limited health care 
resources available. 
Two key elements of knowledge required for potential control as a public health measure require 
elucidation. The first is a deeper understanding of the genetics of the ST131 clone, including greater 
insight into why ST131 has become so finely tuned that it can acquire resistance, virulence and 
rapidly disseminate on a vast scale. Research in this area should also increase our understanding of 
the risk of horizontal transmission of mobile resistance elements amongst ST131, between varying 
E. coli clones, and potentially to other Enterobacteriaceae. The second element is knowledge of the
dynamics of transmission and dissemination of ST131 on a population basis. We have little firm
information on many of the classical descriptors of communicable disease control: reservoirs, mode
of transmission, incubation period, period of communicability, susceptibility and methods of
control.[260]
Given the rapid spread of the ST131 clone and its demonstrated ability to cause severe infection in 
otherwise healthy individuals, consideration must be given to the planning of public health 
measures to attempt to control infection. A parallel could be drawn to community-associated 
methicillin-resistant Staphylococcus aureus. In order to successfully plan and execute interventions 
we will need further information on key aspects of this pathogen and the dynamics of transmission. 
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TABLES 
Table 1 
 Geographical distribution and antimicrobial resistance of E. coli ST131 in humans 
Country/Region Specific 
Location 
Date Range 
of Samples 
Isolate Source Selection criteria 
Used by Study 
Number 
of 
isolates 
% of 
isolates that 
were 
ST131 (n) 
% ST131 
Community 
Onset 
%ST131 
fluoroquinolone 
resistant 
%ST131 
SXT 
resistant 
% ST131  harbouring 
ESBL 
Multinational[1
70] 
Europe, Canada 
& Mid East 
2000-06 Laboratory collection ESBL CTX-M-15 43 42(18) 0 NS NS 100 
Multinational[1
69] 
Europe, Asia & 
Canada 
NS Clinical isolates & 
Laboratory collection 
ESBL CTX-M-15 41 88(36) 39 97 53 100 
Multinational[1
51] 
Worldwide 
excluding 
India/Pakistan 
& Bangladesh 
2004-06 Traveller returned from 
region. Majority UTI 
ESBL 84 19(16) NS NS NS 100 
Europe[176] 2003-06 Community acquired 
UTI 
fluoroquinolone 
resistant 
148 24(35) 100 100 NS NS 
Belgium[186] 2006-07 Clinical Isolates ESBL CTX-M-15 43 72(31) 90 NS NS 100 
Croatia[187] 2002-05 Clinical isolates ESBL CTX-M 12 42(5) NS 100 NS 100 
France[181] 1994-2003 Laboratory collection ESBL 128 6(8) NS NS NS 100 
France[181] Tenon 2002-03 UTI Non-ESBL +B2
phylotype 
129 3(4) NS NS NS 0 
France[182] 2005 Bacteraemia 3GC resistant 41 15(6) NS NS NS 100 
France[183] 2006 Community onset UTI ESBL 48 21(10) 10 100 60 100 
France[181] 2006-07 Laboratory collection ESBL 41 46(19) NS NS NS 100 
France[184] Paris 2006 Stool from healthy 
volunteers 
None 100 7(7) 100 57 NS 0 
Ireland[175] 2003-07 Majority UTI ESBL 371 <10 NS NS NS 100 
Italy[180] Rome 2006 Bacteraemia & UTI fluoroquinolone 
resistant+ESBL 
18 61(11) NS 100 NS 100 
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Northern 
Ireland[174, 
261] 
Belfast 2004-06 Stool samples from 
residents of LTCF 
ESBL+fluoroquinolone 
resistant 
119 ≥54(≥64) 0 100 NS 100 
Norway[185] 2003 Clinical isolates ESBL 45 20(9) NS NS NS 100 
Spain[177] 2004 Clinical isolates ESBL 91 9(8) NS NS NS 100 
Spain[214] Madrid 2004-07 Majority UTI Amp-C 121 6(7) NS NS NS 0 
Spain[178] 2006 Clinical Isolates ESBL CTX-M-15 37 86(32) NS NS NS 100 
Spain[179] Lugo 2006-07 Majority UTI ESBL 105 22(23) NS >96 >96 100 
Spain[179] Lugo 2007-08 Majority UTI ESBL 249 22(54) <50 NS NS 100 
Spain[258] Madrid 2008 UTI ESBL+Fosfomycin 
resistant 
26 92(24) NS NS NS 100 
Turkey[189] Izmir 2004-05 Community acquired 
UTI 
ESBL 17 6(1) 100 100 100 100 
Turkey[181] 2006 Laboratory collection ESBL 10 20(2) NS NS NS 100 
United 
Kingdom[173] 
2001-05 Bacteraemia fluoroquinolone 
resistant+Non-
ESBL+aac(6')-Ib-cr 
10 50(5) NS 100 NS 0 
United 
Kingdom[38, 
171] 
2003-04 Clinical isolates ESBL 287 ≥65(≥188) NS NS NS 100 
United 
Kingdom[172] 
Northwest 
England 
2004-05 UTI & Bacteraemia Cefpodoxime resistant 88 59(52) NS NS NS 98 
United 
Kingdom[181] 
2004-07 Laboratory collection ESBL 103 81(84) NS NS NS 100 
Brazil[181] 2001-05 Laboratory collection ESBL 5 0 NS NS NS 100 
Canada[3] Calgary 2000-07 Bacteraemia ESBL 67 31(21) 62 100 67 100 
Canada[191] 2002-04 UTI fluoroquinolone 
resistant or SXT 
resistant 
199 23(46) 100 96 46 <2 
Canada[181] 2004-06 Laboratory collection ESBL 41 41(17) NS NS NS 100 
Canada[190] Montreal 2005-07 UTI in women Varied resistance 353 <1(2) NS NS NS NS 
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sought 
Canada[168] Montreal 2006 Women with UTI None 256 <3 100 100 NS NS 
Canada[222] 2007 Clinical Isolates ESBL 209 46(96) 57 NS NS 100 
USA[195] Texas 2003-05 Bacteriuria in renal 
transplant recipients 
None 40 35(14) NS 86 NS 0 
USA[192] 2007 Majority Bacteraemia Varied resistance 
sought 
127 †17(54) NS NS NS 56 
USA[194] Pittsburg 2007-08 Clinical isolates ESBL 70 30(21) NS NS NS 100 
USA[193] Chicago 2008 Majority UTI ESBL 30 53(16) NS 100 38 100 
Subcontinent[1
51] 
India, Pakistan 
& Bangladesh 
2004-06 Traveller returned from 
region. Majority UTI 
ESBL 31 61(19) NS NS NS 100 
Cambodia[181] Phnom Penh 2004-05 UTI ESBL 30 27(8) NS NS NS 100 
China[199] 1998-2000 Laboratory collection fluoroquinolone 
resistant 
12 ≥17(≥2) NS 100 NS NS 
Japan[198] 2002-03 Laboratory collection ESBL 142 19(27) NS NS NS 100 
Japan[199] 2003-07 Clinical isolates fluoroquinolone 
resistant 
128 ≥30(≥38) NS 100 NS NS 
Korea[200] 2006-07 Community Onset UTI fluoroquinolone 
resistant 
129 25(32) 100 100 50 19 
Korea[199] 2005 Laboratory collection fluoroquinolone 
resistant 
21 ≥33 (≥7) NS 100 NS NS 
Philippines[201
] 
Manilla 2007 Clinical isolates ESBL 15 7(1) NS NS NS 100 
Thailand[181] 1999 Laboratory collection ESBL 5 0 NS NS NS 100 
Australia[204] Queensland 2007-08 Majority UTI fluoroquinolone 
resistant 
582 35(205) NS 100 NS NS 
Australia[203] Queensland 2008-09 Clinical isolates Cephalosporin resistant 
or fluoroquinolone 
resistant 
49 31(15) NS 47 NS 53 
Central African 
Republic[181] 
Bangui 2004-06 Laboratory collection ESBL 10 50(5) NS NS NS 100 
53 
NS=Not specified by the authors, UTI=Urinary tract infection (or bacteriuria if not specified), ESBL=Extended Spectrum beta-Lactamase, SXT = 
Trimethoprim + Sulfamethoxazole, 3GC=3rd Generation Cephalosporin 
≥, < & > are used to estimate when the text does not give an exact number for the relevant isolate 
†Estimated at 17% of entire collection of E. coli isolates. 
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Table 2  
ESBL, AMPC AND AAC ANTIMICROBIAL RESISTANCE GENES CARRIED BY ST131 
Location Number of ST131 
with Extended 
Spectrum Phenotype 
CTX-M-3 
%(n) 
CTX-M-14 
%(n) 
CTX-M-15 
%(n) 
Other CTX-M Genes 
%(n) 
Other Extended Spectrum Genes 
%(n) 
aac(6')-Ib-cr % of ST131 
†Multiple Continents[151, 169, 
170] 
70 99(69) CTX-M-1=1(1) ‡100 
Australia[203] 
8 
50(4) Untyped CTX-M=(25)2 CMY-2=25(2) 
§Belgium[186] 31 100(31) 
Cambodia[181] 8 75(6) 13(1) CTX-M-27=13(1) 
Canada[3, 181, 222] 134 11(15) 87(117) CTX-M-2=<1(1), CTX-M-61=<1(1) ‡75 
Central African Republic[181] 5 100(5) 
Croatia[187] 5 100(5) 
France[181, 182] 33 21(7) 85(28) TEM-24=3(1) 
India/Pakistan/Bangladesh[151] 19 100(19) 
Italy[180] 11 0 91(10) SHV-12=9(1) 100 
Japan[198] 27 74(20) CTX-M-2=11(3), CTX-M-35=15(4) 
Korea[200] 6 17(1) 67(4) CTX-M-22=17(1) 
Norway[185] 9 89(8) CTX-M-1=11(1) 
Spain[177, 179, 209, 214, 258] ¶82 10(8) 66(54) CTX-M-9=9(7), CTX-M-10=2(1), CTX-M-32=4(3) 
SHV-12=1(1), CMY-2=2(3),c-
AmpC=5(4) 
‡100 
Turkey[181, 189] 3 33(1) 66(3) 
UK[38, 181] 272 19(52) §81(220)
USA[193, 194] 37 14(5) 78(29) SHV-5 or7=8(3) ‡63 
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c-AmpC=Chromosomal AmpC gene
† Isolates selected for CTX-M-15 genotype by researcher 
‡Data only available on a selection of isolates from this country 
§Some isolates CTX-M-28
¶One isolate contained CTX-M-14 and CTX-M-15 
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UPDATE ON ESCHERICHIA COLI ST131 
EPIDEMIOLOGY 
Since 2010 a number of publications have further delineated and tracked changes in the 
epidemiology of ST131. Many of these studies suggest increasing rates of ST131 amongst 
fluoroquinolone resistant and/or ESC-R-EC, including a number of regions now reporting that more 
than half of all ESBL-EC are ST131. 
In North America, three studies have characterised the current epidemiology of ST131 amongst 
systematically collected unselected E. coli originating from bacteraemia or UTI (range 249 to 599 
isolates per study). The ST131 clone comprised 23-28% of all E. coli isolates, the majority of which 
were phenotypically fluoroquinolone resistant and 3GC susceptible.[262-264] Amongst ESBL-EC 
the rate is likely higher, with 54% of isolates identified as ST131 in a large multi-centre study of 
community onset E. coli in five US hospitals.[265] Similarly, Canadian surveillance data 
demonstrated a continuing trend of increasing fluoroquinolone resistance and ESBL production 
amongst E. coli, attributed to expansion of the ST131 clone.[266] By 2011, 72% of the 227 ESBL-
EC collected were ST131, in Canada.[267] 
Fewer studies from Asia have reported ST131 data. A relatively low rate of 20% ST131 was 
identified amongst 103 community onset blaCTX-M producing ESBL E. coli in Seoul, Korea, during 
2006-2011.[268] A second study identified a rate of 29% ST131 amongst 38 episodes of acute 
pyelonephritis caused by ESBL-EC.[269] Taiwanese data indicates that ST131 comprised 29.5% of 
isolates amongst 122 episodes of ESBL-EC bacteraemia over 2005-2010, with a noted numerical 
increase in ST131 infections over the study period.[270] 
In Europe, a number of centres have also continued to publish their experiences. In Copenhagen, 
Denmark, amongst 115 consecutive ESBL-EC isolates, the prevalence of ST131 was 38% and 
accounted for the largest single ‘group’ of isolates in the study. In total, 91% of these were 
community acquired, which was significantly higher than for other ESBL-EC. Over 60% of ST131 
belonged to a single pulsotype (812).[271]  
Swedish national ESBL-EC surveillance data showed 34-38% of 1002 ESBL-EC isolates were 
ST131 over the years 2007-2011, with no clear temporal trend.[272] In Southern Sweden, ST131 
comprised 26% of community ESBL-EC and 20% of hospital ESBL-EC during 2008-2009, 
although with overall low incidence of ESBL-EC in the population (2.5% in hospital, 1.6% in the 
community). The ST131 incidence was significantly higher than in the earlier period of 2003-
2005.[273]  
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A collaborative study amongst four rehabilitation centres in Europe and Israel defined a high rate of 
ST131 amongst this hospitalised population with ST131 comprising 41% of 376 3GCR-EC isolates. 
This included a rate of 41% and 52% in the two Israeli sites, the first time ST131 has been 
identified in this country.[274] A small study of older isolates from neighbouring Egypt (2007-
2008) found that 20% of inpatient and 17% of outpatient E. coli were phenotypic ESBLs with 19% 
(n=5)  of these identified as ST131.[275]  
CARBAPENEM RESISTANT ST131 
Since 2010, descriptions of the ST131 clone harbouring a carbapenemase enzyme have been 
documented in the literature. Many authors have highlighted the grave threat posed by a 
combination of a pathogenic community disseminated clone and carbapenem resistance. Reports 
include ST131 harbouring prevalent and emerging carbapenemases including blaNDM[276] , 
blaKPC[277],  blaOXA-48[278], blaIMP[279] and blaVIM[280] . The majority of reports have been of 
singleton isolates recovered from individual patients or amongst much larger collections of CRE 
isolates. Of concern was a recent report from Italy describing a cluster of patients with blaVIM-1 
harbouring ST131, closely related by PFGE, isolated over a one year period.[280] A similar report 
from Taiwan describes PFGE related ST131 isolates harbouring blaIMP-8 isolates from four non-
hospitalised patients without any epidemiological link.[279]  
RISKS AND RESERVOIRS 
Since 2010, several publications have focused on identifying risks and reservoirs of ST131 E. coli. 
Residence in a long term care facility (LTCF), also referred to as a ‘high level care’ nursing home 
in Australia, has been strongly implicated as a risk for ST131 in a number of recent well-designed 
studies. In Minnesota, USA, a high risk for infection with an ST131 clone (OR=10) was identified 
amongst residents of LTCFs on multivariate analysis of 299 E. coli originating from a urinary tract 
source.[263] In a second study of the same region, ST131 comprised 76% of all LTCF E. coli.[281] 
In Paris, France, multivariate analysis identified a risk (OR=4.4) of LTCF residence comparing 
ST131 and non-ST131 strains amongst 152 patients with blaCTX-M harbouring E. coli 
infection.[282] Supporting data also comes from several surveys showing high rates of ST131 
amongst elderly patients in Ireland[283, 284] and nursing home patients in Germany.[285]  
Whilst ST131 has been classically ‘community associated’, recent studies have associated 
healthcare exposure with ST131, primarily in North America.[263, 264, 284] One study 
demonstrated that 66% of ST131 E. coli infections were healthcare associated and 34% community 
associated. This was approximately inverse to other predominant clones such as ST95 and 
ST73.[281] Interestingly, multivariate analysis has demonstrated that the majority of this 
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relationship is through associations such as antimicrobial resistance phenotype and antimicrobial 
exposure rather than exposure to the healthcare environment.[263]  
 In Israel, widespread transmission of a variety of ST131 sub-clones (defined by PFGE) was 
demonstrated amongst residents of rehabilitation wards.[95] In contrast, in Taiwan few unique 
characteristics of patients with ESBL-EC bacteraemia caused by ST131 could be identified when 
compared to non ST131 ESBL-EC. There was no a significant difference in the odds of ST131 for 
community onset infections caused by ST131 (OR=1.3, p=0.47), and a significant odds ratios for 
ST131 amongst non-catheter associated UTI (OR=2.7).[270] 
A recent Spanish case-control study demonstrated differing risks between ESBL producing ST131 
and non-ESBL producing ST131. For each phenotype, the authors compared patients harbouring 
ST131 clones to those with E. coli of the same phenotype that was not ST131. Amongst the non-
ESBL isolates, risks were similar to those defined in North America. They included female gender, 
diabetes mellitus, bedridden status and antimicrobial use (fluoroquinolone or amoxicillin + 
clavulanate). In contrast, amongst ESBL harbouring ST131, previous antimicrobial use and 
healthcare acquisition were protective for ST131. Male gender was the only delineated risk for 
ST131 ESBL-EC.[286]  
H30 AND OTHER ST131 SUB-CLONES 
Recent insight into subclonality within the ST131 clone has been a significant advance in our 
understanding of the ST131 pandemic. This has been investigated by characterisation of ST131 
collections with pulse field gel electrophoresis (PFGE) and/or characterisation of polymorphisms in 
the fimH gene, which encodes Type 1 fimbrial adhesin.  
A large study of 579 temporally (1967-2009) and geographically dispersed ST131 isolates was 
analysed by PFGE. This study demonstrated considerable temporal clustering of pulsotypes, with 
emergence of a select group of ‘high prevalence’ pulsotypes in the later part of the survey period. 
Three key pulsotypes emerged over 1990-2005. Two in particular (968 and 800) continued to 
dominate collections after this time, and feature heavily in other contemporary studies.[263, 264, 
287] This finding suggested a refinement or evolution of ST131, as the clone has spread. Of note in 
this study, was a demarcation of pulsotypes between human isolates and those from food, food 
animals and companion animals.  This indicates that animals are not the predominant source of 
ST131 in humans.[287]  
Characterisation of polymorphisms in the fimH gene has been another focus of recent efforts to 
understand ST131. This gene is of interest because of two key traits. Firstly, it is more diverse (i.e. 
less strictly conserved) than traditional MLST housekeeping genes, and thus has been successfully 
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utilised in a two-locus typing schema for all E. coli.[40] Secondly, unlike MLST’s housekeeping 
genes, fimH polymorphisms are of functional significance in the uropathogenesis of E. coli. 
Researchers have suggested that polymorphisms in the gene are a pathoadaptive trait and may be 
positively selected due to the integral function of fimH in adhesion to urothelium.[288] 
Applying fimH typing to ST131 has given surprising insight into the clone and served to define a 
core fluoroquinolone resistant sub-clone of ST131. This sub-clone harbours the fimH 
polymorphism, H30, as classified by the schema of Weissman. This is defined by a single amino 
acid change from the consensus fimH sequence at the 166th position (R➔H).[40] In-vitro studies 
indicate that this change significantly enhances the ability of E. coli to bind to urothelium, possibly 
suggesting a competitive advantage of the H30 clone.[288] Studies into the origin of this clone, 
using polymorphisms in fluoroquinolone resistance determining gyrA and parC genes, show a high 
level of conservation amongst H30. The authors suggest a possible single-strain of ST131 E. coli 
led to the emergence and dissemination of this now widespread sub-clone.[289]  
Since the description of H30 sub-clones, several epidemiological studies defined its emergence 
amongst ST131. A multi-national retrospective study of ST131 isolates defined the ‘abrupt 
emergence’ of the sub-clone after 2000. Although not identified in isolates before 2000, it now 
makes up the majority of fluoroquinolone resistant ST131 (58%) and almost all ESBL positive 
isolates (85%).[289] Contemporary studies in two American health systems demonstrate a very 
high prevalence of the H30 sub-clone. This sub-clone constituted 23% and 24% of all E. coli in a 
veterans’ hospitals and in Olmsted county Minnesota respectively.[263, 264] The latter study also 
demonstrated that the H30 sub-clone was spread throughout the dominant 968, 800 pulsotypes and 
many minority pulsotypes of ST131. 
Given the apparent selective advantage of the H30 clone and the 968 and 800 pulsotypes, research 
efforts are now focused on deeper analysis of the unique genetic traits of these sublcones. 
ST131 IN AUSTRALIA AND NEW ZEALAND 
A number of publications have broadened our understanding of ST131 in Australia and New 
Zealand. Three related studies defined the epidemiology of ST131 in a single local region of 
Australia (Central West New South Wales). Rates of ST131 amongst E. coli appear divergent 
amongst population groups. Children (<6 years) and men had a prevalence of 8% (18/212) and 13% 
(49/389) ST131 respectively, amongst isolates of E. coli from UTI.[83, 290] In women of child 
bearing age, the incidence was considerably higher at 21% ST131.[46] All three studies showed a 
gradient, with higher rates of ST131 amongst pyelonephritis than cystitis isolates, demonstrating the 
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clinical virulence of this clone. Beyond demographics, study design limited the ability of these 
studies to elucidate risk factors for ST131. 
Specific patient groups and clinical syndromes have been investigated in two recent studies. In a 
small laboratory based study, researchers compared fluoroquinolone resistant ST131 in humans and 
companion animals in Australia. Amongst 29 isolates they identified a commonality in PFGE 
profile, virulence genes and resistance genes, concluding that this represented exchange of ST131 
clones between humans and animals in Australia. The direction of this exchange (human to animal, 
or vice versa) could not be determined.[291]  
A recent clinical study from New Zealand was a retrospective analysis of 258 episodes of 
bacteraemia from trans-rectal-ultrasound guided prostate biopsy (TRUS biopsy). The authors found 
that 41% of all E. coli causing this syndrome are ST131, compared with 13% of bacteraemia 
causing E. coli from other sources. Almost all TRUS biopsy patients had been exposed to a 
fluoroquinolone as prophylaxis before biopsy. In total 83% of the ST131 were fluoroquinolone 
resistant compared with 25% of non-ST131 isolates.[292] In a follow-up study, the authors 
demonstrated that there were no significant differences in demographics or co-morbidity score 
between patients with ST131 and non-ST131 E. coli after TRUS biopsy.[82] 
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CHAPTER 3. EPIDEMIOLOGY OF COMMUNITY ONSET 
ESCHERICHIA COLI INFECTION RESISTANT TO EXPANDED-
SPECTRUM CEPHALOSPORINS. 
INTRODUCTION 
E. coli resistant to 3GC antimicrobials include those harbouring an ESBL enzyme or other
mechanisms of resistance such as plasmid borne AmpC like genes. These isolates are usually
resistant to 3rd, 4th and 5th generation cephalosporin agents, and thus generally referred to by term
‘Extended’ or ‘Expanded’ spectrum cephalosporin resistant E. coli (ESC-R-EC). Defining risk
factors for community onset ESC-R-EC (CO-ESC-R-EC) infection is important. At a clinical level,
knowledge of risks can guide clinicians’ choice of empiric antimicrobials to avoid potentially
ineffective therapy in sepsis. It can also facilitate the use of narrow-spectrum agents where risks for
ESC-R-EC are not present. At a population level, knowledge of epidemiology and patient-level
risks, can direct efforts to study and control spread of ESC-R-EC and help delineate reservoirs and
temporal trends for ESC-R-EC within communities.
Risk factors for CO-ESC-R-EC have been defined in many regions of the world.[270, 293-296] 
Viewed as a whole, these studies highlight the importance of applying contemporaneous local data 
when considering risks. Many risks are temporally, geographically or population specific. In one 
illustrative example, a validated risk-prediction tool for ESBL producing Enterobacteriaceae 
developed in Italy was trialled in North America. Although it performed reasonably, key 
demographic factors (Age ≥70 years and Charlson comorbidity index ≥4) were not applicable in the 
later cohort. Immunosuppression, which was not identified in the Italian model, was a significant 
risk in North America.[293, 296] In addition, unique reservoirs of 3GCR-EC may occur in certain 
populations. In the Netherlands, retail poultry has been implicated as a significant source of 3GCR-
EC in the community. This appears to be due to specific factors including patterns of antimicrobial 
use in the farming of chickens in the Netherlands.[297] A clear link to animals has been difficult to 
prove in other regions. 
From a local perspective, specific characteristics of Australia and New Zealand may further 
decrease the applicability of risks identified in other regions. Firstly, the background rate of 
community 3GCR-EC is far lower than in the setting of many risk-factor studies. For instance, 
according to the European Antimicrobial Resistance Surveillance Network’s (EARS-NET) most 
62 
current data (2011), the background rate of 3GCR amongst invasive E. coli in Italy, where the risk 
prediction rule was derived, is approximately 20%.[298] Antimicrobial use patterns also vary 
greatly. As discussed in the publications in Chapters 3 and 4, within Australia and New Zealand, 
fluoroquinolone use amongst humans and animals is significantly lower than in most other areas of 
the world.[299] The use of 3GC antimicrobials in food production is also banned.  This has led to a 
presumption of low rates of 3GCR Enterobacteriaceae contamination of meat products, although 
this has never been studied in a systematic manner.[300]  
Finally, the Australian and New Zealand population includes high rates of immigrants from India 
and China, two countries which pose a high risk for GIT carriage of ESBL-EC after return from 
travel.[47] Australian census data from 2010 shows that following the United Kingdom and New 
Zealand, these countries make up the 3rd and 4th largest immigrant groups in Australia. Together 
they comprise 12% of all overseas born Australians.[301] 
Given the notable differences between population demographics, antimicrobial use and other 
potential risk factors for ESC-R-EC in our region compared with other regions globally, we sought 
to determine characteristics of CO-ESC-R-EC in our population. This included locally applicable 
risk factors and the molecular epidemiology of infecting isolates. This was completed through a 
multi-centre collaboration to undertake a case-control study of CO-ESC-R-EC infection. 
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ABSTRACT 
Background 
By global standards the prevalence of community onset expanded-spectrum cephalosporin resistant 
Escherichia coli (ESC-R-EC) remains low in Australia and New Zealand. Of concern, our countries 
are in a unique position with high extramural resistance pressure from close population and trade 
links to Asia-Pacific neighbours with high ESC-R-EC rates. We aim to characterize the risks and 
dynamics of community onset ESC-R-EC in our low-prevalence region. 
Methods 
A case-control methodology was used. Patients with ESC-R-EC or susceptible E. coli isolated from 
blood or urine were recruited at six geographically dispersed tertiary hospitals in Australia and New 
Zealand. Epidemiological data was prospectively collected and bacteria were retained for analysis. 
Results 
In total, 182 patients (91 cases and 91 controls) were recruited.  Multivariate logistic regression 
identified risk factors for ESC-R amongst E. coli including birth on the Indian subcontinent 
(OR=11.13, 2.17-56.98, p=0.003), urinary tract infection in the past year (per infection OR=1.430, 
1.13-1.82, p=0.003), travel to South East Asia, China, Indian subcontinent, Africa and the Middle 
East (OR=3.089, 1.29-7.38, p=0.011), prior exposure to trimethoprim+/-sulfamethoxazole &/or an 
expanded-spectrum cephalosporin (OR=3.665, 1.30-10.35, p=0.014) and healthcare exposure in the 
previous six months (OR=3.16, 1.54-6.46, p=0.02).  
Amongst our ESC-R-EC the blaCTX-M ESBLs was dominant (83% of ESC-R-EC), and the 
worldwide pandemic clone ST-131 was frequent (45% of ESC-R-EC). 
Conclusion 
In our low prevalence setting, ESC-R amongst community onset E. coli may be associated with 
both ‘export’ from healthcare facilities into the community and direct ‘import’ into the community 
from high-prevalence regions. 
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INTRODUCTION 
Despite a dramatic global rise in the prevalence of expanded-spectrum beta-lactamase (ESBL) 
producing E. coli, expanded-spectrum cephalosporin resistant Escherichia coli (ESC-R-EC) 
infections in the Australia, New Zealand, North America and selected European countries remain at 
relatively low levels. Recent Australian national data shows that 3.2% of community isolates carry 
such resistance. Approximately 80% of these harbor a globally dominant blaCTX-M ESBL gene and 
12% a plasmid borne AmpC type mechanism[44]. European surveillance data shows a significant 
proportion of countries have rates below 10% ESC resistance amongst invasive E. coli isolates[26]. 
In the United States, a recent large sample of E. coli indicated 3.9% were ESBL-producing[265]. 
Although these low rates offer reassurance in the near-term, a year-on-year rise in incidence of 
community onset ESC-R-EC in low-prevalence countries is of concern[26, 302]. 
Australia and New Zealand are in a globally unique position. We have low rates of use of 
antimicrobials traditionally identified as a risk for ESC-R-EC. This includes very low 
fluoroquinolone use amongst humans and a ban on the use of ESC and fluoroquinolones in food 
production[299, 300]. In contrast, we have considerable extramural pressure on antimicrobial 
resistance rates. Our countries are located within the Asia-Pacific region, in which we share a 
mobile population[303] and frequent commerce (although no land-borders). A high proportion of 
our regional neighbours have rates of ESC-R amongst E. coli in excess of 25%[52, 202]. 
The aim of our study was to define the risk factors for, and dynamics of, ESC-R amongst 
community onset E. coli infections in the low-prevalence settings of Australia and New Zealand by 
using a case-control methodology. Furthermore, we characterize the resistance genes and 
membership of the worldwide pandemic clone ST131 in implicated isolates.  
PATIENTS AND METHODS 
The COOEE Study (COmmunity Onset  ESBL and AmpC E. coli Study) was a multisite case-
control study, with prospective recruitment of patients and data collection.  Six geographically 
dispersed tertiary centres in Australia (n=5) and New Zealand (n=1) participated. The human 
research ethics committees at The University of Queensland and participating sites approved this 
study. 
Definitions 
E. coli was community onset where a patient was resident in the community (including nursing
homes), or hospitalized less than 48 hours at the time of onset; Expanded-spectrum
cephalosporin resistance included all ‘non-susceptible’ isolates and was identified phenotypically.
For ceftriaxone, a minimum inhibitory concentration (MIC) >1 mg/L was used. For ceftazidime,
laboratories used an MIC >1 mg/L or MIC >4 mg/L, depending on their use of EUCAST or Clinical
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and Laboratory Standards Institute (CLSI) criteria respectively[304, 305]; Site of infection was 
determined by the researcher from available information. For urinary tract infections (UTI), 
guidance was given as follows: ‘Asymptomatic’= a positive urine culture, with no attributable 
symptoms; ‘Lower tract infection’=lower urinary tract symptoms only, such as urgency, frequency 
and dysuria; ‘Upper urinary tract infection’=temperature ≥38oC, flank pain or costo-vertebral angle 
tenderness and/or any bacteremia from a urinary source. Immune Suppression referred to use at 
the time of the sample collection of corticosteroids (>15mg/day prednisolone or equivalent), 
calcineurin inhibitors, other non-biologics (e.g. mycophenylate, methotrexate), cytotoxic agents, 
biological agents or radiation therapy; Charlson co-morbidity index[306] was calculated on data 
available from the survey, with the exception of neurological impairment (dementia and 
hemiplegia) which was inadvertently omitted from the survey questioning. A McCabe score was 
assigned based on the investigator’s estimate of participant survival (<1month, 1month-2years or 
>2years)[307]. International travel (excluding travel between Australia and New Zealand) was
classified into geographical regions as follows South Pacific Islands, South East Asia, Indian
subcontinent, China, Japan, North America, Europe, Africa/Middle East. High-risk travel (regions
of Indian subcontinent, South East Asia, Africa, Middle East and China) was defined a priori based
on Australian data[47]. Healthcare exposure was assessed by the Friedman criteria[308] with two
modifications; a) day procedures were recorded b) the criteria were assessed in three ‘discrete’ time
periods (<1 month ago, 1-6 months ago and 7-12 months ago). In addition, exact dates and details
of any hospital admissions or surgical procedures were recorded and the interval (in days) from the
termination of healthcare contact to the date of first medical review with the enrolling E. coli
infection, was calculated.
Further definitions are found in Supplementary Material. 
Clinical methods 
A case-control methodology was used. Case patients with community onset ESC-R-EC in a culture 
of blood or urine were identified in the microbiology laboratory of participating hospitals. Control 
patients had community onset ESC susceptible E. coli isolated from the same specimen (urine or 
blood) as the case might be. Controls were not matched by any of clinical presentation, co-
morbidity or demographic factors. They were selected as the next appropriate patient, after an 
enrolled case patient, within the same laboratory’s specimen registration system. If the next 
appropriate control patient could not be recruited, the process was repeated at the same time-of-day 
and day-of-week, in a later week of the study. A single control was recruited for each case.  
Inclusions & exclusions 
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A laboratory specific protocol was developed by each site to identify all potentially appropriate 
patients aged ≥16 years with an isolate of ESC-R-EC managed at the participating site. Patients 
cared for by external healthcare providers such as family doctors and external clinics (utilizing the 
participating laboratories as an external provider) were not considered for recruitment, due to the 
complex human-research ethics requirements in our jurisdiction. Initial screening to determine 
likely community onset and the presence of exclusion criteria was by review of available electronic 
laboratory data and/or contact with the clinician caring for the patient. Two exclusion criteria were 
applied: 1) Inability of the patient to give informed consent to participate 2) Extra-anatomical 
urinary drainage such as indwelling urinary catheter (in the community), intermittent 
catheterisation, ileal conduit or similar. These two groups, whom local clinicians already identified 
as high-risk for resistant infection, appeared to have relatively distinct demographic and health 
profiles. Hence, they were excluded in order to focus study resources on a more generalized 
population group. 
 
Data collection 
Hospitalized patients, or those attending ambulatory clinics, were approached for recruitment and 
data collection in person, whereas the remainder were contacted by telephone. By telephone, at least 
three contact attempts on different days were made. After informed consent, including explanation 
of the aims of this study, a structured interview was conducted using a standardized data collection 
form completed by a non-blinded investigator. Data was primarily self-reported by participants. 
Where the participant was uncertain of details (e.g. dates of hospitalization or antimicrobial use) or 
the investigator was unclear from the answer provided, they were able to review patient’s medical 
records held at their institution. 
For intermittent exposures (e.g. travel, healthcare exposure, antimicrobials etc.) participants were 
asked to recall 12 months before presentation. Exact dates of exposure were recorded. If the exact 
date was not recalled it was estimated (‘start’ of month = 1st,  ‘middle’ or none specified = 15th, 
‘end’ of month = last day).  
Data was forwarded to a central co-ordinator where it was checked and entered into a secure 
database. Any omissions or discrepancies were clarified with the individual sites. 
Laboratory methods 
All phenotypic susceptibility data presented in this study has been assessed by EUCAST 
criteria[304]. All non-susceptible isolates were considered ‘resistant’ for the purpose of this 
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analysis. E. coli isolates from each patient were forwarded to the research laboratory with 
phenotypic identification and antimicrobial susceptibility undertaken by disk diffusion 
susceptibility testing (DST), automated system (VITEK2) or agar dilution, based on the criteria in 
use by the laboratory at the time. Where a susceptibility to an ancillary antimicrobial (e.g 
nitrofurantoin) was not available, this was tested by DST in the research laboratory. Where an 
isolate was originally tested by CLSI, DST using EUCAST criteria was undertaken (in the research 
laboratory), for agents where the non-susceptibility breakpoint differed between these two criteria 
(ceftazidime, cefepime, amikacin, gentamicin, ciprofloxacin and nitrofurantion). Where stated, 
MICs were performed by Etest (bioMerieux, France). For each isolate, a summative antimicrobial 
resistance score was calculated from 11 antimicrobials tested (ampicillin, amoxicillin+clavulanate, 
ceftriaxone, ceftazidime, cefepime, meropenem, trimethoprim+sulfamethoxazole (SXT), 
ciprofloxacin, nitrofurantoin, gentamicin and amikacin). 
After overnight culture, bacterial DNA was extracted using an UltraClean microbial DNA isolation 
kit (MO BIO Laboratories, USA). ESC resistance genes were investigated by PCR using previously 
published primers and conditions[194, 309, 310]. A step-wise approach based on local 
epidemiology of resistance mechanisms was employed. All isolates were investigated for blaCTX-M-1 
group and blaCTX-M-9 group genes. Isolates negative for these were investigated for blaCTX-M 
(consensus sequence), blaCMY, blaDHA, blaTEM, blaSHV and blaVEB. All isolates were screened for 
carbapenemase genes using an in-house multiplex PCR (blaNDM, blaKPC and blaIMP)[311] and a 
singleplex PCR for blaOXA-48 like enzymes[312]. All PCR amplicons were sequenced in forward and 
reverse direction using an ABI3730XL (Life Technologies, USA) capillary sequencer and 
compared to published sequences on Genebank (www.ncbi.nlm.nih.gov/genbank). 
Presumptive identification of ST131 E. coli was determined by use of semi-automated rep-PCR 
(DiversiLab, bioMerieux, France). Isolates clustering within 95% similarity to multi-locus sequence 
type (MLST) confirmed ST131 reference clones, using a Pearson correlation co-efficient, were 
considered members of this clone[235]. A random selection of isolates (n=4) were confirmed as 
ST131 by formal MLST[9] . 
Statistical methods 
Sample size was calculated with overseas travel as a risk for resistant infection. With an estimated 
annual rate of overseas travel of 250/1000 population[303], a sample size of 95 cases with matched 
controls was required to detect this risk with an odds ratio ≥2.5 (power of 0.8 and two sided alpha 
of 0.05). 
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Continuous data on healthcare exposure was right-censored at 365 days. Univariate comparison was 
undertaken by X2 squared test, Fischer’s exact, Wilcoxon ranksum and logistic regression as 
indicated. Interactions were examined. A multivariate logistic regression model was constructed 
with variables significant on univariate analysis at a p=0.2 level. Backwards selected variables were 
retained in the final logistic regression model if their significance remained below p=0.2. Models 
were assessed by calculation of a ROC and Hosmer-Lemshow goodness of fit. All statistical tests 
were two tailed, and p<0.05 was considered significant. STATA version 12.1 (Statacorp, USA) was 
used.  
RESULTS 
In total 182 patients (91 cases, 91 controls) were recruited between March 2011 and October 2012 
(Figure 1). Patients were recruited over 12 continuous months at five sites, and over nine months at 
one site. Sites contributed between 8 and 58 patients. 
Bacteremia was detected in 33 patients (18%) and isolated positive urine cultures in the remaining 
149 (82%). An uneven number of bacterememias occurred as one control patient recruited with a 
positive urine culture, subsequently manifested a positive blood culture. Patient’s residence before 
presentation, clinical syndrome of presentation, and characteristics of hospital presentation did not 
differ significantly between case and control patients (Figure 1).  
A further 43 patients with presumed community onset ESC-R-EC infection and no overt exclusion 
criteria were not recruited (declined to participate n=19, not contactable n=18, other n=6).  On 
comparison with recruited study participants, the median age (56 years, p=0.81) and gender (11/43, 
26% male, p=0.39) did not differ significantly from the recruited patients and they were not 
analyzed further. 
Close temporal matching of cases and controls was not frequent. Samples from 9 controls 
originated from the same calendar day as the matched case. For the entire cohort, there was a 
median interval of 22 days between case and control sample collection. 
Phenotype, resistance genes and ST131 
All case patients’ E. coli isolates demonstrated phenotypic ESC resistance (ceftriaxone + 
ceftazidime = 60 (68%), ceftriaxone only = 28 (32%), ceftazidime only = 3 (3%)). For the three E. 
coli with isolated ceftazidime resistance the MICs of ceftazidime in the study laboratory were; >256 
mg/L, 2 mg/L and 0.25 mg/L. All control patient isolates were susceptible to ceftriaxone and 
ceftazidime. For all antimicrobials studied, with the exception of meropenem (100% susceptible) 
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and amikacin (resistance: case=4/91, 4%, control=0/91, 0%, p=0.121), resistance was significantly 
more likely in the ESC-R than ESC susceptible (ESC-S) isolates. For ESC-R-EC there was 
significant resistance to oral therapeutic options investigated including amoxicillin+clavulanate 
(ESC-R=59/91, 65% vs. ESC-S=15/91, 16% p=<0.001), ciprofloxacin (57/91, 63% vs. 6/91, 7% 
p<0.001) and SXT (64/91, 70% vs. 20/91, 22% p<0.01). 
E. coli isolates were available for further analysis from 89 cases (98%) and 90 (99%) controls.
Carbapenemases were not detected in any isolates. Expanded-spectrum cephalosporinase genes
were detected in 87 of 89 (98%) ESC-R-EC as follows: ESBLs blaCTX-M-1 group (36/89, 40%),
blaCTX-M-9 group (35/89, 39%), blaCTX-M-1 & blaCTX-M-9 group (3/89, 3%), blaSHV-5 n=1 (1%); non-
ESBLs blaCMY-2 n=11 (12%), blaDHA-1 n=1 (1%). The two remaining isolates included two of the
three E. coli with isolated ceftazidime resistance (MICs 2 mg/L and 0.25 mg/L) and contained only
blaTEM-1, a non-expanded-spectrum beta-lactamase. ESC non-susceptibility most likely originated
from hyper-production of this enzyme, with loss of this trait during passage and storage in the case
of the lower MIC isolate.
The worldwide pandemic ST131 clone was presumptively identified in 46 patients (24%) who were 
significantly more likely to be case patients than controls (40/89, 45% vs. 6/90, 7%, p<0.001). 
Amongst ESC-R-EC, ST131 was not associated with any non-CTX-M enzymes. They constituted 
54% of the entire CTX-M group isolates. In total 24 (60%) harboured a CTX-M-1 group enzyme 
and 19 (48%) a CTX-M-9 group enzyme (p=0.173 for comparison). This included three isolates 
(8%) harbouring both enzymes. There was no significant difference in the proportion of ST131 by 
sample type (blood vs. urine p=0.514) or hospital site (p=0.574).  With the exception of the smallest 
site (where 0 of 8 were ST131), the clone constituted 19-32% of isolates from each site. 
Demographics, comorbidities and antimicrobial use 
Age was compared by visual inspection of histograms. Cases and controls had a similar bimodal 
distribution with peaks at approximately 25 and 65 years. Median and 25-75th centiles for cases and 
controls respectively were 61 (21-82) and 59 (19-87) years (p=0.769). Univariate comparison of 
demographic factors and medical co-morbidities between cases and controls is in Table 1. Male sex 
was the only variable with a significant difference (Odds Ratio (OR)= 2.3, 95% CI = 1.5-4.6, 
p=0.018). 
Risk from previous urinary tract infection, renal allograft transplant and anatomical abnormality of 
the renal tract was investigated (Table 1). The number of urinary tract infections in the previous 
year was significantly associated with ESC-R-EC with an odds ratio of 1.32 (1.08 -1.63, p=0.008) 
per infection.  
71 
Results of univariate analysis of antimicrobial use in the previous year is in Table 1. Where the 
patient could not recall the antimicrobial taken, it was recorded as ‘unknown’. Exposure to 
trimethoprim +/- sulfamethoxazole (SXT) (OR=3.02, 1.13-8.12, p=0.028) was a significant risk for 
ESC-R-EC. In addition, 7 of 7 patients who had been exposed to an expanded-spectrum 
cephalosporin (ceftriaxone, ceftazidime or cefepime) had an ESC-R-EC isolated. 
Healthcare exposure 
Healthcare exposure was analyzed using two distinct sets of data. Firstly, healthcare exposure, 
classified using Friedman criteria for healthcare associated infection, was analyzed in three time 
windows, with and without the inclusion of day procedures. Exclusion of day procedures performed 
marginally better at predicting ESC-R; exposure 0-1 month ago (OR=3.56, 1.14-11.14, p=0.029) 
and 2-6 months ago (OR=2.99, 1.50-5.98, 0.002) were associated with ESC-R-EC; whereas 
exposure 7-12 months ago (p=0.705) was not (full details are in the Supplementary Material). 
Secondly, a continuous model of the temporal risk of ESC-R-EC after healthcare exposure was 
generated using the exact time interval since last hospital admission. Day procedures were excluded 
based on the results of the first analysis. This smoothed curve of odds ratios shows the lower bound 
of the 95% confidence approaching an odds ratio of 1.0 at approximately 4-5 months (Figure 2). 
Travel, community and occupational exposure 
Travel in the previous year was analyzed by region. Travel to the Indian subcontinent approached 
but did not achieve significance (p=0.09). Birth on the Indian subcontinent was a significant risk 
(OR=6.119, 1.32-28.44, p=0.021) (Table 1). 
Occupational exposure to animals, medical patients and potential household risks were assessed, as 
was consumption of a variety of meats. No factors were significant (Table 1). Probable household 
transmission of ESC-R-EC was suggested in one case where the partner of an enrolled patient had 
an infection with a highly similar isolate (99% identical by rep-PCR using Diversilab) three months 
prior. 
Multivariate analysis 
For the multivariate model, healthcare exposure in the previous six months, excluding day-
procedures, was selected as a pragmatic option (univariate OR=2.95, 1.59-5.46, p=0.001). This 
dichotomous measure was non-significantly different to the four-categories measurement used 
earlier (likelihood ratio test p=0.821). Travel to high-risk regions was selected from the travel group 
(OR 1.97, 0.94-4.11, p=0.071). Use of an expanded spectrum cephalosporin was combined with use 
of trimethoprim or SXT in order to enter the former into the model, given its accepted prominence 
as a risk factor for ESC-R-EC.  
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Significant variables on multivariate analysis were healthcare exposure, excluding day-procedures 
in the previous six months (p=0.002), birth on the Indian subcontinent (p=0.004), travel to high-risk 
regions (p=0.011), SXT/ESC use (p=0.014) and number UTIs in the previous year (p=0.003) (Table 
2). Assessment of the final model demonstrated an area under the ROC curve of 0.77, and a non-
significant Hosmer-Lemshow goodness of fit (p=0.289). 
Interactions and alternative models 
A significant correlation occurred between travel to high-risk regions and region of birth. Those 
born in high-risk regions were more likely to undertake high-risk travel than those born elsewhere 
(17/28, 61% vs. 21/154, 14%, p<0.001). This was particularly noted for birth and travel to the 
Indian subcontinent (7/13, 54% vs. 31/169, 18%, p=0.002). This correlation, and the use of 
differing parameters for healthcare contact and antimicrobial exposure are explored in alternative 
multivariate models (Supplementary Material). Specific population subgroups were also trialled in 
the model (symptomatic patients only, ESC-R blaCTX-M only and ESC-R ST131 only). None 
performed better than the final model, although the significance of healthcare exposure, male sex 
and region of birth/travel varied, depending on the model parameters selected. 
Healthcare associated and non-healthcare associated ESC-R-EC 
A difference in risk between healthcare associated (HA) ESC-R-EC and non-healthcare associated 
(non-HA) ESC-R-EC was investigated by analysis of risks within the healthcare associated (n=73) 
and non-healthcare associated (n=109) cohorts separately (full details are in Supplementary 
Material). Several of the identified risks for ESC-R-EC appeared to be most concentrated in one 
cohort. Travel to high risk regions (p=0.001), birth on the Indian sub-continent (p=0.006) and male 
sex (p=0.018) were only significant amongst the non-HA group. Conversely, a risk from SXT/ESC 
use was significant only in the HA group (p=0.026). The number of UTI’s in the previous year was 
non-significantly different amongst either group separately.  
Correlates of ESC resistance enzymes class 
Correlates of ESC resistance enzyme class were investigated by comparison of patients harbouring 
E. coli with CTX-M group enzyme and other enzymes (‘non-CTX-M’=CMY, DHA, SHV, TEM).
Full details are contained in Supplementary Material.
There was no significant difference in the site of infection between CTX-M and non-CTX-M 
harbouring participants (p=0.473), and although bacteremia was more frequent in the CTX-M 
group, this did not reach statistical significance (13/74, 18% vs. 0/15, 0% p=0.114). A significantly 
higher median resistance score was present in CTX-M compared with non-CTX-M isolates 
(median=6, IQR=5-7 vs. 4, 4-5, p=0.001). Notable differences included higher rates of resistance 
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amongst the CTX-M group to the non-beta-lactam oral agents ciprofloxacin (56/74, 76% vs. 1/15, 
7%, p<0.001) and SXT (60/74, 81% vs. 4/15, 27% p <0.001).  
In regard to potential risk factors, the CTX-M group was significantly more likely to have 
healthcare exposure in the previous six months than the non-CTX-M group (45/74, 61%, vs. 3/15, 
20%, p=0.005), although not in the previous 12 months (p=0.72). Other factors used in the 
multivariate model, trended towards significance amongst the CTX-M group, included more high-
risk travel (p=0.052) and fewer reported UTIs in the previous 12 months (p=0.054). On comparison 
of factors not included in the multivariate model, ‘any overseas travel’ was more likely in the CTX-
M group (27/74, 36% vs. 1/15 7%, p=0.033). 
 
DISCUSSION  
This multicentre prospective case-control study of community onset ESC-R-EC has several key 
findings that have implications for risk based empiric antibiotic prescribing, infection control 
practices and control of ESC-R-EC within communities. 
Firstly, we established that 6 months is a practical, evidence-based definition for the duration of 
increased risk of a community onset E. coli isolate harbouring ESC-R after healthcare exposure. 
The time-dependent relationship of healthcare exposure and resistance seem intuitive in nature, 
however previously there has been little supporting data; hence, authors have used a variety of 
definitions from 1-6 months[294, 313, 314].  
Overall, the significant contribution of healthcare exposure (OR=3.15) as an ongoing ‘exporter’ of 
resistant infection in a low-prevalence setting highlights the importance of controlling ESC 
resistance in the healthcare system. Supporting this hypothesis, United Kingdom data has recently 
demonstrated a broad-based decrease in the rate of ESC resistance amongst invasive 
Enterobacteriaceae following a reduction in ESC and fluorquinolones use within the hospital 
system[315]. 
The recognition of ‘importation’ of ESC-R-EC after travel to countries with a high community 
incidence of ESBLs is starting to be defined[316], although fewer studies have identified infection 
rather than carriage[27, 294, 317]. Whilst the pathophysiology seems clear, the temporality of this 
remains to be confirmed. In our study, analysis of temporality, as presented for healthcare exposure, 
was precluded by the imprecision of the composite ‘high-risk’ group and the small numbers 
involved. However, in absolute terms, 21 of 24 (87.5%) case participants with travel to high-risk 
regions departed these regions within the six months before presentation of infection. This fits with 
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our previous research demonstrating mostly short lived carriage of ESBL E. coli following travel 
overseas and other studies demonstrating a decrease in the risk of resistant infection beyond six 
weeks after return from travel[317, 318]. 
Investigation of risks for community acquisition in the low prevalence countries of Australia and 
New Zealand showed that one quarter (n=23) of ESC-R-EC patients reported neither healthcare 
exposure nor high-risk travel, suggesting there are as yet undefined risk factors for transmission 
within the community[294, 319]. 
Whilst there was some correlation between birth and travel regions, the identification of birth on the 
Indian subcontinent (OR=11.12) as a risk for ESC-R-EC in our cohort appears genuine. The 
etiology of this risk could stem from prolonged carriage of ESC-R-EC after travel more than one 
year previous, leading to delayed community onset ESC-R-EC infection. Alternatively, our 
observation of a mostly short interval between travel and infection, supports the possibility of 
domestic (within Australia and New Zealand) transmission of this resistance. Transmission of ESC-
R-EC may occur from others within the household or community who have had recent travel to the 
Indian subcontinent. Although the true magnitude of risk and the broader applicability require 
further study, this observation is consistent with a previously published study from one of our 
participating sites and other descriptions of household transmission[55, 94]. Recently, ‘birth outside 
of Europe’ was identified as a risk for CTX-M producing E. coli in another study, although 
comparison with our data is complicated, as the European study did not fully account for recent 
travel[319]. 
Our molecular epidemiology data serves to confirm a number of key observations made in other 
regions. The first is a distinct difference in the epidemiology of CTX-M ESBLs and other 
expanded-spectrum cephalosporinase enzymes, which may be mediated by differing modes of 
acquisition, phenotype and characteristics of the E. coli strains harbouring them[194, 320]. Second, 
the high proportion of ST131 amongst ESBLs is no surprise given its global prevalence[165]. More 
surprising is its predominance without significant fluoroquinolone use (<6% of all participants in 
this study), one of the likely drivers in other regions[321]. Exposure to this class of antimicrobials 
within Australia and New Zealand is very low[299]. 
Male sex has been defined as a risk for community onset ESC-R-EC by other researchers[3, 25, 
182, 313, 322] and became significant in some of our alternative models. The patient population of 
studies with this finding gives a clue to the etiology of this risk. On the whole, they are of older age 
with frequent healthcare exposure. This contrasts with studies containing a more traditional UTI 
population of young females that do not identify male sex as a risk[27, 317]. In addition to males 
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experiencing an age dependent rise in overall rates of E. coli infection[23], a limitation of case-
control studies may also contribute to this finding. Aging patients certainly experience changes in 
nuances and dynamics of healthcare exposure and other potential risk factors for ESC-R-EC not 
identified with dichotomous measures such as hospitalization and antimicrobial use that are most 
often collected. 
The strengths of our study include its prospective collaborative nature, a geographically broad 
sample and the case-control methodology used. The low background rates of ESC-R-EC in 
Australia and New Zealand have likely led to more discrete exposures and easier delineation of 
temporal risks than in communities where participants are frequently exposed to this form of 
resistance. 
Limitations of our study include the moderate sample size, rate of non-recruitment; and risk of bias 
due to an absence of investigator or patient blinding and reliance on patient recall for many 
exposures. Other than the demographic details presented we have not been able to assess any 
factors that may have influenced recruitment vs. non-recruitment and subsequently biased the 
results. Recruiting a higher ratio of controls (1:2 or 1:3) would have increased our study power, and 
may have delineated further unidentified risks. The use of a third group of uninfected patients (a 
case-case-control design), would have allowed for delineation of risk factors associated with de 
novo acquisition of ESC-R E. coli, as opposed to delineation of risk factors for ESC-R within those 
that have E. coli[323]. However, pragmatic limitations precluded these options. 
Some unique features of Australia and New Zealand may limit extrapolation of our findings to other 
regions. The exclusion of day-procedures in this study’s definition of healthcare exposure, 
correlated with our local epidemiology, and would need to be reconsidered elsewhere. Furthermore, 
if blaCTX-M was not the predominant ESC resistance mechanism in a local population, risk may 
differ. 
The use of only hospital patients for recruitment allowed consistent access to participants and 
samples, although it may limit the applicability of some risks to the wider community. The 
exclusion of patients unable to consent meant that we could not define risks for patients in long-
term care facilities, a known reservoir of ESBL E. coli in Australia and overseas[48, 261, 263].  
In conclusion, we have defined a critical risk-period ESC-R amongst community onset E. coli after 
healthcare exposure, and demonstrated that ESC-R E. coli infection in a low-prevalence setting may 
be driven by ‘export’ from healthcare exposure in the previous six months and ‘importation’ after 
travel to regions with a high incidence of community ESBLs.  
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FIGURES AND TABLES 
Table 1 
Univariate analysis of demographics, comorbidities, antimicrobial use, region of travel and birth, 
occupational and household exposure. 
Variable Frequency in 
ESC-R Cases 
(%) n=91 
Frequency in 
ESC-S 
Controls (%) 
n=91 
Odds 
Ratio 
(95% CI) p value 
Demographics & co-morbidities 
Male sex 30 (33) 16(18) 2.31 (1.51-4.62) 0.018* 
Age <30 or >59 years 66 (73) 60 (66) 1.36 (0.72-2.57) 0.336 
Immune suppression 19(20) 10(11) 1.99 (0.87-4.60) 0.105* 
Charlson score ≥1 44(48) 34(37) 1.57 (0.87-2.83) 0.135* 
Active malignancy 11(13) 9(8) 1.43 (0.55-3.73) 0.469 
Renal failure 11(13) 9(10) 1.25 (0.49-3.19) 0.636 
McCabe score ≥ 2+ 78 (86) 76(84) 1.18 (0.53-2.65) 0.681 
Indigenous 7(8) 6(7) 1.18 (0.38-3.66) 0.774 
Heart disease 7(8) 7(8) 1 
Long term care facility resident 1 (1) 1(1) 1 
Smoker 12(13) 14 (15) 0.83 (0.36-1.92) 0.672 
Liver disease 3(3) 4(4) 0.74 (0.16-3.41) 0.701 
Lung disease 5(5) 7(8) 0.70 (0.21-2.85) 0.552 
Pregnant or post-partum 3(3) 7(8) 0.41 (0.10-1.63) 0.206 
Renal Tract Background 
Renal transplant 8(9) 4(4) 2.1 (0.61-7.22) 0.241 
Anatomical or structural abnormality 23(25) 15(16) 1.71 (0.83-3.55) 0.147* 
UTIs in past 12 months (per UTI)**  Median = 1 
(IQR = 0-3) 
Median = 0 
(IQR = 0-1) 
1.32 (1.08-1.63) 0.008* 
UTIs in lifetime (per UTI)** Median = 2 
(25-75% = 0-5) 
Median = 2 
(25-75% = 0-5) 
1.03 (0.90-1.18) 0.657 
Healthcare Exposure 
Any healthcare exposure in the past 6 months 56(61) 37(41) 2.33 (1.29-4.23) 0.005 
Antimicrobial use 
Any antimicrobials in past 12 months 69(76) 62(68) 1.47 (0.76-2.81) 0.249 
Trimethoprim+/- sulfamethoxazole 16(17.58) 6(6.59) 3.022 (1.13-8.12) 0.028* 
Expanded-spectrum cephalosporins 7 (8) 0 NA 0.014* 
Fluoroquinolones 7(8) 3 (3) 2.44 (0.61-9.77) 0.206 
ß-lactam + ß-lactamase inhibitor 16(17.58) 11(12.09) 1.552 (0.68-3.56) 0.300 
Carbapenems 3(3.3) 2(2.2) 1.517 (0.25-9.30) 0.652 
Aminoglycosides 5(5) 4(4) 1.26 (0.33-4.87) 0.733 
Macrolide 6(6.59) 5(5.49 1.214 (0.36-4.13) 0.756 
‘Unknown’ antimicrobials 35(38) 33(36) 1.1 (0.60-2.00) 0.759 
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Narrow spectrum cephalosporins 16(17.58) 15(16.48) 1.081 (0.50-2.34) 0.844 
Narrow spectrum penicillins  10(10.99) 14(15.38) 0.679 (0.28-1.62) 0.383 
Travel by region 
Any overseas travel 28 (30.8) 22 (24.18) 1.39 (0.72-2.68) 0.32 
High risk regions 9 24 (26) 14(15) 1.97 (0.94-4.11) 0.071* 
Indian Subcontinent1 6(6.59) 1(1.1) 6.928 (0.75-53.87) 0.09 
North America 2 5(5.49) 2(2.20) 2.199 (0.49-13.69) 0.264 
Africa+ Mid East 3 3(3.3) 2 (2.2) 1.517 (0.25-9.30) 0.652 
South East Asia 4 15(16) 13(14) 1.18 (0.53-2.65) 0.681 
South Pacific 5 3(3.30) 3(3.30) 1 
Europe 6 3(3.30) 5(5.49) 0.586 (0.14-2.53) 0.474 
China 7 4(4.4) 0 0.121 
Japan8 1(1.1) 0 0.500 
Birth by regiona 
High risk regions 18(20) 10 (11) 2.0 (0.87-4.60) 0.105 
Indian Subcontinent 11(13) 2(2) 6.12 (1.32-28.45) 0.021* 
Australia + New Zealand 58 (64) 59(65) 0.95 (0.52-1.75) 0.877 
Europe  15(16) 18(20) 0.80 (0.38-1.71) 0.564 
South East Asia  3(3) 4(4) 0.74 (0.16-3.41) 0.701 
Africa+ Mid East  2(2) 4(4) 0.49 (0.09-2.74) 0.415 
China 2(2) 0 0.497 
South Pacific  0 3(3) 0.246 
Latin America 0 1(1) 1.0 
Occupation and household exposure 
Partner with recent ESC-R-EC infection 2 (2) Not assessed 
Occupational healthcare exposure 10 (11) 7 (8) 1.48 (0.54-4.08) 0.447 
Pet cat/dog at home 32(35) 33(36) 0.95 (0.52-1.75) 0.877 
Occupational animal exposure 4 (4) 5 (5) 0.79 (0.21-3.05) 0.733 
Pre-schoolers at home (<5yo) 7(8) 9 (10) 0.76 (0.27-2.13) 0.601 
Food consumption 
Any meat in past 12 months 89 (98) 87 (98) 2.05 (0.37-11.46) 0.415 
Poultry 88 (97) 83 (92) 2.47 (0.62-9.89) 0.206 
Processed/ preserved meats 51 (56) 52 (58) 0.93 (0.52-1.68) 0.814 
Pork 60 (66) 63(70) 0.83 (0.44-1.55) 0.558 
Red meat 76 (84) 78 (88) 0.72 (0.31-1.66) 0.433 
*Entered into multivariate model
**Infections were recorded numerically 0-5+, with all 5+ results considered 5 for analysis. Summaries presented as median. 
A. Destinations of travel by region were 1. India, Pakistan, Nepal, Bangladesh 2. USA, Canada 3. Zimbabwe, Kenya, Sudan, Liberia, Turkey, Afghanistan 4. Malaysia, Singapore, Thailand, Laos, 
Cambodia, Vietnam, Burma, Indonesia and The Philippines 5. New Caledonia, PNG, Fiji, Samoa, Cook Islands and boat cruises through the South Pacific 6. UK, Italy, Holland, Portugal, Poland. 7. 
China, Hong Kong, Macau 8. Japan 9. High risk regions include the Indian subcontinent, Africa, the Middle East, South East Asia and China regions. 
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Table 2 
Multivariate logistic regression 
Variable Odds Ratio (95% CI) p value 
Healthcare exposure in the previous 6 months 3.16 (1.54-6.46) 0.002 
UTIs in previous year  (per UTI) 1.43 (1.16-1.82) 0.003 
Birth on the Indian subcontinent 11.13 (2.17-56.96) 0.004 
Travel to high-risk regions 3.09 (1.29-7.38) 0.011 
Trimethoprim +/- Sulfamethoxazole  &/or ESC use 3.67 (1.30-10.35) 0.014 
Male sex 2.17 (0.97-4.84) 0.060 
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Figure 1  
Participant identification, recruitment and characteristics of presentation and clinical syndrome. 
Figure 2. 
The risk of ESC-R-EC over a 12-month period after the most-recent episode of healthcare exposure, 
excluding day procedures, estimated with two data sets. 1) Smoothed curve calculated using 
continuous data on months since hospital admission (black line, 95% CI in grey) 2) Discrete 
intervals using Friedman criteria (black dots, 95% CI as vertical dashes). The dashed line represents 
no increased risk (Odds Ratio=1.0)   
134!pa$ents!with!ESC!resistant!E.#coli!in!
blood!or!urine!iden$fied!for!poten$al!
recruitment.!
91!CASES!Recruited!
• 14!=!bacteremia!(15%)!
• 77!=!urine!only!(85%)!
43!pa$ents!NOT!recruited.!
• 19!declined!to!par$cipate!(44%)!!
• 18!not!contactable!(42%)!!
• 6!!other!reasons!(14%)!!
91,CONTROLS,recruited!
• 15!=!bacteremia!(16%)!
• 76!=!urine!only!(84%)!
Residence,at,7me,of,presenta7on,(n=182),
• 170!–!Private!dwelling!(93%)!
• 5!–!Shared!accommoda$on!e.g.!boarding!house!(3%!)!!
• 5!–!Assisted!living!!(3%)!!
• 2=!Long!term!care!facility!(1%)!!Comparison!of!cases!and!controls!p=0.549!!
First,healthcare,provider,for,this,presenta7on,(n=182),
• 100!=!emergency!department!–!enrolling!hospital!(55%)!
• 30!=!outpa$ent!clinic!–!enrolling!hospital!(16%!)!!
• 34!=!family!doctor!(19%)!!
• 18!=!other!loca$ons!(10%)!!Comparison!of!cases!and!controls!p=0.553!!
Case=!Clinical!syndrome*!
• 40!Lower!urinary!tract!
• 26!Upper!urinary!tract!
• 18!Asymptoma$c!urine!
• 3!Prosta$$s!
• 4!Other!
Control=!Clinical!syndrome*!
• 34!Lower!urinary!tract!
• 24!Upper!urinary!tract!
• 23!Asymptoma$c!urine!
• 2!Prosta$$s!
• 8!Other!*p=0.81!for!comparison!of!syndrome!
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CHAPTER 4. MOLECULAR EPIDEMIOLOGY OF COMMUNITY 
ONSET ESCHERICHIA COLI INFECTION 
INTRODUCTION 
The combination of bacterial isolates and extensive prospectively collected epidemiological data 
afforded by the design of the case-control study presented in Chapter 3, provides a unique 
opportunity to explore the molecular epidemiology of E. coli infections in our region. Whilst local 
researchers have investigated a variety of aspects of the molecular epidemiology ESC-R-EC, there 
is less data on the molecular epidemiology of other phenotypes of E. coli.[50, 55, 203] Furthermore, 
as defined in Chapter 3, the distribution of ST131 in our region differs from that in other areas, 
suggesting the clonal structure of E. coli infections in general may also differ from those discussed 
in recently published North American and European works.[191, 262, 264, 283] 
Insight into the overall clonal structure of community onset E. coli infections is also important for 
contextualising risk factors identified in Chapter 3. Relating the difference in clonal structure of 
3GCS-EC and 3GCR-EC to epidemiological features gives insight into potential drivers of the 
spread of resistance. Furthermore, a key tenet of any plan to target patient groups with high rates of 
3GCR-EC, or specific risk factors for 3GCR-EC, would be determining if the pathogenic isolates 
represent clonal spread or diverse strains. 
Many techniques for characterisation of the molecular epidemiology of clinical bacterial isolates 
have been described.[324] We utilised a hybrid of three techniques in order to achieve a resolution 
optimal for our study aims, whilst minimising cost and workload. All isolates underwent semi-
automated rep-PCR, which is a validated technique for delineating bacterial relatedness at a clinical 
level.[325] This technique relies on amplification of short conserved repetitive extragenic 
palindromic ‘rep’ regions of DNA in Enterobacteriaceae.[326]  
One limitation, originating from the proprietary nature of the DiversiLab re-PCR platform used, is a 
lack of generalisability or comparability to other collections and publications. To overcome this 
limitation, we used MLST to relate clusters identified on rep-PCR to broader global data. The 95% 
cut-off selected for this analysis was based upon a previous publication comparing these two 
techniques.[235, 327] Within the ST131 clonal group, which is not otherwise subtyped by rep-PCR, 
we used characterisation of the fimH gene to subtype isolates. The basis for this typing method was 
discussed in Chapter 2. 
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The case-control design of our study provided delineation of molecular epidemiology within ESC-
R-EC and ESC susceptible E. coli groups. However, overall population rates or burdens of each 
clone could not be directly calculated due to the epidemiologically ‘unbalanced’ proportion of 
resistant isolates in the sample. To overcome this, we used external data to adjust for the relative 
prevalence of ESCR and ESC susceptible E. coli within our overall study population (community-
onset E. coli infection). This back-calculation is based upon rates of 3GCR-EC identified in the 
AGAR 2010 community onset E. coli survey. Importantly, the AGAR survey population 
geographically and temporally mirrors our study population. Supporting this similarity, the 
distribution of ESBL genes identified, and resistance rates to a variety of antimicrobials, closely 
match those found in our study.[44] In undertaking this analysis, we are cognisant of the limits of 
data we can infer given the overall sample size. In particular, we were only able to analyse the data 
for the whole of Australia, rather than by state or region. In addition any selection bias (as discussed 
in chapter 2) may have had an unforseen impact on our results. 
Hence, we aimed to take the epidemiological data from the case-control study (Chapter 3), in 
concert with analysis of bacterial isolates, to gain further insight into the molecular epidemiology of 
E. coli infection in our region and globally. 
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ABSTRACT 
Background 
The clonal composition of Escherichia coli causing extra-intestinal infections includes ST131 and 
other common uropathogenic clones. Drivers for the spread of these clones and risks for their 
acquisition have been difficult to define. 
Methods 
We combined molecular epidemiology with clinical data from 182 patients enrolled in a case-
control study of community onset expanded-spectrum cephalosporin resistant E. coli (ESC-R-EC) 
in Australia and New Zealand. Genetic analysis included antimicrobial resistance mechanisms, 
clonality by DiversiLab (rep-PCR) and multilocus sequence typing (MLST), and subtyping of 
ST131 by identification of polymorphisms in the fimH gene. 
Results 
The clonal composition of expanded-spectrum cephalosporin susceptible and ESC-R-EC isolates 
differed, with six MLST clusters in susceptible isolates (median=7 isolates/cluster), and three 
clusters amongst ESC-R-EC, including 40 (40/89, 45%) ST131 isolates.  
Population estimates indicate ST131 comprises 8% (7.6-8.3%) of all E. coli within our population. 
The fluoroquinolone susceptible H41 sub-clone comprised 4.5% and the H30 sub-clone 3.5% of E. 
coli. The H30 sub-clone comprised 39% of all ESC-R-EC and 41% of all fluoroquinolone resistant 
E. coli, within our population. Patients with ST131 were also more likely than non-ST131 to
present with an upper than lower urinary tract infection (RR 1.8, 95%CI 1.01-3.1).
Conclusion 
ST131 and the H30 sub-clone were predominant amongst ESC-R-EC but infrequent among 
susceptible isolates where the H41 sub-clone was more prevalent. Within our population, the 
proportional contribution of ST131 to fluoroquinolone resistance is comparable to that of other 
regions. In contrast, the overall burden of ST131 is low by global standards. 
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INTRODUCTION 
Using contemporary molecular typing techniques, a broad picture of the genetic diversity of 
Escherichia coli causing urinary tract and other invasive infections is beginning to emerge. Recent 
studies have demonstrated that collections of E. coli from urine and blood are largely clonal in 
composition[191, 262, 264, 283]. These clonal components invariably include the global pandemic 
clone, Sequence Type 131 (ST131) E. coli, and other frequently described uropathogenic E. coli 
(e.g. ST95, ST69, ST127). ST131 E. coli has been implicated as a major contributor to 
fluoroquinolone resistant and expanded-spectrum cephalosporin resistant E. coli (ESC-R-EC) 
infections globally[165]. 
Clinical and epidemiological risk factors for colonisation or infection with these clones, in 
particular ST131, have been difficult to define. Recently identified risk factors for ST131 include 
long term care facility (LTCF) residence or bedridden status[263, 282, 286], exposure to 
antimicrobials[263], ethnicity[328], female sex[286] and infection characteristics[263, 270]. 
In our region, a range of ST131 clones have been identified amongst animals and humans, from a 
variety of patient groups[46, 83, 203, 204, 290, 292]. Few facets of epidemiology have been 
investigated, with one study reporting no difference between the co-morbidities of patients infected 
with ST131 and non-ST131 E. coli after prostate biopsy[82], and another demonstrating some 
possible sharing of ST131 clones between human and companion animals[291]. There have been no 
population estimates of prevalence. 
We previously described risk factors for community onset expanded-spectrum cephalosporin 
resistant E. coli (ESC-R-EC) in Australia and New Zealand. These risk factors included healthcare 
contact, travel to high-risk regions (Indian subcontinent, South East Asia (SE Asia), China, Africa 
and the Middle East), trimethoprim +/- sulphamethoxazole use (SXT) and/or expanded-spectrum 
cephalosporin use (ceftriaxone, ceftazidime or cefepime), UTIs in the previous year, and birth on 
the Indian subcontinent. We also demonstrated that ST131 E. coli was spread broadly in our region, 
although with a relatively uncommon distribution. It resided almost exclusively amongst ESC-R-
EC where the prevalence was 45%, compared to 7% amongst ESC susceptible E. coli (ESC-S-EC) 
isolates. In addition there was a non-significant difference in the proportion containing blaCTX-M-9
group and blaCTX-M-1 group enzymes[329]. 
In this follow-up study we aim to define the clonal composition and molecular characteristics of 
community onset expanded-spectrum cephalosporin susceptible and resistant E. coli infections. 
Furthermore, we aim to understand the sub-clonality of ST131 and elucidate factors that may 
influence the distribution of the ST131 world-wide pandemic in our region. To do this we have 
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combined epidemiological data, collected as part of our case-control study, with genetic 
characterisation of E. coli isolates from the study patients. 
MATERIALS AND METHODS 
Clinical data and bacterial isolates 
All bacterial isolates and clinical data are from The COOEE Study (COmmunity Onset ESBL and 
AmpC E. coli Study), a multisite case-control study, with prospective recruitment of patients and 
data collection. It is described in detail elsewhere[329]. In brief, six geographically dispersed 
tertiary centres in Australia (n=5) and New Zealand (n=1) recruited patients over a 9-12 month 
period during 2011 and 2012. In total, 182 patients (91 ESC-R-EC cases, 91 ESC-S-EC controls) 
were recruited. Bacterial isolates were recovered from 98% (179/182) of patients.  
Definitions 
Definitions have been described extensively elsewhere[329]. In brief, Case patients had community 
onset ESC-R-EC in a culture of blood or urine. Control patients had ESC-S-EC isolated, and were 
selected from the same laboratory as the ‘case’ patients. Patients who were unable to give informed 
consent to participate or who had extra-anatomical urinary drainage (e.g. indwelling urinary 
catheter (in the community), intermittent catheterisation, (ileal conduit or similar) were excluded 
from recruitment 
E. coli was community onset where a patient was resident in the community (including long-term
care facility) or hospitalized less than 48 hours at the time of onset; Expanded-spectrum
cephalosporin resistance was identified phenotypically. For ceftriaxone, a susceptibility
breakpoint of >1 mg/L was used. For ceftazidime, laboratories used a breakpoint of MIC >1 mg/L
or MIC >4 mg/l depending on their use of EUCAST or Clinical and Laboratory Standards Institute
(CLSI) criteria respectively[304, 305]. Site of infection was determined by the researcher from
available information. Urinary tract presentations were classified as ‘Asymptomatic’, ‘Lower tract
infection’ or ‘Upper urinary tract infection’ as defined previously[329]. All other infections (non-
urinary source and prostatitis) were classified into a combined ‘Other’ group.
The human research ethics committees at The University of Queensland and participating sites 
approved this study. 
Antimicrobial susceptibility phenotype 
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As described previously, all phenotypic data presented has been assessed by EUCAST criteria[304, 
329]. All non-susceptible isolates were considered resistant for the purpose of this analysis. An 
aggregated resistance score (0-11) was calculated with all antimicrobial phenotypes included in the 
study (ampicillin, amoxicillin+clavulanate, ceftriaxone, ceftazidime, cefepime, meropenem 
trimethoprim+sulfamethoxazole, ciprofloxacin, nitrofurantoin, gentamicin and amikacin). 
Molecular methods 
Bacterial isolates were recovered from storage at -80oC in the research laboratory. After overnight 
culture, bacterial DNA was extracted using an UltraClean microbial DNA isolation kit (MO BIO 
Laboratories, USA). As outlined previously, ESC resistance genes were investigated by PCR using 
published primers and conditions. 
Phylogenetic group was determined by multiplex PCR[230]. Semi-automated rep-PCR using a 
DiversiLab (bioMerieux, France) was undertaken as per the manufacturer’s instructions. 
Dendrograms were constructed from rep-PCR patterns using a Pearson correlation coefficient 
(DiversiLab 3.4 software). All clusters with ≥ 4 isolates demonstrating ≥ 95% similarity[327] were 
then identified by MLST[9] as follows: The two most distant isolates within each cluster underwent 
MLST typing. Where multiple isolates were equally distant, isolates were selected to maximize the 
diversity in geographical origin and phenotype. If isolates from a rep-PCR cluster were discordant 
by MLST, additional isolates underwent MLST to attempt to define the cluster. The worldwide 
pandemic clone, ST131 E. coli, was presumptively identified using the same approach and 95% cut-
off, although a number of MLST confirmed ST131 reference clones were also included in the 
dendrogram[235]. Typing of the fimH allele encoding the type 1 fimbrial adhesin was undertaken in 
ST131 isolates. The gene was sequenced in forward and reverse direction based on published 
primers and conditions[330] using an ABI3730XL (Life Technologies, USA) capillary sequencer. 
Amino acid substitutions up to the 265th position of the putative mature peptide sequence were 
classified as per the schema of Weissman[40]. 
Calculation of whole-population estimates 
Estimates of population prevalence of MLST defined clones were back-calculated by adjusting to 
an overall population prevalence of 3.4% ESC-R-EC, as measured in the 2010 Australian Group on 
Antimicrobial Resistance (AGAR) outpatient survey[44]. The survey sampled a population very 
similar to that of our study: outpatient urine samples from 30 hospital-based laboratories, including 
from 4 of 6 sites in our study. Estimates are provided with a range assuming a possible 50% 
difference in population ESC-R-EC rates from the AGAR survey (i.e. 3.4%, range 2.6 - 4.25%). 
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Statistical methods 
Variables were compared using X2 squared test, Fischer’s Exact, Wilcoxon Rank Sum and 
calculation of relative risks (RR) where appropriate. Continuous data is presented as a median and 
25-75th centile.
Statistical tests were two tailed, and p<0.05 was considered significant. STATA version 12.1 
(Statacorp, USA) was used. 
RESULTS 
In total, 179 bacterial isolate were included in this study (89 ESC-R, 90 ESC-S). Bacteremia was 
detected in 29(16%) patients with the remainder having isolated urine cultures. All isolates were 
community onset, including 2/179 (1%) originating from residents of long-term care facilities. 
Expanded-spectrum cephalosporin resistance genes were present amongst 87/89 (98%) of the 
available ESC-R isolates (36/89, 40% blaCTX-M-1 group; 35/89, 39% blaCTX-M-9 group; 3/89, 3% 
blaCTX-M-1 & blaCTX-M-9 groups; 11/89, 12% blaCMY-2; 1/89 1% blaDHA-1; 1/89 1% blaSHV-5)[329]. 
Phylogenetic group 
Phylogenetic grouping showed a high proportion of pathogenic B2 and D group E. coli (Table 1). 
The clinical syndrome varied significantly for each phylogroup, however, when comparison was 
limited to lower and upper urinary tract infections (the two categories which constituted the vast 
majority of presentations) only B2 isolates demonstrated a significant risk for upper rather than 
lower urinary tract infection (RR=2.3, 95% CI=1.2-4.0). The other phylogroups, A/B1 and D 
demonstrated a non-significant risk, favouring lower tract infection (p=0.083 and p=0.093). There 
was no significant difference in phylogenetic group, comparing urine and bacteraemia isolates 
(p=0.820). 
Multilocus sequence typing 
A dendrogram was constructed for ESC-S-EC (Figure 1), ESC-R-EC (Figure 2) and all isolates 
combined (not shown). There was no obvious geographical or temporal clustering. Twenty-nine 
isolates underwent full MLST. In total, nine clusters comprising 60% (108/179) of all isolates were 
related to six MLSTs (ST131, ST95, ST73, ST69, ST127, ST80) and two clonal complexes sharing 
6 of 7 alleles (ST14 complex, ST648 complex). Whilst the proportion of clonal isolates between 
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ESC-R-EC and ESC-S-EC groups was similar (56/89, 63% vs. 52/90, 58% p=0.482), there was a 
marked difference in the composition of Sequence Types (STs). Amongst ESC-S-EC, six MLST 
defined clusters each contained 5-13 isolates (median=7 isolates). Within the ESC-R-EC, only three 
clusters were identified with a single cluster, ST131, containing 40 isolates.  
ST131 and fimH typing 
As reported previously, 46/189 (24%) isolates clustered within the ST131 worldwide pandemic 
clone, including 40/89 (45%) ESC-R-EC and 6/90 (7%) ESC-S-EC (p<0.001). All ESC-R-EC 
ST131 harboured CTX-M enzymes, and constituted 54% of the entire CTX-M group; 24 (60%) 
harboured a CTX-M-1 group enzyme and 19 (48%) a CTX-M-9 group enzyme (p=0.173 for 
comparison). This included three isolates (8%) harbouring both enzymes. Amongst the 34 non-
ST131 CTX-M harbouring isolates, 19 (56%) were CTX-M-9 group and 15 (44%) CTX-M-1 group 
(p=0.472). 
The fimH gene was typed as fimH 30 (H30) in 37 (80%) ST131 isolates, with the remaining 9(20%) 
typing as fimH 41 (H41) indicating a consensus FimH peptide sequence. By rep-PCR, H41 ST131 
isolates formed distinct clusters within ST131, which branched at approximately 97% similarity 
from the majority of H30 isolates (Supplementary Material). 
There was a significant difference in the rate of ESC resistance between H30 and H41 isolates (H30 
35/37, 95% ESC-R vs. H41 4/9, 44% p=0.009) and concordance between H30 and fluoroquinolone 
resistance was 100% (H30=37/37, 100% ciprofloxacin resistant, H41=0/9, 0% ciprofloxacin 
resistant).  
With the exception of the smallest site, which had no patients with ST131 and small numbers 
overall (n=8), the clone and the H30 sub-clone were present in all sites (Figure 3). There was no 
significant difference in the proportion of ST131 (p=0.574) or H30 (p=0.774) across study sites. 
Clonal prevalence estimates 
When adjusted for the population rate of ESC-R-EC, the (estimated) most prevalent MLST clones 
in our study population were ST95 (14%, 13.9-14.1%), ST73 (13%, 12.8-13%), ST14 complex 
(9%, 8.6-8.7%) and ST131 (8%, 7.6-8.3%) (Figure 4 and Supplementary Material). 
Within ST131 the H41 sub-clone comprised 4.5% (4.5-4.5%) and the H30 sub-clone 3.5% (3.2-
3.8%) of all E. coli in the population. The ciprofloxacin resistant H30 sub-clone constituted 41% of 
all ciprofloxacin resistant community onset E. coli isolates. In total ESC-S ST131 constituted 6.4% 
(6.4-6.5%) of community onset E. coli isolates. (Supplementary Material) 
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Characteristics of ST131 
Comparison of site of infection for various clonal groups is in Table 2. This demonstrated ST131 
clones were significantly more likely to cause upper than lower urinary tract infection (ST131, 
19/35 54% upper vs. non-ST131 30/87 34% upper, Relative Risk=1.8, p=0.04) (Table 1). When 
compared only to other phylogroup B2 isolates (n=57), ST131 did not constitute a significantly 
greater proportion of upper UTIs (Upper UTI - ST131 19/35 54% vs. non-ST131 24/57 42%, 
p=0.256). 
Analysis within the ‘upper tract’ and ‘lower tract’ groups showed no significant difference in the 
characteristics of clinical presentation between ST131 and non-ST131 harbouring patients. No 
patient in either group had evidence of renal abscess, or secondary sites of infection. The duration 
of symptoms before presentation, comparing ST131 to non-ST131 infections, was equivalent for 
lower tract infections (3 days, 1-7.5d vs. 2, 1-7d p=0.486) and upper tract infections (2d, 1-5d vs. 
2d, 1-4d p=0.536). 
There was no significant difference in the proportion of upper-tract infection between H30 and H41 
sub-clones (Upper UTI - H30=15/28 54%, H41=4/7 57%, p=1.0). 
Antimicrobial resistance 
As expected, given ST131’s prevalence amongst resistant isolates, the median resistance scores 
amongst ST131 isolates was significantly higher than for non-ST131 isolates across the whole 
cohort (median=6, 25-75% = 4-7 vs. 2, 0-5 p<0.001). When stratified into a variety of relevant 
groups, the resistance scores did not differ significantly between ST131 and non-ST131 isolates 
within any group (ESC-S-EC p=0.077, ESC-R-EC p=0.116 and CTX-M harbouring ESC-R-EC 
p=0.899). Although total resistance scores were similar, significant differences in rates of resistance 
to individual antimicrobials included greater resistance to ciprofloxacin (p<0.001) and SXT 
(p=0.013) amongst the ESC-R-EC ST131 group. When only the CTX-M harbouring isolates were 
analysed, the difference in ciprofloxacin remained significant (p=0.010) (Supplementary Material). 
DISCUSSION 
Our study provides the first comprehensive molecular epidemiology profile of susceptible and 
resistant E. coli in our region. Previous studies in our region have investigated selected groups such 
91 
as fluoroquinolone resistance or particular clonal groups, limiting their ability to ascertain a broad 
profile[46, 291]. 
At first glance, the global pandemic clone ST131 appears to be dominant in our population. 
However, this must be seen in the perspective of local rates of ESC-R-EC (Figure 4). Our estimates 
indicate ST131 makes up approximately 8% (7.6-8.3%) of community onset E. coli isolates. 
Although less than half of the ST131 would be ciprofloxacin resistant H30 sub-clones, ST131 still 
constitutes a disproportionate 41% of all ciprofloxacin resistant community onset E. coli isolates, as 
demonstrated in Figure 3.  
Whilst the proportion of ST131 amongst ciprofloxacin resistant E. coli is comparable to, the 
estimated absolute rate of ST131 is considerably lower than, that found in other contemporaneous 
studies[165]. Three North America studies reported rates ranging from 23 to 28% ST131 amongst 
E. coli[262-264]. A recent Australian cohort (from a single region amongst a selected patient
population) demonstrated a rate of 21% ST131 amongst females of reproductive age with UTI[46].
Comparing across all these studies the most notable variable was the background rate of
fluoroquinolone resistance amongst E. coli. The rate in the North American studies ranged from 27-
29% resistance, and the Australian study’s 13% rate was high compared to our sample (7% amongst
ESC-S-EC) and other Australian data[43, 44, 329].
The potential relationship between the background rate fluoroquinolone resistant E. coli and ST131 
prevalence is revealing. By global standards, Australia and New Zealand have very low rates of 
fluoroquinolone resistance amongst E. coli. These have been achieved through regulatory control of 
fluoroquinolone use in humans and animals[299]. By way of example, 72% of our study population 
had used antimicrobials in the previous year, though only 5% were exposed to a fluoroquinolone. 
We hypothesize that on a population basis, the low background rate of fluoroquinolone use has kept 
the ST131 clone at bay amongst the majority of Australian and New Zealand E. coli. 
The fimH subtyping of ST131 supports this hypothesis. The dominance of the H30 sub-clone 
amongst ESC-R ST131 isolates reflects an emerging global picture[289]. Conversely, the overall 
dominance/expansion of the fluoroquinolone susceptible H41 sub-clone has not been described 
previously. This sub-clone is somewhat genetically distinct from other ‘clades’ of ST131[331] and 
strongly associated with the otherwise infrequent O16:H5 serotype[332, 333]. In our setting, the 
H41 clone may have a selective advantage given recent research demonstrating high virulence 
coupled with fluoroquinolone susceptibility[332, 333]. This requires further exploration. 
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Whilst the identification of antimicrobial use as one of the drivers/protectors for clones amongst the 
whole population can be supported, it does not fully explain the 40% ST131 rate seen amongst 
ESC-R-EC within our population, a rate similar to that of many other regions[222, 271, 334]. The 
data on ESC-R-EC ST131, 88% of which are the H30 sub-clone provides some answers. Foremost, 
the findings of this study must be considered in the context of our previous analysis of risk for ESC-
R-EC within our population. We defined multiple risk factors for ESC-R-EC, and the majority of 
these remained a risk for ESC-R ST131 in a sensitivity analysis[329]. Hence, within the population 
as a whole, factors including healthcare contact, high-risk travel, birth on the continent and previous 
UTIs are all risk for ST131 in our region. This risk is mediated through ST131’s very tight 
association with CTX-M ESBLs. 
A confluence of virulence and resistance is important in this association. ST131 was associated with 
almost twice the risk of upper tract infection compared with lower tract (RR=1.8), supporting an 
emerging body of literature demonstrating increased clinical virulence of ST131[46, 83, 264], 
despite difficulty demonstrating this in non-clinical settings[84, 85]. 
A key strength of our study is the ability to compare prospectively collected epidemiological data 
with the molecular epidemiological characteristics of our isolates amongst a geographically 
dispersed sample. The presence of equal numbers of ESC susceptible and resistant isolates also 
allowed clear differentiation of the clonal structure of each group which would not have otherwise 
been possible, given the low prevalence of ESC-R-EC in our region. The uniquely low rate of 
fluoroquinolone use in our region has provided us insight into the dynamics of the ST131 clone 
with little selective pressure from this antimicrobial class. 
Limitations of our study include the lack of laboratory virulence data to allow greater exploration of 
our hypotheses and findings. Our power to detect significance of association was also limited by a 
moderate sample size and the sub-group nature of this analysis. Our reliance on back-calculation to 
determine population rates may have led to a lower accuracy of these figures than other methods 
provide. Finally, a number of our findings are hypothesis generating and require further studies for 
confirmation. 
In conclusion, we delineate a markedly different clonal composition between ESC-S and ESC-R-
EC groups in Australia and New Zealand. Overall, ST131 is less frequent than in other regions of 
the world. The fluoroquinolone susceptible H41 sub-clone of ST131 is most prevalent, although the 
H30 sub-clone dominates ESC-R-EC. ST131 was significantly associated with upper urinary tract 
infection presentations, suggesting enhanced virulence. We hypothesize that the factors contributing 
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to the low background rate of fluoroquinolone resistant E. coli in our region may have also afforded 
protection from wider spread of the pathogenic ST131 clone beyond ESC-R-EC. 
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FIGURES AND TABLES 
Table 1 
Comparison of clinical presentations within phylogenetic groups and MLST defined clones. 
Clinical Syndrome 
Total 
Count 
p 
value1 
RR2 of upper 
UTI 
(95%CI) 
p value2 
(upper 
vs. 
lower) 
Asymptomatic 
Count (%) 
Lower UTI 
Count (%) 
Upper UTI 
Count (%) 
Other* 
Count (%) 
Phylogenetic group 
A/B1** 9(45) 8(40) 1(5) 2(10) 20 0.026 0.3 0.083 
B2 27(21) 49(38) 43(34) 9(7) 128 0.017 2.3 (1.1-4.9) 0.010 
D 4(13) 16(52) 5(16) 6(19) 31 0.043 0.5 0.093 
Total 41(23) 74(41) 50(23) 17(9) 179 
MLST groups 
ST131 10(22) 16(35) 19(41) 1(2) 46 0.038 1.8 (1.01-3.1) 0.044 
ST131 H30 8(22) 13(35) 15(41) 1(3) 37 0.149 1.5 0.099 
ST131 H41 2(22) 3(33) 4(44) 0 9 0.682 2.0 0.345 
ST95 0 5(33) 9(60) 1(7) 15 0.014 2.7 (0.96-7.5) 0.050 
ST73 2(15) 5(38) 6(46) 0 13 0.437 1.8 0.310 
ST14 cplx. 4(40) 4(40) 1(10) 1(10) 10 0.407 0.4 0.647 
ST69 0 3(43) 3(43) 1(14) 7 0.412 1.5 0.683 
All groups3 21(19) 39(36) 39(36) 9(8) 108 0.011 2.2 (1.2-4.0) 0.003 
UTI = Urinary Tract Infection ‘cplx’ = clonal complex 
1The p value has been calculated across the four clinical presentation categories. 
2The relative risk (RR) and p value compare only upper and lower urinary tract infection (excluding other illnesses) 
across the three phylogroups. A 95% confidence intervals is given for significant values. 
3All isolates that clustered within an MLST defined group 
* Includes: Intra-abdominal source n=4, prostatitis n=5, bacteremia without focus n=4, others n=5
**A single B1 isolate was combined with the A group for purpose of analysis. 
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Figures 1 & 2 
Dendrogram constructed using a Pearson correlation coefficient, based on DiversiLab rep-PCR 
pattern of ESC susceptible (Figure 1) and ESC resistant (Figure 2) E. coli. Details of figure from 
left to right: Dendrogram, isolate number, virtual gel. Numbered columns from left to right: I = 
Hospital location, II=Phylogenetic group III=Fluoroquinolone susceptibility IV= (only in Figure 2) 
Expanded-spectrum cephalosporinase type, V=MLST typing*  
*Isolates which have been presumptively related to an MLST only by rep-PCR pattern are indicated by ‘like’ after the 
ST e.g. ‘ST131 like’ 
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Figure 3 
Distribution of ST131 and the fimH 30 sub-clone across the study sites for 3GC susceptible and 
3GC resistant E. coli.  ‘fimH Cons’ indicated clones with consensus sequence. 
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Figure 4 
Relative contribution of clones to the burden of fluoroquinolone and expanded-spectrum 
cephalosporin resistance in our population. 
The x-axis represents the proportional contribution of each clone to the total number of E. coli 
isolated within our population. The y-axis represents the proportional contribution to 
fluoroquinolone resistant E. coli in our population. The size of the outlining circle on each data-
point represents the relative contribution to expanded-spectrum cephalosporin resistance within our 
population E. coli. (Dashed reference line represents a balanced contribution to fluoroquinolone 
resistance and overall E. coli burden).  
 
Sporadic= isolates not clustered to an identifiable clone, ST14c = ST14 clonal complex. For clarity some ST labels have been shortened as follows: 
A=ST648, B=ST69 C=ST127 & ST80 (which closely share the same data-point) 
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CHAPTER 5. RETURNED TRAVELLERS AND CARRIAGE OF 
ANTIMICROBIAL RESISTANT ESCHERICHIA COLI. 
INTRODUCTION 
Recent clinical studies have demonstrated a high rate of gastrointestinal carriage of antimicrobial 
resistant E. coli in travellers returning from countries of high-incidence to countries of lower 
incidence. Rates of carriage are frequently in the order of 25% of returned travellers.[47, 164, 335, 
336] High-risk regions invariably include the Indian subcontinent, the Middle East and other parts
of Asia. While most studies have focused on 3GCR-EC, Kennedy et al included fluorquinolone and
aminoglycoside resistance in their sample.[47]
Whilst carriage of resistance can frequently be demonstrated, only a smaller number of studies, 
including the study presented in Chapter 3, have linked travel to high-risk countries with resistant E. 
coli infection.[27, 294, 317, 337] These studies have used a variety of definitions for the duration of 
risk after travel ranging from one month to one year.[294, 337] The use of varied definitions 
highlights a gap in our knowledge of gastrointestinal carriage of antimicrobial resistant E. coli. 
There is little data on the actual duration of carriage after travel, or on any specific risk factors for 
resistant infection related to travel. 
The majority of work on GIT carriage of antimicrobial resistant E. coli originates from healthcare 
associated carriage. Whilst these studies offer some background for understanding carriage after 
travel, there are several reasons to question the specific applicability of durations of carriage found 
in healthcare related studies. This includes differences in mechanisms of acquisition of the 
resistance, patient characteristics, burden of comorbidities and exposure to antimicrobials. On the 
whole, healthcare based studies have demonstrated consistent findings across a number of patient 
groups. In a large retrospective study of patients who were screened on re-admission to hospital, the 
median time to ‘loss’ of carriage was 6.6 months. In addition, patients who had a clinical infection 
rather than a colonising isolate were significantly less likely to clear the strain.[338] In a smaller 
prospective study with active screening, the median duration of carriage was approximately 3 
months.[339] Amongst LTCF residents, the median duration of colonisation with a variety of 
antimicrobial resistant E. coli was approximately 6 months.[340] In contrast, a recent New Zealand 
study demonstrated a longer duration of colonisation, with 75% of patients remaining colonised at 
12 months and 50% at 3 years after first detection. Analysis within this cohort could not identify 
any risk-factors for this extended colonisation.[341]  
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Amongst returned travellers, a small number of studies on duration of carriage have been published. 
Tangden found approximately 25% of travellers had persisting colonisation with ESBL-EC six 
months after travel.[164] In another study designed specifically to map long-term carriage after 
travel, 24% of patients continued to carry ESBL E. coli at a 3-8 month assessment, including almost 
half in whom ESBL strains identified on follow-up had not been present on initial assessment. In 
this group, a small subset (10%), of patients still had carriage at 3 years after travel.[342] Case 
reports have also described prolonged carriage of carbapenenemase harbouring E. coli after 
travel.[343] 
Given the relative paucity of data available, we sought to understand the dynamics of carriage of 
antimicrobial resistant E. coli through in-depth analysis of a previously collected sample.[47] This 
sample was collected as part of a study conducted in Canberra, Australia. The study enrolled 106 
previously healthy volunteers who were 16 years or older and travelling overseas for at least one 
week. Patients provided epidemiological details via a survey and then submitted rectal or peri-anal 
swabs before travel and at intervals after travel. Antimicrobial resistant isolates from these swabs 
were retained by the investigators and have been analysed further in work presented in this chapter. 
Our aim was to explore temporality and clonality of isolates present during prolonged carriage after 
travel. This included the level of diversity of clones present and any evidence of ESBL gene sharing 
via horizontal transfer of mobile plasmids. Such analysis offers another perspective on the findings 
in Chapter 3 by linking the defined clinical risks to a demonstrable molecular epidemiology of 
carriage. 
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ABSTRACT 
Purpose  
To delineate the potential risks and dynamics of prolonged carriage of resistant E. coli in returned 
travellers.  
Methods 
A sample of 274 previously collected E. coli, resistant to ceftriaxone (CRO), ciprofloxacin, 
gentamicin and/or nalidixic acid, and recovered from 102 travellers was studied. Travellers were 
assessed pre-travel then longitudinally (maximum 6 months) with peri-rectal/rectal swabs. Clonality 
was determined by REP-PCR and the presence of O25b-ST131 was assessed. Comparison was 
made longitudinally for individuals and between identified co-travellers. 
Results 
The risk of prolonged carriage was lower for CRO than ciprofloxacin or gentamicin resistance. 
Repeated isolation of the same phenotype at different time points occurred in 19% of initial CRO 
resistant carriers compared with 50% ciprofloxacin or gentamicin resistant carriers. The duration of 
carriage was also longer for the latter resistance phenotypes (75th quartile 8 vs. 62 & 63 days 
respectively). In multivariable analysis, risks for prolonged carriage included antimicrobial use 
whilst travelling (3.3, 1.3-8.4) and phylogenetic group B2 (9.3, 3.4-25.6) and D (3.8, 1.6-8.8). 
Clonality amongst longitudinal isolates from the same participant was demonstrated in 92% of 
participants assessable and most marked amongst CRO resistant isolates. ST-131 was surprisingly 
infrequent (3% of participants). 
Conclusion 
Prolonged carriage of ciprofloxacin and gentamicin resistant isolates is more frequent and 
prolonged than CRO resistance after travel. Risks for prolonged carriage indicate a contribution of 
host and bacterial factors to this carriage. These require further elucidation. The strong clonality 
identified suggests carriage of the ‘phenotype’ was mediated by persistence of bacteria/plasmid 
combinations rather than persistence of the plasmid after horizontal transfer to other bacteria.  
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INTRODUCTION 
A number of recent publications have identified carriage of multi-resistant Enterobacteriaceae, 
primarily E. coli, in the gastrointestinal flora of returned travellers.[47, 164, 335, 336, 344] 
Individuals harbouring antibiotic resistant organisms have frequently travelled from countries of 
low resistance incidence to countries of high incidence e.g., Northern Europe to India. Key 
geographical regions for acquisition of multi-resistant Enterobacteriaceae include South-East Asia, 
the Indian Sub-continent and Africa.  
One limitation of current studies is that they provide only a ‘snapshot’ of a narrow resistome 
immediately after travel, with only two studies thus far providing any longitudinal data.[47, 164] 
Such data helps us to better understand the link between carriage of resistant Enterobacteriaceae in 
travellers and subsequent infection in the carrier (or others within the community). Factors 
impacting on this link may include the risk of acquisition whilst travelling, clonal dynamics and 
duration of carriage, risk factors for prolonged carriage and the potential for spread of resistance by 
carriers within the home community or healthcare setting.  
Even from the perspective of the more frequently described health-care associated carriage of 
resistant Enterobacteriaceae, longitudinal carriage studies are limited and varied. Median durations 
of carriage of E. coli range from 80-178 days with single and multiple clones identified in differing 
settings.[48, 340, 345-348] Furthermore, the dynamics of healthcare associated carriage may vary 
considerably from travellers, given the differing mechanism of acquisition and population involved. 
Complicating our understanding of prolonged carriage of antibiotic resistant Enterobacteriaceae, is 
the potential that any given resistance phenotype may be mediated by persistence of a stable 
bacteria/plasmid combination or persistence of the plasmid after horizontal transfer to other 
bacteria.[349]  
In this study we aimed to define longitudinal and clonal aspects of prolonged carriage of 
antimicrobial resistance in a cohort of returned travellers. Natural history and clonality of individual 
carriers were investigated using a sample of patients selected as unlikely to have acquired new 
resistance after return from travel, by virtue of residence in an area of low background incidence of 
resistance and absence of antimicrobial exposure or re-travel.[23, 47] Shared clonality between 
travel partners and the incidence of the ST-131 O25B worldwide pandemic clone were explored in 
the entire cohort, comprising all samples collected during the study. 
MATERIALS & METHODS 
Bacterial Isolates & Data collection 
Bacterial isolates used for this study consisted of 274 Escherichia coli from 102 participants 
collected during a previous prospective study of returned travellers residing in Canberra, 
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Australia.[47] The original study investigated the rate and duration of colonisation with resistant E. 
coli following international travel.  Isolates presented were resistant to ciprofloxacin (cip-R), 
gentamicin (gent-R) and/or ceftriaxone (CRO-R). In addition, nalidixic acid resistant E. coli also 
recovered from this cohort were included in this analysis. A full description of the methods of 
bacterial isolation and clinical data collection is contained in the original publication.[4] In brief, 
102 prospectively enrolled travellers who completed the study were asked to collect rectal or 
perianal swabs within 14 days before an overseas trip and within 14 days after return to Australia.  
If isolates resistant to ciprofloxacin, gentamicin or ceftriaxone were detected on the first return 
swab, participants were asked to collect regular monthly swabs until resistant bacteria were not 
identified on two sequential swabs or for a maximum of six months. Swabs were subcultured on 
three media, HBA-gentamicin (Oxoid, Australia), MacConkey agar (Oxoid, Australia) containing a 
nalidixic acid disc (Oxoid, UK) and chromID(ESBL) (bioMérieux, France), after an initial 
overnight broth enrichment. Resistant colonies were selected from each plate and underwent 
identification and susceptibility testing using Vitek2 (bioMérieux, USA).  If all colonies on a given 
plate appeared morphologically identical, then only a single colony was sampled. If morphological 
differences between colonies were apparent, each variant was sampled. Mechanisms of ceftriaxone 
resistance were confirmed by PCR and sequencing and are presented in the original study. They 
comprised ESBL and AmpC enzymes.[4] 
All participant and travel data used in this study was collected via a questionnaire completed 
directly by participants during the original study. Variables included travel destinations, 
antimicrobial use, intercurrent illness and food/water consumption whilst travelling.  For this 
analysis, “high risk” regions were defined as regions from which >50% of travellers during the 
original study returned with a resistant isolate.  As travellers frequently visited more than one 
destination, the duration of stay in each region was calculated and included. 
Molecular Methods 
The phylogenetic group was determined on all isolates using triplex PCR.[230] Determination of 
ST-131 O25B world-wide pandemic clone was undertaken by detection of pabB and trpA alleles 
via multiplex PCR with a positive control MLST confirmed as ST-131.[181] Repetitive extragenic 
palindromic PCR (REP-PCR) was undertaken using published methods.[322] The template was 
purified DNA (Mo-Bio, USA), using a BioRad C1000 Thermal Cycler.  Primers REP-1 (5’-
IIIGCGCCGICATCAGGC-3’) and REP-2 (5’-ACGTCTTATCAGGCCTAC-3’) were used. The 
products were separated on a 1% agarose gel (45v, 3 hours) and stained with ethidium bromide. 
Manual visual comparison was used to identify clonal isolates and any difference greater than two 
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non-shared bands was considered non-clonal. Bacteria for comparison were always separated on the 
same agarose gel. 
All isolates of the same phylogenetic group harboured by the same participant or shared by travel 
partners were considered potentially clonal. For CRO-R isolates, all potentially clonal isolates were 
subject to REP-PCR. For cip-R and gent-R resistant isolates, if three or more potentially clonal 
isolates of identical phylogenetic group and phenotypic antimicrobial susceptibility (amoxicillin, 
amoxicillin/clavulanate, cephazolin, ceftriaxone, ciprofloxacin, gentamicin, 
trimethoprim/sulfamethoxazole) occurred within 8 weeks, interval isolates were skipped (e.g., 
sample 2 of samples 1, 2 & 3 skipped). If differing presumptive clonality was identified amongst 
the isolates analysed, then the interval isolate was subject to REP-PCR. 
Definitions 
Duration of carriage was calculated from the date of return to Australia until the date of collection 
of last positive swab. Clearance of carriage was assumed if there was collection of at least one 
swab not containing the given antimicrobial resistance phenotype, without the occurrence of any 
subsequent positive swabs. Clonal carriage was defined as identification of clonal isolates (as 
defined by REP-PCR) at two time points (most > 4 weeks apart). As above, any isolates with 
greater than two non-shared bands were considered unrelated. 
Censoring and exclusions for longitudinal analysis 
Participant results were censored (exclusion of all subsequent swab results) after events that may 
have potentiated new acquisition of resistance including further overseas travel or receipt of 
antimicrobial therapy for suspected or proven infection (n=6 urinary tract infection, n=2 other 
infection site). Participants who were still on doxycycline for malaria prophylaxis at the time of the 
return swab were not excluded. Participants harbouring clonally related isolates pre- and post-travel 
were excluded. To assess this, all pre-travel isolates were compared to post-travel isolates using 
REP-PCR in a similar manner to the longitudinal analysis (n=7 participants). All participants 
remaining who had assessable swabs collected at two or more time points after travel were 
included. 
Statistical Methods 
Kaplan-Meier plots were used to illustrate duration of resistance. Subjects were censored if they 
remained resistant at their final data collection time-point. Parametric survival models were used to 
estimate the magnitude of differences in the distribution of resistance duration due to the three 
antibiotics. More specifically, log normal accelerated failure time models were used as the log 
normal provided the best fit to the observed data from a number of common alternatives (including 
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Weibull and log logistic models) and estimates from accelerated failure time models could be 
reported as proportional increases in resistance durations. Robust variances were used to take into 
account within-patient correlations of resistance to the three antibiotics of interest.  
Potential risk factors were assessed for possible association with duration of resistance to any of the 
three antibiotics, by including these variables as covariates in univariable survival models. All 
variables that showed some evidence of association in univariable analysis (p<0.1) were included in 
multivariable analysis. Backwards elimination was used to remove non-significant (p>0.1) variables 
until the best predictive model was obtained. SAS version 9.1 for Windows and Stata/IC 10.1 for 
Windows were used for analysis.  
RESULTS 
DURATION, CLONAL DYNAMICS AND RISKS OF PROLONGED CARRIAGE. 
Of the 102 original participants in the study, 50 returned carrying antimicrobial resistant E. coli of 
interest (CRO-R, cip-R and/or gent-R), with 44 included in the final analysis after censoring and 
exclusions.(Fig. 1) Three participants reporting ongoing use of doxycycline for malaria prophylaxis 
at the initial return swab were not excluded.  
Duration and Risks for Prolonged Carriage of Resistance 
Upon initial assessment, after return from travel, the carriage of the three specified phenotypes was 
CRO-R 26% (n=27), cip-R 27% (n=28), gent-R 35% (n=36). When compared with CRO resistance, 
cip-R and gent-R were associated with 2.1 (95% CI, 1.1 to 4.1, p = 0.027) and 3.5 (95% CI, 1.6 to 
7.5, p = 0.001) times the duration of carriage of resistance respectively.  There was no significant 
difference between the duration of cip-R and gent-R. The median durations and inter-quartile 
ranges for recovery of resistance from travellers was 3 (IQR, 1 to 8) days for CRO-R, 5 (IQR, 1 to 
62) days for cip-R and 8 (IQR, 3 to 63) days for gent-R. This is represented longitudinally on a
Kaplan-Meier curve (Figure 2), demonstrating the major difference is in the upper quartile of
participants.
Potential risks for prolonged carriage of any resistance were analysed by three groups of factors: 
participant/travel characteristics, duration/location of travel and bacterial factors. Results of 
univariable and multivariable survival models are presented in Tables 1 and 2.  
Clonal dynamics of resistance 
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Clonality was almost always present in prolonged carriage of a given antimicrobial phenotype. Of 
25 participants with isolation of bacteria of the same phenotype at two time points, the carriage of 
exclusively clonal isolates was demonstrated in 14 (56%) participants. Carriage of a mixture of 
clonal and non-clonal isolates occurred in 9 (36%). Three participants (12%) carried more than one 
prolonged clone simultaneously. Only 2 (8%) had no clonal relationship between bacteria isolated. 
In both cases bacteria were only recovered on the return swab and a single subsequent swab. These 
patterns are illustrated in Figure 3.  
The dynamics of clonality differed between CRO-R and cip-R or gent-R resistant isolates. With the 
exception of a single bacterial isolate, repeated isolation of CRO-R Enterobacteriaceae was 
invariably due to the presence of clonal bacteria. The carriage of ciprofloxacin and gentamicin 
resistance demonstrated more diversity, although by month 5, all isolates recovered were clonal 
with earlier isolates.(Figure 4) 
Travel Partners 
From the cohort of 102 travellers, 70 (68%) travelled with other study members.(Figure 1) This 
included 29 ‘pairs’ (travel & sexual partners) and six ‘mixed groups’ containing participants of 
other relationships (friends travelling together, families, and one unknown relationship).  For 
analysis, pairs within mixed groups were considered, within the ‘pairs’ cohort. 
Analysis of the 29 ‘pairs’ revealed 14 (48%) with neither partner returning with resistance, 8 (28%) 
with a single partner doing so and 9 (31%) with both partners harbouring resistance. Thus, if one 
person was colonised, there was a 53% (9/17) chance of the partner also harbouring one of the three 
resistant phenotypes sought. However, using clonal analysis, just 2 of 9 couples (22%) shared 
clones.  
Shared clonality was also identified amongst one of six ‘mixed’ groups of travellers. 
ST-131 World Wide Pandemic Clone. 
The presence of the clone was assessed amongst all 274 E. coli isolates recovered from 102 
participants. This included all CRO-R, gent-R, cip-R and/or nalidixic acid resistant isolates 
recovered from participants throughout the study duration. (Figure 1) Pre-travel prevalence of the 
clone was 2% (2/102). An additional two individuals acquired ST-131 E. coli while travelling. With 
the exclusion of the pre-travel carriers, only one prolonged clonal carrier was colonised with a ST-
131 strain. All ST-131 E. coli isolated were phylogenetic group B2.  
DISCUSSION 
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Carriage of multi-resistant Enterobacteriaceae upon return from travel is a real and concerning 
phenomenon.  The most serious outcome of such carriage is infection with resistant organisms after 
return home. Although we did not specifically assess infections in returned travellers, two recent 
studies have demonstrated this risk in diverse populations. Overseas travel afforded a relative risk 
of 2.7 for any infection after TRUS biopsy[337], and a relative risk of 5.7 for ESBL E. coli 
infection in a regional Canadian study.[27] Our analysis helps to delineate the complex link 
between acquisition and carriage during travel and infection after return. 
The rapid decline in carriage of resistant isolates after travel is to some extent encouraging, 
however persistence is significant. Analysis of the longitudinal nature of carriage highlights the 
marked persistence of cip-R & gent-R isolates beyond CRO resistance, with 10% of participants in 
the longitudinal arm of this study harbouring cip-R &/or Gentamicin resistance at six months after 
return. This is noteworthy, given that fluoroquinolones and aminoglycosides are heavily relied upon 
for the treatment of E. coli infection, including urinary sepsis, in many national guidelines.[13, 350] 
The prolonged duration of carriage of fluoroquinolones resistance identified, concurs with 
descriptions of healthcare associated carriage.[340, 345, 348] Explanations for the shorter duration 
of CRO resistance potentially include the higher fitness cost of maintaining this resistance plasmid 
for bacterium, in the absence of ongoing selection pressure and genetic differences between the host 
bacteria that harbour each resistance element. 
Risk factors for prolonged carriage are intriguing. Antimicrobial use whilst travelling was strongly 
associated, leading to a 3.4 times increase in duration of carriage. Kennedy, in travellers[47], and 
many authors in other settings, have identified antimicrobial use as a risk for acquisition of 
resistance, an intuitive conclusion. However, this study examines a group who all harboured 
resistance and did not have further antimicrobial exposure to potentiate this risk. Another 
mechanism apart from simple selection of antimicrobial resistance may apply. We hypothesize 
potential modification of intestinal microbiota after antimicrobial use, leading to the loss of other 
potentially competitive non-resistant E. coli and other integral commensal bacteria.[351] 
The analysis of clonality answers interesting questions about acquisition and carriage of such 
resistance. Whilst the ‘mobility’ of resistance elements, particularly CRO resistance plasmids, was 
initially hypothesized in this study and is frequently discussed and demonstrated in ‘high stress’ 
situations such as healthcare settings and antimicrobial use[349], it appears not to be significant in 
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travellers. In fact clonality was almost absolute for plasmid mediated CRO resistance. The strong 
clonality of isolates amongst all phenotypes gives us insight into the environment of acquisition. 
The identification of clonality amongst travel partners and mixed groups (where direct transmission 
from person to person was unlikely) suggests exposure and ingestion of a common source of 
resistant isolates, potentially food or water. This is also supported by the relatively low rate (22%) 
of shared clonality between partners. The pattern of contraction of a variety of resistant isolates on 
return to persistence of a single (or very few) clones, implies the presence of only a limited number 
of clones in circulation able to colonise and persist amongst individuals even in such 
‘environments’ with high resistance burden. The shared clonality amongst partners/mixed groups 
and the correlation with period of exposure in ‘high-risk’ regionsm supports this hypothesis. This 
can be compared to the observation of clonality amongst E. coli causing urinary tract infection, 
where a small handful of adapted clonal groups are thought to cause a significant proportion (10-
20%) of all such infections[168]. Although not investigated in this study, other than ST131, further 
exploration of clonality across travellers and regions would be worthwhile. 
The identification of ‘persistent’ clones also highlights the issue of potential infection and both 
community and healthcare related transmission of resistant isolates. It is unknown whether 
travellers may be the point of introduction of antibiotic resistant bacteria into a community, as 
compared to imported food, animals or de novo development of resistance via antibiotic use. 
Importation of antibiotic resistant bacteria into hospitals has been well documented via individuals 
who have been treated in hospitals in high-risk areas.[96] With respect to travellers, we speculate 
that a long duration after return from travel, e.g., 3-6 months, may be the most problematic in a 
healthcare system, given these clones have been selected as the best adapted for colonisation and 
persistence.  
The relationship between persistence of colonisation and subsequent infection needs further 
exploration. The phylogenetic groups, as identified in this study, represent a broad family of 
bacterial characteristics related to virulence. The markedly increased duration of the more virulent 
B2 and D groups, compared to commensal E. coli (predominantly groups A & B2)[352], indicates 
bacterial genetic factors other than the presence of resistance genes, which may aid in persistence. 
Potential mechanisms requiring exploration include biofilm formation, competitive bacterial toxin 
production, e.g., colicins, and virulence factors including siderophore and fimbriae production 
mediating competitive advantages in iron capture and adhesion.  Furthermore, the relation of factors 
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that determine persistence to those that determine the classical virulence of invasion and infection, 
also requires elucidation.  
Limitations of this study include the exploratory nature, using a previously collected sample. The 
collection method of recovering a single isolate from the plate has led to some limitation in 
determining clonality. To investigate this, a model was constructed using the assumption that clones 
recovered on a given swab were present but not identified on all previous swabs due to this 
methodological issue. This model indicated that approximately one third of clones were not 
recovered on any given swab, suggesting that with the repeat sampling undertaken, there was a low 
chance of failing to identify truly persisting clones (data not shown).  
In the multivariable analysis, only a limited number of factors were assessed. There may be other 
significant participant and isolate features that were not included in this analysis. Furthermore, the 
assumption that resistance was only acquired whilst travelling and did not occur after return is 
relied heavily upon in the data. We believe this was reasonable given the very low background rates 
of resistance in Canberra[23, 47]; however is likely not absolute. Acquisition of resistant clones 
after return (or the emergence of ‘low-level’ pre-travel resistant clones due to antimicrobial use) 
may have led to over-estimation of duration of carriage and diversity of clonality. A control group 
of matched non-travellers from Canberra would have been optimal in assessing this situation.  
Conclusion 
Prolonged gastrointestinal carriage of resistant bacteria after return from travel is a complex 
phenomenon. The duration of carriage of CRO resistance was significantly shorter than 
Ciprofloxacin or Gentamicin resistance.  Risk factors for prolonged carriage of resistance include 
antimicrobial use whilst travelling and the duration of travel in ‘high risk’ regions. Clonality was 
present amongst all phenotypes, however almost absolute amongst CRO resistance. The contraction 
to a small number of clones and shared clonality amongst travel partners suggests a limited number 
of clones adapted to prolonged carriage circulating in regions of acquisition.  ST-131, the world 
wide pandemic clone, was surprisingly infrequent amongst the phenotypes assessed. The 
identification of clonality amongst travel partners and mixed groups (where direct transmission 
from person to person was unlikely) suggests exposure and ingestion of a common source of 
resistant isolates, potentially food or water. 
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FIGURES AND TABLES 
Table 1 
Univariable analysis of risk factors for prolonged carriage of resistance. 
Variable Estimate 
Lower 95% 
CI Upper 95% CI P-value
Age at departure 1.00 0.96 1.05 0.86 
Female gender 1.17 0.34 4.01 0.80 
Whilst travelling 
Antibiotic use 9.12 3.16 26.05 <0.0001 
Diarrhoea 2.34 0.70 7.77 0.17 
Consumed ‘tap’ water 0.53 0.16 1.79 0.30 
Duration and destination 
Total travel (per week) 1.30 1.06 1.60 0.012 
High risk regions (per week) 1.32 1.08 1.63 0.008 
Other regions (per week) 1.03 0.72 1.46 0.87 
India/Sri Lanka/Nepala 1.03 1.00 1.06 0.022 
SE Asia/Pacifica 0.98 0.91 1.05 0.55 
Middle East/Africaa 1.03 0.97 1.10 0.33 
China/Hong Kong/Taiwan/Koreaa 1.02 0.93 1.11 0.70 
South America/Mexicoa 1.00 0.93 1.08 0.93 
Bacterial factors 
Multiple resistanceb 1.82 0.54 6.23 0.33 
Phylogenetic group A 0.82 0.23 2.86 0.76 
Phylogenetic group B1 1.62 0.47 5.58 0.44 
Phylogenetic group B2 7.03 1.65 29.96 0.008 
Phylogenetic group D 5.16 1.68 15.80 0.004 
a Per day in this region 
SE Asia (Malaysia, Thailand, Singapore, Vietnam, Philippines, Laos, Indonesia, Cambodia, Papua New Guinea, Solomon Islands), Middle 
East/Africa (Jordan, Israel, UAE, Egypt, Zambia, Tanzania, Kenya) 
bResistance to at least two of Ciprofloxacin, Gentamicin, and Ceftriaxone 
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Table 2 
Multivariable analysis of risk factors for prolonged carriage 
Variable Estimate 95% CI P-value
Travel in high risk regions 
(per week) 
1.27 1.09 to 1.49 0.002 
Antibiotic use 3.34 1.33 to 8.36 0.01 
Phylogenetic group B2 9.32 3.39 to 25.6 <0.0001 
Phylogenetic group D 3.81 1.64 to 8.82 0.002 
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Figure 1 
Selection and exclusion of 102 participants for the three arms of this study. (The same participants 
and bacterial isolates were used in each arm) 
Figure 2 
Kaplan-Meier survival curve comparing duration of carriage of the three resistance phenotypes 
across 44 selected participants. (p=0.007)
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Figure 3 
Travellers representative of different patterns of carriage of resistant isolates. A time-line is 
displayed across the top (days). Arrows represent the submission of swabs by travellers. Shaded 
squares indicate bacterial clones. The diamond in each square shows the time points at which the 
bacteria were isolated in a sample.  
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Figure 4 
Graphical representation of the clonality of isolates amongst each individual 
Left - Comparison of CRO resistant isolates to other CRO resistant isolates amongst the same individual. Right- Comparison of Ciprofloxacin and/or 
Gentamicin resistant isolates to other isolates of the same phenotype amongst the same individual. (Isolates harbouring CRO resistance have been 
excluded. Phenotypes only recovered at a single time point could not be assessed for clonality and are indicated in white/hash.) 
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CHAPTER 6. INFECTION CONTROL MANAGEMENT OF MULTI-
RESISTANT ESCHERICHIA COLI 
INTRODUCTION 
As outlined in Chapter 1, our understanding of the infection control requirements of ESBL-E is 
evolving. Given the recent suggestion of relatively low transmission of ESBL-E in acute care 
settings, we present a national survey of infection control practice for ESBL harbouring 
Enterobacteriaceae, CRE and patients with overseas healthcare contact. 
This survey was conducted as an online open-invitation survey using a commercially available web-
based survey tool. One consideration in the timing of this survey is that it was conducted before the 
drafting of national guidelines on the management of CRE in healthcare settings,[63] thus it may 
serve as a baseline for further surveys on this topic in the future. Patients with overseas healthcare 
contact were included, given the emerging threat this group pose and their infrequent inclusion in 
general infection control recommendations.  
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ABSTRACT 
Introduction 
Despite the global expansion of extended spectrum beta-lactamase harbouring Enterobacteriaceae 
(ESBL-E) and carbapenem resistant Enterobacteriaceae (CRE), only limited research on the 
infection control management of patients with these organisms is available. 
Methods 
We present a national survey of infection control practice amongst adult acute-care hospitals in 
Australia, for ESBL-E, CRE and the emerging threat of patients with overseas healthcare contact. 
Results 
In total, 97 health services responded, representing 9% of all eligible hospitals. The proportion of 
hospitals that reported the use of contact precautions (CP) was 96% (93/97) for ESBL-E, 81% 
(79/97) for CRE and 72% (48/67) for patients transferred from an international hospital. For ESBL-
E, hospitals frequently employed risk-stratification to limit the use of CP (40/97, 41%). 
On multivariate analysis, predictors of a strategy to limit use of CP for ESBL-E were government 
funding (OR=4.8, p=0.003) and a metropolitan location (OR=3.2, 0.014); predictors of any use of 
CP for CRE, were location in a state with a specific legislation on CRE (p=0.030) and the presence 
of a written policy on CRE (p=0.011). 
Conclusion 
Infection control management of MRGNBs varies considerably across Australian hospitals 
surveyed. A lower rate of reported CP use for CRE than ESBL-E was unexpected and indicates the 
vulnerability of some Australian hospitals. Multivariate analysis reveals various drivers influencing 
infection control practice in Australia.  
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INTRODUCTION 
A marked expansion of community onset ESBL harbouring Enterobacteriaceae (ESBL-E), and the 
burgeoning of carbapenem resistant Enterobacteriaceae (CRE) has occurred in the past decade.[80, 
353] Furthermore, patients with overseas healthcare contact are increasingly identified as a vector
for the global movement of new antimicrobial resistance mechanisms including those mediating
CRE.[96]
The majority of current infection-control guidelines include recommendations for the control of 
multi-resistant gram-negative bacilli (MRGNBs), including CRE and ESBL-E. Fewer guidelines 
include recommendations for patients with overseas healthcare contact.[354] Given the small 
number of published studies on which to base recommendations[355] and the rapidly changing 
epidemiology of  MRGNBs, guidelines in this area risk being out-paced by on-the ground events.  
Australia is a low-prevalence country for ESBL-E, with a 2010 national survey of community onset 
isolates indicating 3.4% of E. coli and 3.6% of K. pneumoniae were ESBL producing.[44] CRE in 
Australia originate from two key sources: low-level endemicity of metallo-beta-lactamase (MBL) 
producing Enterobacteriaceae within critical-care areas and some speciality units on the country’s 
eastern coast;[61] and residents returning after overseas healthcare contact.[66, 71] We have 
previously described variation in the infection control practice used for patients hospitalised with 
expanded-spectrum cephalosporin resistant E. coli as part of an Australasia-wide study.[329, 356] 
Such a disparity has been noted in other reports.[357, 358] 
In follow-up, we present a national survey of practice in infection control management of patients 
harbouring ESBL-E, CRE and patients with overseas healthcare contact, amongst acute-care adult 
hospitals in Australia. Our aim was to define the scope of variation in infection control practice for 
these groups in Australia, and to identify factors that determine which policy and practice is applied 
in differing health services. 
METHODS 
The study population was adult acute care hospitals within Australia. At the time of the survey, 
Australia (population 23 million) was serviced by approximately 700 publically funded hospitals 
and 300 private hospitals across its six states and two administrative territories.[359, 360] 
A draft survey was constructed including questions based on those used in a previously published 
work.[357] The survey was piloted on five experienced infection control practitioners and modified 
based on their feedback. The survey questioned health service’s practice of infection control, rather 
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than the details of written policy. Where a service used varied practice within their network, they 
were asked to answer for the area which best fitted the description of an ‘adult acute care’ facility. 
The full survey is in Supplementary Material. 
The survey was conducted as an open invitation on-line survey, using a web-based interface to 
collect responses.  An email invitation was disseminated via two frequently used national email 
discussion groups: one hosted by the Australasian College for Infection Prevention and Control, and 
the other hosted by the Australasian Society for Infectious Diseases.[361] The former emails went 
to approximately 500 email addresses (personal communications, Mr Michael Wishart, HSN 
Hospital, QLD, Australia) and the latter to approximately 900 addresses (personal communication, 
Dr Ashley Watson, Canberra Hospital, ACT, Australia). Follow-up emails were disseminated via 
these channels. The survey was open for a two-month period (November 2012 to January 2013). A 
small token of appreciation (a gift hamper) was offered to one randomly selected responding site. 
Human research ethics approval for the conduct of this study was received from The University of 
Queensland. 
We requested that the nominal ‘head’ of infection control complete or delegate completion of the 
survey at each site, to minimise multiple responses. If multiple responses from a single site were 
received, these were collapsed to a single survey as follows: Answers were classified as 
concordant, relative agreement (e.g. difference in details only) or discordant. Answers in the 
latter two groups were combined using the following rules: a) affirmative responses (indicating the 
presence of a given policy) were presumed to be correct; b) the most restrictive application of a 
policy or most conservative numerical was presumed to be correct. Infection control services were 
not re-contacted, as permission for this had not been sought in the ethics approval. 
Where a single respondent answered for a health service/network of multiple adult acute-care 
hospitals, this was maintained as a single answer, with demographics from the single largest 
hospital used for analysis. 
External data sources 
Data is primarily as reported by the respondent. Key demographics (hospital size, funding and 
referral services) were confirmed with public data sources (Supplementary Material). Denominator 
data for Australian hospitals was extracted from the Australian Institute of Health and Welfare 
(AIHW) annual report 2011-2012.[360]  
Definitions 
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Contact precautions was defined as the use of any combination of gloves, gown and or a single or 
cohort room.[86] Infection control practice was considered Inclusive when all patients with a given 
resistance phenotype were managed in contact precautions or Permissive if non-use of contact 
precautions was allowed in some circumstance (risk stratification by bacterial species or patient 
characteristic) or was not used at all.  Hospital type was stratified by funding source; Public 
hospitals are fully funded by the Australian state and/or federal governments. They provide the vast 
majority of supra-regional referral services in Australia; Private hospitals draw funding from 
patient billing revenue and primarily service patients covered by voluntary private-health insurance 
or other third parties; Supra-regional referral services were highly-specialised referral services as 
follows: Transplant service (solid organ or allogeneic bone-marrow transplant services) and other 
supra-regional services (major burns, spinal injury and cystic fibrosis services).  An Infectious 
Disease (ID) service was an ID physician providing consultation or in-patient services at the 
hospital. A written policy specifically pertained to the resistance phenotype (or patient group) 
queried, rather than a generic ‘MRO’ type policy. Hospital size was classified by the AIHW ‘Peer 
Group’ system.[362] As private hospitals are not classified by this system, two researchers (BR, 
SH) independently assigned a peer group after review of any available hospital demographic data 
(from the survey and publicly available information on the hospital’s website). Disagreement was 
resolved by discussion. Principal referral hospitals (A1 by AIHW classification) are major city 
hospitals with more than 20,000 and regional hospitals with more than 16,000 (casemix-adjusted) 
separations per year. Large hospitals (A1, A2, B1, B2) included principal referral, specialist 
women’s hospitals, large metropolitan (>10,000 casemix-adjusted separations), and large regional 
hospitals (>8000 or >5000 casemix-adjusted separations, depending on location).  
Relevant legislation and recommendations 
At the time of the survey there were no national infection control management recommendations or 
legislation specifically pertaining to CRE or patients with overseas healthcare contact. Some 
recommendations for ESBL-E are provided in the national infection control guidelines[86]. Two 
Australian states work within state-level legislation (operational directives). One encompasses all 
‘multi-resistant organisms’ (MRO Directive),[363] and the other specifically CRE (CRE 
Directive).[364] See Supplementary Material for a comparison of state and national documents. 
Statistical Methods 
Univariate analysis was undertaken using X2, Fisher’s exact test and calculation of odds ratios 
(OR). Multivariate logistic regression included all variables significant on univariate analysis at a 
p=0.2 level. Using backwards selection variables was retained in the final logistic regression model 
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if their significance remained below p=0.2. Models were assessed by calculation of a ROC and 
Hosmer-Lemshow goodness of fit test. Robust estimates of variance were used to account for a 
potential lack of independence between hospitals, given some operate in shared jurisdictions where 
standardisation of policy may have occurred. In addition, when the geographical variable of state-
based legislation was entered into multivariate analysis, it was maintained as a tripartite set (MRO 
policy, CRE Policy, No Policy). All statistical tests were two tailed, and p<0.05 was considered 
significant. STATA version 12.1 (Statacorp, USA) was used.  
 
RESULTS 
Valid responses were received from 97 unique hospitals or health services. Eight further responses 
were excluded as they originated from institutions that did not meet the study population (hospital 
type: exclusively paediatric n=3, elective day-procedure sites or sub-acute care only n=3, psychiatry 
only n=2) 
Hospital demographics and national coverage 
Responses were received from 68 public hospitals and 29 private hospitals. This included 75% 
(31/41) of all sites accredited to train fellows in adult infectious diseases within Australia.[365] 
Approximately 9% of all Australian hospitals within the survey population responded (68/736, 9% 
public hospitals, 25/285, 9% private hospitals - excluding private hospitals in three states that do not 
provide denominator data). 
In total, 58(60%) hospitals were situated in metropolitan locations, 32(33%) in regional locations 
and 7(7%) in remote locations. Stratified by state location, the geographical distribution of 
respondents approximately mirrored that of the Australian population (Supplementary Material). 
 
Respondents 
In total there were 108 respondents, including 9 sites with duplicate responses. The majority of 
survey respondents identified their role as a nursing trained infection control practitioner (81/108, 
75% - including nurse-managers and clinical nurse specialists), or an MD trained clinician (22/108, 
20% - including infectious disease, infection control or clinical microbiology specialists). The 
remainder of respondents were in managerial or academic positions (5/108, 6%).  
There was at least one responding MD for 19/97(20%) health services. Significantly more principal 
referral centres compared with other centres, had an MD respond (18/43, 42% vs. 1/54, 2% 
p=0.002).  
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Control of Specific Organisms and Patients 
ESBL ENTEROBACTERIACEAE 
Contact precautions (CP) were used by 93/97 (96%) hospitals in the management of patients ESBL-
E. (Table 1) The most common implementation of these precautions was ‘inclusive’ (48/97, 49%), 
with CP used for every patient with any ESBL-E. A variety of ‘permissive’ practices, including the 
use of risk stratification by organism genera and/or patient characteristics, were used in other sites 
(Figure 1). Data was missing from 5/97 (5%) sites. 
A descriptive analysis of factors predicating the presence of a permissive practice for the 
application of CP in patients with ESBL-E, as compared with an inclusive practice, is in Table 2. 
On multivariate analysis, the predictors of use of a permissive practice were hospital funding type 
(p=0.003) and a metropolitan location (p=0.014) (Table 3). 
CARBAPENEM RESISTANT ENTEROBACTERIACEAE 
Use of CP for patients harbouring CRE was reported by 79/97 (81%) hospitals (Table 1). An 
inclusive practice was most common, occurring in 56/97 (58%) hospitals (Figure 1).  Descriptive 
analysis of the predictors of use of any CP on patients harbouring CRE is in Table 2. On 
multivariate analysis, the significant predictors of any use of CP for patients harbouring CRE were 
the presence of a written policy on CRE infection control (p=0.011) and location in the state with a 
CRE directive (p=0.030) (Table 3). 
INTERNATIONAL TRANSFER PATIENTS 
In total, 67/97 (69%) hospitals provided information on infection control management of patients 
received after an international transfer between hospitals (IT-patients). 25/97 (26%) indicated they 
did not know the policy or had never faced this situation and 5/97 (5%) did not respond to the 
question (Table 1). 
CP was used in 72% (48/67) of hospitals that provided details (Figure 1). Descriptive analysis is in 
Table 2. On multivariate analysis, positive predictors of the use of any CP for IT-patients was the 
presence of a written policy on IT-patients (p=0.025) and location in the state with a CRE directive 
(p=0.003) (Table 3).  
Some form of enhanced infection control management (CP &/or screening) was applied to patients 
reporting overseas healthcare contact (although not directly transferred from a hospital) by 45/97 
(46%) hospitals, with 46/97 (47%) reporting no use of precautions and 6/97 (6%) not responding. 
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‘AMP-C’ TYPE ORGANISMS 
For patients harbouring AmpC producing organisms, 48/97 (49%) hospitals reported no use of CP, 
41/97 (42%) an identical management strategy to ESBL harbouring organisms, 7/97 (7%) a stand-
alone strategy and 1/97 (1%) did not respond. 
Policy basis and origin 
The most commonly utilised publications in the preparations of infection control policy for 
MRGNBs was the Australian National Health and Medical Research Council (NHMRC) 
guideline[86] (87/97, 90%) and departmental guidelines or directives issued by State or Territory 
governments (80/97, 82%). Hospitals based in the states with compulsory directives were 
significantly more likely to identify this source than other states (36/38, 95% vs. 44/59, 76% 
p=0.015). International guidelines were used less frequently, including those originating from the 
American CDC[87] (43/97, 44%) and other countries’ guidelines (21/97, 22%). 
Variability of survey response 
Analysis of responding health services showed a disproportionate number of responses from ‘large’ 
public hospitals. This group comprised 68% (48/68) of survey respondents within the public 
hospital group, although numerically accounted for only 18% (131/736) of public hospitals within 
Australia. Within responses on IT-patient management missing data was most often from smaller 
hospitals. In total, 86% (37/43) of principal referral hospitals provided details on their management 
compared with 56% (30/54) of other sites (p=0.001 for comparison). 
Analysis by respondent type showed significant differences in reported CRE management. All sites 
with an MD respondent (19/19) reported use of CP for CRE, whereas only 60/78 (77%) sites with a 
non-MD respondent reported this use (p=0.019 for comparison). When further analysis was 
undertaken within the subgroup of principal referral hospitals, in order to account for the 
disproportionate number of MD respondents within this group, this difference was still apparent, 
although not statistically significant due to the small numbers involved (18/18, 100% MD 
respondents used CP for CRE vs. 20/25, 80% non-MD respondent sites p=0.064). 
Analysis of intra-site correlation for the nine sites that submitted multiple responses to the survey is 
contained in Supplementary Material. Across (seven) major themes in the survey, no single site 
showed concordance for all answers. Across all sites, 51% (32/63) of details reported were 
concordant, 27% (17/63) were in relative agreement and 22%(14/63) were discordant. 
126 
The highest discordance was on the presence of written policies (7/9, 88% discordant) and the use 
of CP for IT-patients (3/9, 33% discordant). Relative agreement occurred most often when 
describing CP use for ESBL-E and CRE (each 6/9 67% relative agreement). In the relative 
agreement group, differences between respondents were in the description of details of risk 
stratification practice and the use of cohort rooms. 
DISCUSSION 
Our national survey demonstrates widely varied infection control practice for MRGNBs across at 
least 97 hospitals in all regions of Australia. Such variation has been demonstrated in other parts of 
the world.[357, 358]  
Foremost, our unexpected finding is that CP use is reported more frequently for ESBL-E than for 
CRE. Several explanations are apparent. First, our data indicates many infection control policies 
and/or practitioners rely on the use of a laboratory ‘ESBL phenotype’ to trigger CP use, as 
evidenced by the lower rates of any CP use for ‘AmpC’ organisms compared with ESBL-E (50% 
vs. 96%). A number of CRE will not possess this phenotype (nor even an MBL phenotype) and will 
not be detected unless decreased carbapenem susceptibility is the trigger for infection control 
intervention. 
Second, misclassification may have occurred due to unfamiliarity with the term ‘CRE’. This was 
unforseen in the survey design and specific examples of ‘carbapenem’ and ‘Enterobacteriaceae’ 
were not given. This finding is supported by the significantly higher proportion of MD trained 
respondents’ (who are all trained and certified sub-specialists), compared to others’, reporting of 
use of CP for CRE. Other respondents (94% from a nursing background) would have a more varied 
clinical and academic background than the MDs, and may not have managed patients with CRE or 
have  been familiar with aspects of CRE, given its relative infrequency in Australia.[43] 
To some extent, both possibilities indicate a number of vulnerable Australian hospitals, where 
patients with CRE may not have an appropriate assessment of their infection control needs. Within 
misclassification, it is difficult to determine for what proportion the issue is simply a lack of 
knowledge of current terminology, as opposed to a greater knowledge gap around the potentially 
varied clinical and laboratory characteristics of CRE and the serious implications of the phenotype. 
Our findings on the predictors of ESBL-E and CRE practice offer insight into some of the 
pragmatic aspects of determining MRGNB policy.  
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For ESBL-E infection control, practitioners have potentially sought a balance between the low risk 
of nosocomial transmission of ESBL-E[94] and the various burdens of CP. Hospitals that were 
likely to have a high load of ESBL-E harbouring patients, due to their generally higher acuity 
(metropolitan and public hospitals), were more likely to use a permissive policy to limit use of CP 
for this phenotype. Interestingly, the only four sites that did not use any CP for ESBL-E were 
principal referral sites with a supra-regional referral patient load. 
Predictors of CP use in CRE illustrate the benefits and risks of layering state-based legislation on 
healthcare services. When used in a targetted manner, this can be effective in filling a void in 
national policy. Operating under a CRE directive was a significant predictor of the use of CP for 
CRE (and for IT-patients who are also covered by the policy).  
In contrast, the general MRO directive appears to be ineffective. Despite 90% of sites in the state 
indicating they used directives to formulate policy, it did not have a significant impact on infection 
control practice for the emerging threats of CRE and IT-patients. Even for ESBL organisms (which 
are specifically mentioned in the document), sites have either disregarded, or gradually moved away 
from the stipulated management. 
IT-patients are an emerging risk group with which other regions are also grappling.[366] For the 
use of CP, the significant predictive value of the presence of a written policy for IT-patients, should 
be interpreted in light of the 31% missing-data and 33% discordance rate on answers to this 
question. There is some misclassification. Taken as a whole, these pieces of data indicate a limited 
knowledge of this risk-group and of details of policy even where this does exist. 
A key strength of our study is the national sample and the broad mix of hospital types, including 
thought leading sites where future infectious disease and infection control physicians train. Other 
studies in this area have looked either within smaller more homogenous groups or across multiple 
countries.[357, 358] 
A limitation of our study is selection bias. ‘Large’ hospitals were over-represented amongst 
respondents. Similarly, the methodology biased our sample towards a subset of infection control 
departments; those that are active on infection control, email bulletins and were motivated to 
participate.  
Our survey design captured practice rather than exact policy content. Thus, the answers reflect one 
or few individuals’ practice, and may not be representative of the majority at the site. This is 
demonstrated by the analysis of multiple responders. With the exception of the questions on written 
policy (for which the question text required a subjective decision), discordant answers occurred in 
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aspects of policy that may be less commonly used (CRE, IT-Patients and AmpC organisms). 
However, differing interpretations of policy were very frequent. Exploration of the relationship 
between rates of discordant answers and actual variation in practice should be an area of  future 
research.  
Misclassification complicates interpretation of our results. For CRE and IT-patients, it is difficult to 
untangle whether findings represent a gap in knowledge of terminology/policy content or a true 
absence of policy. We believe misclassification is a lesser problem for ESBL-E data as the 
terminology is common in Australian infection control literature.[86] 
An important factor not easily accounted for in our analysis is the exchange of information and 
centralisation of policy amongst local regions or private sector groups, independent of binding-
directives or published recommendations. 
Finally, the applicability of our findings may vary by country. The impact of state-based policy will 
differ depending on the governance structure of the country involved. The frequency, nature and 
risk of IT-patients will vary by country and travel patterns. 
In conclusion, infection control management of MRGNBs varies widely amongst adult acute care 
hospitals in Australia. We demonstrate a vulnerability of some Australian hospital’s infection 
control practice in the management of CRE harbouring and IT-patients. This is due to a limited 
knowledge of aspects of these risk-groups amongst some practitioners, an absence of policy and a 
lack of knowledge of policy. We await the likely positive impact of recently released national 
recommendations on infection control management of CRE in improving and harmonising practice 
within Australia.[63] 
Acknowledgements 
We gratefully acknowledge the ICPs who took the time to pilot our survey and provide feedback. 
We thank Dr Muller and the other authors of the Canadian survey for allowing us to use questions 
from their survey. Many thanks to Dr Lisa Hall (QUT, Queensland, Australia) for her critical 
appraisal of an earlier draft of this manuscript. 
Conflicts of Interest 
BAR is supported by an Australian Post Graduate Award Scholarship 
DLP has received honoraria from AstraZeneca, Merck and Pfizer 
SMH is supported by an Australian Post Graduate Award Scholarship 
	  
 
129 
TMB - None  
	  
 
130 
FIGURES AND TABLES 
Table 1 
Infection control management of ESBL-E, CRE and internationally transferred patients (n=97). 
 ESBL-E CRE International Transfer of patients 
Precautions used Use Do not use Unknown Use Do not use Unknown Use Do not use Unknown 
Any CP use 93(96) 4(4) 0 79(81) 18(19) 0 48 (49) 19(20) 30 (31) 
Glove and Gown  88(91) 8(9) 0 73(75) 20(21) 4(4) 36 (37) 31(32) 30 (31) 
Single Room* 91(94) 5(5) 1(1) 75(77) 18(19) 4(4) 48 (49) 19(20) 30 (31) 
Cohort Room 28(29) 69(71) 0 21(22) 76 (78) 0 NA NA NA 
*For International transfer single room & cohort were not differentiated in the survey.  
ESBL-E = Extended spectrum beta-lactamase harbouring Enterobacteriaceae, CRE=Carbapenem resistant Enterobacteriace 
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Table 2. 
Descriptive analysis of predictors of infection control management. 
The second column contains data on the proportion of hospitals with the specified characteristic amongst the entire cohort. The three groups of 
data following this are descriptive analysis of the use of CP as follows: i) A permissive policy for ESBL-E ii) Any use of CP for CRE iii) Any 
use of CP for IT-patients. 
ESBL-E CRE International transfers of patients 
Predictive 
Characteristics 
Count amongst all 
hospitals (%) 
N=97 
Count with 
permissive use of 
CP for ESBL-E (% 
of total with 
permissive use) 
n=44 
Count with 
inclusive use of 
CP for ESBL-E 
(% of total with 
inclusive use) 
n=48 
Odds Ratio 
(95%CI) 
p value 
Count with any use 
of CP for CRE (% 
of total using CP for 
CRE) 
N=79 
Count who do not 
use CP for CRE (% 
of total not using 
CP) 
N=18 
Odds Ratio 
(95%CI) 
p value 
Count with any 
use of CP for 
International 
transfers (% of 
total with using 
CP) 
N=48 
Count who do 
not use CP for 
International 
transfers (% 
of total not 
using CP) 
N=19 
Odds Ratio 
(95%CI) 
p value 
Public (vs. private) 68 (70) 37(84) 31(65) 4.1(1.5-11.1) 0.005 54(68) 25(32) 0.6(0.2-2.1) 0.436 33(69) 15(29) 0.6(0.2-2.1) 0.411 
Metropolitan location  
(vs. regional and rural) 
58 (60) 32 (73) 26 (54) 2.7 (1.1-6.4) 0.028 51 (72) 7 (39) 2.9 (1.0-8.3) 0.052 33 (69) 13 (68) 1.0 (0.3-3.2) 0.979 
ID service 57 (59) 29(66) 28(58) 1.5 (0.6-3.5) 0.347 49(62) 8(44) 2.0(0.7-5.8) 0.179 30(63) 16(84) 0.3(0.1-1.2) 0.097 
Written policy on 
phenotype/patient 
group 
ESBL-E =38 (39) 
CRE = 22 (23) 
IT-Patients – 50 (52) 
17(39) 21(44) 0.8(0.4-1.9)  0.621 22(23) 0(0) 0.011 36 (75) 8(42) 3.2(1.4-7.6) 0.006 
Written policy on MBL 21 (22) NA NA NA NA 18 (23) 3(17) 1.5 (0.4-5.7) 0.571 NA NA NA NA 
MRO directive 21 (22) 9(20) 12(25) 0.8(0.3-2.1) 0.606 19(24) 2(11) 3.6(0.7-17.1) 0.116 9(19) 7(37) 0.7(0.2-2.3) 0.522 
CRE directive 17 (18) 9(20) 8(17) 1.3(0.4-3.7) 0.642 17(100) 0(0) 0.030 16(33) 0(0) 0.003 
Regular international 
transfers* 
28 (33) 16(41) 12(25) 1.7(0.7-4.4) 0.244 27(39) 1(6) 10.3(1.3-
83.1) 
0.029 21(46) 7(41) 1.2(0.4-3.7) 0.753 
Large hospital  59 (61) 32(73) 27(56) 2.25(0.9-5.4) 0.069 49(62) 10(56) 1.3(0.5-3.7) 0.614 32(68) 15(79) 0.5(0.2-1.9) 0.330 
Principal referral vs. 43 (44) 25(57)) 18(34) 2.6(1.1-5.9) 0.026 38(48) 5(28) 2.4(0.8-7.4) 0.126 25(52) 12(63) 0.6(0.2-1.9) 0.416 
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other 
Transplant service ** 20 (21) 14/25(56) 6/18(33) 2.3(0.6-8.4) 0.196 19/38(50) 1/5(20) 4.0(0.4-40.2)  0.239 13(52) 5(42) 1.5(0.4-6.2) 0.562 
Other supra-regional 
referral services** 
21 (22) 14/25(56) 7/18(39) 2.3(0.6-8.4) 0.196 20/38(53) 1/5(20) 4.4(0.4-44.7) 0.205 15(60) 4(33) 3.0(0.7-12.9) 0.141 
CP= Contact Precautions, ESBL-E = Extended spectrum beta-lactamase harbouring Enterobacteriaceae, CRE= Carbapenem resistant Enterobacteriaceae MBL= Metallo beta-
lactamase harbouring bacteria 
* Hospitals considered to have ‘Regular international transfer’ of patients hospitals reported a frequency of ‘less than monthly’ or greater. ** Variables analysed only within
principal referral hospitals.
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Table 3 
Multivariate analysis of the predictors of a permissive practice for ESBL-E, and any use of precautions for CRE and international transfer 
patients 
Predictive Characteristics 
Permissive policy for CP use 
for ESBL-E 
Any CP use for CRE Any CP use for 
International transfer patients 
n=44/92 (48%) with permissive policy 
n=5 with missing data
n=79/97 (81%) use CP
n=38/67 (72%) 
n=30 with missing data
Multivariate OR (95%CI)  p value Multivariate OR (95%CI)  p value Multivariate OR (95%CI)   p value 
Public (vs. private) 4.8 (1.7-13.4) 0.003 
Metropolitan location  (vs. regional and rural) 3.2 (1.3-8.1) 0.014 
ID service 0.2 (0.3-0.9) 0.041 
Specific written policy* 0.011 3.4 (1.2-9.7) 0.025 
MRO directive 2.8 (0.4-14.8) 0.218 
CRE directive 0.030 0.003 
Regular international transfers 4.6 (0.5-40.3) 0.166 
Non-Transplant Supra-Regional Services** 3.4(0.7-15.5) 0.118 
ID service = Infectious Disease service, ESBL-E = Extended spectrum beta-lactamase harbouring Enterobacteriaceae, CRE=Carbapenem resistant Enterobacteriaceae, MRO = Multi-resistant organism 
*Written policy on infection control of phenotype or patient group.
**Cystic Fibrosis, Burns, Spinal Injury 
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Figure 1 
Breakdown of strategies for the use of contact precautions for ESBL-E, CRE and IT-
Patients. Boxes shaded in white indicate an inclusive or unknown strategy. Boxes 
shaded in grey indicate a permissive strategy. 
Panel A – ESBL Enterobacteriaceae 
Panel B – Carbapenem Resistant Enterobacteriaceae 
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Panel C – International Transfer of Patients 
 
1 Organisms considered for CP amongst ESBL-E=Escherichia coli + Klebsiella pneumoniae (11/22, 50%), K. pneumoniae (5/22, 
23%), E. coli (2/22, 10%) and neither/unsure (5, 23%). Amongst CRE = E. coli + K. pneumoniae (n=2/7, 29%), K. pneumoniae 
only (n=3/7,43%), neither/unsure (n=2/7, 29%). 
2Patient-assessment for CP for ESBL-E included; Ward location (15/29, 51%); and clinical features of the patient (e.g. sample of 
origin for isolate, presence of diarrhoea) (23/29, 79%); Three sites 3/29 (10%) indicated neither of these factors was used in their 
assessment. For CRE patient-based assessment included the ward location (3/11, 27%) and clinical features (8/11, 73%). Three 
sites (3/11, 27%) indicated neither of these was used for their assessment. 
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CHAPTER 7. CONCLUSION 
The previous decades have seen a marked expansion of antimicrobial resistant E. coli, increasing 
the burden of antimicrobial resistant infections amongst humans worldwide. Two plasmid-borne 
beta-lactamase antimicrobial resistance mechanisms, ESBLs and carbapenemase, have been major 
contributors to this change. The research program presented in this thesis aimed to gain further 
insight into significant aspects of antimicrobial resistant E. coli worldwide. 
A review of the published literature defined key phenomenon pertinent to the spread of 
antimicrobial resistance. The ST131 E. coli pandemic clone represents a new convergence of 
virulence and resistance. As delineated in the review of ST131, this facilitated a rapid geographical 
spread of the ST131 clone, harbouring a surprising diversity of resistance mechanisms. The ultimate 
consequence of this spread is an ongoing incursion of ESBL harbouring and/or fluoroquinolone 
resistant E. coli into many clinical infections.[165] 
Spread of antimicrobial resistance due to human travel is not new. However, in the previous decade 
several factors have increased the risk to humans posed by this mechanism of dissemination. 
Firstly, human travel patterns have changed with a greater number of people undertaking long 
distance and/or intercontinental travel. This includes more travellers with potential overseas 
healthcare contact either due to pre-existing medical conditions or from seeking medical treatment 
abroad. Secondly, we have seen the emergence of several new carbapenemase mechanisms such as 
blaNDM and blaoxa-48, initially in geographically defined distributions.[96] The review presented on 
this topic has acted as a fulcrum for discussion and research in this sphere, with many authors citing 
this work as background for further scientific study. 
With Australia and New Zealand a central focus of the clinical and laboratory research, new 
insights into ESC-R-EC, both regionally and worldwide   have been gained. The unique geography, 
demography and antimicrobial use patterns in our region have led to a distinct epidemiology of 
3GCR-EC. From the case-control study we demonstrate a persisting mix of ‘old’ and ‘new’ 
epidemiology. Whilst traditional risks, such as healthcare contact and antimicrobial use, remain 
highly significant, we see risks defining this new epidemiology including overseas travel, and 
transmission in ethnic groups that originate from regions of high community transmission. Within 
this analysis, the modelling of healthcare associated 3GCR-EC shows, for the first time, the 
persistence of risk after healthcare contact, and the implications this has within and outside 
healthcare institutions.[329]  
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Work on the dynamics and carriage of resistant E. coli in returned travellers gives further insight 
into the carriage and spread within the community after return from high-incidence countries. 
Delineation of prolonged clonal carriage after travel indicates a potential source of transmission 
within communities that include frequent travellers to high incidence areas. The prolonged carriage 
and potential introduction of fluoroquinolone and aminoglycoside resistance have significant 
implications in communities where this resistance is otherwise infrequent. At the same time, we 
offer some optimism demonstrating a relatively rapid clearance of GIT carriage of ESBL-EC from 
selected carriers.[318]  
Within returned travellers and the case-control study group, laboratory research included a 
significant focus on ST131 E. coli, given its global importance.  This offered several novel insights 
into our region. The first was the surprisingly low overall prevalence of the clone and the 
implication of a relationship this may have with low overall rates of fluoroquinolone use.  
The second was the globally comparable rates of ST131 and the H30 sub-clone within ESC-R-EC 
and the relative homogeneity amongst ST131 and other ESBL harbouring E. coli in our 
region.[367] This confirms the rise of ST131 as the preeminent ESBL E. coli in almost all corners 
of the globe. 
Finally, the analyses of the infection control management of patients harbouring ESBL-E, CRE and 
those with overseas healthcare contact, complemented the clinical and laboratory research within 
this thesis.  It identified key challenges for the infection control community in Australia and abroad. 
Locally, there is an apparent lack of understanding of new mechanisms of resistance, such as CRE, 
and a potential underestimation of the risk of introduction and spread into health services.[368] 
Secondly, whilst we appropriately defined many permutations of infection control policy for these 
pathogens, many points of difference between policies lack rigorous scientific research to support 
the approach taken.  
In summary, key findings of the research program within this thesis include 
• Demonstration that healthcare contact remainings the pre-eminent risk for ESC-R-EC in
Australia and the emergence of new risk factors related to travel and country of birth.
• Identification of a unique molecular epidemiology of antimicrobial susceptible and resistant
E. coli in the Australian region.
• Demonstration of a relatively short average duration of carriage of ESC-R-EC in returned
travellers harbouring these isolates in their gastrointestinal flora.
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• Demonstrating wide spread variation in infection control management of patients with ESC-
R-EC and CRE within Australia. 
FUTURE RESEARCH 
Epidemiology 
This thesis has focused on aspects of antimicrobial resistant E. coli in a cross-sectional manner. 
Equally important in the thesis is the delineation of the temporal and geographical trends of 
resistance. Current information gleaned by comparing widely spaced snapshot samples has obvious 
limitations. Expansion of epidemiological investigation beyond humans is also important. This 
includes in-depth investigation of E. coli resistance in animals, including ESC and other 
antimicrobial classes, food and companion animals. The dynamics of bacterial sharing between 
humans and animals via food or other contact is at present poorly understood. 
From a regional perspective, whilst animal antimicrobial use patterns may differ from many other 
areas, there has been no recent comprehensive investigation of this topic to confirm ongoing low 
rates of resistance, as have been presumed in Australia and New Zealand. Finally, the case-control 
study indicates undefined risks for transmission within our community that require further 
elucidation. 
Modification of risk factors and active decolonisation 
A number of the new risk factors for ESC-R-EC infection such as overseas travel and membership 
of certain ethnic groups are complex in nature. Within these exposures some components (e.g. 
water or food consumption, hygiene practices) likely represent the major contributors to the risk of 
ESC-R-EC colonisation and infection. These components could be identified and trialled as 
modifiable risk factors. Furthermore, the potential role of decolonisation, either through 
pharmacological or non-pharmacological measures, could be investigated for high-risk patients who 
have become colonised.  
Infection control 
Although we now have a basic understanding of the transmissibility of ESBL-E in some clinical 
environments, much empiric research is still required. A greater diversity of clinical settings must 
be studied to more broadly understand ESBL-E transmission in healthcare settings and the 
community.  Likewise, differences in the transmissibility of carbapenem resistant E. coli, compared 
with ESBL-E must also be investigated. Rigorous studies to support strategies such as risk 
stratification of patients are also required.  
Genetics and genomics 
In the years since publication of this review, there has been a considerable increase in scientific 
effort to understand the genetic basis and clinical implications of the ST131 clone. A number of 
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these studies are now coming to fruition, providing insight into the clone’s pathogenicity and 
propensity to acquire resistance. However, further research is still required to understand the genetic 
mechanisms supporting the rapid global spread of this clone, and its apparent selective advantage 
over other E. coli. 
One area of bacterial genetics poorly investigated is that of colonising bacteria. As our traveller 
analysis demonstrated, there was considerable variability in the persistence of given clones. 
Investigation of the genetic mechanisms that predispose bacteria to colonisation and genetic and 
metabolic changes that occur in bacteria with prolonged colonisation, will give considerable insight 
into this phenomenon and may identify future therapeutic targets. 
Thus far, there is also little data available to understand the human genetic contribution to 
antimicrobial resistant E. coli infection. Potentially, some of the difference in incidence of 
resistance across communities may originate from the genetic background of the colonised or 
infected people.  
Therapy 
Whist therapy of ESC-R-EC was not covered in this thesis, further study in this area remains 
crucial. Few controlled studies have been undertaken to define optimal antimicrobial therapy for 
severe ESC-R-EC infection. Likewise there are no rigorously investigated oral therapy options 
defined for non-severe ESC-R-EC infection. Given our emerging insight into the genetics of clones 
such as ST131, non-antimicrobial therapies also warrant further investigation. Mechanisms 
governing bacterial pathogenicity such as cell adhesion and migration may be important future 
therapeutic targets. 
Economic implications 
It is important to establish the true economic impact of antimicrobial resistant E. coli in the 
community and hospital. When available, data of this type acts as a strong imperative for funding 
further research in the area. In addition it allows for detailed cost-effectiveness assessment of any 
proposed therapies or other control measures. 
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SUPPLEMENTARY MATERIAL FOR CHAPTER 3 
Escherichia coli infection resistant to expanded-spectrum cephalosporins in low-prevalence countries 
Antimicrobial Agents and Chemotherapy, Volume 58, 2014 
Benjamin A Rogers, Paul R Ingram, Naomi Runnegar, Matthew C Pitman, Joshua T Freeman, Eugene Athan, Sally N Havers, Hanna E Sidjabat, Mark 
Jones, Earleen Gunning, Mary De Almeida, Kaylene Styles, David L Paterson, on behalf of the Australasian Society for Infectious Diseases Clinical 
Research Network 
A. Additional definitions
B. Details of healthcare exposure by Friedman classification
C. Comparison of multivariate models using alternative definitions
D. Comparison of multivariate models using alternative patient groups
E. Comparison of healthcare associated and non-healthcare associated ESC-R-EC
F. Analysis of correlates of ESC resistance enzyme class
G. References for Supplementary Material
A. Additional Definitions
Chronic renal failure was a baseline creatinine clearance <50ml/min/m2; Chronic heart failure[369], chronic lung disease[370] were based on published functional definitions;
Chronic liver disease included a history of cirrhosis or hepatic decompensation; Active malignancy was any malignancy, except isolated skin malignancy;; Indigenous patients
were members of the Australian Aboriginal, Maori or Torres Strait islander community.  Meat consumption (red meat, poultry, pork and processed meat) was any consumption in
the month preceding infection.
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B. Healthcare exposure analysis using the Friedman classification 
Details of healthcare exposure using the Friedman classification with and without the inclusion of day-procedures as healthcare exposure. 
Time since exposure1 Frequency in 
ESC-R Cases 
(%) n=91 
Frequency in 
ESC-S 
Controls (%) 
n=91 
Odds 
Ratio  
(95% CI) p value 
Including day surgical and medical procedures2 
No healthcare exposure 26 (29) 42 (46) Reference   
Healthcare <1 month ago 16 (18) 7 (8) 3.692 (1.34-10.18) 0.012 
2-6 months ago 40(44) 30 (33) 2.154 (1.09-4.25) 0.027 
7-12 months ago 9 (10) 12 (13) 1.212 (0.45-3.27) 0.705 
Excluding day surgical and medical procedures3 
No healthcare exposure 55 (60) 34 (37) Reference   
Healthcare <1 month ago 11 (12) 5 (5) 3.559 (1.14-11.14) 0.029 
2-6 months ago 37(41) 20 (22) 2.993 (1.50-5.98) 0.002 
7-12 months ago 9 (10) 11 (12) 1.323 (0.50-3.52) 0.575 
 
1Durations are calculated from the date-of-discharge to date of first presentation of the current infection. 
2With day-procedures: AUC = 0.62, Sensitivity = 62% Specificity = 59%.  
3Without day-procedures: AUC = 0.64, Sensitivity=53% Specificity = 73%. 
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C. Comparison of the final multivariate model and models using alternative definitions.
Parameters changed in the alternative models are underlined. Where the significance (of the odds ratios) has moved across the pre-defined (p=0.05) 
threshold when compared with the final model, this is shaded in grey. 
Final Model  Final Model 
Odds Ratio  
(95% CI) 
p value 
Alternative 1 
Healthcare 
Including day 
procedures 
Alternative 1 
Odds Ratio  
(95% CI) 
p value 
Alternative 2 
Any healthcare 
exposure in the 
previous year 
Alternative 2 
Odds Ratio  
(95% CI) 
p value 
Alternative 3 
Birth in high-risk 
regions 
Alternative 3 
Odds Ratio  
(95% CI) 
p value 
Alternative 4 
Travel to Indian 
subcontinent 
Alternative 4 
Odds Ratio  
(95% CI) 
p value 
Alternative 5 
Exposure to 
TMP/SMX 
without combining 
ESC 
Alternative 5 
Odds Ratio  
(95% CI) 
p value 
Healthcare 
exposure in the 
previous 6 months 
(excluding day 
prodecdures 
3.16 
(1.54-6.46) 
0.002 
Healthcare 
exposure in the 
previous 6 months  
2.22 
(1.11-4.43) 
0.023 
Any healthcare 
exposure in the 
previous year 
1.90 
(0.90-3.99) 
0.092 
As per final model 2.68 
(1.33-5.41) 
0.006 
As per final model 2.58  
(1.30-5.10) 
0.006 
As per final model 3.24 
(1.59-6.60) 
0.001 
UTIs in previous 
year  (per UTI) 
1.43 
(1.16-1.82) 
0.003 
As per final model 1.44 
(1.14-1.83) 
0.002 
As per final model 1.44 
(1.14-1.83) 
0.002 
As per final model 1.38 
(1.09-1.75) 
0.008 
As per final model 1.39 
(1.10-1.75) 
0.005 
As per final model 1.43 
(1.13-1.81) 
0.003 
Birth on the Indian 
subcontinent 
11.13 
(2.17-56.96) 
0.004 
As per final model 10.63  
(2.08-54.26) 
0.004 
As per final model 9.67  
(1.91-48.95) 
0.006 
Birth in high-risk 
regions 
2.05 
(0.6-5.52) 
0.0157 
As per final model 8.48 
(1.43-50.41) 
0.019 
As per final model 10.60 
(2.08-54.09) 
0.005 
Travel to high-risk 
regions 
3.09 
(1.29-7.38) 
0.011 
As per final model 2.60 
(1.10-6.13) 
0.029 
As per final model 2.65 
(1.12-6.28) 
0.027 
As per final model 2.76 
(1.13-6.74) 
0.026 
Travel to the Indian 
subcontinent 
2.99  
(0.23-39.38) 
0.23 
As per final model 2.88 
(1.21-6.85) 
0.016) 
Trimethoprim +/- 
Sulfamethoxazole   
&/or ESC 
3.67 
(1.30-10.35) 
0.014 
As per final model 3.75  
(1.33-10.54) 
0.012 
As per final model 3.57 
(1.27-10.08) 
0.016 
As per final model 3.48 
(1.24-9.79) 
0.018 
As per final model 3.10 
(1.12-8.60) 
0.003 
Trimethoprim+/- 
Sulfamethoxazole  
2.66 
(0.91-7.75) 
0.073 
Male sex 2.17 
(0.97-4.84) 
0.060 
As per final model 2.20 
(0.99-4.87) 
0.052 
As per final model 2.34 
(1.07-5.13) 
0.034 
As per final model 2.30 
(1.05-5.06) 
0.037 
As per final model 2.52 
(1.14-5.54) 
0.022 
As per final model 2.31 
(1.04-5.12) 
0.039 
Characteristics: 
ROC AUC 
GOF=Goodness of 
fit 
0.772 
GOF=0.289 
0.766 
GOF = 0.36 
0.762 
GOF = 0.15 
0.752 
GOF=0.12 
0.7614 
GOF=0.35 
0.763 
GOF=0.28 
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D. Comparison of multivariate model using alternative patient groups 
The group used in the alternative model is contained in the first row. Where the significance (of the 
odds ratios) has moved across the pre-defined (p=0.05) threshold when compared with the final 
model, this is shaded in grey. 
 
Final Model  Final Model 
 
Odds Ratio  
(95% CI) 
p value 
Alternative 1 
Exclusion of 
asymptomatic 
patients 
Case n=73 
Control n=68 
 
Odds Ratio  
(95% CI) 
p value 
Alternative3 
Inclusion of only 
CTX-M E. coli 
cases  
Case n=74 
Control n=91 
 
Odds Ratio  
(95% CI) 
p value  
 
Alternative3 
Inclusion of only 
ST131 E. coli 
cases  
Case n=40 
Control n=91 
 
Odds Ratio  
(95% CI) 
p value  
 
Healthcare 
exposure in the 
previous 6 months 
(excluding day 
prodecdures 
3.16 
(1.54-6.46) 
0.002 
3.66 
(1.61-8.32) 
0.002 
6.62 
(2.81-15.61) 
<0.001 
7.67 
(2.66-4.15) 
<0.001 
UTIs in previous 
year  (per UTI) 
1.43 
(1.16-1.82) 
0.003 
1.47 
(1.10-1.95) 
0.008 
1.30 
(0.99-1.72) 
0.062 
1.39 
(1.01-1.92) 
0.044 
Birth on the Indian 
subcontinent 
11.13 
(2.17-56.96) 
0.004 
9.19  
(2.02-57.42) 
0.004 
18.1 
(3.21-102.04) 
0.001 
34.11 
(5.25-221.49) 
<0.001 
Travel to high-risk 
regions 
3.09 
(1.29-7.38) 
0.011 
2.60 
(1.01-6.65) 
0.047 
5.72 
(2.10-15.54) 
0.001 
4.10 
(1.10-15.29) 
0.036 
Trimethoprim +/- 
Sulfamethoxazole   
&/or ESC 
3.67 
(1.30-10.35) 
0.014 
3.02 
(0.94-9.73) 
0.064 
3.91 
(1.29-12.21) 
0.016 
3.52 
(0.91-13.70) 
0.069 
Male sex 2.17 
(0.97-4.84) 
0.060 
2.56 
(1.06-6.16) 
0.036 
2.09 
(0.88-4.98) 
0.095 
2.17 
(0.77-6.15) 
0.143 
Characteristics: 
ROC AUC 
GOF=Goodness of 
fit 
0.772 
GOF=0.289 
0.780 
GOF = 0.247 
0.818 
GOF = 0.138 
0.830 
GOF = 0.018 
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E. Differences in risks between healthcare associated (HA) and non-healthcare associated (non-HA) ESC-R-EC groups after
stratification by healthcare contact in the previous six months excluding day-procedures.
Healthcare associated cohort (n=73) Non-healthcare associated cohort (n=109) 
Potential Risk Count of cases with 
characteristic n=48 (%) 
Count of controls with 
characteristic n=25 (%)  
p value for comparison 
case vs. controls 
Count of cases with 
characteristic n=43 (%) 
Count of controls with 
characteristic n=66 (%)  
p value for comparison 
case vs. controls 
Birth on the Indian 
subcontinent 
2 (4) 0 (0) 0.543 9 (21) 2 (3) 0.006 
Travel to high-risk 
regions 
4 (8) 3 (12) 0.685 20 (47) 11 (17) 0.001 
Trimethoprim +/- 
Sulfamethoxazole &/or 
ESC use 
15 (31) 2 (8) 0.039 5 (12) 4(6) 0.313 
Male sex 16 (33) 7 (28) 0.642 14 (33) 9(14) 0.018 
UTIs in previous year 
(Count, 25-75%) 
1, 0-3 1, 0-1 0.347 0, 0-3 0, 0-1 0.146 
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F. Analysis of correlates of ESC resistance enzyme class 
Comparing characteristics of patients harbouring CTX-M group enzymes to those harbouring ‘Non-CTX-M’ group enzymes. 
Variable Frequency in CTX-M group (%) n=74 Frequency in non-CTX-M group (%) n=15 
p value  
CTX-M vs. Non-CTX-M 
Variables included in the multivariate model 
Male Sex 26 (35) 4(27) 0.527 
Charlson score ≥1 38 (51) 6(40) 0.423 
Immune suppression 17 (23) 1(7) 0.288 
Anatomical or structural abnormality 18(24) 4(26) 1.0 
UTIs in past 12 months (Median & (25-
75th centile)) 0 (0-2) 2(0-4) 0.054 
SXT use 14 (19) 2(13) 1.0 
ESC use 5 (7) 2(13) 0.336 
High risk travel 23(31) 1(7) 0.061 
Birth on Indian Subcontinent 11 (15) 0(0) 0.199 
Healthcare Exposure (6 months) 45(61) 3(20) 0.005 
Other variables 
Age (Median & (25-75th centile)) 60 (41-71) 70(58-78) 0.061 
Any overseas travel 27 (36) 1(7) 0.031 
Any antimicrobial use 54 (73) 14(93) 0.108 
Renal transplant 8 (11) 0 (0) 0.342 
Fluoroquinolone use 6(8) 1(7) 1.0 
ß-lactam + ß-lactamase inhibitor use 9 (12) 5(33) 0.055 
Carbapenem use 3(4) 0(0) 1.0 
Aminoglycosides use 5(7) 0(0) 0.584 
Macrolide use 4(5) 1(7) 1.0 
Narrow spectrum cephalosporin use 13(18) 2(13) 1.0 
Narrow spectrum penicillins use 8(9) 0(0) 0.342 
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SUPPLEMENTARY MATERIAL FOR CHAPTER 4 
Sequence Type 131 fimH30 and fimH41 Subclones Amongst Escherichia coli Isolates in 
Australia and New Zealand 
Under Review, Antimicrobial Agents and Chemotherapy, 2014 
Benjamin A Rogers, Paul R Ingram, Naomi Runnegar, Matthew C Pitman, Joshua T Freeman, 
Eugene Athan, Sally Havers, Hanna E Sidjabat, Earleen Gunning, Mary De Almeida, Kaylene 
Styles, David L Paterson, ASID CRN 
Supplementary 1. 
Comparison of phenotypic resistance of ST131 and non-ST131 isolates amongst different cohorts. 
 Whole 3GC resistant cohort 
Count of  resistant isolates (%) 
CTX-M harbouring 
Count of  resistant 
isolates (%) 
Whole 3GC susceptible cohort 
Count of  resistant isolates (%) 
 
ST131 
n=40 
Non-
ST131 
n=49 p value 
Non-
ST131 
N=34 
p value* 
 
ST131 
N=6 
Non-
ST131 
N=84 p value 
Individual agents         
Ampicillin 40(100) 49(100) 1.0 34(100) 1.0 4(67) 46(55) 0.689 
Amox + clav 23(57) 34(69) 0.245 17(56) 0.889 4(66) 2(33) 0.261 
Ceftriaxone 40(100) 46 (94) 0.111 34(100) 1.0 NA NA NA 
Ceftazidime 26(65) 35(71) 0.516 20(59) 0.585 NA NA NA 
Cefepime 23(58) 26(53) 0.675 23(68) 0.370 0 0 1.0 
Amikacin 2(5) 2(4) 1.0 2(6) 1.0 0 0 1.0 
Gentamicin 14(35) 25(51) 0.130 24(71) 0.005 2(33) 1 (1) 0.011 
Ciprofloxacin 35(87) 22(45) <0.001 21(62) 0.010 2(33) 4(5) 0.050 
SXT 34(85) 30(61) 0.013 26(76) 0.351 2(33) 18(21) 0.611 
Nitrofurantoin 3(8) 5(10) 0.726 4(12) 0.696 0 3(4) 1.0 
Meropenem 0  0  NA 0  NA 0  0  NA 
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Combinations         
Total resistance score 
Median (25-75%) 6(4-7) 5 4-6) 0.116 5(5-8) 0.899 2(1-3) 1(0-2) 0.077 
Ciprofloxacin + SXT 
resistance 30(75) 19(39) <0.001 19(73) 0.083 0 3(4) 1.0 
Amoxicillin + clav = Amoxicillin + clavulanic acid 
SXT= Trimethoprim + sulfamethoxazole 
* Comparator group is the ESC-R ST131 isolates (first column of this table).  
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Supplementary 2 
Estimated population burden of MLST defined clones including total E. coli, fluoroquinolone 
resistant E. coli and expanded-spectrum cephalosporin resistant E. coli. 
Clone 
Count	  
amongst	  
ESC-­‐S-­‐EC	  
(n=90) 
Count	  
amongst	  
ESC-­‐R-­‐
EC	  
(n=89) 
Count	  of	  
FQ	  
resistant	  
amongst	  
ESC-­‐S-­‐EC 
Count	  of	  
FQ	  
resistant	  
amongst	  
ESC-­‐R-­‐
EC 
Adjusted	  
population	  
prevalence	  1 
Lower	  
estimate	  1 
Upper	  
estimate	  1 
Proportional	  
contribution	   to	  
fluoroquinolone	  
resistance 
Proportional	  
contribution	   to	  
3GC	  resistance 
All	   ESC-­‐R	  
isolates 0 89 0 56 0.034 0.026 0.043 0.249 1 
All	  ST131 6 40 2 35 0.08 0.076 0.083 0.406 0.449 
ST131	   -­‐	  
H30 2 35 2 35 0.0348 0.032 0.038 0.406 0.393 
ST131-­‐	  H41 4 5 0 0 0.045 0.045 0.045 0 0.056 
ESC-­‐S	  
ST131	   6	   0	   4	   0	   0.064	   0.064	   0.065	   0.025	   0	  
ST95 13 2 1 1 0.14 0.141 0.139 0.130 0.022 
ST73 12 1 0 0 0.129 0.130 0.128 0 0.011 
ST14c 8 2 2 1 0.087 0.087 0.086 0.255 0.022 
ST80 5 0 0 0 0.054 0.054 0.053 0.0 0 
ST127 5 1 0 0 0.054 0.054 0.054 0.0 0.011 
ST69 2 5 0 0 0.023 0.023 0.024 0.0 0.056 
ST648 1 5 0 2 0.013 0.012 0.013 0.008 0.056 
Sporadic 38 33 1 18 0.42 0.421 0.420 0.207 0.371 
1Prevalence estimates are based on a 3.4% ESC-R E. coli rate amongst the population. Lower estimates are based on 
2.6% ESC-R and upper on a 4.3% ESC-R E. coli rate. ESC-S-EC = expanded-spectrum cephalosporin susceptible E. 
coli. ESC-R-EC = expanded-spectrum cephalosporin resistant E. coli. FQ = fluoroquinolone, ST14C= ST14 complex, 
Sporadic = isolates not typed to an MLST cluster.  
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Supplementary 3 
Dendrogram constructed using a Pearson correlation coefficient, based on DiversiLab rep-PCR 
pattern of ST131 E. coli. Details of figure from left to right: Dendrogram, isolate number, virtual 
gel. Numbered columns from left to right: I = expanded-spectrum cephalosporin susceptibility, 
II=fluoroquinolone susceptibility, III=fimH type. 
II"I" III"
fimH"41"
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! !
!
Isolate"
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SUPPLEMENTARY MATERIAL FOR CHAPTER 6 
Predictors of use of infection control precautions for multi-resistant gram-negative bacilli 
in Australian hospitals: Analysis of a national survey 
American Journal of Infection Control, In-Press, May 2014 
Rogers BA, MBBS, FRACP1, Havers SM, BNurs MPH1, Brown TM, BNurs MPH1, Paterson DL, 
MBBS, FRACP, FRCPA, PhD1 
Supplementary Material 
1. Synopsis of infection control guidelines and directives
2. External data used to confirm hospital demographics
3. Numerical comparison of survey respondents to national demographics
4. Analysis of multiple responders
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1.  Comparison of National Infection Control Guidelines and relevant state-based directives. 
Issuing Body Australian National Health and Medical 
Research Council  
Ministry of Health, New South Wales Government of Western Australia, 
Department of Health 
Title Guidelines for the Prevention and Control of 
Infection in Healthcare 
Infection Control Policy: Prevention & 
Management of 
Multi-Resistant Organisms (MRO) 
Infection Prevention and Control of 
Carbapenem-resistant Enterobacteriaeceae 
(CRE) in Western Australian Healthcare 
Facilities 
Issued 2010 2007 2012 
(Released October, circulated in draft since 
June) 
Applicability Non-binding recommendations Binding for all public hospitals. Recommended 
for private hospitals 
Binding for all facilities in the state. 
MRGNBs specified in text. Enterobacteriaceae, Pseudomonas and 
Acinetobacter mentioned. 
ESBL producing organisms mentioned 
Multi-resistant Acinetobacter, Pseudomonas and 
coliforms. 
ESBL producing organisms mentioned 
CRE 
Examples of clinically important 
Enterobacteriaceae given as: Escherichia, 
Klebsiella, Enterobacter, Citrobacter, Proteus 
and Morganella  
Definition of Resistance Gram-negative bacteria with multiple classes of 
drug resistance or resistant mechanisms to 
critically important antibiotics 
A bacterium that is resistant to two or more 
commonly used antibiotics from different 
classes (to which it would not be expected to be 
susceptible) 
Enterobacteriaceae that are non-susceptible to 
carbapenem antibiotics 
Other pathogens included Many pathogens. MRSA, VRE None. 
General recommendation 
(in addition to standard precautions) 
Contact precautions for all patients with MRO Contact precautions for direct contact with 
patients infected or colonised with MRO (+ 
other precautions as required by potential routes 
of transmission e.g. droplet precautions) 
Contact precautions for all CRE positive patients 
Qualification of recommendation Consider local circumstances and patient 
treatment plans in application of these 
recommendations in local guidelines 
None provided Risk based application may be used for non-
carbapenemase producing CRE 
Room placement Single room (or cohort with patients with same 
‘strain’)  
Single room with en suite if this is available. 
Cohort only after consultation with experts. 
Single, non-carpeted room with en suite. Cohort 
only after consultation with experts 
Gloves and Gown Before entering the patient care area If direct contact with patient or environment. If direct contact with patient or environment. 
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Epidemiological Surveillance Recommended for all facilities in some form. 
Also recommends increased surveillance for 
MROs with high incidence or prevalence. 
Active and passive epidemiological surveillance 
recommended for all facilities 
Laboratory based reporting and referral to 
reference lab of all CRE isolates. 
Microbiological screening of patient contacts. 
Reporting Not applicable Laboratories must have protocol to detect and 
notify MROs to relevant clinical team. No wider 
notification. 
Notification of all carbapenemase producing 
Enterobacteriaceae to state based communicable 
diseases body. 
Patient risk assessment and microbiological 
screening  
Optional, based on local epidemiology. Targeted 
(patient and/or ward) microbiological screening 
for MROs with high incidence or prevalence 
Risk-assessment of whole service/ward location 
(e.g. ICU, Maternity ward) rather than patients.  
Microbiological screening of specific patient 
groups optional based on healthcare facility 
policy. 
All patients entering facilities must be clinically 
risk-assessed. Microbiological screening of 
patient in specific circumstances. 
Inter-facility transfer & Overseas healthcare 
contact 
Only covers management of patients with 
known MRO colonisation. 
No mention of international origin of patients. 
Routine application of CP not recommended. 
Patients at ‘high risk of MRO’ should be 
screened and can be managed in CP whilst 
awaiting results.  
Single room, CP and microbiological screening 
for any person with hospitalisation of residence 
in a LTCF overseas in the past 12 months. 
Other Details in policy Very extensive on many aspects of infection 
control 
Hand hygiene, antimicrobial stewardship, 
environmental cleaning. Extensive detail on 
aspects of MRSA 
Antimicrobial stewardship, outbreak 
management. management of CRE in LTCFs, 
Environmental cleaning. 
Other related directives. Not applicable NSW Ministry of Health, Infection Control 
Policy, (2007) 
WA Department of Health, MRSA (2005) and 
VRE (2011, 2012) Directives 
URL. http://www.nhmrc.gov.au/guidelines/publication
s/cd33 
 
http://www0.health.nsw.gov.au/policies/pd/2007
/PD2007_084.html 
http://www.health.wa.gov.au/circularsnew/circul
ar.cfm?Circ_ID=12908 
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2. External data used to confirm hospital demographics
Detail Organisation URL 
Basic Hospital 
Demographics 
National Health Performance Agency http://www.myhospitals.gov.au 
Hospital Size 
Classification 
Australian Institute of Health and Welfare http://www.aihw.gov.au/hospitals-data/ 
Allogeneic bone-marrow 
transplant service 
Australian Bone Marrow Donor Registry http://www.abmdr.org.au/dynamic_menus.p
hp?id=2&menuid=9&mainid=2 
Burns Service Australian & New Zealand Burns Association http://anzba.org.au/resources/burn-units/ 
Spinal Service Royal Australian College of Physicians 
Spinal Cord Injury Special Interest Group 
http://www.racp.edu.au/index.cfm?objectid=
66166EBC-BDF4-C80F-
208C08FF6FE1485C 
Solid Organ Transplants 
(excluding kidney) 
The Transplantation Society of Australia and 
New Zealand 
http://www.tsanz.com.au/downloads/16thM
ayTSANZConsensusStatementVs1.2_000.p
df 
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3. Distribution of survey respondents compared to various national demographics
State Population 
(million) 
(% of total 
Australian 
population*) 
Total number of 
hospitals 
responding 
(% of all 
respondents) 
Private hospitals 
responses 
 Count (% of total 
responses within 
private hospitals) 
Public hospital 
responses 
Count (% total 
responses within 
public hospitals) 
ID training 
responses on total 
count/ all 
accredited sites 
(% of accredited 
sites in state) 
Proportion of 
responding sites 
in principal 
referral category 
Proportion of 
responding sites 
in metropolitan 
location 
New South Wales 7.4 (32) 21 (22) 5 (17) 16 (24) 10/12 (83) 13(62) 17 (81) 
Victoria 5.7 (25) 24 (25) 4 (17) 20 (29) 7/10 (70)  9 (38) 9 (38) 
Queensland 4.6 (20) 21 (22) 11 (38) 10 (15) 4/6 (66) 9 (43) 12 (57) 
Western Australia 2.5 (11) 17 (18) 5 (17) 12 (18) 3/3 (100) 5 (29) 11 (65) 
South Australia 1.7 (7) 5 (5) 0 5 (7) 3/4 (75) 3 (60) 3 (60) 
Tasmania 0.5 (2) 4 (4) 3 (10) 1 (1) 1/1 (100) 1(25) 3 (75) 
ACT 0.4 (2) 2 (2) 1 (3) 1 (1) 1/1 (100) 1(50) 2 (100) 
NT 0.2 (1) 3 (3) 0 3 (4) 2/2 (100) 2(66) 1 (33) 
Total 23 million 97 29 68 31/41 (76) 43 58 
* Data from:  Australian Demographic Statistics, Dec 2012. Canberra: Australian Bureau of Statistics; 2013.
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4. Analysis of concordance amongst answers from multiple responders from the same hospital site.
Answer/Policy aspect Concordant Relative Agreement Discordant Details of Relative 
Agreement 
Hospital Services & Policies 
Presence of supra-regional 
referral services*  
8 (89) NA 1 (11) 
Presence of Infectious 
Disease service 
8 (89) NA 1 (11) 
Presence of written policies 
(ESBL, CRE, AmpC, IT-
Patient) 
2 (22) NA 7 (78) 
CP Use 
ESBL CP use 3 (33) 6(67) 0 Five sites – differing risk 
stratification criteria 
Two sites- differing cohorting 
CRE CP use 2 (22) 6 (67) 1(11) Two sites - differing risk 
stratification criteria 
Three site - differing cohorting 
IT-patient CP use 3 (33) 3 (33) 3 (33) Differing risk-stratification 
criteria 
AmpC CP use 6(67) 2(22) 1(11) Two sites differing reporting of 
policy details 
Analysis of concordance by hospital 
Hospital (number of 
respondents) 
Concordant Relative Agreement Discordant 
Hospital 1 (2) 2 2 3 
Hospital 2  (2) 3 3 1 
Hospital 3 (2) 5 2 0 
Hospital 4 (3) 2 2 3 
Hospital 5 (3) 2 3 2 
Hospital 6 (2) 6 1 0 
Hospital 7 (2) 5 1 1 
Hospital 8 (2) 5 1 1 
Hospital 9 (2) 2 2 3 
Total (%) 32 (51) 17 (27) 14 (22) 
178 
CP= Contact Precautions, ESBL-E = Extended spectrum beta-lactamase harbouring Enterobacteriaceae, CRE= Carbapenem resistant Enterobacteriaceae, IT-patient = Patient who 
has undergone international hospital-to-hospital transfer. 
*Only supra-regional referral services that could not be externally validated are included
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Country-to-Country Transfer of Patients and the
Risk of Multi-Resistant Bacterial Infection
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Management of patients with a history of healthcare contact in multiple countries is now a reality for many
clinicians. Leisure tourism, the burgeoning industry of medical tourism, military conflict, natural disasters, and
changing patterns of human migration may all contribute to this emerging epidemiological trend. Such
individuals may be both vectors and victims of healthcare-associated infection with multiresistant bacteria.
Current literature describes intercountry transfer of multiresistant Acinetobacter spp and Klebsiella
pneumoniae (including Klebsiella pneumoniae carbapenemase– and New Delhi metallo-b-lactamase–producing
strains), methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and hypervirulent
Clostridium difficile. Introduction of such organisms to new locations has led to their dissemination within
hospitals. Healthcare institutions should have sound infection prevention strategies to mitigate the risk of
dissemination of multiresistant organisms from patients who have been admitted to hospitals in other
countries. Clinicians may also need to individualize empiric prescribing patterns to reflect the risk of
multiresistant organisms in these patients.
Although the world may not be truly getting smaller, the
increasing use of air transport could give this impres-
sion. The exponential growth of international air travel
means almost 1 billion passengers are projected to take
an international flight during 2011 [1]. An in-
tercontinental journey now takes a matter of hours,
rather than the weeks or months of old. Any medical
practitioner could be faced with a person who may have
been in the hospital in any part of the world in preceding
days. Confounding this, practitioners are increasingly
managing patients who have traveled vast distances
primarily for the purpose of seeking medical or surgical
treatment for an illness. This emerging and diverse
category of patient has previously been described in
various relevant contexts [2–5]. Collectively we term
members of this group the ‘‘intercountry’’ patient. It
includes the military and civilian aeromedical evacuee,
the ‘‘medical tourist’’ who travels specifically to seek
medical treatment internationally, and a larger, less well-
defined group of informal medical tourists: those whose
medical care is divided between countries for a variety of
social, familial, or financial reasons.
Diseases such as malaria and arbovirus infection are
classically described in returned travelers. The acquisi-
tion of blood-borne viruses such as the human immu-
nodeficiency virus, hepatitis B, and hepatitis C has
been associated with medical care in some developing
healthcare systems [6]. The intercountry patient is
also at high risk of the more prosaic infection,
however. Healthcare-associated multiresistant bacterial
infection is greatly heterogeneous, and not necessarily
divided along lines of economic development and
industrialization. Even ubiquitous nosocomial patho-
gens such as Staphylococcus aureus and Klebsiella pneu-
moniae will harbor vastly differing antimicrobial
resistance patterns depending on the location of acqui-
sition [7, 8]. Unsuspected resistance has implications on
many levels. At an individual level, inadequate empirical
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antimicrobial therapy of severe bacterial infection is now clearly
linked to decreased survival [9]. At an institutional level such
patients may be the index case for nosocomial outbreaks of new
pathogens. At a community level, inadvertent human carriage
has been associated with the global spread of antimicrobial re-
sistance in community pathogens [5].
This review categorizes patients at risk of transferring multi-
resistant bacterial pathogens from healthcare facilities in one
country to another. We outline known examples of country-to-
country transfer of specific multiresistant bacterial pathogens of
emerging and contemporary importance. Data were identified
from a systematic search of the Medline and Ovid databases, the
reference lists of published works, and web-based resources
identified in these works.
PATIENTS AT RISK
Aeromedical Evacuation of Civilians
Aeromedical evacuation, defined as international patient transfer
to a medical facility by long-distance air flight, is increasingly
common. It is noteworthy that people with an increasing burden
of comorbid disease are now traveling internationally and may
have been hospitalized while abroad [10]. Collated statistics on
civilian aeromedical evacuation are not readily available, although
anecdotal reports indicate rising numbers [11]. A French insurer
reported over 400 evacuations and repatriations in a single year
[12]. The indications for transfer from a foreign hospital include
a broad spectrum of medical and surgical conditions, occurring in
both the military and civilian domains. Recently, mass mobiliza-
tion of civilian evacuation services has been utilized in the setting
of natural disasters such as the southeast Asian tsunami in 2004
andman-made disasters such as the Bali bombing terrorist attacks
in 2002 [13, 14]. In both disasters, there were reports of transfer of
multiresistant Gram-negative bacilli to institutions with low
background rates of these organisms [4, 15].
There are factors in the dynamics of aeromedical evacuation
that may increase the risk that such patients harbor multiresistant
bacterial pathogens (Table 1). Two European studies have in-
vestigated rates of carriage of multiresistant organisms (MROs) in
patients repatriated via air transfer. Although one study showed
rates of methicillin-resistant S. aureus (MRSA) and multiresistant
Gram-negative bacilli colonization in patients undergoing aero-
medical evacuation to be similar to rates at their receiving in-
stitutions [18], a second study showed far higher rates [19]. The
risk of MRSA was found to be highest in those with a prolonged
intensive care unit (ICU) stay prior to transfer [18] while risk of
multiresistant Gram-negative bacilli was found to be highest in
patients transferred from Asia and Eastern Europe [19].
Aeromedical Evacuation of Military Personnel
Military patient movements are frequent, with the United States
Air Force Aeromedical Evacuation system reporting over 40,000
patient movements globally during an 18-month period [20].
Recent military operations reveal a contemporary view of evac-
uees from the theater of war. High rates of infection caused by
multiresistant Gram-negative bacilli have been reported in in-
jured military personnel evacuated from Iraq and Afghanistan
[21, 22]. Some studies estimate bacterial infection complicating
15% to 25% of admissions [17, 23]. Etiological investigation of
infections has implicated both environmental contamination of
field hospitals and frequent nosocomial transmission within the
military health system [16, 24]. Risk factors for infection during
evacuation included abdominal injuries, soft tissue injuries, and
a high overall injury severity score. Additionally, the occurrence
Table 1. Factors Predisposing to Increased Risk of Infection and Carriage of Multiresistant Bacterial Organisms in Aeromedical
Evacuees and Medical Tourists
Facilities
d Hospital accreditation varies vastly between nations, providing variable levels of oversight for institutional infection control and antimi-
crobial use.
d Medical tourists may undergo procedures in unlicensed settings occasionally using unproven and experimental techniques.
d Evacuees may transit through multiple health facilities in a short space of time during the process of evacuation. For example, con-
temporary US military evacuees averaged 4 facilities in 7 days [16].
d Confined spaces and limited facilities of transport vehicles used for evacuation may make some regular infection control practices
impossible.
d Barriers including language and differing clinical practice may limit the scope of information exchanged with a patient.
Patients
d Common scenarios for evacuation such as road trauma and combat injuries have high background rates of secondary infection [17].
d High acuity of illness in transferred patientsmeans theymay be transferred directly from intensive care units, which traditionally have high
rates of multiresistant organisms.
d Medical tourists undergoing solid-organ transplant or cancer therapy acquire the additional risk factor of immunosuppression while
abroad.
d Medical tourism packages are frequently combined with a vacation, putting patients at risk for exposure to a broader range of community
pathogens.
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of such infection increased the likelihood of the evacuee re-
quiring ICU management [17]. At receiving institutions in
North America, increasing MRO infection has led to a marked
escalation in the use of broader spectrum and higher cost anti-
microbials in the military healthcare system [21].
Medical Tourists
Medical tourism has been defined as ‘‘organized travel outside
one’s natural health care jurisdiction for the enhancement or
restoration of the individual’s health through medical in-
tervention’’ [25]. With increasing globalization, such travel is
now increasingly common [26]. For many years, patients have
traveled internationally to access new and advanced treatment
unobtainable in their home country. Patients are now in-
creasingly traveling from developed countries to centers in South
and Central America, South Africa, and Asia where treatment
may be obtained at a lower cost, without the delay incurred by
publicly funded health systems in their home location, or with
greater privacy for cosmetic and other procedures [27, 28].
Destinations for medical tourists now encompass most corners
of the globe. Patients travel internationally for procedures
ranging from cosmetic surgery to fertility treatment, major joint
replacement, and even life-saving cardiac surgery and organ
transplant. Some health insurers in North America utilize for-
eign medical care in order to defray cost [26]. The American
Medical Association and the American College of Surgeons have
recently issued position statements pertaining to medical tour-
ism [29, 30]. The exact numbers of medical tourists has not been
documented. Recent estimates suggest that by 2012, 1.6 million
patients per year will travel from North America to receive
healthcare in another country [26–28]. Thailand, Hungary, In-
dia, and Singapore are all expected to receive 1 million or more
medical tourists by 2012 [31].
Certain aspects of medical tourism may increase the risk of
acquisition and complicate the management of MRO infection
(Table 1). There have been no prospective studies of the in-
fections associated with medical tourism, likely due to the dif-
ficulty in prospectively capturing this group. Available data come
from retrospective case series and surveys of patients and
physicians [32]. The largest published experiences arise from
solid-organ transplantation owing to the obligate need for
medical contact in the recipient’s home country [33–36]. Illus-
trating the difficulty of such studies, a single-center experience
from North America found fewer bacterial infections in those
who received transplants abroad compared with local recipients.
The authors felt this was significantly confounded by the in-
ability to measure the incidence of early transplant infection in
the patients who received transplants abroad [33]. Few series
have specified the infecting bacterial pathogens. Canadian ex-
perience reported 8 of 20 patients with bacterial infection after
renal transplant abroad, although the location of the transplant
procedure was not specified. Four of these patients suffered in-
fection with bacteria likely producing an extended-spectrum ß-
lactamase (ESBL) [36].
Care Shared Across Countries
Similar in nature is a broader group of informal medical tourists:
patients for whom care of an acute or chronic condition is spread
across multiple nations. Factors influencing the country of care
may include the proximity to friends and family, financial fac-
tors, and access to advanced facilities. The term ‘‘diaspora’’ has
been used in reference to large permanent expatriate populations
from many nations. Recently this term has been applied to
thriving expatriate Indian and Pakistani communities, which
likely number more than 24 million and 7 million individuals,
respectively [37, 38]. A nation’s diaspora may maintain strong
familial and cultural links to their nation of origin, including
frequent return travel and potentially medical treatment for
acute and chronic conditions spread across multiple nations
[39–41]. This group is likely more numerous than medical
tourists or aeromedical evacuees.
INFECTIONS OF CURRENT CONCERN
Gram-Negative Bacilli
Acinetobacter Species
In a large outbreak of carbapenem-resistant A. baumannii in
a Belgian hospital, the 2 index patients were evacuated from
a Greek ICU after road trauma. Despite increased infection
prevention precautions, 17 subsequent cases of a clonal isolate
were identified over the next 6 months [42]. A smaller outbreak
was also described in northern Italy, also secondary to evacuees
from Greece [43].
A widespread carbapenem-resistant Acinetobacter outbreak in
medical facilities involved in the treatment of aeromedical
evacuees from military operations in Iraq and Afghanistan has
been reported [22, 44]. More than 100 cases of bacteremia over
an 18-month period occurred within military hospitals in the
United States and Germany [44]. Although Acinetobacter is as-
sociated with traumatic injury in many settings, molecular and
clinical studies have shown that the majority of infection in this
outbreak was due to nosocomial acquisition [16, 24]. The United
Kingdom has also reported the introduction of new strains of
Acinetobacter from evacuees from Iraq [22]. In the setting of
traumatic burns and blast injuries after the 2002 terrorist attacks
in Bali, frequent Acinetobacter infection was noted in patients
evacuated to Australia. Subsequent nosocomial spread in re-
ceiving hospitals was again reported [15].
Bacteria Harboring KPC and NDM Carbapenem
Resistance Genes
Epidemiological investigation suggests that introduction of the
Klebsiella pneumoniae carbapememase (KPC) gene into several
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regions has been due to carriage by the intercountry patient.
Israel was the first nation outside the United States to report
a large outbreak of KPC-harboring K. pneumoniae. Widespread
healthcare-associated transmission occurred of a strain identified
as of North American origin [45]. Greece has identified wide-
spread clonal KPC-producing K. pneumoniae indistinguishable
from contemporary Israeli clones [46]. In neither case was
a single point of introduction identified. The likely index case in
a single-center outbreak in Germany was a patient who had been
previously hospitalized in Greece [47]. Many additional coun-
tries including the United Kingdom and France have reported
episodes of colonization or infection of patients transferred from
endemic countries [48, 49] (Figure 1).
The New Delhi metallo-ß-lactamase gene (NDM-1) also con-
fers almost complete ß-lactam resistance. NDM-1 has been
identified in a broad range of Gram-negative bacteria including K.
pneumoniae, Escherichia coli, and Citrobacter freundii. Almost all
isolates are also resistant to aminoglycosides, fluoroquinolones,
and other classes of antimicrobials. Of concern, some isolates
exhibited resistance to the agents of last resort, tigecycline and
colistin [50]. The NDM-1 gene was first described in Sweden [51]
and the United Kingdom [52], and was strongly associated with
healthcare received on the Indian subcontinent. In the United
Kingdom, 9 of 19 patients had recently been hospitalized in India
or Pakistan for treatment ranging from solid-organ trans-
plantation to cosmetic surgery. Subsequently, imported cases as-
sociated with healthcare contact in India and Bangladesh have
been reported in other regions including the United States, Aus-
tralia, Canada, Japan, and several European nations [39, 53, 54].
Cases have also been identified among patients repatriated to
locations inWestern Europe from hospitals in Balkan nations, and
a cluster of cases was identified in Kenya [41, 55]. These epide-
miological observations require further elucidation (Figure 1).
Bacteria Harboring ESBL Enzymes
Carriage of bacteria harboring ESBL enzymes by the in-
tercountry patient is well established and still remains a sig-
nificant risk [56]. Early reports include intercontinental
transfer of common nosocomial ESBL-producing bacteria
such as K. pneumoniae [57]. Current literature reflects the
emergence of E. coli harboring CTX-M ESBLs, with health-
care-associated acquisition responsible for approximately
15% of travel-related infections due to ESBL producers in
some studies [58, 59].
Gram-Positive Organisms
Methicillin-Resistant S. aureus
Almost 50 years after its emergence, the spread of MRSA by
the intercountry patient still poses a threat to institutions that
have maintained low MRSA prevalence. The prevalence
among hospital-acquired S. aureus isolates in the Netherlands
and Scandinavia remains ,1%, contrasting with levels in
other European nations and North America (6%–63%) [7].
Two outbreaks in the Netherlands were directly linked to the
transfer of patients from institutions in France and Turkey
where MRSA is endemic [60]. A study in Sweden demon-
strated that one-quarter of 1733 MRSA cases reported be-
tween 2000 and 2003 were likely acquired abroad; over half of
these were healthcare associated [61]. The potential in-
tercountry spread of MRSA via healthcare workers, rather
than patients, is illustrated by the report of a Swiss physician
found to have a new nasopharyngeal colonization with
a North American clone of MRSA after returning from
a clinical fellowship in North America [62].
Vancomycin-Resistant Enterococci (VRE)
Reports of intercountry spread of VRE come primarily from
molecular epidemiologic assessments. VRE clonal complex-17
(CC-17), a group consisting of a number of closely related VRE
sequence types, has been responsible for VRE dissemination in
countries including the UK, Australia, and North America [63].
Investigators linked a sharp rise in the rate of VRE in southwest
Germany to the likely importation of CC-17 VRE to their hos-
pital system [64]. An outbreak due to CC-17 has also been re-
ported in Turkey [65]. Neither report identified a single point of
introduction.
Clinical reports of VRE transfer between nations have
been prevalent in Europe [66]. Low-incidence Nordic
countries (where VRE accounts for ,1% of enterococcal
isolates) have had sporadic importation and outbreaks from
other nations since the early 1990s [66]. Molecular studies
were strongly suggestive of intercountry spread of a distinc-
tive VRE clone from North America to Norway and also to
Ireland [67]. In a prospective study from the Netherlands,
VRE was identified in approximately 3% of patients re-
patriated from a number of countries, with Asian origin
being a significant risk [19].
Hypervirulent Clostridium Difficile
Since the initial description of hypervirulent ribotype O27, there
have been repeated descriptions of transfer of the strain via the
intercountry patient [68, 69]. A retrospective study in 2007
identified the transfer of a patient infected with the hyperviru-
lent strain from the United Kingdom to Ireland very soon after
the initial descriptions in 2005; fortunately, no outbreak oc-
curred [68]. Introduction of the strain into France in 2006,
which now has sustained transmission, was speculated to be due
to transfer with patients from neighboring Belgium [70]. Aus-
tralia has reported a single case of importation in a patient re-
cently hospitalized in North America [69].
APPROACH TO THE PATIENT
All hospitals should have a predefined approach to manage-
ment of patients transferred from other institutions, including
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those in other countries (Table 2). Preemptive contact
isolation may be considered when there is a risk of in-
troduction of an MRO not currently found in the institution
receiving the patient. In institutions with few or no endemic
MROs, there will likely be a greater willingness to institute
preemptive contact isolation. In some institutions, there may
already be a high prevalence of MROs and it may seem to
matter little that a patient has come from another institution
which also has endemic MROs. However, introduction of new
mechanisms of antibiotic resistance or new ‘‘hospital adap-
ted’’ bacterial strains may pose risks of amplifying antibiotic
resistance. An example may be the receipt in a hospital in the
United States with endemic KPC producers of a patient from
a hospital in India or Pakistan where NDM producers are
endemic.
In the setting of management of an individual patient with
suspected bacterial infection we suggest a considered approach
to the use of empirical therapy (Table 3).
Healthcare staff must adopt a pragmatic and nonjudgmental
approach to the management of the intercountry patient who
has acquired an MRO infection. This may be challenging in the
setting of a patient who has sought a healthcare intervention
believed inappropriate or unethical by the home treating clini-
cian, such as commercial organ transplantation, or experimental
or cosmetic procedures. This attitude is crucial in order to avoid
the patient feeling stigmatized and to facilitate open
Table 2. Recommendations for the Management of Patients Who Have Been Hospitalized Internationally
1. Maintain vigilance.
Ask specifically about healthcare contact whenever a patient reports international travel within the previous 12 months.
2. Preemptive isolation and screening should be used in patients with a history of international hospitalization and who have a high
risk of carriage of multiresistant organisms.
Isolate patients who have had direct hospital-to-hospital transfer or recent international hospitalization involving prolonged hospital stay,
intensive care or critical care admission, major trauma, burns, or receipt of chemotherapy or immunosuppression (eg, solid-organ or stem-cell
transplant).
3. Screening needs to be customized to the receiving institution: Focus screening on organisms that are not already endemic at your
site.
Basic screening may include axillary, inguinal, and nose/throat swabs PLUS rectal swab or stool sample PLUS clinical specimens including
catheter urine, surgical drain, or wound discharges—screen for MRSA-, VRE-, and ESBL-producing or carbapenem-resistant GNB.Only screen
for Clostridium difficile if diarrhea is present.
4. Receive transferred patients in an area of the hospital equipped to manage isolation for multiresistant organisms.
Patients may initially require management in an area of higher acuity than required for their medical care (eg, patients for rehabilitation may
need to go to an acute ward until screened).
5. All receiving institutions should have a readily accessible infection prevention policy defining at-risk patients, screening proce-
dures, and preemptive isolation criteria.
If your institution frequently receives patients from a particular location, a customized protocol should be developed and maintained for this
location: Including an outline of the current pathogens of concern and empirical therapy is recommended in the case of infection.
NOTE. ESBL, extended-spectrum b-lactamase; GNB, Gram-negative bacilli; MRSA, methicillin-resistant Staphyloccus aureus; VRE, vancomycin-resistant
enterococci.
Table 3. Approach to Suspected Bacterial Sepsis in Patients Previously Hospitalized in Another Country
1. Ensure appropriate microbiology samples for the clinical presentation (eg, blood cultures, urine culture, respiratory tract cultures)
if required.
Notify the microbiology laboratory of the patients’ origin. They may broaden their testing beyond their normal scope (eg, detection of NDM-1,
Clostridium difficile ribotype).
2. If screening has identified MROs: These bacteria must be targeted in empirical therapy.
If susceptibilities are available use these to guide antimicrobial selection. If susceptibilities are not available, empirical therapy may include
agents such as linezolid or daptomycin (for VRE andMRSA) and polymyxin B, colistin, or amikacin for multidrug-resistant gram-negative bacilli.
If available, consultation with an infectious disease physician or clinical microbiologist may be helpful in selecting the optimal agent for
identified pathogens.
3. If no screening results are available: Therapy must target the prevalent pathogens at the transferring institution.
When possible, ascertain these by direct discussionwith this institution as recent outbreaksmay not be publicized. See suggestions above for
empirical therapy.
4. If screening does not detect an MRO: Treat as per local guidelines. However, screening is not 100% sensitive.
If the patient fails to improve on empirical therapy then reassess for occult sites of infection and reculture as extensively as possible. Consider
empirical therapy for organisms prevalent at the transferring institution as outlined above.
NOTE. MRO,multiresistant organism;MRSA, methicillin-resistant Staphyloccocus aureus; NDM-1, NewDelhi metallo-b-lactamase; VRE, vancomycin-resistant
enterococci.
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communication of information between the patient, family, and
clinician. International institutions may operate with constraints
and resource limitations that are not present in the patient’s
country of residence. Furthermore, the patient may have felt they
had no option but to utilize the facilities available in a foreign
country due to the urgency of care required or the financial cost
of care at home.
Local, national, and international regulations may pertain to
the notification, transit, and control of patients harboring
MROs [71]. This is a complex and evolving area that varies
between jurisdictions.
CONCLUSION
The management of patients transferred from other in-
stitutions is a daily reality for almost all healthcare practi-
tioners. The patient with international healthcare contact may
present to healthcare institutions in a variety of forms, rang-
ing from the overt (eg, aeromedical evacuee) to the un-
suspected (eg, elective surgical day case). In some settings,
ready identification of a patient’s origin in foreign hospitals is
difficult and requires specific questioning. Similarly, a multi-
tude of communication barriers may lead to difficulty ob-
taining information pertaining to a patient’s medical care in
another country.
Contemporary molecular epidemiological techniques have
allowed us considerable insight into the origins and movement
of healthcare-associated MROs. The range of potential MROs
acquired by the intercountry patient is broad. We have outlined
a small number with current significance. A key concept is the
dynamic nature of such outbreaks. These may emerge and dis-
seminate before reaching the general medical literature. At
times, outbreaks may go undetected in their country of origin
until exported with the intercountry patient [46, 50].
Figure 1. Schematic representation of epicenters (black) and reported/potential importations (gray) of Klebsiella pneumoniae carbapenemase (A) and
New Delhi metallo-b-lactamase-1 (B) ß-lactamase-producing organisms [39, 41, 45–49, 53–55].
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Furthermore, emerging data now suggest that the risk of ac-
quisition of someMROsmay extend to those without healthcare
contact during travel to countries of high endemicity [72, 73].
Given the large pool of international travelers, this area requires
further exploration to better define risk factors and the potential
magnitude of this problem.
For an individual patient, the significance of an MRO in-
fection will largely depend on his or her current medical con-
dition and may range from an incidental finding to a life-
threatening infection. For an institution, the significance of
importation of MROs depends on the preexisting milieu of
MROs and the likelihood of spread, determined by infection
prevention practices.
In conclusion, there are many factors that may complicate the
identification and management of infections with MROs in the
intercountry patient. Clinical vigilance in the form of sensitive
and thorough questioning coupled with a high standard of
baseline infection prevention practice in all patients must be the
first line of defense.
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Escherichia coli O25b-ST131: a pandemic, multiresistant,
community-associated strain
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Escherichia coli sequence type 131 (ST131) is a worldwide pandemic clone, causing predominantly community-
onset antimicrobial-resistant infection. Its pandemic spread was identified in 2008 by utilizing multilocus
sequence typing (MLST) of CTX-M-15 extended-spectrum b-lactamase-producing E. coli from three continents.
Subsequent research has confirmed the worldwide prevalence of ST131 harbouring a broad range of virulence
and resistance genes on a transferable plasmid. A high prevalence of the clone (30%–60%) has been ident-
ified amongst fluoroquinolone-resistant E. coli. In addition, it potentially harbours a variety of b-lactamase
genes; most often, these include CTX-M family b-lactamases, and, less frequently, TEM, SHV and CMY
b-lactamases. Our knowledge of ST131’s geographical distribution is incomplete. A broad distribution has
been demonstrated amongst antimicrobial-resistant E. coli from human infection in Europe (particularly the
UK), North America, Canada, Japan and Korea. High rates are suggested from limited data in Asia, the
Middle East and Africa. The clone has also been detected in companion animals, non-companion animals
and foods. The clinical spectrum of disease described is similar to that for other E. coli, with urinary tract infec-
tion predominant. This can range from cystitis to life-threatening sepsis. Infection occurs in humans of all ages.
Therapy must be tailored to the antimicrobial resistance phenotype of the infecting isolate and the site of infec-
tion. Phenotypic detection of the ST131 clone is not possible and DNA-based techniques, including MLST and
PCR, are described.
Keywords: b-lactamases, molecular epidemiology, bacterial infections
Introduction
Escherichia coli is a finely tuned, ubiquitous human pathogen. It
is a common cause of urinary tract infection (UTI) and bacterae-
mia in humans of all ages. In addition, it is a frequent cause of
varied organ infections, ranging from the biliary system to the
CNS. The spectrum of pathology can range from a spontaneously
resolving cystitis to life-threatening sepsis syndrome.1 Not con-
fined to the community, E. coli infection is also a common
hospital-acquired pathogen.2
Over the past five decades, we have witnessed increasing
antimicrobial resistance in E. coli in the community setting.
Initially, resistance was described to particular agents, such as
ampicillin, trimethoprim, sulphur-based antimicrobials or tetra-
cyclines.3 More recently, the horizon of resistance has broadened,
with the emergence of broad resistance to large families of
agents. In particular, plasmid-mediated extended-spectrum
b-lactamases (ESBLs) have become prominent in community-
onset E. coli infection.4,5 In addition to the resulting resistance
to most b-lactam antibiotics, ESBL producers are frequently
also resistant to aminoglycosides and fluoroquinolones.
There are a variety of reasons for the increased prevalence of
antibiotic-resistant E. coli. E. coli is an organism known for its
mobile genome and propensity to exchange genetic material.6
However, the dissemination of ‘clonal’ organisms harbouring
resistance is also well documented. Clonal outbreaks of E. coli
clinical infection previously described include ‘Clonal Group A’
(CGA) in North America7 and O15:K52:H1 in multiple nations.7,8
It is estimated that 10%–20% of all E. coli UTIs may be caused
by a small set of clonal groups.9 In 2008, two research groups
analysing the population biology of ESBL-producing E. coli
almost simultaneously described ‘serogroup O25b, sequence
type 131 (ST131)’ occurring in multiple countries on three conti-
nents. This previously unremarkable molecular clone harboured
a CTX-M ESBL gene and a larger armamentarium of virulence
genes.10,11Since this discovery in 2008, research has retrospectively
documented a ‘pandemic’ emergence amongst ESBL-producing
and other antimicrobial-resistant clinical isolates in the middle
of this decade. Previous to this, only sporadic isolates of this clone
can be identified in multilocus sequence typing (MLST) databases
and published series. The rapid and apparently boundless rise
of the ST131 E. coli clone is the subject of this review.
Epidemiology
Human infection and colonization
Published research detailing the geographical distribution and
antimicrobial resistance of human infection and colonization by
E. coli ST131 are summarized in Table 1.
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Table 1. Geographical distribution and antimicrobial resistance of E. coli ST131 in humans
Country/Region Specific location
Date range
of samples Isolate source
Selection criteria used by
study
Number of
isolates
Percentage of isolates
that were ST131 (n)
Percentage of ST131 that
were community onset
Percentage of ST131 that
were fluoroquinolone resistant
Percentage
of ST131 that were
SXT resistant
Percentage
of ST131 that
harboured ESBL
Multinational11 Europe, Canada
and Middle
East
2000–06 laboratory
collection
ESBL CTX-M-15 43 42 (18) 0 NS NS 100
Multinational10 Europe, Asia and
Canada
NS clinical isolates
and
laboratory
collection
ESBL CTX-M-15 41 88 (36) 39 97 53 100
Multinational45 worldwide,
excluding
India/Pakistan
and
Bangladesh
2004–06 traveller returned
from region;
majority UTI
ESBL 84 19 (16) NS NS NS 100
Europe18 2003–06 community-
acquired UTI
fluoroquinolone resistant 148 24 (35) 100 100 NS NS
Belgium28 2006–07 clinical isolates ESBL CTX-M-15 43 72 (31) 90 NS NS 100
Croatia29 2002–05 clinical isolates ESBL CTX-M 12 42 (5) NS 100 NS 100
France23 1994–2003 laboratory
collection
ESBL 128 6 (8) NS NS NS 100
France23 Tenon 2002–03 UTI non-ESBL+B2 phylotype 129 3 (4) NS NS NS 0
France24 2005 bacteraemia 3GC resistant 41 15 (6) NS NS NS 100
France25 2006 community-onset
UTI
ESBL 48 21 (10) 10 100 60 100
France23 2006–07 laboratory
collection
ESBL 41 46 (19) NS NS NS 100
France26 Paris 2006 stools from
healthy
volunteers
none 100 7 (7) 100 57 NS 0
Ireland17 2003–07 majority UTI ESBL 371 ,10 NS NS NS 100
Italy22 Rome 2006 bacteraemia and
UTI
fluoroquinolone
resistant+ESBL
18 61 (11) NS 100 NS 100
Northern
Ireland16,109
Belfast 2004–06 stool samples
from residents
of LTCFs
ESBL+fluoroquinolone
resistant
119 ≥54 (≥64) 0 100 NS 100
Norway27 2003 clinical isolates ESBL 45 20 (9) NS NS NS 100
Spain19 2004 clinical isolates ESBL 91 9 (8) NS NS NS 100
Spain61 Madrid 2004–07 majority UTI Amp-C 121 6 (7) NS NS NS 0
Spain20 2006 clinical isolates ESBL CTX-M-15 37 86 (32) NS NS NS 100
Spain21 Lugo 2006–07 majority UTI ESBL 105 22 (23) NS .96 .96 100
Spain21 Lugo 2007–08 majority UTI ESBL 249 22 (54) ,50 NS NS 100
Spain106 Madrid 2008 UTI ESBL+ fosfomycin
resistant
26 92 (24) NS NS NS 100
Turkey31 Izmir 2004–05 community-
acquired UTI
ESBL 17 6 (1) 100 100 100 100
Turkey23 2006 laboratory
collection
ESBL 10 20 (2) NS NS NS 100
UK15 2001–05 bacteraemia fluoroquinolone
resistant+non-
ESBL+aac(6′)-Ib-cr
10 50 (5) NS 100 NS 0
UK12,13 2003–04 clinical isolates ESBL 287 ≥65 (≥188) NS NS NS 100
UK14 north-west
England
2004–05 UTI and
bacteraemia
cefpodoxime resistant 88 59 (52) NS NS NS 98
Review
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UK23 2004–07 laboratory
collection
ESBL 103 81 (84) NS NS NS 100
Brazil23 2001–05 laboratory
collection
ESBL 5 0 NS NS NS 100
Canada34 Calgary 2000–07 bacteraemia ESBL 67 31 (21) 62 100 67 100
Canada33 2002–04 UTI fluoroquinolone resistant
or SXT resistant
199 23 (46) 100 96 46 ,2
Canada23 2004–06 laboratory
collection
ESBL 41 41 (17) NS NS NS 100
Canada32 Montreal 2005–07 women with UTI varied resistance sought 353 ,1 (2) NS NS NS NS
Canada9 Montreal 2006 women with UTI none 256 ,3 100 100 NS NS
Canada69 2007 clinical isolates ESBL 209 46 (96) 57 NS NS 100
USA38 Texas 2003–05 bacteriuria in
renal
transplant
recipients
none 40 35 (14) NS 86 NS 0
USA35 2007 majority
bacteraemia
varied resistance sought 127 17 (54)a NS NS NS 56
USA37 Pittsburgh 2007–08 clinical isolates ESBL 70 30 (21) NS NS NS 100
USA36 Chicago 2008 majority UTI ESBL 30 53 (16) NS 100 38 100
Indian
subcontinent45
India, Pakistan
and Bangladesh
2004–06 traveller returned
from region;
majority UTI
ESBL 31 61 (19) NS NS NS 100
Cambodia23 Phnom Penh 2004–05 UTI ESBL 30 27 (8) NS NS NS 100
China42 1998–2000 laboratory
collection
fluoroquinolone resistant 12 ≥17 (≥2) NS 100 NS NS
Japan41 2002–03 laboratory
collection
ESBL 142 19 (27) NS NS NS 100
Japan42 2003–07 clinical isolates fluoroquinolone resistant 128 ≥30 (≥38) NS 100 NS NS
Korea43 2006–07 community-onset
UTI
fluoroquinolone resistant 129 25 (32) 100 100 50 19
Korea42 2005 laboratory
collection
fluoroquinolone resistant 21 ≥33 (≥7) NS 100 NS NS
Philippines44 Manila 2007 clinical isolates ESBL 15 7 (1) NS NS NS 100
Thailand23 1999 laboratory
collection
ESBL 5 0 NS NS NS 100
Australia48 Queensland 2007–08 majority UTI fluoroquinolone resistant 582 35 (205) NS 100 NS NS
Australia47 Queensland 2008–09 clinical isolates cephalosporin resistant
or fluoroquinolone
resistant
49 31 (15) NS 47 NS 53
Central African
Republic23
Bangui 2004–06 laboratory
collection
ESBL 10 50 (5) NS NS NS 100
NS, not specified by the authors; UTI, urinary tract infection (or bacteriuria if not specified); ESBL, extended-spectrum b-lactamase; LTCFs, long-term care facilities; SXT, trimethoprim/
sulfamethoxazole; 3GC, third-generation cephalosporin.
≥, , and . are used to estimate when the text does not give an exact number for the relevant isolate.
aEstimated at 17% of entire collection of E. coli isolates.
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Europe
ST131 E. coli is widely disseminated amongst ‘antibiotic-
resistant’ community and hospital-onset E. coli in the UK.
Originally identified as the ‘CTX-M ESBL-producing UK epidemic
strains A–E’,12 between 2003 and 2004, these strains have
subsequently been confirmed as ST131.12,13 In one UK region,
ST131 comprised 64% of community-acquired and 84% of
hospital-acquired cefpodoxime-resistant E. coli infections.14 A UK
national study of fluoroquinolone-resistant, non-ESBL-producing
E. coli bacteraemia isolates illustrates the rapid emergence of this
strain, with isolates first identified only in 2004.15 High rates of
asymptomatic carriage of fluoroquinolone-resistant ST131 strains
have been demonstrated in Northern Ireland nursing home
patients.16 In the Republic of Ireland, ST131 was also widely disse-
minated amongst CTX-M ESBL-producing E. coli.17 No data exist on
ST131 among relatively ‘antibiotic-susceptible’ strains.
The epidemiology of the clone throughout mainland Europe
is less well characterized. Current data suggest a heterogeneous
distribution of infection and carriage, with prominence of
the clone amongst antibiotic-resistant isolates. A collection of
fluoroquinolone-resistant E. coli from eight European countries
showed ST131 comprised 24% of this entire group. However,
the number of isolates varied markedly between countries, with
Spain and Italy most prominent.18 Spanish ESBL-producing
E. coli data from 2004 revealed that 9% of isolates were
ST131.18 A follow-up national study in Spain in 2006 demon-
strated that 13% of ESBL-producing E. coli were ST131 and that
they had a nationwide distribution.19,20 More recent data from a
single region in Spain found that 22% of similar isolates from
2006–08 were ST131—50% originated from nursing home
patients.21 A study of a single region in Italy found that 61% of
isolates selected from a collection with fluoroquinolone resistance
and harbouring ESBL genes were ST131.22 French data demon-
strate the emergence of this clone primarily amongst resistant
isolates. ST131 was first identified in France in 2001 and it rose
to comprise 46% of ESBL-producing E. coli from 2006 to 2007 in
one series.23,24 Nationwide data from community-onset ESBL-
producing E. coli infections identified that 25% were ST131,
although only 1 of 40 patients was felt to have ‘true
community-acquired’ infection.25 Data on non-ESBL-producing
E. coli from UTIs from 2002–03 revealed that only 3% were
ST131, with the authors calculating an overall rate of 1.5% of
UTIs caused by this clone.23 Similarly, carriage of ST131 without
CTX-M ESBLs has been identified in 7% of healthy volunteer
stools in France.26 In Norway, 20% of all national CTX-M-producing
E. coli in 2003 were ST131.27 Belgian data from 2006 to 2007
demonstrate a high prevalence of ST131 in community-acquired
ESBL-producing isolates. All of the CTX-M-15-carrying E. coli that
were assayed, comprising 62% of all isolates, were ST131.28
The epidemiology of other European nations can only be
inferred from case reports and smaller studies. Primarily hospital-
based outbreaks have been described in Croatia,29 Portugal11
and Germany.30 The clone has also been identified in Austria,
Germany, Hungary, Russia, Switzerland and Turkey.10,18,31
The Americas
The epidemiology of ST131 is well characterized in Canada, with
low rates in susceptible E. coli and high rates in resistant isolates.
Two studies comprising UTI isolates, with little antimicrobial
resistance, from the years 2005–07, have demonstrated
rates of ST131 in isolate collections of ,3% and 1%.9,32 In
contrast, in ambulatory patient isolates selected for fluoroquino-
lone or trimethoprim/sulfamethoxazole resistance from 2002 to
2004, ST131 comprised 23% of all isolates and 44% of
fluoroquinolone-resistant isolates.33 Blood culture isolates of
ESBL-producing E. coli from a single region in Canada mirror
the UK experience, with emergence of the strain in 2003 and a
rapid rise to comprise 41% of isolates from 2004 to 2007.
An overall rise in the incidence of ESBL-producing E. coli bacter-
aemia was also attributed to the emergence of the clone.34
Recent data from North America suggest ST131 as ‘the major
cause of significantly antimicrobial-resistant E. coli infections in
the United States’.35 A geographically widespread selection of
isolates primarily from bloodstream infections suggested that
ST131 comprised 67%–69% of isolates resistant to fluoroquino-
lone or extended-spectrum cephalosporins. In this study, no sus-
ceptible samples were ST131.35 Recent studies from Chicago and
Pittsburgh also identified high rates amongst resistant isolates.
ST131 comprised 53% of CTX-M ESBL-producing E. coli in
Chicago and 30% of ESBL-producing E. coli in Pittsburgh, with a
range of accompanying ESBL genes.36,37 ST131 E. coli has also
been identified in renal transplant recipients and haematology
patients in Texas, both of which are groups with high background
antimicrobial use.38,39
A single report has identified ST131 in South America. The
clone comprised 8% of 28 ESBL-producing E. coli hospital-
associated isolates from Rio de Janeiro, Brazil.40
Asia and the Middle East
ST131 has been frequently identified among antimicrobial-resistant
isolates in Japan and Korea. A national survey in Japan identified
the clone in 21% of ESBL-producing E. coli from 2002 to 2003.
Interestingly, a greater genetic diversity within the clone and
a greater variety of accompanying CTX-M ESBL genes was
found in this region than elsewhere.41 The clone comprised
33%–63% of fluoroquinolone-resistant isolates from various
Japanese regions.42 Amongst ciprofloxacin-resistant isolates
causing community-onset infections in Korea, ST131 comprised
25% of isolates, only 19% of which harboured an ESBL gene.43
In a small Cambodian sample, ST131 clones comprised 27%
of community-onset UTIs due to ESBL-producing E. coli during
2004–05.23 Infrequent isolates have been detected among
larger collections of clinical isolates in China42 and the Philip-
pines.44 Faecal carriage was identified in a small number of hos-
pital patients with ESBL-producing E. coli in stools in Lebanon.10
The epidemiology in other Asian countries has been inferred from
studies of returned travellers, and from the high proportion of
ESBL-producing E. coli ST131 isolates from India, Pakistan, Iran
and Lebanon.45 Supporting these data, the SMART study
showed remarkably high background rates of 79% ESBL pro-
duction amongst E. coli isolated from intra-abdominal infections
in India.46
Australia
Two studies from a single region of Australia recently confirmed
the presence of the ST131 clone in this country. In one study of
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E. coli selected for fluoroquinolone or cephalosporin resistance,
31% of isolates were ST131; ,50% were CTX-M producing.47 In
a second study, 35% of fluoroquinolone-resistant isolates from
a mix of hospital and community clinics were ST131.48
Africa
Little data exist on the presence of ST131 in Africa. Two small
samples have suggested high rates amongst ESBL-producing
E. coli. In Cape Town, South Africa, 43% of 23 such isolates
were ST131 and expressed either CTX-M-14 or CTX-M-15
enzymes.49 In the Central African Republic, 50% of
CTX-M-15-producing E. coli were ST131.23 A high proportion
of ST131 have also been identified in a small number of
travel-related ESBL-producing E. coli infections from Africa.45
Non-human carriage and infection
ST131 is represented amongst resistant isolates in companion
and non-companion animals, although the extent is unclear
thus far. A collection from eight European countries confirmed
the presence of ST131, comprising 6% of ESBL-producing E. coli
isolates recovered from companion animals.50 Australian data
show a surprisingly low incidence amongst fluoroquinolone-
resistant isolates from companion animals (7.2% were ST131)
compared with humans (35% were ST131).48 Johnson et al.51
demonstrated intrahousehold sharing of the clone between
domesticated animals; however, transmission from companion
animals to humans has not been confirmed.
In non-companion animals, ST131 has been identified among
ESBL-producing isolates in seagulls49 and rats,50 both of which
have close contact with human populations. Two Spanish
studies have suggested a low prevalence of the clone amongst
poultry and pig farms in that nation.52,53 Mora et al. found that
the clone comprised 1.5% of E. coli strains recovered from
Spanish poultry between 2007 and 2009.53 Surprisingly, in this
study, the prevalence amongst E. coli recovered from retail
chicken meat was considerably higher, comprising 7% of
strains. In addition, PFGE identified a cluster of poultry and
human strains, all of which carried the CTX-M-9 gene and a
similar virulence profile, suggesting recent crossover between
human and avian hosts.53 The high similarity of an isolate
from raw chicken and two human infections in the same
geographical region in Canada was suggestive of transmission
from foodstuff to humans.32 Although these links are tantalizing,
there remains to be a solid molecular epidemiological connection
between human infection and prior consumption of food
containing ST131 E. coli.
Molecular epidemiological observations
Thus far, there are 48 entries of ST131 voluntarily submitted to
the largest publicly accessible E. coli MLST database, with
isolation dates ranging from 1992 to 2009. Notably, only a
handful of other STs have a greater number of entries. This
may equally reflect the current interest in ST131 and/or the
ubiquity of this ST amongst E. coli. The majority of the isolates
originate from human infection, primarily UTIs. In addition,
ST131 E. coli from domesticated and farm animals, birds and
food produce are also recorded in this database.54
Utilizing the discriminating power of PFGE to analyse
MLST-defined ST131 isolates has given considerable insight into
the origin of the clone. Collections from focal outbreaks and
those selected for suspected clonality have confirmed genetic
similarity in excess of 85% on PGFE.10,21 In contrast, collections
with less selected samples from human or animal origin have
shown ST131 isolates with considerable diversity (,65% simi-
larity by PFGE), at times unrelated by traditional definitions.
Even in such broad collections, small groups of identical or very
closely related isolates are identified, often at distant
locations.13,50 This pattern likely reflects the dual phenomenon
of recent divergence of the clone from a common ancestor
together with ongoing transmission of the clone.10 Clinical
reports support this hypothesis. There is convincing description
of direct transmission between humans55,56 and between
animals,48 and, in contrast, of surprising diversity amongst iso-
lates from closely associated patient groups.38 The ancestry
and significance of occasional widely divergent or unrelated
ST131 isolates remains unclear.50
Elucidating the worldwide distribution, transmission and
reservoirs of ST131 is of importance in understanding the poten-
tial mechanisms of its dissemination and control. To date, this
epidemiology has not been clearly defined. Since the initial
descriptions in 2008, research has focused on identifying this
strain in particular groups or collections selected for antimicrobial
resistance phenotype or epidemiological clustering. There have
been fewer opportunities to study this strain in unselected collec-
tions of pathogenic and non-pathogenic isolates.
Reservoirs of ST131
Potential reservoirs of ST131, including food or water sources,
and travel from nations with a high prevalence of the clone
have been proposed as explanations for the rapid emergence
of the clone on multiple continents.57 To date, reservoirs have
been detected only at a local level, with high carriage and infec-
tion rates in nursing-home residents in several nations.16,21
Investigations have only found sporadic isolates of ST131
amongst commercial animals and food sources, although
studies are limited.32,53 The potential spread of ST131 after
introduction from international travellers has only been demon-
strated indirectly. Pitout et al.45 found the highest proportion
of ST131 clones amongst travellers with ESBL-producing
infections in those returning from the Indian subcontinent and
the Middle East. Freeman et al.58 demonstrated a strong
relationship between travel to India and community-onset
CTX-M-15-producing E. coli infection in New Zealand. Countries
implicated in these reports, such as India and Pakistan, have
known high rates of ESBL-producing E. coli infection, but no
data on the prevalence of the ST131 clone as yet.46
Antibiotic resistance
The ST131 ‘pandemic’ was initially described amongst E. coli
harbouring the CTX-M-15 ESBL gene on a relatively
homogenous plasmid.10,11 Subsequent investigation identified a
high incidence of the clone amongst fluoroquinolone-resistant
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non-ESBL-producing isolates and a low incidence amongst col-
lections of susceptible E. coli isolates.15,18,33,38,42 With further
work, many authors have now confirmed surprising diversity
amongst key transferable resistance elements, including ESBL
genes, fluoroquinolone resistance genes and the plasmid
scaffold harbouring them.30,43,59 This diversity amongst a
‘clonal’ E. coli offers insight into the evolution of the clone and
its resistance. Lee et al.43 suggested the acquisition of
transferable resistance elements as independent events from
ST131 dissemination. However, the timing and sequence of
resistance acquisition remains unclear. Potential explanations
offered include the spread of ciprofloxacin-resistant isolates,
which then acquire a CTX-M gene, or, possibly, the simultaneous
spread of clonal organisms and genes.19,42,43 Johnson et al.,35
analysing North American isolates, demonstrated both vertical
and horizontal transfer of the blaCTX-M-15 gene. The gene was
found in isolates closely related by PFGE; however, even within
these clusters there was blaCTX-M-15 discordance, suggesting
horizontal gene transfer or, potentially, gene loss. Given the
clone’s propensity for the acquisition of resistance, a fine-tuning
or evolutionary convergence between the clone, plasmid and
acquisition of ESBL genes is likely.11
ESBL and AmpC enzymes
Resistance to b-lactam antibiotics in ST131 can be mediated
by b-lactam-hydrolysing enzymes from three Ambler classes
(A, C and D) and five distinct families. Among the ESBLs, CTX-M
is the most prevalent in ST131, while SHV and TEM have been
infrequently detected.25,39,47 Of the AmpC b-lactamases, CMY
has been most frequently reported.22,37,47,60,61 Carriage of
the genes encoding these b-lactamases is usually on a large
plasmid (64–160 kb), which frequently carries genes encoding
additional non-extended-spectrum b-lactamases, blaTEM-1 and
blaOXA-1, and the aminoglycoside-modifying enzyme AAC(6′)-
Ib-cr.10,11,34,62
CTX-M-15, the enzyme most closely associated with ST131,
was first identified in India in 1999.63 – 65 It is now the most
widely distributed CTX-M worldwide.66 The enzyme is responsible
for resistance to the penicillins, cephalosporins (excluding the
cephamycins) and monobactams. CTX-M takes its name from
the enzyme’s propensity to confer a higher level of resistance
to cefotaxime than to ceftazidime (the M refers to its discovery
in Munich).67 Other CTX-M-type b-lactamases reported in associ-
ation with the clone include CTX-M-2, CTX-M-3, CTX-M-9,
CTX-M-14, CTX-M-27, CTX-M-32 and CTX-M-61.23,41,53 A chromo-
somal rather than plasmid location of CTX-M-15 amongst ST131
isolates had also been reported and could potentially be a con-
tributing factor in the clonal spread of CTX-M-15-producing
ST131 E. coli.11,22 The SHV and TEM variants described in ST131
include SHV-12, SHV-5, SHV-7, TEM-24 and TEM-116.22,23,37,50
Isolates expressing these ESBLs may be susceptible to cefoxitin,
b-lactamase inhibitors (clavulanic acid, sulbactam and tazobac-
tam) and carbapenems. However, the co-production of ESBLs
with inhibitor-resistant b-lactamases (most prominently OXA-1)
renders these strains resistant to commonly used b-lactamase
inhibitors like clavulanic acid. AmpC b-lactamases (such as
CMY) are also resistant to b-lactamase inhibitors, as well as to
cephamycins such as cefoxitin. Spanish data identified 6% of
AmpC-producing E. coli as ST131. The remainder had mutations
leading to increased expression of chromosomally located AmpC
genes.61 The range and prevalence of ESBL and AmpC genes
associated with ST131 are summarized in Table 2.
Resistance to other antibiotics
Fluoroquinolone resistance is common amongst ST131 in most
studies.22,33,38 Johnson et al.33,35 found that fluoroquinolone
resistance and also trimethoprim/sulfamethoxazole resistance
were significant markers of ST131 E. coli in Canada. This finding
is not consistent through all regions, however.47 The mechanism
of fluoroquinolone resistance in ST131 isolates varies, depending
on the level of resistance. Amongst E. coli, low-level fluoroquino-
lone resistance is usually due to a single mutation in genes
encoding fluoroquinolone targets.68 The presence of plasmid-
mediated quinolone resistance genes, including qnrA, qnrS and
qnrB, may also contribute to low-level resistance, although
they are infrequently described in the ST131 clone.34,36,43,69
Less common variations, including qnrB1 and qnrB2, have also
been reported associated with ST131.22,70 The ‘dual substrate’
aminoglycoside-modifying enzyme AAC(6′)-Ib-cr also contributes
to quinolone resistance via acetylation of selected fluoroquino-
lones.71,72 The effect of these plasmid-mediated genes on fluoro-
quinolone MICs is greater in combination than in isolation.72
When present, high-level fluoroquinolone resistance in ST131
is generally due to chromosomal mutations of genes coding the
fluoroquinolone targets gyrA, gyrB, parC and parE, as described
in other E. coli.68,73 Studies of a ciprofloxacin-resistant clone
(MIC90 ≥32 mg/L) showed multiple mutations in gyrA at codons
Ser-83 and Asp-87, generating Ser-83Leu, Asp-87Asn,
Asp-87 Gly or Asn-87Tyr amino acid changes, and further
single or double mutations of parC at Ser-80 and/or Glu-84
codons (Ser-80Ile and Glu-84Val or Glu-84Gly).22
The aminoglycoside-modifying enzyme AAC(6′)-Ib-cr is fre-
quently associated with ST131 (Table 2).10,11,34,62 Other amino-
glycoside resistance enzymes have been detected less
frequently and sometimes in combination.74 Resistance to ami-
noglycosides remains variable, despite the presence of the
acc(6′)-Ib-cr gene. In one study where 69% of 96 ST131 E. coli iso-
lates possessed this gene, 35%, 49% and 35% of isolates were
resistant to gentamicin, tobramycin and amikacin, respectively.69
Plasmids
The initial descriptions of ST131 demonstrated the IncFII group
of plasmids harbouring CTX-M-15.11 IncFII plasmids may also
encode other types of b-lactamases found in ST131 E. coli,
including SHV-12 and CMY-2.22,50,60 Greater clonal complexity
among plasmids encoding CTX-M-15 is now apparent, with the
multireplicons FIA, FIB and FII having been described in
CTX-M-15-carrying plasmids of ST131 E. coli.11,27,36,75 In a Nor-
wegian study of 23 ST131 strains, the CTX-M-15 gene was
related to IncFII, FIB and FIA (87%, 44% and 42%,
respectively).27
The full sequences of two CTX-M-15-carrying plasmids of
representative ST131 E. coli have been characterized and demon-
strated extensive resistance gene profiles. The plasmid of one
isolate, pEK499 (strain A: 117536 bp), a fusion of type FII and
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Table 2. ESBL, AmpC and aminoglycoside-modifying enzyme genes carried by E. coli ST131
Location
Number of ST131 with
extended-spectrum phenotype
CTX-M-3
% (n)
CTX-M-14
% (n)
CTX-M-15
% (n) Other CTX-M genes % (n)
Other extended-
spectrum genes
% (n)
aac(6′)-Ib-cr
% of ST131
Multiple
continents10,11,45a
70 99 (69) CTX-M-1¼1 (1) 100b
Australia47 8 50 (4) untyped CTX-M¼25 (2) CMY-2¼25 (2)
Belgium28d 31 100 (31)
Cambodia23 8 75 (6) 13 (1) CTX-M-27¼13 (1)
Canada23,34,69 134 11 (15) 87 (117) CTX-M-2¼,1 (1), CTX-M-61¼,1 (1) 75b
Central African
Republic23
5 100 (5)
Croatia29 5 100 (5)
France23,24 33 21 (7) 85 (28) TEM-24¼3 (1)
India/Pakistan/
Bangladesh45
19 100 (19)
Italy22 11 0 91 (10) SHV-12¼9 (1) 100
Japan41 27 74 (20) CTX-M-2¼11 (3), CTX-M-35¼15 (4)
Korea43 6 17 (1) 67 (4) CTX-M-22¼17 (1)
Norway27 9 89 (8) CTX-M-1¼11 (1)
Spain19,21,53,61,106 82c 10 (8) 66 (54) CTX-M-9¼9 (7), CTX-M-10¼2 (1),
CTX-M-32¼4 (3)
SHV-12¼1 (1),
CMY-2¼2 (3),
c-AmpC¼5 (4)
100b
Turkey23,31 3 33 (1) 66 (3)
UK12,23 272 19 (52) 81 (220)d
USA36,37 37 14 (5) 78 (29) SHV-5 or -7¼8 (3) 63b
c-AmpC, chromosomal AmpC gene.
aIsolates selected for CTX-M-15 genotype by researcher.
bData only available on a selection of isolates from this country.
cOne isolate contained CTX-M-14 and CTX-M-15.
dSome isolates CTX-M-28.
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FIA replicons, harboured resistance genes for 10 antibiotics from
eight classes: blaCTX-M-15; blaOXA-1; blaTEM-1; aac(6′)-Ib-cr; mph(A);
catB4; tet(A); and the integron-borne dfrA7, aadA5 and sulI
genes. These were responsible for cephalosporin, b-lactamase
inhibitor, aminoglycoside, chloramphenicol, tetracycline and tri-
methoprim/sulfamethoxazole resistance.74
Detection of O25b-ST131
The three major characteristics of O25b-ST131 E. coli are its
serogroup (O25b), its phylogenetic group (B2) and its ST
(ST131). Each of these characteristics has been used to aid
detection. Of note, a variety of molecular techniques have
been used to determine clonality in previously described
clones. The ST131 ‘pandemic’ is amongst the first examples
where MLST has been the defining technique in describing a
widespread bacterial strain. The power of this technique is
demonstrated in several studies where reanalysis by MLST of
previously defined PFGE groups has confirmed a much broader
clonality than originally suspected.13,33 This increased resolution
does complicate comparison of the scope of ST131 to previous
outbreaks, however.
MLST
MLST first delineated the pandemic clone and remains the ‘gold
standard’ for identification. This requires the sequencing of
pre-specified regions of highly conserved housekeeping genes,
allowing comparison of nucleotide sequences with publically
accessible databases. Hitherto, two separate schemas for
sequencing and classification are available. Achtman et al.6
defined and continue to maintain the database most
frequently utilized in ST131 studies (http://mlst.ucc.ie/mlst/dbs/
Ecoli).9,10,14,37,47,76 This scheme is based on the alleles of seven
housekeeping genes: adk (adenylate kinase); fumC (fumarate
hydratase); gryB (DNA gyrase); icd (isocitrate dehydrogenase);
mdh (malate dehydrogenase); purA (adenylosuccinate synthe-
tase); and recA (ATP/GTP binding motif). An alternate E. coli
MLST scheme also using seven housekeeping genes, operated
by Michigan State University, USA (http://www.shigatox.net/
ecmlst), has also been used.34,45 All but one of the housekeeping
genes used in this scheme differ from the method proposed by
Achtman et al.6
PCR-based rapid detection methods
Rapid detection methods have been developed to overcome the
labour intensity of MLST. Rapid detection of ST131 using a single-
nucleotide polymorphism (SNP) method based on only two
housekeeping genes from the Achtman MLST schema (mdh
and gryB) has been developed. The O25b variants showed the
SNP on C288T and C525T for mdh; and on C621T, C729T and
T735C for gyrB.33 This method has shown 100% sensitivity.
When verified on a broader sample, it is likely that this method
can be used as an alternative option to full MLST.
PCR-based methods to detect the phylogenetic77 and O25
type,76 followed by the confirmation of selected samples using
MLST, have also been used.10,27,31,38,76 This technique for detect-
ing the O serotype O25b is based on a method originally used to
type important E. coli causing septicaemia.78 This O25b typing
uses the specific primers rfb1bis.f (5′-ATACCGACGACGCCGATC
TG-3′) and rfbO25b.r (5′-TGCTATTCATTATGCGCAGC-3′).76 A more
accurate duplex PCR-based method to detect this clone was
developed by the same group. This duplex PCR-based detection
method for O25b-ST131 uses allele-specific PCR for the pabB
gene unique to phylogenetic group B2 subgroup I isolates of O
type 25b.23 The duplex PCR has been successfully used as a
rapid screening method for O25b-ST131 E. coli in many
countries.23,36,47,79
A PCR method on a real-time platform has recently been
described. This assay utilizes amplicon melt curve analysis of
two regions of the pabB gene. A third amplicon based on the
group 1 CTX-M gene can be used to simultaneously detect the
presence of blaCTX-M-15.
80
A third technique using triplex PCR to specifically detect
CTX-M-15-producing O25b-ST131 E. coli is also described,
based on the detection of the operon afa FM955459, rfbO25b
and the 3′ end of blaCTX-M-15.
21
Repetitive sequence PCR
A semi-automated repetitive sequence-based PCR typing tech-
nique (DiversiLabw, bioMerieux) has been found to reliably ident-
ify the pandemic clone.47,69,81,82 Although ≥95% similarity to a
known ST131 strain was used to define presumed ST131 by
DiversiLab in a Canadian study,69,82 other authors have shown
that ST131 strains may have similarities as low as 92%.47,81
PFGE
PFGE has been used to determine relationships amongst the
ST131 complex, rather than to identify the clone in broader col-
lections. The similarity of ST131 on PFGE depends on the origin of
the collection. The majority of ST131 strains have similarities of
≥80% by PFGE, corresponding to differences of four to six
bands.83 However, a minority of isolates show quite a diverse
PFGE pattern. For example, the similarities of ST131 E. coli from
the UK, Chicago and Japan were only 73%,13 67%36 and
70%,41 respectively.
Virulence
E. coli ST131 is primarily an extraintestinal pathogenic E. coli
(ExPEC) harbouring virulence genes required for successful
pathogenic invasion of a human or animal host. These virulence
genes allow the clone to do the following: to attach; to avoid
and/or subvert host defence mechanisms within extraintestinal
sites; to scavenge limiting nutrients, such as iron, from the
host; and to incite a noxious host inflammatory response, cumu-
latively leading to extraintestinal diseases. The putative virulence
genes possessed by ExPEC can be classified into at least five cat-
egories based on their function: adhesins; toxins; protectins
(capsule synthesis); siderophores; and other additional virulence
genes. There are 10 commonly described virulence genes in
ST131 E. coli. They include iha and fimH (encoding the adhesin-
siderophore receptor and type I fimbriae, respectively), sat
(secreted autotransporter, a type of toxin), kpsM (encoding pro-
tectin II, involved in group II capsular polysaccharide synthesis),
fyuA and iutA (encoding siderophores involved in synthesis and
uptake of ferric yersiniabactin and aerobactin, respectively), usp
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(uropathogenic-specific protein), traT (surface exclusion, serum
resistance-associated), ompT (outer membrane protease), and
malX (pathogenicity island marker).10,33 The adhesins, iha and
fimH, were identified in 91%–100% of O25b-ST131.10 In addition
to iha, Canadian O25b-ST131 E. coli isolates possessed the
P fimbriae subunit F10 allele (98%).33 Unlike the other
typical ExPEC E. coli, including CGA and O15:K52:H1 E. coli,
O25b-ST131 E. coli did not possess typical fimbriae and pilus
tip adhesion molecules for pyelonephritis, such as those
encoded by the papA allele, the P fimbriae structural subunit
F16 allele and the papG II allele.33 In Korean isolates, however,
the papG III allele was identified in all ST131 studied.43 The sat
gene was present in 95%–100% of O25b-ST131 E. coli.10,33
This is also a common toxin possessed by the other two types
of E. coli (CGA and O15:K52:H1).33 The fyuA and iutA genes,
encoding the two siderophore virulence factors, were present in
95%–100% of O25b-ST131 E. coli.10,33 The kpsM II gene was
detected in 94% of O25b-ST131 CTX-M-15-producing E. coli.10
In contrast, this gene appeared less frequently (54%) amongst
O25b-ST131 E. coli in Canada that were mostly non-ESBL produ-
cers but fluoroquinolone resistant.33 The other common E. coli
virulence genes usp, traT, ompT and malX also appeared in
nearly all ST131 E. coli.10,33
A clinical report of septic shock and emphysematous pyelone-
phritis, in a previously healthy individual with CTX-M-15-produ-
cing ST131, described the presence of these 10 virulence genes
plus afa and dra (central region of Dr antigen-specific fimbriae,
associated with binding and invasion in the mammalian
urinary tract84).55 These latter two virulence genes occurred in
20% of ST131 isolates tested.10
The ibeA gene, encoding an invasion determinant associated
with neonatal meningitis, has been detected in 34% of
non-ESBL-producing ST131 E. coli blood culture isolates from
north-west Spain.53 This gene has only been infrequently
reported in other collections.33,43
The ST131 clone has also been identified amongst
adherent-invasive E. coli (AIEC) from intestinal and extraintest-
inal disease. This pathovar, distinguished from other ExPEC
strains by a unique phenotype of adhesion and invasion proper-
ties, is associated with inflammatory bowel disease.85 The intes-
tinal AIEC phenotype ST131 carried multiple virulence genes
infrequently described in the clone, including papC, hlyA and
cnf1.53,86
Clermont et al.76 demonstrated in vitro and in vivo virulence of
the ST131 clone. Biofilm formation identified in vitro is a potential
contributor to the long-term persistence of the clone in various
environments and its resistance to host immune defences.
High virulence in a ‘mouse lethality’ model of extraintestinal viru-
lence was speculated to be due to unspecified virulence genes
harboured by the clone.
Human infection
The spectrum of clinical infection caused by the ST131 clone
appears broadly similar to that of other E. coli. UTI, representing
the most common site of human infection with E. coli, is predo-
minant. Description ranges from uncomplicated cystitis to severe
infection complicated by bacteraemia, renal abscess and
emphysematous pyelonephritis.32,55 Pitout et al.34 identified a
propensity for urinary sepsis above other sites of infection
when comparing ST131 and non-ST131 E. coli bacteraemia.
Johnson et al.,38 studying urinary tract origin isolates, found no
clear correlation between ST131 and any particular clinical syn-
drome of renal tract infection.
Other sites of infection have included the respiratory tract,
ascitic fluid, intra-abdominal abscess, bones/joints and bacterae-
mia without a clinically apparent focus.41,56,87 ST131 has also
been reported as a prominent cause of E. coli neonatal
sepsis.56 An exception to the usual spectrum of E. coli infection
has been the description of E. coli ST131 pyomyositis amongst
patients with haematological malignancy.39
Two reports illustrate direct transmission or the sharing of an
identical ST131 clone between humans. Transmission of ST131
E. coli from an elderly father with pyelonephritis to his adult
daughter after brief contact caused her to suffer a similar
illness.55 Similarly, an identical isolate was recovered from an
osteoarticular infection in a young child and a faecal sample
from her mother.56
Treatment
As mentioned above, the ST131 clone can harbour a diverse
range of antimicrobial resistance mechanisms. Few descriptions
of infections with the clone include details of antimicrobial
therapy. Isolates harbouring CTX-M genes have been successfully
treated with carbapenems alone or in combination with amika-
cin.39,55 For the clinician, even with identification and suscepti-
bilities of a pathogenic E. coli, the ST of the isolate is unlikely to
be known. Hence, comment on therapy is based on the com-
monly encountered antibiotic resistance phenotypes of ST131,
which would be expected to respond in a similar manner to
other STs with the same antimicrobial phenotype.
Non-ESBL-producing, fluoroquinolone-resistant isolates
Fluoroquinolone resistance is a hallmark of ST131 in many series.
Although not harbouring an ESBL gene, such clones frequently
carry resistance to other antibiotics. Among UTI isolates, the inci-
dence of co-resistance to trimethoprim/sulfamethoxazole was
42% in Canada,33 47% in Korea43 and 70% in a European collec-
tion (including other STs).18 Carriage of non-extended-spectrum
b-lactamase enzymes confers resistance to narrow-spectrum
b-lactams, with ampicillin resistance rates ranging from 90% to
94%.18,33,43 Fortunately, almost all isolates not producing ESBLs
or AmpC remain susceptible to the third-generation cephalospor-
ins, such as ceftriaxone and cefotaxime.38,43 In severe infection
with a strain not producing ESBLs or AmpC, these would be poten-
tially reliable treatment options. Oral therapy with an agent such
as amoxicillin/clavulanate or trimethoprim/sulfamethoxazole, if
susceptibility is confirmed, could also be used in less severe infec-
tion, such as uncomplicated UTI.
ESBL-producing isolates
Parenteral therapy
Using older breakpoints, ESBL-producing E. coli isolates may test
within the susceptible MIC range to some third-generation
cephalosporins. In this circumstance, many regions’ laboratory
Review
9 of 14
JAC
196
standards suggest reporting resistance to these agents due to
uncertainty about their efficacy in this setting.88 Concern arises
from studies suggesting poorer outcomes with third- and fourth-
generation cephalosporin therapy against ESBL producers.89,90
Some authors suggest that b-lactam/b-lactamase inhibitor
combinations may be effective where in vitro susceptibility of
the isolate is demonstrated.91,92 The parenteral combination
piperacillin/tazobactam has been used for UTIs and other infec-
tions, including bacteraemia, skin structure infection and pneu-
monia, although published experience is limited.91,92
Amongst ST131 clones, including those not producing ESBLs,
concurrent aminoglycoside resistance is frequent. Reported
rates of gentamicin resistance range from 44% amongst
non-ESBL-producing isolates in Korea43 to 86% resistance in
CTX-M ESBL-producing isolates.34 Amikacin resistance is less
well characterized, but also present at high rates amongst ESBL-
producing isolates.10 Even in the setting of in vitro susceptibility,
uncertainty remains about therapeutic efficacy in severe infec-
tions, such as bloodstream infection.93
Carbapenems are the treatment of choice in serious ESBL-
producing infection.94 Several studies demonstrate successful
therapy of UTI and non-urinary tract serious infection with mer-
openem or imipenem/cilastatin.95,96 Ertapenem, a newer nar-
rower spectrum agent, has a limited body of experience that
also suggests successful therapy in ESBL-producing E. coli infec-
tion.97,98 There is a report of the emergence of carbapenem
resistance in E. coli whilst on ertapenem therapy.99
Tigecycline is a glycylcycline derived from minocycline with
good in vitro activity against ESBL-producing E. coli.100 There is
some uncertainty about its potential drug concentrations
achieved in the urinary tract.101 However, a case report has
documented successful outcomes in UTI caused by ESBL-
producing E. coli and other highly resistant Enterobacteria-
ceae.102 Temocillin, a derivative of ticarcillin with stability to
b-lactamase hydrolysis and in vitro activity against the majority
of ESBL-producing Enterobacteriaceae, is a potential therapeutic
option in this setting. There is limited published experience in the
treatment of a variety of ESBL-producing infections.103
Oral therapy
The oral combination amoxicillin/clavulanate has been used effec-
tively in uncomplicated ESBL-producing E. coli cystitis when in vitro
susceptibility is confirmed.104 Of note, ESBL strains co-producing
the non-extended-spectrum b-lactamase OXA-1 may be resistant
to b-lactamase inhibitor combinations.105
Fosfomycin is an oral antimicrobial that inhibits cell wall bio-
synthesis. It has been used for the treatment of ESBL-producing
E. coli cystitis with a high success rate.104 Of concern, a recent
report demonstrates a rapid rise in resistance rates amongst
ESBL-producing ST131 clones to 22% in Spain, which is closely
tied to increasing use of fosfomycin.106
Nitrofurantoin is a synthetic nitrofuran antimicrobial with a
long history of use in uncomplicated UTI.107 No papers directly
describe the susceptibility of ST131 isolates. Amongst a Euro-
pean collection of fluoroquinolone-resistant non-ESBL-producing
isolates, including ST131, 86% were susceptible to this agent.18
Amongst Spanish ESBL-producing E. coli, 87% were susceptible.20
It must be noted that nitrofurantoin is only useful in cystitis and
not in renal infection per se.
Conclusions
Emerging from ‘molecular obscurity’ in the first decade of this
century, ST131 E. coli is now a worldwide pathogen causing
potentially severe antimicrobial-resistant infections. Disseminat-
ing in conjunction with this clone is resistance to many
low-cost and easily available antimicrobials commonly used to
treat E. coli infection. Due to the rapid evolution of this worldwide
pandemic, relatively little is known about this foe.
Molecular epidemiological study is increasingly describing the
clone’s widespread but heterogeneous distribution amongst
humans and animals. The vast majority of these data emanate
from the developed world. Little is known about the distribution
of ST131 in many parts of the developing world, areas suspected
to have high rates of infection and which have even been postu-
lated as reservoirs of the pathogen.57 These areas, in addition,
have a population particularly vulnerable to morbidity and mor-
tality from resistant infection due to the limited healthcare
resources available.
Two key elements required for potential control on a broader
scale as a public health measure require fuller elucidation. The
first is a deeper understanding of the genetics of the ST131
clone, including greater insight into why ST131 has become so
finely tuned to acquire both resistance and virulence, and to
rapidly disseminate on a vast scale. Research in this area
should also increase our understanding of the risk of horizontal
transmission of mobile resistance elements amongst ST131,
between varying E. coli clones and, potentially, to other Entero-
bacteriaceae. The second element is knowledge of the dynamics
of transmission and dissemination of ST131 on a population
basis. We have little firm information on many of the classical
descriptors of communicable disease control: reservoirs; mode
of transmission; incubation period; period of communicability;
susceptibility; and methods of control.108
Given the rapid spread of the ST131 clone and its demon-
strated ability to cause severe infection in otherwise healthy indi-
viduals, consideration must be given to the planning of public
health measures to attempt to control infection. A parallel
could be drawn to community-associated methicillin-resistant
Staphylococcus aureus. In order to successfully plan and
execute interventions, we will need further information on key
aspects of this pathogen and the dynamics of transmission.
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Community-Onset Escherichia coli Infection Resistant to Expanded-
Spectrum Cephalosporins in Low-Prevalence Countries
Benjamin A. Rogers,a Paul R. Ingram,b,c Naomi Runnegar,d,e Matthew C. Pitman,f Joshua T. Freeman,g Eugene Athan,h
Sally M. Havers,a Hanna E. Sidjabat,a Mark Jones,i Earleen Gunning,e Mary De Almeida,f Kaylene Styles,h David L. Paterson,a on
behalf of the Australasian Society for Infectious Diseases Clinical Research Network
The University of Queensland, UQ Centre for Clinical Research, Herston, Brisbane, Queensland, Australiaa; Departments of Microbiology and Infectious Diseases,
Royal Perth Hospital, Perth, Western Australia, Australiab; School of Pathology and Laboratory Medicine, University of Western Australia, Perth, Australiac; Infection
Management Services, Princess Alexandra Hospital, Woolloongabba, Queensland, Australiad; The University of Queensland, School of Medicine, Brisbane,
Australiae; Microbiology Department, The Royal Darwin Hospital, Tiwi, Northern Territory, Australiaf; Department of Clinical Microbiology, Auckland City Hospital,
Auckland, New Zealandg; Infectious Diseases, Barwon Health, Geelong, Victoria, Australiah; The University of Queensland, School of Population Health, Herston,
Brisbane, Queensland, Australiai
By global standards, the prevalence of community-onset expanded-spectrum-cephalosporin-resistant (ESC-R) Escherichia
coli remains low in Australia and New Zealand. Of concern, our countries are in a unique position, with high extramural resis-
tance pressure from close population and trade links to Asia-Pacific neighbors with high ESC-R E. coli rates. We aimed to char-
acterize the risks and dynamics of community-onset ESC-R E. coli infection in our low-prevalence region. A case-control meth-
odology was used. Patients with ESC-R E. coli or ESC-susceptible E. coli isolated from blood or urine were recruited at six
geographically dispersed tertiary care hospitals in Australia and New Zealand. Epidemiological data were prospectively col-
lected, and bacteria were retained for analysis. In total, 182 patients (91 cases and 91 controls) were recruited. Multivariate logis-
tic regression identified risk factors for ESC-R among E. coli strains, including birth on the Indian subcontinent (odds ratio
[OR] 11.13, 95% confidence interval [95% CI] 2.17 to 56.98, P 0.003), urinary tract infection in the past year (per-infec-
tion OR 1.430, 95% CI 1.13 to 1.82, P 0.003), travel to southeast Asia, China, the Indian subcontinent, Africa, and the
Middle East (OR 3.089, 95% CI 1.29 to 7.38, P 0.011), prior exposure to trimethoprim with or without sulfamethoxa-
zole and with or without an expanded-spectrum cephalosporin (OR 3.665, 95% CI 1.30 to 10.35, P 0.014), and
health care exposure in the previous 6 months (OR 3.16, 95% CI 1.54 to 6.46, P 0.02). Among our ESC-R E. coli
strains, the blaCTX-M ESBLs were dominant (83% of ESC-R E. coli strains), and the worldwide pandemic ST-131 clone was fre-
quent (45% of ESC-R E. coli strains). In our low-prevalence setting, ESC-R among community-onset E. coli strains may be asso-
ciated with both “export” from health care facilities into the community and direct “import” into the community from high-
prevalence regions.
Despite adramatic global rise in theprevalenceof expanded-spec-trum-beta-lactamase (ESBL)-producing Escherichia coli, infec-
tionsbyexpanded-spectrum-cephalosporin-resistant (ESC-R)E. coli
in Australia, NewZealand,North America, and selected European
countries remain at relatively low levels. Recent Australian na-
tional data show that 3.2% of community isolates carry such re-
sistance. Approximately 80% of these harbor a globally dominant
blaCTX-M ESBL gene and 12% a plasmid-borne AmpC-typemech-
anism (1). European surveillance data show that a significant pro-
portion of countries have ESC resistance rates rates below 10%
among invasive E. coli isolates (2). In the United States, a recent
large sample of E. coli isolates indicated that 3.9% were ESBL-
producing strains (3). Although these low rates offer reassurance
in the near term, a year-on-year rise in the incidence of commu-
nity-onset ESC-R E. coli infections in low-prevalence countries is
of concern (2, 4).
Australia and New Zealand are in a globally unique position. We
have low rates of useof antimicrobials traditionally identified as a risk
factor forESC-RE. coli. This includes very lowfluoroquinoloneuse
among humans and a ban on the use of ESC and fluoroquinolones
in food production (5, 6). In contrast, we have considerable extra-
mural pressure on antimicrobial resistance rates. Our countries
are located within the Asia-Pacific region, with which we share a
mobile population (7) and frequent commerce (although no land
borders). A high proportion of our regional neighbors have rates
of ESC-R among E. coli strains in excess of 25% (8, 9).
The aim of our study was to define the risk factors for, and
dynamics of, ESC-R among community-onset E. coli infections in
the low-prevalence settings of Australia andNewZealand by using
a case-control methodology. Furthermore, we characterized the
resistance genes and membership of the worldwide pandemic
clone ST131 in implicated isolates.
MATERIALS AND METHODS
The COOEE Study (COmmunity Onset ESBL and AmpC E. coli Study)
was a multisite case-control study, with prospective recruitment of pa-
tients and data collection. Six geographically dispersed tertiary centers in
Australia (n  5) and New Zealand (n  1) participated. The human
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research ethics committees at The University of Queensland and partici-
pating sites approved this study.
Definitions. E. coli infectionwas defined as “community onset” where
a patient was resident in the community (including nursing homes) or
had been hospitalized less than 48 h at the time of onset; “expanded-
spectrum cephalosporin resistance” included all “nonsusceptible” isolates
and was identified phenotypically. For ceftriaxone, MIC 1 mg/liter was
used. For ceftazidime, laboratories used MIC  1 mg/liter or MIC  4
mg/liter, depending on their use of EUCAST or Clinical and Laboratory
Standards Institute (CLSI) criteria, respectively (10, 11); “site of infec-
tion”was determined by the researcher from available information. Guid-
ance for urinary tract infections (UTI) was given as follows: “asymptom-
atic”  a positive urine culture, with no attributable symptoms; “lower
tract infection”  lower-urinary-tract-only symptoms such as urgency,
frequency, and dysuria; and “upper urinary tract infection”  tempera-
ture  38°C, flank pain, or costovertebral angle tenderness and/or any
bacteremia from a urinary source. “Immune suppression” referred to use
at the time of the sample collection of corticosteroids (15 mg/day pred-
nisolone or equivalent), calcineurin inhibitors, other nonbiologics (e.g.,
mycophenylate and methotrexate), cytotoxic agents, biological agents, or
radiation therapy; the Charlson comorbidity index (12) was calculated on
the basis of data available from the survey, with the exception of neuro-
logical impairment (dementia and hemiplegia), which was inadvertently
omitted from the survey questioning. AMcCabe score was assigned based
on the investigator’s estimate of participant survival (1month, 1month
to 2 years, or2 years) (13). “International travel” (excluding travel be-
tween Australia and New Zealand) was classified into geographical re-
gions as follows: South Pacific islands, southeast Asia, Indian subconti-
nent, China, Japan, North America, Europe, and Africa/the Middle East.
“High-risk travel” (regions of the Indian subcontinent, southeast Asia,
Africa, the Middle East, and China) was defined a priori based on Austra-
lian data (14). “Health care exposure” was assessed by the Friedman cri-
teria (15) with two modifications: (i) day procedures were recorded, and
(ii) the criteria were assessed in three “discrete” time periods (1 month
earlier, 1 to 6 months earlier, and 7 to 12 months earlier). In addition,
exact dates and details of any hospital admissions or surgical procedures
were recorded and the interval (in days) from the termination of health
care contact to the date of the firstmedical reviewwith the enrolling E. coli
infection subject was calculated. Further definitions are provided in the
supplemental material.
Clinical methods. A case-control methodology was used. Case pa-
tients with community-onset ESC-R E. coli in a culture of blood or urine
were identified in the microbiology laboratory of participating hospitals.
Control patients had community-onset ESC-susceptible (ESC-S) E. coli
isolated from the same specimen type (urine or blood) as the case. Con-
trols were not matched by any clinical presentation, comorbidity, or de-
mographic factors. They were selected as the next appropriate patient,
after an enrolled case patient, within the same laboratory’s specimen reg-
istration system. If the next appropriate control patient could not be re-
cruited, the process was repeated, at the same time of day and day of week,
in a later week of the study. A single control was recruited for each case.
Inclusions and exclusions. A laboratory-specific protocol was devel-
oped by each site to identify all potentially appropriate patients aged16
years with an isolate of ESC-R E. coli managed at the participating site.
Patients cared for by external health care providers such as family doctors
and external clinics (utilizing the participating laboratories as an external
provider) were not considered for recruitment, due to the complex hu-
man-research ethics requirements in our jurisdiction. Initial screening to
determine likely community onset and the presence of exclusion criteria
was by review of available electronic laboratory data and/or contact with
the clinician caring for the patient. Two exclusion criteria were applied: (i)
inability of the patient to give informed consent to participate, and (ii)
extra-anatomical urinary drainage such as an indwelling urinary catheter
(in the community), intermittent catheterization, ileal conduit, or similar.
These two groups whose members local clinicians had already identified
as a high risk factor for resistant infection appeared to have relatively
distinct demographic and health profiles. Hence, they were excluded in
order to focus study resources on a more generalized population group.
Data collection.Hospitalized patients or those attending ambulatory
clinics were approached for recruitment and data collection in person,
whereas the remainder were contacted by telephone. By telephone, at least
three contact attempts on different days were made. After informed con-
sent, including explanation of the aims of this study, a structured inter-
view was conducted using a standardized data collection form completed
by an investigator under non-blind conditions. Data were primarily self-
reported by participants. Where the participant was uncertain of details
(e.g., dates of hospitalization or antimicrobial use) or the details were not
clear to the investigators on the basis of the answer(s) provided, the inves-
tigators were able to review the patient’s medical records held at their
institution.
For intermittent exposures (e.g., travel, health care exposure, use of
antimicrobials, etc.), participants were asked to recall 12 months before
presentation. Exact dates of exposure were recorded. If the exact date was
not recalled, it was estimated (“start of month”  the 1st of the month,
“middle” or no date specified 15th, “end of month” last day).
Datawere forwarded to a central coordinatorwhere theywere checked
and entered into a secure database. Any omissions or discrepancies were
clarified with the individual sites.
Laboratory methods. All phenotypic susceptibility data presented in
this study have been assessed by EUCAST criteria (10). All nonsusceptible
isolates were considered “resistant” for the purpose of this analysis. E. coli
isolates from each patient were forwarded to the research laboratory, with
phenotypic identification and antimicrobial susceptibility undertaken by
the use of disk diffusion susceptibility testing (DST), an automated system
(VITEK 2), or agar dilution, based on the criteria in use by the laboratory
at the time. Where data for susceptibility to an ancillary antimicrobial
(e.g., nitrofurantoin) were not available, this was assessed by DST in the
research laboratory. Where an isolate was originally tested by CLSI, DST
using EUCAST criteria was undertaken (in the research laboratory) for
agents for which the nonsusceptibility breakpoints of these two criteria
differ (ceftazidime, cefepime, amikacin, gentamicin, ciprofloxacin, and
nitrofurantoin). Where stated, MICs were performed by Etest (bioMéri-
eux, France). For each isolate, a summative antimicrobial resistance score
was calculated from 11 antimicrobials tested (ampicillin, amoxicillin
plus clavulanate, ceftriaxone, ceftazidime, cefepime, meropenem, trim-
ethoprim-sulfamethoxazole [SXT], ciprofloxacin, nitrofurantoin, genta-
micin, and amikacin).
After overnight culture, bacterial DNA was extracted using an Ultra-
Cleanmicrobial DNA isolation kit (Mo Bio Laboratories). ESC resistance
genes were investigated by PCR using previously published primers and
conditions (16–18). A stepwise approach based on local epidemiology of
resistance mechanisms was employed. All isolates were investigated for
blaCTX-M-1 group and blaCTX-M-9 group genes. Isolates negative for these
were investigated for blaCTX-M (consensus sequence), blaCMY, blaDHA,
blaTEM, blaSHV, and blaVEB. All isolates were screened for carbapenemase
genes (blaNDM, blaKPC, and blaIMP) using an in-housemultiplex PCR (19)
and a singleplex PCR for blaOXA-48-like enzymes (20). All PCR amplicons
were sequenced in the forward and reverse directions using anABI3730XL
(Life Technologies) capillary sequencer and compared to published se-
quences in GenBank (www.ncbi.nlm.nih.gov/GenBank).
Presumptive ST131 E. coli isolates were determined by use of semiau-
tomated repetitive sequence-based PCR (rep-PCR) (DiversiLab, bioMéri-
eux, France). Isolates clustering within 95% similarity to multilocus se-
quence type (MLST)-confirmed ST131 reference clones, using a Pearson
correlation coefficient, were considered members of this clone (21). A
selection of isolates (n  4) were confirmed as ST131 by formal MLST
analysis (22).
Statistical methods. Sample sizes with overseas travel as a risk factor
for resistant infection were calculated. With an estimated annual rate of
overseas travel of 250/1,000 population (7), a sample size of 95 cases with
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matched controls was required to detect this risk with odds ratio  2.5
(power of 0.8 and two-sided alpha of 0.05).
Continuous data on health care exposure was right-censored at 365
days. Univariate comparison was undertaken by a 2 test, Fischer’s exact
test, Wilcoxon rank sum test, and logistic regression as indicated. Inter-
actionswere examined. Amultivariate logistic regressionmodel with vari-
ables significant in univariate analysis at a P 0.2 level was constructed.
Using backward selection, variables were retained in the final logistic re-
gressionmodel if their significance remained below P 0.2. Models were
assessed by calculation of a receiver operating characteristic (ROC) curve
and Hosmer-Lemeshow goodness of fit. All statistical tests were two-
tailed, and P  0.05 was considered significant. STATA version 12.1
(Statacorp) was used.
RESULTS
In total, 182 patients (91 cases and 91 controls) were recruited
between March 2011 and October 2012 (Fig. 1). Patients were
recruited over 12 continuous months at five sites and over 9
months at one site. Sites contributed between 8 and 58 patients.
Bacteremia was detected in 33 patients (18%), and positive
cultures were grown from urine samples collected from the re-
maining 149 (82%). Uneven numbers of bacteremias occurred as
one control patient recruited with a positive urine culture subse-
quently manifested a positive blood culture. The residences of the
patients before presentation, clinical syndromes of presentation,
and characteristics of hospital presentation did not differ signifi-
cantly between case and control patients (Fig. 1).
A further 43 patients with presumed community-onset ESC-R
E. coli infection and no overt exclusion criteria were not recruited
(declined to participate, n  19; not contactable, n  18; other,
n 6). On comparison with recruited study participants, the me-
dian age (56 years, P  0.81) and gender (11/43, 26% male, P 
0.39) did not differ significantly from those of the recruited pa-
tients and they were not analyzed further.
Close temporal matching of cases and controls was not fre-
quent. Samples from9 controls originated from the same calendar
day as those from the matched case. For the entire cohort, there
was amedian interval of 22 days between the dates of collection of
the case and control samples.
Phenotype, resistance genes, and ST131. All case patients’ E.
coli isolates demonstrated phenotypic ESC resistance (ceftriaxone
plus ceftazidime 60 [68%], ceftriaxone only 28 [32%], cefta-
zidime only  3 [3%]). For the three E. coli isolates with ceftazi-
dime resistance, the MICs of ceftazidime in the study laboratory
were256mg/liter, 2 mg/liter, and 0.25mg/liter, respectively. All
control patient isolates were susceptible to ceftriaxone and cefta-
zidime. For all antimicrobials studied, with the exception ofmero-
penem (100% susceptible) and amikacin (case  4 resistant/91
[4%], control  0 resistant/91 [0%], P  0.121), resistance was
significantly more likely in the ESC-R isolates than in the ESC-
susceptible (ESC-S) isolates. For ESC-R E. coli, there was signifi-
cant resistance to the oral therapeutic options investigated, in-
cluding amoxicillin plus clavulanate (ESC-R  59/91 [65%]
versus ESC-S 15/91 [16%], P0.001), ciprofloxacin (57/91
[63%] versus 6/91 [7%], P 0.001) and SXT (64/91 [70%] versus
20/91 [22%], P 0.01).
E. coli isolates from 89 cases (98%) and 90 (99%) controls were
available for further analysis. Carbapenemases were not detected
in any isolates. Expanded-spectrum cephalosporinase genes were
detected in 87 of 89 (98%) ESC-R E. coli isolates as follows: for
134 patients with ESC resistant E. coli in 
blood or urine identified for potential 
recruitment. 
91 CASES Recruited 
•  16 - bacteremia (18%) 
•  75 - urine only (82%) 
43 patients NOT recruited. 
•  19 declined to participate (44%)  
•  18 not contactable (42%)  
•  6  other reasons (14%)  
91 CONTROLS recruited 
•  17 - bacteremia (19%) 
•  74 - urine only (81%) 
Residence at time of presentation (n=182) 
•  170 – Private dwelling (93%) 
•  5 – Shared accommodation e.g. boarding house (3% )  
•  5 – Assisted living  (3%)  
•  2- Long term care facility (1%)  
Comparison of cases and controls p=0.549  
First healthcare provider for this presentation (n=182) 
•  100 - emergency department – enrolling hospital (55%) 
•  30 - outpatient clinic – enrolling hospital (16% )  
•  34 - family doctor (19%)  
•  18 - other locations (10%)  
Comparison of cases and controls p=0.553  
Case- Clinical syndrome* 
•  40 Lower urinary tract 
•  26 Upper urinary tract 
•  18 Asymptomatic urine 
•  3 Prostatitis 
•  4 Other 
Control- Clinical syndrome* 
•  34 Lower urinary tract 
•  24 Upper urinary tract 
•  23 Asymptomatic urine 
•  2 Prostatitis 
•  8 Other *p=0.81 for comparison of syndrome 
FIG 1 Participant identification and recruitment and characteristics of presentation and clinical syndrome.
Rogers et al.
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ESBLs, the blaCTX-M-1 group (36/89, 40%), blaCTX-M-9 group (35/
89, 39%), blaCTX-M-1 and blaCTX-M-9 group (3/89, 3%), and
blaSHV-5 group (n  1; 1%); and for non-ESBLs, the blaCMY-2
group (n  11; 12%) and blaDHA-1 group (n  1; 1%). The two
remaining samples included two of the three E. coli isolates with
ceftazidime resistance (MICs, 2 mg/liter and 0.25 mg/liter) and
contained only blaTEM-1, a non-expanded-spectrum beta-lacta-
mase. ESC nonsusceptibility most likely originated from hyper-
production of this enzyme, with loss of this trait during passage
and storage in the case of the isolate with the lower drug MIC.
The worldwide pandemic ST131 clone was presumptively
identified in 46 patients (24%), who were significantlymore likely
to be case patients than controls (40/89 [45%] versus 6/90 [7%],
P  0.001). Among ESC-R E. coli isolates, ST131 was not associ-
ated with any non-CTX-M enzymes. They constituted 54% of the
entire group of CTX-M isolates. In total, 24 (60%) harbored a
CTX-M-1 group enzyme and 19 (48%) aCTX-M-9 group enzyme
(P 0.173 for the comparison). This includes three isolates (8%)
harboring both enzymes. There was no significant difference in
the proportions of ST131 by sample type (blood versus urine, P
0.514) or hospital site (P  0.574). With the exception of the
smallest site (where 0 of 8 were ST131), the clone constituted 19%
to 32% of the isolates from each site.
Demographics, comorbidities, and antimicrobial use. Age
data were compared by visual inspection of histograms. Cases and
controls had similar bimodal distributions, with peaks at approx-
imately 25 and 65 years. Median and 25th to 75th percentiles for
ages of cases and controls, respectively, were 61 years (21 to 82)
and 59 years (19 to 87) (P 0.769). Results of univariate compar-
isons of demographic factors and medical comorbidities between
cases and controls are shown in Table 1. Male sex was the only
variable with a significant difference (odds ratio [OR] 2.3, 95%
confidence interval [CI] 1.5 to 4.6, P 0.018).
Risk from previous urinary tract infection, renal allograft
transplant, and anatomical abnormality of the renal tract was in-
vestigated (Table 1). The number of urinary tract infections in the
previous year was significantly associated with ESC-R E. coli, with
an odds ratio of 1.32 (95% CI  1.08 to 1.63, P  0.008) per
infection.
Results of univariate analysis of antimicrobial use in the previ-
ous year are shown in Table 1. Where the patient could not recall
the antimicrobial taken, it was recorded as “unknown.” Exposure
to trimethoprim or trimethoprim with sulfamethoxazole (SXT)
(OR 3.02, 95% CI 1.13 to 8.12, P 0.028) was a significant
risk factor for ESC-R E. coli. In addition, 7 of 7 patients who had
been exposed to an expanded-spectrum cephalosporin (ceftriax-
one, ceftazidime, or cefepime) had ESC-R E. coli isolated.
Health care exposure. Health care exposure was analyzed us-
ing two distinct sets of data. First, health care exposure, classified
using Friedman criteria for health care-associated (HA) infection,
was analyzed in three time windows, with and without the inclu-
sion of day procedures. Exclusion of day procedures performed
marginally better at predicting ESC-R; exposure 0 to 1 month
earlier (OR 3.56, 95% CI 1.14 to 11.14, P 0.029) and 2 to 6
months earlier (OR 2.99, 95%CI 1.50 to 5.98, P 0.002) was
associated with ESC-R E. coli whereas exposure 7 to 12 months
earlier (P  0.705) was not (full details are provided in the sup-
plemental material).
Second, a continuous model of the temporal risk of ESC-R E.
coli infection after health care exposure was generated using the
exact time interval since last hospital admission. Day procedures
were excluded based on the results of the first analysis. This
smoothed curve of the odds ratios shows the lower bound of the
95% CI approaching an odds ratio of 1.0 at approximately 4 to 5
months (Fig. 2).
Travel, community, andoccupational exposure.Travel in the
previous year was analyzed by region. Travel to the Indian sub-
continent approached but did not achieve significance (P 0.09).
Birth on the Indian subcontinent was a significant risk factor
(OR 6.119, 95% CI 1.32 to 28.44, P 0.021) (Table 1).
Occupational exposure to animals, medical patients, and po-
tential household risks was assessed, as was consumption of a va-
riety of meats. No factors were significant (Table 1). Probable
household transmission of ESC-R E. coliwas suggested in one case
where the partner of an enrolled patient had an infection with a
highly similar isolate (99% identical by rep-PCR usingDiversilab)
3 months prior.
Multivariate analysis. For the multivariate model, health care
exposure in the previous 6months, excluding day procedures, was
selected as a pragmatic option (univariate OR 2.95, 95% CI
1.59 to 5.46, P 0.001). This dichotomous measure was nonsig-
nificantly different from the four-categorymeasurement used ear-
lier (likelihood ratio test P  0.821). Travel to high-risk regions
was selected from the travel group (OR 1.97, 95% CI 0.94 to
4.11,P 0.071).Use of an expanded-spectrumcephalosporinwas
combinedwith use of trimethoprim and SXT, in order to enter the
former into the model, given its accepted prominence as a risk
factor for ESC-R E. coli infection.
Significant variables in multivariate analysis were health care
exposure, excluding day procedures in the previous 6 months
(P 0.002), birth on the Indian subcontinent (P 0.004), travel
to high-risk regions (P  0.011), SXT/ESC use (P  0.014), and
number of UTIs in the previous year (P  0.003) (Table 2). As-
sessment of the final model demonstrated an area under the ROC
curve of 0.77 and a nonsignificant Hosmer-Lemeshow goodness
of fit (P 0.289).
Interactions and alternativemodels.A significant correlation
between travel to high-risk regions and region of birth occurred.
Those born in high-risk regions were more likely to undertake
high-risk travel than those born elsewhere (17/28 [61%] versus
21/154 [14%], P  0.001). This was particularly noted for birth
and travel to the Indian subcontinent (7/13 [54%] versus 31/169
[18%], P  0.002). This correlation, and the use of differing pa-
rameters for health care contact and antimicrobial exposure, were
explored in alternative multivariate models (see the supplemental
material). Specific population subgroups (symptomatic patients
only, ESC-R blaCTX-M patients only, and ESC-R ST131 patients
only)were also tested in themodel.None of the alternativemodels
performed better than the final model, although the levels of sig-
nificance of health care exposure, male sex, and region of birth/
travel differed depending on the model parameters selected.
HAandnon-HAESC-RE. coli.Adifference in the levels of risk
of health care-associated (HA) ESC-R E. coli and non-HA ESC-R
E. coli was separately investigated by analysis of risks within the
HA (n  73) and non-HA (n  109) cohorts (full details are
provided in the supplemental material). Several of the identified
risks for ESC-R E. coli appeared to be most concentrated in one
cohort. Data corresponding to travel to high-risk regions (P 
0.001), birth on the Indian subcontinent (P  0.006), and male
sex (P 0.018) were statistically significant only among themem-
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TABLE 1 Univariate analysis of demographics, comorbidities, antimicrobial use, region of travel and birth, occupational and household exposure
Subject variable
Frequency in ESC-R cases
(%) (n 91)
Frequency in ESC-S controls
(%) (n 91)
Odds
ratio 95% CI P value
Demographics comorbidities
Male sex 30 (33) 16 (18) 2.31 1.51–4.62 0.018b
Age 30 or 59 yrs 66 (73) 60 (66) 1.36 0.72–2.57 0.336
Immune suppression 19 (20) 10 (11) 1.99 0.87–4.60 0.105b
Charlson score 1 44 (48) 34 (37) 1.57 0.87–2.83 0.135b
Active malignancy 11 (13) 9 (8) 1.43 0.55–3.73 0.469
Renal failure 11 (13) 9 (10) 1.25 0.49–3.19 0.636
McCabe score 2 78 (86) 76 (84) 1.18 0.53–2.65 0.681
Indigenous 7 (8) 6 (7) 1.18 0.38–3.66 0.774
Heart disease 7 (8) 7 (8) 1
Long-term-care-facility resident 1 (1) 1 (1) 1
Smoker 12 (13) 14 (15) 0.83 0.36–1.92 0.672
Liver disease 3 (3) 4 (4) 0.74 0.16–3.41 0.701
Lung disease 5 (5) 7 (8) 0.70 0.21–2.85 0.552
Pregnant or postpartum 3 (3) 7 (8) 0.41 0.10–1.63 0.206
Renal tract background
Renal transplant 8 (9) 4 (4) 2.1 0.61–7.22 0.241
Anatomical or structural abnormality 23 (25) 15 (16) 1.71 0.83–3.55 0.147b
UTIs in past 12 mos (per UTI)c Median 1; IQR 0–3 Median 0; IQR 0–1 1.32 1.08–1.63 0.008b
UTIs in lifetime (per UTI)c Median 2; IQR 0–5 Median 2; IQR 0–5 1.03 0.90–1.18 0.657
Antimicrobial use
Any antimicrobials in past 12 mos 69 (76) 62 (68) 1.47 0.76–2.81 0.249
Trimethoprim sulfamethoxazole 16 (17.58) 6 (6.59) 3.022 1.13–8.12 0.028b
Expanded-spectrum cephalosporin(s) 7 (8) 0 NA 0.014b
Fluoroquinolone(s) 7(8) 3 (3) 2.44 0.61–9.77 0.206
-Lactam ß-lactamase inhibitor 16 (17.58) 11 (12.09) 1.552 0.68–3.56 0.300
Carbapenem(s) 3 (3.3) 2 (2.2) 1.517 0.25–9.30 0.652
Aminoglycoside(s) 5 (5) 4 (4) 1.26 0.33–4.87 0.733
Macrolide 6 (6.59) 5 (5.49) 1.214 0.36–4.13 0.756
“Unknown” antimicrobial(s) 35 (38) 33 (36) 1.1 0.60–2.00 0.759
Narrow-spectrum cephalosporin(s) 16 (17.58) 15 (16.48) 1.081 0.50–2.34 0.844
Narrow-spectrum penicillin(s) 10 (10.99) 14 (15.38) 0.679 0.28–1.62 0.383
Travel by regiona
Any overseas travel 28 (30.8) 22 (24.18) 1.39 0.72–2.68 0.32
High-risk regions 24 (26) 14 (15) 1.97 0.94–4.11 0.071b
Indian subcontinent 6 (6.59) 1 (1.1) 6.928 0.75–53.87 0.09
North America 5 (5.49) 2 (2.20) 2.199 0.49–13.69 0.264
Africa the Middle East 3 (3.3) 2 (2.2) 1.517 0.25–9.30 0.652
Southeast Asia 15 (16) 13 (14) 1.18 0.53–2.65 0.681
South Pacific 3 (3.30) 3 (3.30) 1
Europe 3 (3.30) 5 (5.49) 0.586 0.14–2.53 0.474
China 4 (4.4) 0 0.121
Japan 1 (1.1) 0 0.500
Birth by region
High-risk region 18 (20) 10 (11) 2.0 0.87–4.60 0.105
Indian subcontinent 11 (13) 2 (2) 6.12 1.32–28.45 0.021b
Australia New Zealand 58 (64) 59 (65) 0.95 0.52–1.75 0.877
Europe 15 (16) 18 (20) 0.80 0.38–1.71 0.564
Southeast Asia 3 (3) 4 (4) 0.74 0.16–3.41 0.701
AfricaMiddle East 2 (2) 4 (4) 0.49 0.09–2.74 0.415
China 2 (2) 0 0.497
South Pacific 0 3 (3) 0.246
Latin America 0 1 (1) 1.0
Occupation and household exposure
Partner with recent ESC-R E. coli infection 2 (2) Not assessed
Occupational health care exposure 10 (11) 7 (8) 1.48 0.54–4.08 0.447
(Continued on following page)
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bers of the non-HA group. Conversely, data corresponding to a
risk from SXT or ESC use were statistically significant only among
members of the HA group (P 0.026). The numbers of UTIs in
the previous yearwere nonsignificantly different among themem-
bers of either group assessed separately.
Correlates of the classes of ESC resistance enzymes. Corre-
lates of ESC resistance enzyme classes were investigated by a com-
parison of patients harboringE. coliwithCTX-Mgroup enzyme to
those harboring other enzymes (“non-CTX-M”  CMY, DHA,
SHV, TEM). Full details are provided in the supplemental mate-
rial.
There was no statistically significant difference with respect to
the site of infection between CTX-M-harboring and non-CTX-
M-harboring participants (P  0.473), and although bacteremia
was more frequent in the CTX-M group, this did not reach statis-
tical significance (15/73 [21%] versus 0/15 [0%], P  0.063). A
significantly higher median resistance score was present in
CTX-M isolates than in non-CTX-M isolates (median 6 [inter-
quartile range 5 to 7] versus median 4 [interquartile range
4 to 5], P  0.001). Notable differences included higher rates of
resistance to the non-beta-lactam oral agents ciprofloxacin (56/74
[76%] versus 1/15 [7%], P 0.001) and SXT (60/74 [81%] versus
4/15 [27%], P 0.001) among the members of CTX-M group.
In regard to potential risk factors, the members of the CTX-M
group were significantly more likely to have had health care expo-
sure in the previous 6 months than the members of the non-
CTX-M group (45/74 [61%] versus 3/15 [20%], P  0.005) al-
though the same was not true with respect to health care exposure
in the previous 12 months (P  0.72). Other factors used in the
multivariate model that trended toward significance among the
members of the CTX-M group included more high-risk travel
(P  0.052) and fewer reported UTIs in the previous 12 months
(P 0.054). Comparisons of factors not included in themultivar-
iate model showed that “any overseas travel” was more likely in
the CTX-M group (27/74 [36%] versus 1/15 [7%], P 0.033).
DISCUSSION
This multicenter prospective case-control study of community-
onset ESC-R E. coli infection has several key findings that have
implications for risk-based empirical antibiotic prescription and
infection control practices and for control of ESC-R E. coli infec-
tions within communities.
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FIG 2 The risk of ESC-R E. coli infection over a 12-month period after the
most-recent episode of health care exposure, excluding day procedures, esti-
mated with two data sets. The smoothed curve was calculated using continu-
ous data corresponding to the months since hospital admission (black line;
95% CI in gray). Discrete intervals determined using Friedman criteria are
indicated (black dots; 95%CI as vertical dashes). The dashed line represents no
increased risk (odds ratio 1.0).
TABLE 2 Multivariate logistic regression
Subject variable
Odds
ratio 95% CI
P
value
Health care exposure in the previous 6 mos 3.16 1.54–6.46 0.002
UTIs in previous yr (per UTI) 1.43 1.16–1.82 0.003
Birth on the Indian subcontinent 11.13 2.17–56.96 0.004
Travel to high-risk region(s) 3.09 1.29–7.38 0.011
Trimethoprim sulfamethoxazole ESC use 3.67 1.30–10.35 0.014
Male sex 2.17 0.97–4.84 0.060
TABLE 1 (Continued)
Subject variable
Frequency in ESC-R cases (%)
(n 91)
Frequency in ESC-S controls
(%) (n 91)
Odds
ratio 95% CI P value
Pet cat or dog or both at home 32 (35) 33 (36) 0.95 0.52–1.75 0.877
Occupational animal exposure 4 (4) 5 (5) 0.79 0.21–3.05 0.733
Preschoolers at home (5 yrs of age) 7 (8) 9 (10) 0.76 0.27–2.13 0.601
Food consumption
Any meat in past 12 mos 89 (98) 87 (98) 2.05 0.37–11.46 0.415
Poultry 88 (97) 83 (92) 2.47 0.62–9.89 0.206
Processed/preserved meats 51 (56) 52 (58) 0.93 0.52–1.68 0.814
Pork 60 (66) 63 (70) 0.83 0.44–1.55 0.558
Red meat 76 (84) 78 (88) 0.72 0.31–1.66 0.433
a Destinations of travel by region were as follows: for the Indian subcontinent, India, Pakistan, Nepal, and Bangladesh; for North America, the United States and Canada; for Africa
and the Middle East, Zimbabwe, Kenya, Sudan, Liberia, Turkey, and Afghanistan; for Southeast Asia, Malaysia, Singapore, Thailand, Laos, Cambodia, Vietnam, Burma, Indonesia,
and The Philippines; for South Pacific, New Caledonia, Papua New Guinea (PNG), Fiji, Samoa, Cook Islands, and boat cruises through the South Pacific; for Europe, the United
Kingdom, Italy, Holland, Portugal, and Poland; for China, China, Hong Kong, and Macau; for Japan, Japan. High-risk regions include the Indian subcontinent, Africa, the Middle
East, Southeast Asia, and China regions.
b Entered into multivariate model.
c Infections were recorded numerically on a scale of 0 to 5, with all 5 results considered 5 for analysis. Summaries are presented as a median value and an interquartile range
(IQR).
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First, we established that 6 months is a practical, evidence-
based definition for the duration of increased risk of a communi-
ty-onset E. coli isolate harboring ESC-R after health care exposure.
The time-dependent relationship of health care exposure to resis-
tance seems intuitive in nature; however, previously there has
been little supporting data. Hence, authors have used a variety of
definitions from 1 to 6 months (23–25).
Overall, the significant contribution of health care exposure
(OR  3.15) as an ongoing “exporter” of resistant infection in a
low-prevalence setting highlights the importance of controlling
ESC resistance in the health care system. Supporting this hypoth-
esis, United Kingdom data have recently demonstrated a broad-
based decrease in the rate of ESC resistance among invasive Enter-
obacteriaceae strains following a reduction in the use of ESC and
fluoroquinolones within the hospital system (26).
The “importation” of ESC-R E. coli after travel to countries
with a high community incidence of ESBLs is starting to be de-
fined (27), although fewer studies have identified infection rather
than carriage (25, 28, 29). While the pathophysiology seems clear,
the temporality of this remains to be confirmed. In our study,
analysis of temporality, as presented for health care exposure, was
precluded by the imprecision of data from the composite “high-
risk” group and the low numbers involved. However, in absolute
terms, 21 of 24 (87.5%) case participants with travel to high-risk
regions departed those regions within the 6 months before pre-
sentation of infection. This fits with our previous research dem-
onstrating mostly short-lived carriage of ESBL E. coli following
travel overseas and with other studies demonstrating a decrease in
the risk of resistant infection beyond 6 weeks after return from
travel (29, 30).
Investigation of risks for community acquisition in the low-
prevalence countries of Australia and New Zealand showed that
one-quarter (n  23) of ESC-R E. coli patients reported neither
health care exposure nor high-risk travel, suggesting there are as-
yet-undefined risk factors for transmission within the community
(25, 31).
While there was some correlation between birth and travel
region data, the identification of birth on the Indian subcontinent
(OR  11.12) as a risk factor for ESC-R E. coli infection in our
cohort appears genuine. The etiology of this risk could stem from
prolonged carriage of ESC-R E. coli after travel more than 1 year
previous, leading to delayed community-onset ESC-R E. coli in-
fection. Alternatively, our observation of a mostly short interval
between travel and infection supports the possibility of domestic
(within Australia and New Zealand) transmission of this resis-
tance. Transmission of ESC-R E. coli from others within the
household or communitywho have had recent travel to the Indian
subcontinentmay occur. Although the truemagnitude of risk and
the broader applicability require further study, this observation is
consistent with a previously published study from one of our par-
ticipating sites andwith other descriptions of household transmis-
sion (32, 33). Recently, “birth outside Europe” was identified as a
risk factor for infection by CTX-M-producing E. coli in another
study, although comparison with our data is complicated, as the
European study did not fully account for recent travel (31).
Our molecular epidemiology data serve to confirm a number
of key observations made in other regions. The first is a distinct
difference between the epidemiology of CTX-MESBLs and that of
other expanded-spectrum cephalosporinase enzymes, which may
be mediated by the differing modes of acquisition, phenotypes,
and characteristics of the E. coli strains harboring them (16, 34).
Second, the high proportion of the ST131 clone among ESBLs is
no surprise given its global prevalence (35). More surprising is its
predominance without significant fluoroquinolone use (6% of
all participants in this study), one of the likely drivers in other
regions (36). Exposure to this class of antimicrobials within Aus-
tralia and New Zealand is very low (5).
Male sex has been defined by other researchers as a risk factor
for community-onset ESC-R E. coli infection (23, 37–40) and be-
came significant in some of our alternative models. The patient
population of studies with this finding gives a clue to the etiology
of this risk. On the whole, they are of older age with frequent
health care exposure. This contrasts with studies conducted with a
more traditional UTI population of young females that did not
identify male sex as a risk factor (28, 29). In addition to males
experiencing an age-dependent rise in the overall rates of E. coli
infection (41), a limitation associated with case-control studies
may also contribute to this finding. Aging patients certainly expe-
rience changes in the nuances and dynamics of health care expo-
sure and other potential risk factors for ESC-R E. coli infection not
identified with the data corresponding to dichotomous measures
such as hospitalization and antimicrobial use that are most often
collected.
The strengths of our study include its prospective collaborative
nature, a geographically broad sample range, and the case-control
methodology used. The low background rates of ESC-R E. coli
infection in Australia and New Zealand have likely led to more
discrete exposures and easier delineation of temporal risks than in
communities where participants are frequently exposed to this
form of resistance.
Limitations of our study include themoderate sample size, rate
of nonrecruitment, and risk of bias due to an absence of blind
investigator or patient procedures and reliance on patient recall
for many exposures. Recruiting a higher ratio of controls (1:2 or
1:3) would have increased our study power andmight have delin-
eated further unidentified risks. The use of a third group of unin-
fected patients (a case-case-control design) would have allowed
for delineation of risk factors associated with de novo acquisition
of ESC-R E. coli, as opposed to delineation of risk factors for
ESC-R within those that have E. coli (42). However, pragmatic
limitations precluded these options.
Some unique features of Australia and New Zealand may limit
extrapolation of our findings to other regions. The exclusion of
day procedures in this study’s definition of health care exposure
correlated with our local epidemiology and would need to be re-
considered elsewhere. Furthermore, in cases in which blaCTX-M
was not the predominant ESC resistance mechanism in a local
population, risk data might differ.
The use of only hospital patients for recruitment allowed con-
sistent access to participants and samples, although it might limit
the applicability of some risks to the wider community. The ex-
clusion of patients unable to consent meant that we could not
define risks for patients in long-term-care facilities, a known res-
ervoir of ESBL E. coli in Australia and overseas (43–45).
In conclusion, we have defined a critical ESC-R risk period
after health care exposure among community-onset E. coli infec-
tions and demonstrated that ESC-R E. coli infection in a low-
prevalence settings may be driven by “export” from health care
exposure in the previous 6months and importation after travel to
regions with a high incidence of community ESBLs.
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The  clonal  composition  of  Escherichia  coli  causing  extra-intestinal  infections  includes  ST131  and  other
common  uropathogenic  clones.  Drivers  for the spread  of these  clones  and risks  for  their  acquisition  have
been  difficult  to define.  In this  study,  molecular  epidemiology  was  combined  with  clinical  data  from
182  patients  enrolled  in  a case–control  study  of community-onset  expanded-spectrum  cephalosporin-
resistant  E.  coli (ESC-R-EC)  in Australia  and  New  Zealand.  Genetic  analysis  included  antimicrobial
resistance  mechanisms,  clonality  by DiversiLab  (rep-PCR)  and  multilocus  sequence  typing  (MLST),  and
subtyping  of  ST131  by  identification  of  polymorphisms  in  the  fimH  gene.  The  clonal  composition  of
expanded-spectrum  cephalosporin-susceptible  E. coli and  ESC-R-EC  isolates  differed,  with  six  MLST
clusters  amongst  susceptible  isolates  (median  7  isolates/cluster)  and  three  clusters  amongst  resistant
isolates,  including  40 (45%)  ST131  isolates.  Population  estimates  indicate  that  ST131  comprises  8% of
all  E.  coli  within  our  population;  the  fluoroquinolone-susceptible  H41  subclone  comprised  4.5%  and
the  H30 subclone  comprised  3.5%.  The  H30  subclone  comprised  39%  of  all ESC-R-EC  and  41%  of  all
fluoroquinolone-resistant  E. coli  within  our  population.  Patients  with  ST131  were  also  more  likely  than
those  with  non-ST131  isolates  to present  with  an upper  than  lower  urinary  tract infection  (RR  =  1.8,  95%
CI  1.01–3.1).  ST131  and  the  H30  subclone  were  predominant  amongst  ESC-R-EC  but were  infrequent
amongst  susceptible  isolates  where  the  H41  subclone  was  more  prevalent.  Within  our population,  the
proportional  contribution  of  ST131  to fluoroquinolone  resistance  is  comparable  with  that  of  other  regions.
In  contrast,  the  overall  burden  of ST131  is low  by  global  standards.
©  2015  Elsevier  B.V.  and  the  International  Society  of  Chemotherapy.  All  rights  reserved.
1. Introduction
Using contemporary molecular typing techniques, a broad pic-
ture of the genetic diversity of Escherichia coli causing urinary
tract infections (UTIs) and other invasive infections is beginning
to emerge. Recent studies have demonstrated that collections of E.
coli from urine and blood are largely clonal in composition [1–4].
These clonal components invariably include the global pandemic
∗ Corresponding author. Tel.: +61 411408738.
E-mail  address: benrogers@uq.edu.au (B.A. Rogers).
clone, sequence type 131 (ST131) E. coli, as well as other fre-
quently described uropathogenic E. coli (e.g. ST95, ST69, ST73 and
ST127). ST131 E. coli has been implicated as a major contributor to
fluoroquinolone-resistant and expanded-spectrum cephalosporin-
resistant E. coli (ESC-R-EC) infections globally [5].
Clinical and epidemiological risk factors for colonisation or
infection with these clones, in particular ST131, have been diffi-
cult to define. Recently identified risk factors for ST131 include
long-term care facility (LTCF) residence or bedridden status [6–8],
exposure to antimicrobials [6], ethnicity [9], female sex [8], age [6,8]
and infection characteristics [6,10].
In Australia and New Zealand, a range of ST131 clones have
been identified amongst animals as well as humans from a variety
http://dx.doi.org/10.1016/j.ijantimicag.2014.11.015
0924-8579/© 2015 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
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of patient groups [11–16]. Few facets of epidemiology have been
investigated, with one study reporting no difference between the
co-morbidities of patients infected with ST131 and non-ST131
E. coli following prostate biopsy [17], and another demonstrating
some possible sharing of ST131 clones between human and com-
panion animals [18]. There have been no population estimates of
prevalence.
We previously described risk factors for community-onset
ESC-R-EC in Australia and New Zealand. These risk fac-
tors included healthcare contact, travel to high-risk regions
(Indian subcontinent, Southeast Asia, China, Africa and the
Middle East), trimethoprim ± sulfamethoxazole and/or expanded-
spectrum cephalosporin use (ceftriaxone, ceftazidime or cefepime),
UTI in the previous year, and birth on the Indian subcontinent.
We also demonstrated that ST131 E. coli was spread broadly in
our region, although with a relatively uncommon distribution. It
resided almost exclusively amongst ESC-R-EC, where the preva-
lence was 45% compared with 7% amongst expanded-spectrum
cephalosporin-susceptible E. coli (ESC-S-EC) isolates. In addition,
there was a non-significant difference in the proportion containing
blaCTX-M-9 group and blaCTX-M-1 group enzymes [19].
The aim of this follow-up study was to define the clonal compo-
sition and molecular characteristics of community-onset ESC-S-EC
and ESC-R-EC infections. A further aim was to understand the sub-
clonality of ST131 and to elucidate factors that may influence the
distribution of the ST131 worldwide pandemic in our region. To do
this, epidemiological data, collected as part of a case–control study,
were combined with genetic characterisation of E. coli isolates from
the study patients.
2.  Materials and methods
2.1.  Clinical data and bacterial isolates
All bacterial isolates and clinical data are from The COOEE
Study (COmmunity Onset ESBL and AmpC E. coli Study), a multi-
site case–control study with prospective recruitment of patients
and data collection. The study has been described in detail else-
where [19]. In brief, six geographically dispersed tertiary centres
in Australia (n = 5) and New Zealand (n = 1) recruited patients over
a 9–12-month period during 2011 and 2012. In total, 182 patients
(91 ESC-R-EC cases and 91 ESC-S-EC controls) were recruited. Each
site recruited a single unmatched control for each case. Bacterial
isolates were recovered from 98% (179/182) of patients, with the
remainder unable to be recovered from the clinical laboratory.
Expanded-spectrum cephalosporin resistance genes were
present amongst 87/89 (98%) of the available ESC-R-EC isolates [36
(40%) blaCTX-M-1 group, 35 (39%) blaCTX-M-9 group, 3 (3%) blaCTX-M-1
and blaCTX-M-9 groups, 11 (12%) blaCMY-2, 1 (1%) blaDHA-1 and 1 (1%)
blaSHV-5] [19].
2.2.  Definitions
Definitions have been described extensively elsewhere [19].
In brief, case patients had community-onset ESC-R-EC in a cul-
ture of blood or urine. Control patients had ESC-S-EC isolated and
were selected from the same laboratory as the ‘case’ patients.
Patients who were unable to give informed consent to partici-
pate or who had extra-anatomical urinary drainage [e.g. indwelling
urinary catheter (in the community), intermittent catheterisation,
ileal conduit or similar] were excluded from recruitment.
Escherichia coli was considered community-onset when a
patient was resident in the community (including LTCFs) or was
hospitalised for <48 h at the time of onset. Expanded-spectrum
cephalosporin resistance was identified phenotypically. For
ceftriaxone  laboratories used a minimum inhibitory concentration
(MIC) breakpoint of ≤1 mg/L. For ceftazidime, laboratories used
an MIC  breakpoint of ≤1 mg/L or ≤4 mg/L depending on their use
of European Committee on Antimicrobial Susceptibility Testing
(EUCAST) or Clinical and Laboratory Standards Institute (CLSI)
criteria, respectively, within the participating laboratory [20,21].
Site of infection was  determined by the researcher from available
information. This included the researcher’s clinical assessment if
they were involved with patient care, or information relayed by the
treating clinician if the researcher was  not involved in care. Urinary
tract presentations were classified as ‘asymptomatic’, ‘lower tract
infection’ or ‘upper urinary tract infection’ as defined previously
[19]. All other infections (non-urinary source and prostatitis) were
classified into a combined ‘Other’ group.
The Human Research Ethics Committees at The University of
Queensland (Brisbane, Queensland, Australia) and participating
sites approved this study.
2.3.  Antimicrobial susceptibility phenotype
As described previously, all phenotypic data presented here
have been assessed by EUCAST criteria [19,20]. All non-susceptible
isolates were considered resistant for the purpose of this anal-
ysis. An aggregated resistance score (0–11) was calculated with
all antimicrobial phenotypes included in the study [ampicillin,
amoxicillin/clavulanic acid, ceftriaxone, ceftazidime, cefepime,
meropenem trimethoprim/sulfamethoxazole (SXT), ciprofloxacin,
nitrofurantoin, gentamicin and amikacin].
2.4. Molecular methods
Bacterial  isolates were recovered from storage at −80 ◦C in
the research laboratory. Following overnight culture, bacterial
DNA was  extracted using an UltraClean® Microbial DNA Isolation
Kit (MO-BIO Laboratories, Carlsbad, CA). As outlined previously,
expanded-spectrum cephalosporin resistance genes were investi-
gated by PCR using published primers and conditions.
Phylogenetic group was determined by multiplex PCR [22].
Semi-automated repetitive sequence-based PCR (rep-PCR) using
a DiversiLab® system (bioMérieux, 69280 Marcy-l’Étoile, France)
was undertaken according to the manufacturer’s instructions. Den-
drograms were constructed from rep-PCR patterns using a Pearson
correlation coefficient (DiversiLab 3.4 software). All clusters with
at least four isolates demonstrating ≥95% similarity [23] were
then identified by multilocus sequence typing (MLST) [24] as fol-
lows. The two most distant isolates within each cluster underwent
MLST. Where multiple isolates were equally distant, isolates were
selected to maximise the diversity in geographical origin and phe-
notype. If isolates from a rep-PCR cluster were discordant by
MLST, additional isolates underwent MLST to attempt to define the
cluster. The worldwide pandemic clone, ST131 E. coli, was  presump-
tively identified using the same approach and 95% cut-off, although
a number of MLST-confirmed ST131 reference clones were also
included in the dendrogram [25]. Typing of the fimH  allele encod-
ing the type 1 fimbrial adhesin was undertaken in ST131 isolates.
The gene was sequenced in forward and reverse direction based on
published primers and conditions [26] using an ABI 3730XL (Life
Technologies, Waltham, MA)  capillary sequencer. Amino acid sub-
stitutions up to the 265th position of the putative mature peptide
sequence were classified as per the schema of Weissman et al. [27].
2.5. Calculation of whole-population estimates
Estimates of the population prevalence of MLST-defined clones
were back-calculated by adjusting to an overall population preva-
lence of 3.4% ESC-R-EC, as measured in the 2010 Australian Group
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on Antimicrobial Resistance (AGAR) outpatient survey [28]. The
survey sampled a population very similar to that of the current
study, in the 12 months before this study: outpatient urine sam-
ples from 30 hospital-based laboratories including from 4 of 6 sites
in the current study. Estimates are provided with a range assum-
ing a possible 50% difference in population ESC-R-EC rates from the
AGAR survey (i.e. 3.4%, range 2.6–4.25%).
2.6. Statistical methods
Variables  were compared using !2, Fisher’s exact and Wilcoxon
rank-sum tests and calculation of relative risks (RRs) where
appropriate. Continuous data are presented as the median and
interquartile range (IQR). Statistical tests were two  tailed, and P-
value of <0.05 was considered significant. STATA v.12.1 (StataCorp
LP, College Station, TX) was used for statistical analysis.
3.  Results
In total, 179 bacterial isolates were included in this study
(89 ESC-R-EC and 90 ESC-S-EC). Bacteraemia was detected in 29
patients (16%), with the remainder having isolated urine cultures.
All isolates were community-onset, including 2/179 (1.1%) origi-
nating from residents of LTCFs.
3.1. Phylogenetic group
Phylogenetic  grouping showed a high proportion of pathogenic
B2 and D group E. coli (Table 1). The clinical syndrome varied sig-
nificantly for each phylogroup, however when comparison was
limited to lower and upper UTIs (the two categories that constituted
the vast majority of presentations) only B2 isolates demonstrated
a significant risk for upper rather than lower UTI (RR = 2.3, 95%
confidence interval 1.1–4.9). The other phylogroups (A/B1 and D)
demonstrated a non-significant risk favouring lower UTI (P = 0.083
and P = 0.093, respectively). There was no significant difference
in phylogenetic group comparing urine and bacteraemia isolates
(P = 0.820).
3.2. Multilocus sequence typing
A dendrogram from the rep-PCR data was constructed for ESC-
S-EC (Fig. 1), ESC-R-EC (Fig. 2) and all isolates combined (data
not  shown). There was  no obvious geographical or temporal clus-
tering. Twenty-nine isolates underwent full MLST. In total, nine
clusters comprising 60.3% (108/179) of all isolates were related
to six MLSTs (ST131, ST95, ST73, ST69, ST127 and ST80) and two
clonal complexes sharing six of seven alleles (ST14 complex and
ST648 complex). Whilst the proportion of clonal isolates between
ESC-R-EC and ESC-S-EC groups was  similar [56/89 (63%) vs. 52/90
(58%); P = 0.482), there was  a marked difference in the composition
of sequence types. Amongst ESC-S-EC, six MLST-defined clusters
each contained 5–13 isolates (median 7 isolates). Within the ESC-R-
EC, only three clusters were identified with a single cluster, ST131,
containing 40 isolates.
3.3.  ST131 and fimH typing
As  reported previously, 46/189 isolates (24%) clustered within
the ST131 worldwide pandemic clone, including 40/89 (45%)
ESC-R-EC and 6/90 (7%) ESC-S-EC (P < 0.001). All ESC-R-EC ST131
harboured CTX-M enzymes and constituted 54% of the entire CTX-
M group; 24 (60%) harboured a CTX-M-1 group enzyme and 19
(48%) harbouring a CTX-M-9 group enzyme (P = 0.173 for compar-
ison). This included three isolates (8%) harbouring both enzymes.
Amongst the 34 non-ST131 CTX-M-harbouring isolates, 19 (56%)
were CTX-M-9 group and 15 (44%) were CTX-M-1 group (P = 0.472).
The fimH gene was  typed as fimH30  (H30) in 37 (80%) ST131
isolates, with the remaining 9 (20%) typing as fimH41  (H41), indi-
cating a consensus FimH peptide sequence. By rep-PCR, H41 ST131
isolates formed distinct clusters within ST131, which branched at
ca. 97% similarity from the majority of H30 isolates (Supplementary
material).
There was  a significant difference in the rate of expanded-
spectrum cephalosporin resistance between H30 and H41 isolates
[H30 35/37 (95%) ESC-R-EC vs. H41 4/9 (44%); P = 0.009] and
concordance between H30 and fluoroquinolone resistance was
100% [H30 = 37/37 (100%) ciprofloxacin-resistant; H41 = 0/9 (0%)
ciprofloxacin-resistant].
With the exception of the smallest site, which had no patients
with ST131 and small numbers overall (n = 8), the clone and the H30
subclone were present in all sites (Fig. 3). There was  no significant
difference in the proportion of ST131 (P = 0.574) or H30 (P = 0.774)
across study sites.
Table 1
Comparison of clinical presentations within phylogenetic groups and MLST-defined clones.
Clinical syndrome [n (%)] P-valueb RR of upper vs.
lower  UTI (95% CI)c
P-value (upper vs.
lower  UTI)c
Asymptomatic Lower UTI Upper UTI Othera Total
Phylogenetic group
A/B1d 9 (45) 8 (40) 1 (5) 2 (10) 20 0.026 0.3 0.083
B2  27 (21) 49 (38) 43 (34) 9 (7) 128 0.017 2.3 (1.1–4.9) 0.010
D  4 (13) 16 (52) 5 (16) 6 (19) 31 0.043 0.5 0.093
Total  40 (22) 73 (41) 49 (27) 17 (9) 179
MLST groups
ST131 10 (22) 16 (35) 19 (41) 1 (2) 46 0.038 1.8 (1.01–3.1) 0.044
ST131  H30 8 (22) 13 (35) 15 (41) 1 (3) 37 0.149 1.5 0.099
ST131  H41 2 (22) 3 (33) 4 (44) 0 9 0.682 2.0 0.345
ST95  0 5 (33) 9 (60) 1 (7) 15 0.014 2.7 (0.96–7.5) 0.050
ST73  2 (15) 5 (38) 6 (46) 0 13 0.437 1.8 0.310
ST14  cplx. 4 (40) 4 (40) 1 (10) 1 (10) 10 0.407 0.4 0.647
ST69  0 3 (43) 3 (43) 1 (14) 7 0.412 1.5 0.683
All  groupse 21 (19) 39 (36) 39 (36) 9 (8) 108 0.011 2.2 (1.2–4.0) 0.003
MLST, multilocus sequence typing; UTI, urinary tract infection; RR, relative risk; CI, confidence interval; cplx., clonal complex.
a Includes intra-abdominal source (n = 4), prostatitis (n = 5), bacteraemia without focus (n = 4) and others (n = 4).
b The P-value has been calculated across the four clinical presentation categories.
c The RR and P-value compare only upper and lower UTI (excluding other illnesses) across the three phylogroups. A 95% CI is given for significant values.
d A single B1 isolate was  combined with the A group for purpose of analysis.
e All isolates that clustered within an MLST-defined group(see Supplementary material for full MLST groupings).
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Fig. 1. Dendrogram constructed using a Pearson correlation coefficient, based on DiversiLab® repetitive sequence-based PCR (rep-PCR) pattern of expanded-spectrum
cephalosporin (ESC)-susceptible Escherichia coli. Details of figure from left to right: dendrogram: isolate number; virtual gel. Numbered columns from left to right: I, hospital
location; II, phylogenetic group; III, fluoroquinolone susceptibility; V, multilocus sequence typing (MLST) sequence type. Isolates that have been presumptively related to a
MLST  only by rep-PCR pattern are indicated by ‘like’, e.g. ‘ST131 like’. cplx., clonal complex.
3.4. Clonal prevalence estimates
When adjusted for the population rate of ESC-R-EC, the esti-
mated most prevalent MLST clones in this study population were
ST95 (14%, 13.9–14.1%), ST73 (13%, 12.8–13%), ST14 complex (9%,
8.6–8.7%) and ST131 (8%, 7.6–8.3%) (Fig. 4; Supplementary mate-
rial).
Within ST131, the H41 subclone comprised 4.5% (4.5–4.5%) and
the H30 subclone comprised 3.5% (3.2–3.8%) of all E. coli in the popu-
lation. The ciprofloxacin-resistant H30 subclone constituted 41% of
all ciprofloxacin-resistant community-onset E. coli isolates. In total,
ESC-S-EC ST131 constituted 6.4% (6.4–6.5%) of community-onset
E. coli isolates (Supplementary material).
3.5. Characteristics of ST131
A comparison of the site of infection for various clonal groups
is shown in Table 1. This demonstrated that ST131 clones were
significantly more likely to cause upper UTI than lower UTI [ST131,
19/35 (54%) upper UTI vs. non-ST131 30/87 (34%) upper UTI;
RR = 1.8, P = 0.044] (Table 1). When compared only with other phy-
logroup B2 isolates (n = 57), ST131 did not constitute a significantly
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Fig. 2. Dendrogram constructed using a Pearson correlation coefficient, based on DiversiLab® repetitive sequence-based PCR (rep-PCR) pattern of expanded-spectrum
cephalosporin (ESC)-resistant Escherichia coli. Details of figure from left to right: dendrogram: isolate number; virtual gel. Numbered columns from left to right: I, hospital
location; II, phylogenetic group; III, fluoroquinolone susceptibility; IV, expanded-spectrum cephalosporinase type; V, multilocus sequence typing (MLST) sequence type.
Isolates  that have been presumptively related to a MLST only by rep-PCR pattern are indicated by ‘like’, e.g. ‘ST131 like’. cplx., clonal complex.
greater proportion of upper UTIs [upper UTI, ST131 19/35 (54%) vs.
non-ST131 24/57 (42%); P = 0.256).
Analysis  within the ‘upper tract’ and ‘lower tract’ groups showed
no significant difference in the characteristics of clinical presen-
tation between ST131- and non-ST131-harbouring patients. No
patient in either group had evidence of renal abscess or secondary
sites of infection. The duration of symptoms before presentation
comparing ST131 with non-ST131 infections was equivalent for
lower UTIs [3 days (1–7.5 days) vs. 2 days (1–7 days); P = 0.486]
and upper UTIs [2 days (1–5 days) vs. 2 days (1–4 days); P = 0.536].
There was no significant difference in the proportion of upper
UTIs between H30 and H41 subclones (upper UTI, H30 = 15/28
(54%), H41 = 4/7 (57%); P = 1.0).
3.6. Antimicrobial resistance
As  expected, given the prevalence of ST131 amongst resistant
isolates, the median resistance score amongst ST131 isolates was
significantly higher than for non-ST131 isolates across the whole
cohort [median 6 (IQR 4–7) vs. 2 (IQR 0–5); P < 0.001]. When strat-
ified into a variety of relevant groups, the resistance scores did not
differ significantly between ST131 and non-ST131 isolates within
any group (ESC-S-EC, P = 0.077; ESC-R-EC, P = 0.116; and CTX-M-
harbouring ESC-R-EC, P = 0.899). Although total resistance scores
were similar, significant differences in rates of resistance to indi-
vidual antimicrobials included greater resistance to ciprofloxacin
(P < 0.001) and SXT (P = 0.013) amongst the ESC-R-EC ST131 group.
215
356 B.A. Rogers et al. / International Journal of Antimicrobial Agents 45 (2015) 351–358
Fig. 3. Distribution of sequence type 131 (ST131) and the fimH subclones across the study sites for expanded-spectrum cephalosporin-susceptible (ESC-S) and expanded-
spectrum cephalosporin-resistant (ESC-R) Escherichia coli.
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When only the CTX-M-harbouring isolates were analysed, the
difference in ciprofloxacin remained significant (P = 0.010) (Sup-
plementary material).
4.  Discussion
This study provides the first comprehensive molecular epidemi-
ological profile of susceptible and resistant E. coli in our region.
Previous studies in our region have investigated selected groups
such as fluoroquinolone resistance or particular clonal groups, lim-
iting their ability to ascertain a broad profile [13,18].
At first glance, the global pandemic clone ST131 appears to
be dominant in our population. However, this must be seen in
the perspective of local rates of ESC-R-EC (Fig. 4). Our estimates
indicate that ST131 makes up 8% (7.6–8.3%) of community-onset
E. coli isolates. Although less than one-half of the ST131 would be
ciprofloxacin-resistant H30 subclones, ST131 still constitutes a dis-
proportionate 41% of all ciprofloxacin-resistant community-onset
E. coli isolates, as shown in Fig. 3.
Whilst the proportion of ST131 amongst ciprofloxacin-resistant
E. coli is comparable with that found in other contemporaneous
studies, the estimated absolute rate of ST131 is considerably lower
[5]. Three North America studies reported rates ranging from 23% to
28% ST131 amongst E. coli [1,4,6]. A recent Australian cohort (from a
single region amongst a selected patient population) demonstrated
a rate of 21% ST131 amongst females of reproductive age with UTI
[13]. Comparing across all these studies, the most notable variable
was the background rate of fluoroquinolone resistance amongst
E. coli. The rate in the North American studies ranged from 27%
to 29% resistance, and the rate in the Australian study of 13% was
high compared with our sample (7% amongst ESC-S-EC) and other
Australian data [19,28,29].
The  potential relationship between the background rate of
fluoroquinolone-resistant E. coli and ST131 prevalence is reveal-
ing. By global standards, Australia and New Zealand have very
low rates of fluoroquinolone resistance amongst E. coli. These have
been achieved through regulatory control of fluoroquinolone use
in humans and animals [30]. By way of example, 72% of our study
population had used antimicrobials in the previous year, although
only 5% were exposed to a fluoroquinolone. We  hypothesise that on
a  population basis, the low background rate of fluoroquinolone use
has kept the ST131 clone at bay amongst the majority of Australian
and New Zealand E. coli.
The fimH  subtyping of ST131 supports this hypothesis. The
dominance of the H30 subclone amongst ESC-R-EC ST131 isolates
reflects an emerging global picture [31]. Conversely, the overall
dominance/expansion of the fluoroquinolone-susceptible H41 sub-
clone has not been described previously. This subclone is somewhat
genetically distinct from other ‘clades’ of ST131 [32] and is strongly
associated with the otherwise infrequent O16:H5 serotype [33,34].
In our setting, the H41 clone may  have a selective advantage given
recent research demonstrating high virulence coupled with fluoro-
quinolone susceptibility [33,34]. This requires further exploration.
Whilst the identification of antimicrobial use as one of the
drivers/protectors for clones amongst the whole population can
be supported, it does not fully explain the 45% ST131 rate seen
amongst ESC-R-EC within our population, a rate similar to that of
many other regions [35–37]. The data on ESC-R-EC ST131, 88% of
which are the H30 subclone, provides some answers. Foremost, the
findings of this study must be considered in the context of our
previous analysis of risk for ESC-R-EC within our population. We
defined multiple risk factors for ESC-R-EC, and the majority of these
remained a risk for ESC-R-EC ST131 in a sensitivity analysis [19].
Hence, within the population as a whole, factors including health-
care contact, high-risk travel, birth on the continent and previous
UTI are all risk for ST131 in our region. This risk is mediated through
the  very tight association of ST131 with CTX-M extended-spectrum
!-lactamases (ESBLs).
A  confluence of virulence and resistance is important in this
association. ST131 was  associated with almost twice the risk
of upper UTI compared with lower UTI (RR = 1.8). Whether this
virulence is greater than other B2 phylogroup isolates remains
controversial, with mixed findings amongst clinical [4,13,14] and
non-clinical studies of ST131 virulence [38,39].
A key strength of this study is the ability to compare
prospectively collected epidemiological data with the molecular
epidemiological characteristics of our isolates amongst a geograph-
ically dispersed sample. The presence of equal numbers of ESC-S-EC
and ESC-R-EC isolates also allowed clear differentiation of the
clonal structure of each group, which would not otherwise have
been possible, given the low prevalence of ESC-R-EC in our region.
The uniquely low rate of fluoroquinolone use in our region has pro-
vided us insight into the dynamics of the ST131 clone with little
selective pressure from this antimicrobial class.
Limitations of this study include the lack of laboratory virulence
data to allow greater exploration of our hypotheses and findings.
The power to detect significance of association was also limited by
a moderate sample size and the subgroup nature of this analysis.
The reliance on back-calculation to determine population rates may
have led to a lower accuracy of these figures than other methods.
Finally, a number of the findings are hypothesis generating and
require further studies for confirmation.
5. Conclusion
We  delineate a markedly different clonal composition between
ESC-S-EC and ESC-R-EC groups in Australia and New Zealand. Over-
all, ST131 is less frequent than in other regions of the world. The
fluoroquinolone-susceptible H41 subclone of ST131 is most preva-
lent, although the H30 subclone dominates ESC-R-EC. ST131 was
significantly associated with upper UTI presentation, suggesting
enhanced virulence. We hypothesise that the factors contributing
to the low background rate of fluoroquinolone-resistant E. coli in
our region may  also have afforded protection from wider spread of
the pathogenic ST131 clone beyond ESC-R-EC.
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Abstract The aim of this study was to delineate the poten-
tial risks and dynamics of the prolonged carriage of resistant
E. coli in returned travellers. A sample of 274 previously
collected E. coli resistant to ceftriaxone (CRO), ciproflox-
acin, gentamicin and/or nalidixic acid recovered from 102
travellers was studied. Travellers were assessed pre-travel
then longitudinally (maximum 6 months) with peri-rectal/
rectal swabs. Clonality was determined by REP-PCR and
the presence of O25b-ST131 was assessed. Comparison was
made longitudinally for individuals and between identified
co-travellers. The risk of prolonged carriage was lower for
CRO than for ciprofloxacin or gentamicin resistance. Re-
peated isolation of the same phenotype at different time
points occurred in 19% of initial CRO-resistant carriers
compared with 50% of ciprofloxacin- or gentamicin-
resistant carriers. The duration of carriage was also longer
for the latter resistance phenotypes (75th quartile 8 vs 62
and 63 days respectively). In multivariate analysis, risks of
prolonged carriage included antimicrobial use whilst
travelling (3.3, 1.3–8.4) and phylogenetic group B2 (9.3,
3.4–25.6) and D (3.8, 1.6–8.8). Clonality amongst longitu-
dinal isolates from the same participant was demonstrated in
92% of participants who were assessable and most marked
amongst CRO-resistant isolates. ST-131 was surprisingly
infrequent (3% of participants). Prolonged carriage of
ciprofloxacin- and gentamicin-resistant isolates is more fre-
quent and prolonged than CRO resistance after travel. Risks
of prolonged carriage indicate a contribution of host and
bacterial factors to this carriage. These require further elu-
cidation. The strong clonality identified suggests that car-
riage of a “phenotype” was mediated by persistence of
bacteria/plasmid combinations rather than persistence of
the plasmid after horizontal transfer to other bacteria.
Introduction
A number of recent publications have identified carriage of
multi-resistant Enterobacteriaceae, primarily E. coli, in the
gastrointestinal flora of returned travellers [1–5]. Individuals
harbouring antibiotic-resistant organisms have frequently
travelled from countries of low resistance incidence to
countries of high incidence, e.g., Northern Europe to India.
Key geographical regions for acquisition of multi-resistant
Enterobacteriaceae include South-East Asia, the Indian Sub-
continent and Africa.
One limitation of the current studies is that they provide
only a “snapshot” of a narrow resistome immediately after
travel, with only two studies thus far providing any longi-
tudinal data [2, 4]. Such data help us to better understand the
link between carriage of resistant Enterobacteriaceae in
travellers and subsequent infection in the carrier (or others
within the community). Factors impacting on this link may
include the risk of acquisition whilst travelling, clonal
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dynamics and duration of carriage, risk factors for pro-
longed carriage and the potential for spread of resistance
by carriers within the home community or healthcare
setting.
Even from the perspective of the more frequently de-
scribed health-care-associated carriage of resistant Entero-
bacteriaceae, longitudinal carriage studies are limited and
varied. Median durations of carriage of E. coli range from
80 to 178 days with single and multiple clones identified in
differing settings [6–11]. Furthermore, the dynamics of
healthcare-associated carriage may vary considerably
from that of travellers, given the differing mechanism
of acquisition and population involved. Complicating
our understanding of prolonged carriage of antibiotic-
resistant Enterobacteriaceae is the potential that any given
resistance phenotype may be mediated by persistence of a
stable bacteria/plasmid combination or persistence of the
plasmid after horizontal transfer to other bacteria [12].
In this study we aimed to define longitudinal and clonal
aspects of the prolonged carriage of antimicrobial resistance
in a cohort of returned travellers. The natural history and
clonality of individual carriers was investigated using a
sample of patients selected as being unlikely to have ac-
quired new resistance after return from travel, by virtue of
residence in an area of low background incidence of resis-
tance and absence of antimicrobial exposure or re-travel [4,
13]. Shared clonality between travel partners and the inci-
dence of the ST-131 O25B worldwide pandemic clone were
explored in the entire cohort, comprising all samples col-
lected during the study.
Materials and methods
Bacterial isolates and data collection
Bacterial isolates used for this study consisted of 274
Escherichia coli from 102 participants collected during a
previous prospective study of returned travellers residing in
Canberra, Australia [4]. The original study investigated the
rate and duration of colonisation with resistant E. coli fol-
lowing international travel. Isolates presented were resistant
to ciprofloxacin (cip-R), gentamicin (gent-R) and/or cef-
triaxone (CRO-R). In addition, nalidixic acid-resistant E.
coli also recovered from this cohort were included in this
analysis. A full description of the methods of bacterial
isolation and clinical data collection is contained in the
original publication [4]. In brief, 102 prospectively enrolled
travellers who completed the study were asked to collect
rectal or perianal swabs within 14 days before an overseas
trip and within 14 days after return to Australia. If isolates
resistant to ciprofloxacin, gentamicin or ceftriaxone were
detected on the first return swab, participants were asked
to collect regular monthly swabs until resistant bacteria were
not identified on two sequential swabs or for a maximum of
6 months. Swabs were subcultured on three media, HBA-
gentamicin (Oxoid, Adelaide, SA, Australia), MacConkey
agar (Oxoid) containing a nalidixic acid disc (Oxoid,
Basingstoke, Hampshire, UK) and chromID (ESBL; bio-
Mérieux, Craponne, France), after initial overnight broth
enrichment. Resistant colonies were selected from each
plate and underwent identification and susceptibility testing
using Vitek2 (bioMérieux, Durham, NC, USA). If all colo-
nies on a given plate appeared morphologically identical,
then only a single colony was sampled. If morphological
differences between colonies were apparent, each variant
was sampled. Mechanisms of ceftriaxone resistance were
confirmed by PCR and sequencing and are presented in the
original study. They comprised ESBL and AmpC enzymes
[4].
All participant and travel data used in this study were
collected via a questionnaire completed directly by partic-
ipants during the original study. Variables included travel
destinations, antimicrobial use, intercurrent illness and food/
water consumption whilst travelling. For this analysis “high
risk” regions were defined as regions where >50% of trav-
ellers during the original study returned with a resistant
isolate. As travellers frequently visited more than one des-
tination, the duration of stay in each region was calculated
and included.
Molecular methods
The phylogenetic group was determined on all isolates using
triplex PCR [14]. Determination of the ST-131 O25B world-
wide pandemic clone was undertaken by detection of pabB
and trpA alleles via multiplex PCR with a positive control
MLST, confirmed as ST-131 [15]. Repetitive extragenic
palindromic PCR (REP-PCR) was undertaken using pub-
lished methods [16]. The template was purified DNA (Mo-
Bio, USA), using a BioRad C1000 Thermal Cycler. Primers
REP-1 (5’-IIIGCGCCGICATCAGGC-3’) and REP-2 (5’-
ACGTCTTATCAGGCCTAC-3’) were used. The products
were separated on a 1% agarose gel (45 v, 3 h) and stained
with ethidium bromide. Manual visual comparison was used
to identify clonal isolates and any difference greater than
two non-shared bands was considered non-clonal. Bacteria
for comparison were always separated on the same agarose
gel.
All isolates of the same phylogenetic group harboured by
the same participant or shared by travel partners were con-
sidered potentially clonal. For CRO-R isolates, all potential-
ly clonal isolates were subject to REP-PCR. For cip-R and
gent-R isolates, if three or more potentially clonal isolates of
the identical phylogenetic group and phenotypic antimicro-
bial susceptibility (amoxicillin, amoxicillin/clavulanate,
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cephazolin, ceftriaxone, ciprofloxacin, gentamicin, trimeth-
oprim/sulfamethoxazole) occurred within 8 weeks, interval
isolates were skipped (e.g. sample 2 of samples 1, 2 and 3
skipped). If differing presumptive clonality was identified
amongst the isolates analysed then the interval isolate was
subject to REP-PCR.
Definitions
Duration of carriage was calculated from the date of return
to Australia until the date of collection of the last positive
swab. Clearance of carriage was assumed if there was
collection of at least one swab not containing the given
antimicrobial resistance phenotype, without the occurrence
of any subsequent positive swabs. Clonal carriage was
defined as identification of clonal isolates (as defined by
REP-PCR) at two time points (most>4 weeks apart). As
above, any isolates with more than two non-shared bands
were considered unrelated.
Censoring and exclusions for longitudinal analysis
Participant results were censored (exclusion of all subse-
quent swab results) after events that may have potentiated
new acquisition of resistance including further overseas
travel or receipt of antimicrobial therapy for suspected or
proven infection (n06 urinary tract infection, n02 other
infection site). Participants who were still on doxycycline
for malaria prophylaxis at the time of the return swab were
not excluded. Participants harbouring clonally related iso-
lates pre- and post-travel were excluded. To assess this, all
pre-travel isolates were compared with post-travel isolates
using REP-PCR in a similar manner to the longitudinal
analysis (n07 participants). All participants remaining who
had assessable swabs collected at two or more time points
after travel were included.
Statistical methods
Kaplan–Meier plots were used to illustrate duration of re-
sistance. Subjects were censored if they remained resistant
at their final data collection time-point. Parametric survival
models were used to estimate the magnitude of differences
in the distribution of resistance duration due to the three
antibiotics. More specifically, log normal accelerated failure
time models were used, as the log normal provided the best
fit to the observed data from a number of common alter-
natives (including Weibull and log-logistic models) and
estimates from accelerated failure time models could be
reported as proportional increases in resistance duration.
Robust variances were used to take into account within-
patient correlations of resistance to the three antibiotics of
interest.
Potential risk factors were assessed for possible associa-
tion with duration of resistance to any of the three antibiotics
by including these variables as covariates in univariate sur-
vival models. All variables that showed some evidence of
association in univariate analysis (p<0.1) were included in
multivariate analysis. Backwards elimination was used to
remove non-significant (p>0.1) variables until the best pre-
dictive model was obtained. SAS version 9.1 for Windows
and Stata/IC 10.1 for Windows were used for analysis.
Results
Duration, clonal dynamics and risks of prolonged carriage
Of the 102 original participants in the study, 50 returned
carrying antimicrobial-resistant E. coli of interest (CRO-R,
cip-R and/or gent-R), with 44 included in the final analysis
after censoring and exclusions (Fig. 1). Three participants
reporting ongoing use of doxycycline for malaria prophy-
laxis at the initial return swab were not excluded.
Duration and risks of prolonged carriage of resistance
Upon initial assessment, after return from travel, the carriage
of the three specified phenotypes was CRO-R 26% (n027),
cip-R 27% (n028), gent-R 35% (n036). When compared
with CRO resistance, cip-R and gent-R were associated with
2.1 (95% CI, 1.1 to 4.1, p00.027) and 3.5 (95% CI, 1.6 to
7.5, p00.001) times the duration of carriage of resistance
respectively. There was no significant difference between
the duration of cip-R and gent-R. The median durations and
inter-quartile range for recovery of resistance from travellers
was 3 (IQR, 1 to 8) days for CRO-R, 5 (IQR, 1 to 62) days
for cip-R and 8 (IQR, 3 to 63) days for gent-R. This is
represented longitudinally on a Kaplan–Meier curve
(Fig. 2), demonstrating that the major difference is in the
upper quartile of participants.
Potential risks for prolonged carriage of any resistance
were analysed by three groups of factors: participant/travel
characteristics, duration/location of travel and bacterial fac-
tors. Results of the univariate and multivariate survival
model are presented in Tables 1 and 2.
Clonal dynamics of resistance
Clonality was almost always present in prolonged carriage
of a given antimicrobial phenotype. Of 25 participants with
isolation of bacteria of the same phenotype at two time
points, the carriage of exclusively clonal isolates was dem-
onstrated in 14 participants (56%). Carriage of a mixture of
clonal and non-clonal isolates occurred in 9 (36%). Three
participants (12%) carried more than one prolonged clone
Eur J Clin Microbiol Infect Dis (2012) 31:2413–2420 2415
221
simultaneously. In only 2 (8%) was no clonal relationship
found between the bacteria isolated. In both cases bacteria
were only recovered on the return swab and a single subse-
quent swab. These patterns are illustrated in Fig. 3.
The dynamics of clonality differed between CRO-R and
cip-R or gent-R isolates. With the exception of a single
bacterial isolate, repeated isolation of CRO-R E. coli was
invariably due to the presence of clonal bacteria. The car-
riage of ciprofloxacin and gentamicin resistance demonstrat-
ed more diversity, although by month 5 all the isolates
recovered were clonal with earlier isolates (Fig. 4).
Travel partners
From the cohort of 102 travellers, 70 (68%) travelled with
other study members (Fig. 1). This included 29 “pairs” (travel
and sexual partners) and six “mixed groups” containing partic-
ipants of other relationships (friends travelling together, fami-
lies and one unknown relationship). For analysis, pairs within
mixed groups were considered, within the “pairs” cohort.
Analysis of the 29 “pairs” revealed 14 with neither
returning with resistance (48%), 8 (28%) with a single
partner and 9 (31%) with both partners harbouring resis-
tance. Thus, if one person was colonised, there was a 53%
chance of the partner also harbouring one of the three
resistant phenotypes sought (9 out of 17). However, using
clonal analysis, just 2 of the 9 couples (22%) shared clones.
Shared clonality was also identified amongst one in six
“mixed” groups of travellers.
ST-131 worldwide pandemic clone
The presence of the clone was assessed amongst all 274 E.
coli isolates recovered from 102 participants. This included
all CRO-R, gent-R, cip-R and/or nalidixic acid-resistant
isolates recovered from participants throughout the study
duration (Fig. 1). Pre-travel prevalence of the clone was
2% (2 out of 102). An additional two individuals acquired
ST-131 E. coli while travelling. With the exclusion of the
pre-travel carriers, only one prolonged clonal carrier was
colonised with an ST-131 strain. All ST-131 E. coli isolated
were phylogenetic group B2.
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Fig. 2 Kaplan–Meier survival curve comparing the duration of
carriage of the three resistance phenotypes across 44 selected
participants (p00.007)
Fig. 1 Selection and exclusion
of 102 participants for the
three arms of this study.
(The same participants
and bacterial isolates were
used in each arm)
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Discussion
Carriage of multi-resistant Enterobacteriaceae upon return
from travel is a real and concerning phenomenon. The most
serious outcome of such carriage is infection with resistant
organisms after return home. Although we did not specifically
assess infections in returned travellers, two recent studies have
demonstrated this risk in diverse populations. Overseas travel
afforded a relative risk of 2.7 for any infection after TRUS
biopsy [17], and a relative risk of 5.7 for ESBL E. coli
infection in a regional Canadian study [18]. Our analysis helps
to delineate the complex link between acquisition and carriage
during travel and infection after return.
The rapid decline in carriage of resistant isolates after
travel is to some extent encouraging; however, persistence is
significant. Analysis of the longitudinal nature of carriage
highlights the marked persistence of cip-R and gent-R
isolates beyond CRO resistance, with 10% of participants
in the longitudinal arm of this study harbouring cip-R and/or
gen-R at 6 months after return. This is noteworthy, given
that fluoroquinolones and aminoglycosides are heavily re-
lied upon for the treatment of E. coli infection, including
urinary sepsis, in many national guidelines [19, 20]. The
prolonged duration of carriage of fluoroquinolones resis-
tance identified concurs with descriptions of healthcare-
associated carriage [6, 7, 10]. Explanations for the shorter
duration of CRO resistance potentially include the higher
fitness cost for bacterium of maintaining this resistance
plasmid in the absence of ongoing selection pressure and
genetic differences between the host bacteria that harbour
each resistance element.
Risk factors for prolonged carriage are intriguing. Antimi-
crobial use whilst travelling was strongly associated, leading
to a 3.4 times increase in duration of carriage. Kennedy, in
travellers [4], and many authors in other settings have identi-
fied antimicrobial use as a risk factor for the acquisition of
resistance, an intuitive conclusion. However, this study exam-
ines a group who all harboured resistance and did not have
further antimicrobial exposure to potentiate this risk. Another
mechanism apart from simple selection of antimicrobial resis-
tance may apply. We hypothesise potential modification of
intestinal microbiota after antimicrobial use, leading to the
loss of other potentially competitive non-resistant E. coli and
other integral commensal bacteria [21].
Table 1 Univariate analysis of
risk factors for prolonged
carriage of resistance. The esti-
mates provided represent a pro-
portional increase in the duration
of carriage (e.g. 1.00 represent-
ing no increased duration,
2.00 represents two times the
duration of carriage)
SE Asia includes Malaysia,
Thailand, Singapore, Vietnam,
Philippines, Laos, Indonesia,
Cambodia, Papua New Guinea,
Solomon Islands; Middle
East/Africa includes Jordan,
Israel, UAE, Egypt, Zambia,
Tanzania, Kenya
aPer day in this region
bResistance to at least two out
of ciprofloxacin, gentamicin
and ceftriaxone
Variable Estimate Lower 95% CI Upper 95% CI P value
Age at departure 1.00 0.96 1.05 0.86
Female gender 1.17 0.34 4.01 0.80
Whilst travelling
Antibiotic use 9.12 3.16 26.05 <0.0001
Diarrhoea 2.34 0.70 7.77 0.17
Consumed “tap” water 0.53 0.16 1.79 0.30
Duration and destination
Total travel (per week) 1.30 1.06 1.60 0.012
High-risk regions (per week) 1.32 1.08 1.63 0.008
Other regions (per week) 1.03 0.72 1.46 0.87
India/Sri Lanka/Nepala 1.03 1.00 1.06 0.022
SE Asia/Pacifica 0.98 0.91 1.05 0.55
Middle East/Africaa 1.03 0.97 1.10 0.33
China/Hong Kong/Taiwan/Koreaa 1.02 0.93 1.11 0.70
South America/Mexicoa 1.00 0.93 1.08 0.93
Bacterial factors
Multiple resistanceb 1.82 0.54 6.23 0.33
Phylogenetic group A 0.82 0.23 2.86 0.76
Phylogenetic group B1 1.62 0.47 5.58 0.44
Phylogenetic group B2 7.03 1.65 29.96 0.008
Phylogenetic group D 5.16 1.68 15.80 0.004
Table 2 Multivariate analysis of risk factors for prolonged carriage
Variable Estimate 95% CI P value
Travel in high-risk regions
(per week)
1.27 1.09 to 1.49 0.002
Antibiotic use 3.34 1.33 to 8.36 0.01
Phylogenetic group B2 9.32 3.39 to 25.6 <0.0001
Phylogenetic group D 3.81 1.64 to 8.82 0.002
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The analysis of clonality answers interesting questions
about the acquisition and carriage of such resistance. Whilst
the “mobility” of resistance elements, particularly CRO
resistance plasmids, was initially hypothesised in this
study and is frequently discussed and demonstrated in
“high stress” situations such as healthcare settings and
antimicrobial use [12], it appears not to be significant in
travellers. In fact, clonality was almost absolute for
plasmid-mediated CRO resistance. The strong clonality
of isolates amongst all phenotypes gives us an insight
into the environment of acquisition. The identification of
clonality amongst travel partners and mixed groups
Fig. 3 Travellers representative
of different patterns of
carriage of resistant isolates.
A time-line is displayed across
the top (days). Arrows represent
the submission of swabs by
travellers. Shaded squares
indicate bacterial clones with
the diamond in each square
showing time points at which
the bacteria were isolated
in a sample
Fig. 4 Graphical representation of the clonality of isolates amongst
each individual. Left Comparison of CRO-resistant isolates with other
CRO-resistant isolates amongst the same individual. Right Comparison
of ciprofloxacin- and/or gentamicin-resistant isolates with other
isolates of the same phenotype amongst the same individual. (Isolates
harbouring CRO resistance have been excluded.) (Phenotypes that
were only recovered at a single time point could not be assessed for
clonality and are indicated in white/hash)
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(where direct transmission from person to person was
unlikely) suggests exposure and ingestion of a common
source of resistant isolates, potentially food or water.
This is also supported by the relatively low rate (22%)
of shared clonality between partners. The pattern of
contraction of a variety of resistant isolates on return to
persistence of a single (or very few) clones implies the
presence of only a limited number of clones in circula-
tion able to colonise and persist amongst individuals
even in such “environments” with high resistance burden.
The shared clonality amongst partners/mixed groups and
the correlation with period of exposure in “high-risk”
regions supports this hypothesis. This can be compared
with the observation of clonality amongst E. coli causing
urinary tract infection, where a small handful of adapted
clonal groups are thought to cause a significant propor-
tion (10–20%) of all such infections [22]. Although not
investigated in this study, other than ST131, further
exploration of clonality across travellers and regions
would be worthwhile.
The identification of “persistent” clones also highlights
the issue of potential infection and both community- and
healthcare-related transmission of resistant isolates. It is
unknown whether travellers might be the point of intro-
duction of antibiotic-resistant bacteria into a community,
rather than imported food, animals or de novo develop-
ment of resistance via antibiotic use. Importation of
antibiotic-resistant bacteria into hospitals has been well
documented via individuals who have been treated in
hospitals in high-risk areas [23]. With respect to travellers,
we speculate that a long duration after return from travel, e.g.
3–6 months, may be the most problematic in a healthcare
system, given that these clones have been selected as those
best adapted for colonisation and persistence.
The relationship between persistence of colonisation
and subsequent infection needs further exploration. The
phylogenetic groups, as identified in this study, represent
a broad family of bacterial characteristics related to vir-
ulence. The markedly increased duration of the more
virulent B2 and D groups, compared with commensal
E. coli (predominantly groups A and B2) [24], indicates
bacterial genetic factors other than the presence of resis-
tance genes that may aid in persistence. Potential mech-
anisms requiring exploration include biofilm formation,
competitive bacterial toxin production, e.g. colicins, and
virulence factors including siderophore and fimbriae pro-
duction mediating competitive advantages in iron capture
and adhesion. Furthermore, the relation of factors that
determine persistence to those that determine the classi-
cal virulence of invasion and infection also requires
elucidation.
Limitations of this study include the exploratory nature
using a previously collected sample. The collection
method of recovering a single isolate from the plate has
led to some limitation in determining clonality. To inves-
tigate this, a model was constructed using the assumption
that clones recovered on a given swab were present, but
not identified on all previous swabs because of this
methodological issue. This model indicated that approx-
imately one third of clones were not recovered on any
given swab, suggesting that with the repeat sampling
undertaken, there was a low chance of failing to identify
truly persisting clones (data not shown).
In the multivariate analysis, only a limited number of
factors were assessed. There may be other significant par-
ticipant and isolate features that were not included in this
analysis. Furthermore, the assumption that resistance was
only acquired whilst travelling and did not occur after return
is relied heavily upon in the data. We believe this was
reasonable given the very low background rates of resis-
tance in Canberra [4, 13]; however, it is likely not absolute.
Acquisition of resistant clones after return (or the emergence
of “low-level” pre-travel resistant clones owing to antimi-
crobial use) may have led to over-estimation of the duration
of carriage and diversity of clonality. A control group of
matched non-travellers from Canberra would have been
optimal in assessing this situation.
Conclusion
Prolonged gastrointestinal carriage of resistant bacteria
after return from travel is a complex phenomenon. The
duration of carriage of CRO resistance was significantly
shorter than for ciprofloxacin or gentamicin resistance.
Risk factors for prolonged carriage of resistance include
antimicrobial use whilst travelling and the duration of
travel in “high risk” regions. Clonality was present
amongst all phenotypes, but was almost absolute
amongst CRO resistance. The contraction to a small
number of clones and shared clonality amongst travel
partners suggests a limited number of clones adapted to
prolonged carriage circulating in regions of acquisition.
ST-131, the worldwide pandemic clone, was surprisingly
infrequent amongst the phenotypes assessed. The identi-
fication of clonality amongst travel partners and mixed
groups (where direct transmission from person to person
was unlikely) suggests exposure and ingestion of a com-
mon source of resistant isolates, potentially food or
water.
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Predictors of use of infection control precautions for multiresistant
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Introduction: Despite the global expansion of extended spectrum belactamase-harboring Entero-
bacteriaceae (ESBL-E) and carbapenem-resistant Enterobacteriaceae (CRE), only limited research on the
infection control management of patients with these organisms is available.
Methods: We present a national survey of infection control practices amongst adult acute-care hospitals
in Australia, for ESBL-E, CRE, and the emerging threat of patients with overseas health care contact.
Results: In total, 97 health services responded, representing 9% of all eligible hospitals. The proportion of
hospitals that reported use of contact precautions (CP) was 96% (93 out of 97) for ESBL-E, 81% (79 out of
97) for CRE, and 72% (48 out of 67) for patients transferred from an international hospital. For ESBL-E
hospitals frequently employed risk-stratification to limit the use of CP (40 out of 97; 41%). On multi-
variate analysis predictors of a strategy to limit use of CP for ESBL-E were government funding (odds
ratio, 4.8; P ¼ .003) and a metropolitan location (odds ratio, 3.2; P ¼ .014); predictors of any use of CP for
CRE were location in an Australian state with a specific legislation on CRE (P ¼ .030) and the presence of a
written policy on CRE (P ¼ .011).
Conclusions: Infection control management of multiresistant gram-negative bacilli varied considerably
across the Australian hospitals surveyed. A lower rate of reported CP use for CRE than for ESBL-E was
unexpected and indicates a vulnerability in some Australian hospitals. Multivariate analysis revealed
various drivers influencing infection control practice in Australia.
Copyright ! 2014 by the Association for Professionals in Infection Control and Epidemiology, Inc.
Published by Elsevier Inc. All rights reserved.
A marked expansion of community-onset extended-spectrum
b-lactamase harboring Enterobacteriaceae (ESBL-E), and the bur-
geoning of carbapenem-resistant Enterobacteriaceae (CRE) has
occurred during the past decade.1,2 Furthermore, patients with
overseas health care contact are increasingly identified as a vector
for the global movement of new antimicrobial resistance mecha-
nisms, including those mediating CRE.3
The majority of current infection-control guidelines include
recommendations for the control of multiresistant gram-negative
bacilli (MRGNBs), including CRE and ESBL-E. Fewer guidelines
include recommendations for patients with overseas health care
contact.4 Given the small number of published studies on which to
base recommendations5 and the rapidly changing epidemiology of
MRGNBs, guidelines in this area risk being outpaced by on-the-
ground events.
Australia is a low-prevalence country for ESBL-E, with a 2010
national survey of community onset isolates indicating 3.4% of
Escherichia coli and 3.6% of Klebsiella pneumonia were ESBL produc-
ing.6 CRE in Australia originate from 2 key sources: low-level ende-
micity of metallo-b-lactamase-producing Enterobacteriaceae within
critical-care areas and some specialty units on the country’s eastern
coast,7 and residents returning after overseas health care contact.8,9
We have previously described variations in the infection control
practices used for patients hospitalized with expanded-spectrum
cephalosporin-resistant Escherichia coli as part of an Australasia-
wide study.10,11 Such a disparity has been noted in other reports.12,13
In summary, we present a national survey of practice in infec-
tion control management of patients harboring ESBL-E, CRE, and
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patients with overseas health care contact, amongst acute-care
adult hospitals in Australia. Our aim was to define the scope of
variation of infection control practices for these groups in Australia
and to identify factors that determine which policy and practice is
applied in differing health services.
METHODS
The study population was adult acute care hospitals within
Australia. At the time of the survey Australia (population 23
million) was serviced by approximately 700 publically funded
hospitals and 300 private hospitals across its 6 states and 2
administrative territories.14,15
A draft survey was constructed, including questions based on
those used in a previously published work.12 The survey was pilot
tested on 5 experienced infection control practitioners and modi-
fied based on their feedback. The survey questioned health service
practice of infection control, rather than the details of written
policy. Where a service used varied practices within their network,
respondents were asked to answer for the area that best fit the
description of an adult acute care facility. The full survey is in the
Supplementary material.
The survey was conducted as an open invitation online survey,
using aWeb-based interface to collect responses. Ane-mail invitation
was disseminated via 2 frequently used national e-mail discussion
groups, 1 hosted by the Australasian College for Infection Prevention
and Control and the other hosted by the Australasian Society for In-
fectious Diseases.16 The former sends e-mail messages to approxi-
mately 500 e-mail addresses (personal communication, Michael
Wishart, HSN Hospital, Queensland, Australia, May 5, 2014) and the
latter to approximately 900 e-mail addresses (personal communi-
cation, Dr Ashley Watson, Canberra Hospital, Australian Capital Ter-
ritory, Australia, April 24, 2014). Follow-up e-mail messages were
disseminated via these channels. The surveywas open for a 2-month
period (November 2012-January 2013). A small token of appreciation
(a gift hamper) was offered to 1 randomly selected responding site.
Human research ethics approval for the conduct of this study
was received from University of Queensland.
We requested that the nominal head of infection control
complete or delegate completion of the survey at each site, to
minimize multiple responses. If multiple responses from a single
site were received, these were collapsed as follows: concordant,
relative agreement (eg, difference in details only), or discordant.
Answers in the latter 2 groups were combined using the following
rules: affirmative responses (indicating the presence of a given
policy) were presumed to be correct, and the most restrictive
application of a policy or most conservative numerical was pre-
sumed to be correct. Infection control services were not recon-
tacted because permission for this had not been sought in the
ethics approval.
Where a single respondent answered for a health service/
network of multiple adult acute-care hospitals, this wasmaintained
as a single answer, with demographics from the single largest
hospital used for analysis.
External data sources
Data are primarily as reported by the respondent. Key de-
mographics (eg, hospital size, funding, and referral services) were
confirmed with public data sources (Supplementary material 1-4).
Denominator data for Australian hospitals was extracted from the
Australian Institute of Health and Welfare (AIHW) annual report
2011-2012.15
Definitions
Contact precautions were defined as the use of any combination
of gloves, gown, and or a single or cohort room.17 Infection control
practice was considered inclusive when all patients with a given
resistance phenotype were managed in contact precautions or
permissive if nonuse of contact precautions was allowed in some
circumstance (risk stratification by bacterial species or patient
characteristic) or was not used at all. Hospital type was stratified by
funding source; public hospitals are fully funded by the Australian
state and/or federal governments. They provide the vast majority of
supraregional referral services in Australia, whereas private hos-
pitals draw funding from patient billing revenue and primarily
service patients covered by voluntary private health insurance or
other third parties. Supraregional referral services were highly
specialized referral services such as transplant service (ie, solid
organ or allogeneic bone marrow transplant services) and other
supraregional services (ie, major burns, spinal injury, and cystic
fibrosis services). An infectious disease (ID) service was an ID
physician providing consultation or inpatient services at the hos-
pital. A written policy specifically pertained to the resistance
phenotype (or patient group) queried, rather than a generic mul-
tiresistant organism (MRO)-type policy. Hospital size was classified
by the AIHWPeer Group system.18 Because private hospitals are not
classified by this system, 2 researchers (BR and SH) independently
assigned a peer group after review of any available hospital de-
mographic data (from the survey and publicly available information
on the hospital’s Website). Disagreement was resolved by discus-
sion. Principal referral hospitals (A1 by AIHW classification) are
major city hospitals with >20,000 and regional hospitals with
>16,000 (casemix-adjusted) separations per year. Large hospitals
(A1, A2, B1, and B2) included principal referral, specialist women’s
hospitals, large metropolitan (>10,000 casemix-adjusted separa-
tions), and large regional hospitals (>8,000 or >5,000 casemix-
adjusted separations, depending on location).
Relevant legislation and recommendations
At the time of the survey there were no national infection
control management recommendations or legislation specifically
pertaining to CRE or patients with overseas health care contact.
Some recommendations for ESBL-E are provided in the national
infection control guidelines.17 Two Australian states work within
state-level legislation (operational directives). One encompasses all
MROs (MRO directive),19 and the other specifically CRE (CRE
directive).20 See Supplementary material 1-4 for a comparison of
state and national documents.
Statistical methods
Univariate analysis was undertaken using c2 test, Fisher exact
test, and calculation of odds ratios. Multivariate logistic regression
included all variables significant on univariate analysis at a P ¼ .2
level. Using backward selection variables were retained in the final
logistic regression model if their significance remained below
P ¼ .2. Models were assessed by calculation of a receiver operator
curve and Hosmer-Lemshow goodness of fit test. Robust estimates
of variance were used to account for a potential lack of indepen-
dence between hospitals, given some operate in shared jurisdic-
tions where standardization of policy may have occurred. In
addition, when the geographic variable of state-based legislation
was entered into multivariate analysis, it was maintained as a
tripartite set (MRO policy, CRE policy, or no policy). All statistical
tests were 2 tailed, and P < .05 was considered significant. STATA
version 12.1 (Statacorp, College Station, Texas) was used.
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RESULTS
Valid responses were received from 97 unique hospitals or
health services. Eight further responses were excluded because
they originated from institutions that did not meet the study
population (hospital type: exclusively pediatric n ¼ 3, elective day-
procedure sites or subacute care only n ¼ 3, or psychiatry only
n ¼ 2).
Hospital demographics and national coverage
Responses were received from 68 public hospitals and 29 pri-
vate hospitals. This included 75% (31 out of 41) of all sites accredited
to train fellows in adult ID within Australia.21
Approximately 9% of all Australian hospitals within the survey
population responded (9% public hospitals [68 out of 736] and 9%
private hospitals [25 out of 285], excluding private hospitals in 3
states that do not provide denominator data).
In total, 58 hospitals (60%) were situated in metropolitan loca-
tions, 32 were located in regional locations (33%), and 7 were
located in remote locations (7%). Stratified by state location, the
geographic distribution of respondents approximately mirrored
that of the Australian population (Supplementary material 1-4).
Respondents
In total there were 108 respondents, including 9 sites with
duplicate responses. The majority of survey respondents identified
their role as a nursing-trained infection control practitioner (81 out
of 108; 75%, including nurse-managers and clinical nurse special-
ists), or a physician (22 out of 108; 20%, including ID, infection
control, or clinical microbiology specialists). The remainder of
respondents were in managerial or academic positions (5 out of
108; 6%).
There was at least 1 responding physician for 19 out of 97 (20%)
health services. Significantly more principal referral centers
compared with other centers had a physician respond (18 out of 43
[42%] vs 1 out of 54 [2%]; P ¼ .002).
Control of specific organisms and patients
ESBL-E
Contact precautions were used by 93 out of 97 hospitals (96%) in
the management of patients with ESBL-E. (Table 1) The most
common implementation of these precautions was inclusive (48
out of 97; 49%), with contact precautions used for every patient
with any ESBL-E. A variety of permissive practices, including the use
of risk stratification by organism genera and/or patient character-
istics were used in other sites (Fig 1). Datawasmissing from 5 out of
97 sites (5%).
A descriptive analysis of factors predicating the presence of a
permissive practice for the application of contact precautions in
patients with ESBL-E, compared with an inclusive practice, is
shown in Table 2. Onmultivariate analysis, the predictors of use of a
permissive practice were hospital funding type (P ¼ .003) and a
metropolitan location (P ¼ .014) (Table 3).
CRE
Use of contact precautions for patients harboring CRE was re-
ported by 79 out of 97 hospitals (81%) (Table 1). An inclusive
practice was most common, occurring in 56 out of 97 hospitals
(58%) (Fig 1). Descriptive analysis of the predictors of use of any
contact precautions on patients harboring CRE is in Table 2. On
multivariate analysis the significant predictors of any use of contact
precautions for patients harboring CRE were the presence of a
written policy on CRE infection control (P¼ .011) and location in the
state with a CRE directive (P ¼ .030) (Table 3).
International transfer patients
In total 67 out of 97 hospitals (69%) provided information on
infection control management of patients received after an inter-
national transfer between hospitals, 25 out of 97 (26%) indicated
they did not know the policy or had never faced this situation, and 5
out of 97 (5%) did not respond to the question (Table 1).
Contact precautions was used in 72% of hospitals that provided
details (48 out of 67) (Fig 1). Descriptive analysis of infection con-
trol management is presented in Table 2. On multivariate analysis
positive predictors of the use of any contact precautions for inter-
nationally transferred patients was the presence of a written policy
on internationally transferred patients (P¼ .025) and location in the
state with a CRE directive (P ¼ .003) (Table 3).
Some form of enhanced infection control management (contact
precautions and/or screening) was applied to patients reporting
overseas health care contact (although not directly transferred
from a hospital) by 45 out of 97 hospitals (46%), with 46 out of 97
(47%) reporting no use of precautions and 6 out of 97 (6%) not
responding.
AmpC-type organisms
For patients harboring AmpC-producing organisms, 48 out of 97
hospitals (49%) reported no use of contact precautions, 41 out of 97
hospitals (42%) reported an identical management strategy to
ESBL-harboring organisms, 7 out of 97 hospitals (7%) reported a
standalone strategy, and 1 out of 97 hospitals (1%) did not respond.
Policy basis and origin
The most commonly utilized publications in the preparations of
infection control policy for MRGNBs was the Australian National
Health and Medical Research Council guideline17 (87 out of 97;
90%) and departmental guidelines or directives issued by state or
Table 1
Infection control management of extended-spectrum b-lactamase harboring Enterobacteriaceae (ESBL-E), carbapenem-resistant Enterobacteriaceae (CRE), and internationally
transferred patients (IT-patients) (N ¼ 97)
Precautions used
ESBL-E CRE IT-patients
Use Do not use Unknown Use Do not use Unknown Use Do not use Unknown
Any contact precaution use 93 (96) 4 (4) 0 79 (81) 18 (19) 0 48 (49) 19 (20) 30 (31)
Glove and gown 88 (91) 8 (9) 0 73 (75) 20 (21) 4 (4) 36 (37) 31 (32) 30 (31)
Single room* 91 (94) 5 (5) 1 (1) 75 (77) 18 (19) 4 (4) 48 (49) 19 (20) 30 (31)
Cohort room 28 (29) 69 (71) 0 21 (22) 76 (78) 0 NA NA NA
NOTE. Data are presented as n (%).
NA, not applicable.
*For IT-patients, single room and cohort were not differentiated in the survey.
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territory governments (80 out of 97; 82%). Hospitals based in states
with compulsory directives were significantly more likely to
identify this source than other states (36 out of 38 [95%] vs 44 out
of 59 [76%]; P ¼ .015). International guidelines were used less
frequently, including those originating from the Centers for Disease
Control and Prevention22 (43 out of 97; 44%) and other countries’
guidelines (21 out of 97; 22%).
Variability of survey response
Analysis of responding health services showed a dispropor-
tionate number of responses from large public hospitals. This group
comprised 68% (48 out of 68) of survey respondents within
the public hospital group, although numerically accounts for only
18% of public hospitals (131 out of 736) within Australia. Within
responses on internationally transferred patient management
missing data was most often from smaller hospitals. In total 86% of
principal referral hospitals (37 out of 43) provided details on their
management compared with 56% of other sites (30 out of 54)
(P ¼ .001 for comparison).
Analysis by respondent type showed significant differences in
reported CRE management. All sites with a physician respondent
(19 out of 19) reported use of contact precautions for CRE, whereas
only 60 out of 78 sites (77%) with a nonphysician respondent re-
ported this use (P ¼ .019 for comparison). When further analysis
was undertakenwithin the subgroup of principal referral hospitals,
to account for the disproportionate number of physician re-
spondents within this group, this difference was still apparent,
although not statistically significant due to the small numbers
involved (18 out of 18 physician respondents (100%) used contact
precautions for CRE versus 20 out of 25 nonphysician respondent
sites [80%]; P ¼ .064).
Fig 1. Breakdown of strategies for the use of contact precautions (CP) for extended-spectrum b-lactamase harboring Enterobacteriaceae (ESBL-E), carbapenem-resistant Enter-
obacteriaceae (CRE), and internationally transferred patients. Boxes shaded in white indicate an inclusive or unknown strategy. Boxes shaded in grey indicate a permissive strategy.
(A) ESBL-E. (B) CRE. (C) Internationally transferred patients. *Organisms considered for CP amongst ESBL-E include Escherichia coli þ Klebsiella pneumoniae (11 out of 22; 50%),
K pneumoniae (5 out of 22; 23%), Escherichia coli (2 out of 22; 10%), and neither/unsure (5 out of 23; 23%). Organisms considered for CP amongst CRE¼ Escherichia coli þ K pneumonia
(2 out of 7; 29%), K pneumonia only (3 out of 7; 43%), and neither/unsure (2 out of 7; 29%). yPatient-assessment for CP for ESBL-E included ward location (15 out of 29; 51%) and
clinical features of the patient (eg, sample of origin for isolate and presence of diarrhea) (23 out of 29; 79%). Three sites (out of 29; 10%) indicated neither of these factors was used in
their assessment. For CRE, patient-based assessment included the ward location (3 out of 11; 27%) and clinical features (8 out of 11; 73%). Three sites (out of 11; 27%) indicated
neither of these were used for their assessment.
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Table 2
Descriptive analysis of predictors of infection control management. The 3 groups of data are descriptive analysis of the use of contract precautions (CP) as a permissive policy for extended-spectrum b-lactamase harboring
Enterobacteriaceae (ESBL-E), any use of CP for carbapenem-resistant Enterobacteriaceae (CRE), or any use of CP for internationally transferred patients (IT-patients)
Predictive characteristic
Count amongst
all hospitals (%)
(N ¼ 97)
ESBL-E CRE IT-patients
Count with
permissive
use of CP
for ESBL-E
(% of total with
permissive use)
(n ¼ 44)
Count with
inclusive use
of CP for ESBL-E
(% of total with
inclusive use)
(n ¼ 48)
Odds ratio
(95% CI)
P
value
Count with any use
of CP for CRE
(% of total using
CP for CRE)
(n ¼ 79)
Count who do
not use CP for
CRE (% of total
not using CP)
(n ¼ 18)
Odds ratio
(95% CI)
P
value
Count with
any use of
CP for IT-patients
(% of total with
using CP)
(n ¼ 48)
Count who
do not use CP
for IT-patients
(% of total
not using CP)
(n ¼ 19)
Odds ratio
(95% CI)
P
value
Public (vs private) 68 (70) 37 (84) 31 (65) 4.1 (1.5-11.1) .005 54 (68) 25 (32) 0.6 (0.2-2.1) .436 33 (69) 15 (29) 0.6 (0.2-2.1) .411
Metropolitan location
(vs regional and
rural)
58 (60) 32 (73) 26 (54) 2.7 (1.1-6.4) .028 51 (72) 7 (39) 2.9 (1.0-8.3) .052 33 (69) 13 (68) 1.0 (0.3-3.2) .979
Infectious disease
service
57 (59) 29 (66) 28 (58) 1.5 (0.6-3.5) .347 49 (62) 8 (44) 2.0 (0.7-5.8) .179 30 (63) 16 (84) 0.3 (0.1-1.2) .097
Written policy on
phenotype/patient
group
ESBL-E ¼ 38 (39)
CRE ¼ 22 (23)
IT-patients ¼ 50 (52)
17 (39) 21 (44) 0.8 (0.4-1.9) .621 22 (23) 0 (0) .011 36 (75) 8 (42) 3.2 (1.4-7.6) .006
Written policy on MBL 21 (22) NA NA NA NA 18 (23) 3 (17) 1.5 (0.4-5.7) .571 NA NA NA NA
MRO directive 21 (22) 9 (20) 12 (25) 0.8 (0.3-2.1) .606 19 (24) 2 (11) 3.6 (0.7-17.1) .116 9 (19) 7 (37) 0.7 (0.2-2.3) .522
CRE directive 17 (18) 9 (20) 8 (17) 1.3 (0.4-3.7) .642 17 (100) 0 (0) .030 16 (33) 0 (0) .003
Regular international
transfers*
28 (33) 16 (41) 12 (25) 1.7 (0.7-4.4) .244 27 (39) 1 (6) 10.3 (1.3-83.1) .029 21 (46) 7 (41) 1.2 (0.4-3.7) .753
Large hospital 59 (61) 32 (73) 27 (56) 2.25 (0.9-5.4) .069 49 (62) 10 (56) 1.3 (0.5-3.7) .614 32 (68) 15 (79) 0.5 (0.2-1.9) .330
Principal referral
vs other
43 (44) 25 (57) 18 (34) 2.6 (1.1-5.9) .026 38 (48) 5 (28) 2.4 (0.8-7.4) .126 25 (52) 12 (63) 0.6 (0.2-1.9) .416
Transplant servicey 20 (21) 14/25 (56) 6/18 (33) 2.3 (0.6-8.4) .196 19/38 (50) 1/5 (20) 4.0 (0.4-40.2) .239 13 (52) 5 (42) 1.5 (0.4-6.2) .562
Other supra-regional
referral servicesy
21 (22) 14/25 (56) 7/18 (39) 2.3 (0.6-8.4) .196 20/38 (53) 1/5 (20) 4.4 (0.4-44.7) .205 15 (60) 4 (33) 3.0 (0.7-12.9) .141
MBL, metallo-b-lactamase harboring bacteria; MRO, multiresistant organism; NA, not applicable.
*Hospitals were considered to accept international transfers regularly if they reported a frequency of less than monthly or greater.
yVariables analyzed only within principal referral hospitals.
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Analysis of intrasite correlation for the 9 sites that submitted
multiple responses to the survey is presented in Supplementary
material 4. Across 7 major themes in the survey, no single
site showed concordance for all answers. Across all sites, 51% of
details reported were concordant (32 out of 63), 27% were in
relative agreement (17 out of 63), and 22% were discordant (14
out of 63).
The highest discordance was on the presence of written policies
(7 out of 9; 88% discordant) and the use of contact precautions for
internationally transferred patients (3 out of 9; 33% discordant).
Relative agreement occurred most often when describing contact
precautions use for ESBL-E and CRE (each 6 out of 9; 67% relative
agreement). In the relative agreement group, differences between
respondents were in the description of details of risk stratification
practice and the use of cohort rooms.
DISCUSSION
Our national survey demonstrates widely varied infection con-
trol practice for MRGNBs across at least 97 hospitals in all regions of
Australia. Such variation has been demonstrated in other parts of
the world.12,13
Foremost, our unexpected finding is that contact precautions
use is reported more frequently for ESBL-E than for CRE. Several
explanations are apparent. First, our data indicate many infection
control policies and/or practitioners rely on the use of a laboratory
ESBL phenotype to trigger contact precautions use, as evidenced by
the lower rates of any contact precautions use for AmpC organisms
compared with ESBL-E (50% vs 96%). A number of CRE will not
possess this phenotype (nor even an metallo-b-lactamase pheno-
type) and will not be detected unless decreased carbapenem sus-
ceptibility is the trigger for infection control intervention.
Second, misclassification may have occurred due to unfamil-
iarity with the term CRE. This was unforeseen in the survey design
and specific examples of carbapenem and Enterobacteriaceae were
not given. This finding is supported by the significantly higher
proportion of physician-trained respondents (who are all trained
and certified subspecialists), compared with others, reporting of
use of contact precautions for CRE. Other respondents (94% from a
nursing background) would have a more varied clinical and aca-
demic background than the physicians, and may not be familiar
with aspects of CRE, given its relative infrequency in Australia.23
To some extent both possibilities indicate a number of vulner-
able Australian hospitals, where patients with CREmay not have an
appropriate assessment of their infection control needs. Within
misclassification it is difficult to determine for what proportion the
issue is simply a lack of knowledge of current terminology, as
opposed to a greater knowledge gap around the potentially varied
clinical and laboratory characteristics of CRE and the serious im-
plications of the phenotype.
Our findings on the predictors of ESBL-E and CRE practice offer
insight into some of the pragmatic aspects of determining MRGNB
policy.
For ESBL-E infection control practitioners have potentially
sought a balance between the low risk of nosocomial transmission
of ESBL-E24 and the various burdens of contact precautions. Hos-
pitals that were likely to have a high load of ESBLeE-harboring
patients, due to their generally higher acuity (metropolitan and
public hospitals), were more likely to use a permissive policy to
limit use of contact precautions for this phenotype. Interestingly,
the only 4 sites that did not use any contact precautions for ESBL-E
were principal referral sites with a supraregional referral patient
load.
Predictors of contact precautions use in CRE illustrate the ben-
efits and risks of layering state-based legislation on health care
services. When used in a targeted manner, this can be effective in
filling a void in national policy. Operating under a CRE directive was
a significant predictor of the use of contact precautions for CRE (and
for internationally transferred patients, which are also covered by
the policy).
In contrast, the general MRO directive appears to be ineffective.
Despite 90% of sites in the state indicating they used directives to
formulate policy, directives did not have a significant influence
on infection control practice for the emerging threats of CRE and
internationally transferred patients. Even for ESBL organisms
(which are specifically mentioned in the document), sites have
either disregarded, or gradually moved away from, the stipulated
management.
Internationally transferred patients are an emerging risk
group with which other regions are also grappling.25 The sig-
nificant predictive value for the use of contact precautions of the
presence of a written policy for internationally transferred pa-
tients should be interpreted in light of the 31% missing data and
the 33% discordance rate on answers to this question. There is
some misclassification. Taken as a whole these data indicate
limited knowledge of this risk group and of details of policy
even where policies do exist.
A key strength of our study is the national sample and the broad
mix of hospital types, including thought-leading sites where future
ID and infection control physicians train. Other studies in this area
have looked either within smaller, more homogenous groups or
across multiple countries.12,13
Table 3
Multivariate analysis of the predictors of a permissive practice for extended-spectrum b-lactamase harboring Enterobacteriaceae (ESBL-E), carbapenem-resistant Enter-
obacteriaceae (CRE), and any use of contact precautions (CP) for CRE and internationally transferred patients (IT-patients)
Predictive characteristic
Permissive policy for CP use for ESBL-E* Any CP use for CREy Any CP use for IT-patientsz
Multivariate OR (95% CI) P value Multivariate OR (95% CI) P value Multivariate OR (95% CI) P value
Public (vs private) 4.8 (1.7-13.4) .003
Metropolitan location (vs regional and rural) 3.2 (1.3-8.1) .014
Infectious disease service 0.2 (0.3-0.9) .041
Specific written policyx .011 3.4 (1.2-9.7) .025
Multiresistant organism directive 2.8 (0.4-14.8) .218
CRE directive .030 .003
Regular international transfers 4.6 (0.5-40.3) .166
Nontransplant supraregional servicesjj 3.4 (0.7-15.5) .118
CI, confidence interval; OR, odds ratio.
*n ¼ 44 out of 92 (48%) with permissive policy, n ¼ 5 with missing data.
yn ¼ 79 out of 97 (81%) use CP.
zn ¼ 38 out of 67 (72%), n ¼ 30 with missing data.
xWritten policy on infection control of phenotype or patient group.
jjCystic fibrosis, burns, or spinal injury.
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A limitation of our study is selection bias. Large hospitals were
overrepresented amongst respondents. Similarly, the methodology
biased our sample toward a subset of infection control departments
that are active on infection control e-mail bulletins and were
motivated to participate.
Our survey design captured practice rather than exact policy
content. Thus, the answers reflect 1 or a few individuals’ prac-
tice, and may not be representative of the majority at the site.
This is demonstrated by the analysis of multiple responders.
With the exception of the questions on written policy (for
which the question text required a subjective decision), discor-
dant answers occurred in aspects of policy that may be less
commonly used (eg, CRE, internationally transferred patients,
and AmpC organisms). However, differing interpretations of
policy was very frequent.
Misclassification complicates the interpretation of our results.
For CRE and internationally transferred patients it is difficult to
untangle if findings represent a gap in knowledge of terminol-
ogy/policy content or a true absence of policy. We believe
misclassification is a lesser problem for ESBL-E data because the
terminology is common in Australian infection control
literature.17
An important factor not easily accounted for in our analysis is
the exchange and centralization of policy amongst local regions or
private sector groups, independent of binding directives or pub-
lished recommendations.
Finally, applicability of our findings may vary by country. The
influence of state-based policy will differ depending on the
governance structure of the country involved. The frequency, na-
ture, and risk of internationally transferred patients will vary by
country and travel patterns.
CONCLUSIONS
Infection control management of MRGNBs varies widely
amongst adult acute care hospitals in Australia. We have demon-
strated a vulnerability of some Australian hospitals’ infection con-
trol practice in the management of CRE-harboring patients and
internationally transferred patients. This is due to limited knowl-
edge of aspects of these risk groups amongst some practitioners, an
absence of policy, and a lack of knowledge of policy. We await the
likely positive influence of recently released national recommen-
dations on infection control management of CRE in improving and
harmonizing practice within Australia.26
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Antibiotic resistance among gram-nega-
tive bacilli shows no signs of abatement.
Resistance of Pseudomonas aeruginosa,
Acinetobacter baumannii, and the Enter-
obacteriaceae to multiple antibiotic classes
is a growing clinical problem worldwide
[1]. Two trends are particularly notewor-
thy. First, there has been increased rec-
ognition of successful antibiotic-resistant
clones appearing in multiple geographic
regions. Multilocus sequence typing anal-
yses of contemporary collections of mul-
tidrug-resistant strains have shown that
carbapenem-resistant A. baumannii ST92
[2], K. pneumoniae carbapenemase–pro-
ducing K. pneumoniae ST258 [3], and ex-
tended-spectrum b-lactamase–producing
Escherichia coli ST131 [4] are global prob-
lems. Second, new mechanisms of mul-
tidrug resistance are becoming evident.
These include aminoglycoside 16S ribo-
somal RNA methylation [5] and produc-
tion of the New Delhi metallo-b-lacta-
mase [6].
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From a clinical viewpoint, the end result
of these and other mechanisms of anti-
biotic resistance is loss of susceptibility to
all penicillins (including combinations
with b-lactamase inhibitors), cephalospo-
rins, carbapenems, aminoglycosides, and
fluoroquinolones. There are desperately
few treatment options available for strains
with this resistance profile. Possibilities for
“salvage therapy” include polymyxins (eg,
colistin) [7], tigecycline [1], and fosfo-
mycin [8]. As is illustrated in the article
by Kofteridis et al [9] in this issue of Clin-
ical Infectious Diseases, much attention has
been paid to the potential use of novel
salvage regimens, including combinations
of different antibiotics or use of multiple
modes of antibiotic administration.
Kofteridis et al [9] evaluated the com-
bination of aerosolized plus intravenous co-
listin in contrast with monotherapy with
intravenous colistin. They concluded that
this combination of administration routes
did not provide additional therapeutic ben-
efit in patients with ventilator-associated
pneumonia (VAP) due primarily to A. bau-
mannii. Before this therapeutic strategy is
“written off” as ineffective, it is useful to
look more deeply into the design and results
of this study. Using a matched case-control
study design, Kofteridis and colleagues
demonstrated that 54% of patients in the
dual–administration route arm had clinical
cure, compared with 32.5% in the intra-
venous only arm (Pp .05). There were also
trends toward superiority in the end points
“clinical success” (74% vs 60%; Pp .10)
and mortality in the intensive care unit
(24% vs 42%; Pp .066). In a multivariable
model, trends toward superior clinical cure
with the dual route of administration per-
sisted (odds ratio, 2.375; 95% confidence
interval, 0.901–6.258; Pp .08) [9].
There are a number of potential reasons
why these results should not lead to the
combination of aerosolized plus intrave-
nous colistin being discarded as a potential
treatment option. First, the study methods
give no indication of sample size delib-
erations; it may well be that the study was
underpowered to truly show a significant
difference between the 2 treatment op-
tions. Second, the diagnosis of VAP is al-
ways fraught with difficulties, even when
quantitative cultures are used. Given that
patients with airway colonization may
have been labeled as having VAP, we have
a real chance of bias toward the null hy-
pothesis, because the outcomes for pa-
tients with airway colonization should not
be affected by therapy, thereby necessitat-
ing an even greater sample size to show a
real difference. Third, the dosages of co-
listin were not based on modern phar-
macokinetic analyses, and it is possible
that dosing regimens were not optimal.
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Table 1. Potential Randomised, Controlled Trials in the Arena of Treatment of Infection with
Gram-Negative Bacilli That Could Be Evaluated for Fast-Tracked Funding
b-Lactam antibiotics plus aminoglycosides versus b-lactam antibiotics alone for serious Pseudo-
monas aeruginosa infection
Pharmacodynamically optimized versus standard therapy for serious infections due to gram-
negative bacilli
Combinations including colistin versus colistin alone for bacterial infections resistant to all other
options
Inhaled plus intravenously administered antibiotics versus intravenous administration alone for
ventilator-associated pneumonia
Short-course versus long-course therapy for bloodstream infection due to gram-negative bacilli
Table 2. Predicted Issues in Gram-Negative Bacteria Resistance in the Next Decade
Widespread occurrence of carbapenem resistance in hospitalized patients necessitating “rou-
tine” use of polymyxins or tigecycline
Resistance to polymyxins and tigecycline commonplace in some hospitals
Loss of improvement in intensive care unit survival rates due to impact of resistance in gram-
negative bacilli
Calls for universal screening for multidrug-resistant gram-negative bacilli at hospital admission
Increased acquisition of carbapenem-resistant organisms outside of hospitals
Increased hospitalizations for community-onset urinary tract infections due to pathogens resis-
tant to all orally administered antibiotics
In addition, few details are provided
about the mode of aerosolization of co-
listin. The science of aerosolization of
drugs has advanced rapidly in the past de-
cade [10]. A different approach to drug
delivery is necessitated in the intubated
versus the awake patient because of char-
acteristics including the patient’s supine
position, artificial airway, and the use of
humidified air [10]. With use of a tradi-
tional jet nebulizer, it is estimated that only
6%–10% of the nominal dose would be
inhaled by the patient [11]. Newer tech-
nologies, such as the vibrating-mesh neb-
ulizer, significantly improve delivery and
have yielded promising results in the neb-
ulized delivery of other antimicrobials,
such as amikacin, in this setting [12].
Although the combination of aerosol-
ized plus intravenous colistin is potentially
promising for the treatment of VAP due
to multidrug-resistant gram-negative bac-
teria, combinations of different antibiotics
also need to be considered. James Rahal
and Carl Urban from New York City have
pioneered the study of combination ther-
apy and have shown synergistic effects of
the combination of carbapenems, rifam-
pin and a polymyxin against carbapenem-
resistant Gram negative organisms [13,
14]. A number of other combinations
have been assessed by a variety of groups
around the world. Numerous observa-
tional studies have been performed, in ad-
dition to this one by Kofteridis et al [9].
Unfortunately, conflicting results abound,
but some studies have yielded encouraging
results [15].
It is important to temper the potential
advantages of combination therapy with
experience from management of serious,
antibiotic-susceptible P. aeruginosa infec-
tion. The parallels are significant. In vitro,
synergy has been widely shown between
certain combinations of antibiotics (eg, an-
tipseudomonal b-lactam antibiotics plus
aminoglycosides) [16]. Some observational
studies have shown substantial benefits of
combination therapy, including significant
reductions in mortality when combination
therapy is used [17]. Yet, there is a paucity
of randomized, controlled trials showing
superiority of combination therapy ver-
sus monotherapy. Indeed, meta-analyses
of randomized, controlled trials have
shown no benefit of combination therapy
over monotherapy for P. aeruginosa or
other common serious infections with
gram-negative bacteria [18, 19].
We desperately need randomized, con-
trolled trials in the field of treatment of
infections with multidrug-resistant gram-
negative bacilli. We acknowledge that the
severity of illness and the clinical complex-
ities of patients usually affected by multi-
drug-resistant gram-negative bacilli greatly
hamper conduct of such studies. Further-
more, substantial resources are needed to
conduct randomized, controlled trials: the
pharmaceutical industry will not fund such
studies until new antibiotics are developed
that have significant activity against mul-
tidrug-resistant organisms. Even then, in-
dustry is likely to take the easy way out and
conduct studies of conditions such as uri-
nary tract infection or complicated intra-
abdominal infections. Therapy for multi-
drug-resistant organisms will continue to
be regarded as an off-label use, with clini-
cians persisting to use therapy without data
from randomized, controlled trials. It is
hoped that the US Food and Drug Ad-
ministration would demand studies of
patients at high risk of developing infec-
tion due to multidrug-resistant organ-
isms. Whether this imposition of addi-
tional hurdles on the path to drug ap-
proval would discourage development of
new drugs active against these organisms
is highly contentious.
It may be several years before the phar-
maceutical industry has sufficient new
compounds to be studied. In the meantime,
is there a way we can rigorously study ex-
isting options? The National Institutes of
Health is to be congratulated for their pro-
gram to fund “Targeted Clinical Trials to
Reduce the Risk of Antimicrobial Resis-
tance.” A randomized, controlled trial com-
paring the combination of colistin and im-
ipenem versus colistin monotherapy for
multidrug-resistant A. baumannii infection
has recently been funded by this program
(K. Kaye, personal communication). On
the basis of the work of Kofteridis et al [9],
it would seem that an randomized, con-
trolled trial comparing the combination of
aerosolized plus intravenous colistin ver-
sus monotherapy with intravenous co-
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listin may also be a reasonable proposition
(Table 1). Studies evaluating combinations
with rifampin may also be worthy of fur-
ther consideration.
The sad news is that multidrug-resistant
A. baumannii and P. aeruginosa have been
noted for more than a decade [20]. On
the basis of the global epidemiology of
infection, we need to be planning ran-
domized, controlled trials for treatment of
a variety of infections with a high prob-
ability of being widespread in the next de-
cade (Table 2). How soon should we act?
Now!
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Abstract
The new Australian Therapeutic Guidelines: Antibiotic, version 14 have revised the
recommendations for the use and monitoring of aminoglycosides. The guidelines have
clear distinctions between empirical and directed therapy as well as revised recommen-
dations about the monitoring of aminoglycosides. This has led many clinicians to review
their current practice with regard to the use of aminoglycosides. This review summarizes
why aminoglycosides are still a valid treatment option and discusses the rationale for
current dosing regimens in Gram-negative infections. In particular it focuses on the
various methods for monitoring aminoglycosides that are currently being used. The
aminoglycoside monitoring methods can be categorized into three groups: linear regres-
sion analysis (one compartment model), population methods and Bayesian estimation
procedures. Although the population methods are easy to use and require minimal
resources they can recommend clinically inappropriate doses as they have constant
pharmacokinetic parameters and are not valid in special population groups, that is, renal
impairment. The linear regression and Bayesian methods recommend more accurate
dosage regimens; however, they require additional resources, such as information tech-
nology and healthcare personnel with background training in pharmacokinetics. The
Bayesian methods offer additional advantages, such as calculation of doses based on a
single serum concentration and optimization of the patient’s previous pharmacokinetic
data, in order to determine subsequent dosage regimens. We recommend the Bayesian
estimation procedures be used, wherever feasible. However, they require the expertise
of healthcare practitioners with a good understanding of pharmacokinetic principles,
such as clinical pharmacists/clinical pharmacologists, in order to make appropriate
recommendations.
Introduction
The aminoglycoside antimicrobials have a long and con-
troversial history. First developed in the 1940s, they
are derived from antimicrobial substances produced
by the soil dwelling bacterial species Streptomyces and
Micromonospora. The ‘workhorse’ of aminoglycosides,
gentamicin, has been used for the treatment of serious
Gram-negative bacterial infections since the early 1960s
and continues in this role today.1,2
Aminoglycoside are bactericidal. Their primary site
of action is the 30S subunit of the prokaryotic ribosome,
interrupting bacterial protein synthesis. To reach this site
they bind to the bacterial cell wall and undergo active
transport into the cell cytosol.3
The three commonly used parenteral agents are
gentamicin, tobramycin and amikacin. Other routes of
administration include inhalation through a nebulizer
(tobramycin), intraperitoneal and intraventricular admi-
nistration (gentamicin). Two further agents paromomy-
cin and neomycin are used orally for their bowel
intra-luminal activity, as they are not systemically
absorbed.4 Streptomycin, the first aminoglycoside agent
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in widespread use, along with netilmicin and kanamycin
are now infrequently used.
Indications for use
With the advent of broad-spectrum b-lactam antimicro-
bials (anti-pseudomonal penicillins, third generation
cephalosporins and carbapenems), we have seen a shift
away from the prolonged administration of aminoglyco-
sides. This change has been driven by the improved safety
profile and improved pharmacokinetic parameters of
these newer agents. However, in the latest edition of the
Therapeutic Guidelines: Antibiotic, version 14 (TG14:
Antibiotic), there remains a broad group of indications
for the use of aminoglycosides. The guidelines clearly
delineate empirical and directed therapy. For empirical
therapy the recommended treatment duration is now
limited to 48 h and monitoring of plasma concentrations
is not required. Aminoglycosides are used in this setting
because of their rapid bactericidal activity and low rates
of resistance in community and healthcare settings.2 For
prolonged directed therapy (>48 h), aminoglycosides are
now reserved for a limited number of specific indications;
infections when resistance to other safer antimicrobials
has been shown, combination therapy for serious
Pseudomonas aeruginosa infections and brucellosis, and in
low doses as synergistic treatment of streptococcal and
enterococcal endocarditis.
Common indications for parenteral aminoglycosides
administration are summarized in Table 1. There are
very few absolute contraindications to aminoglycosides;
however, they should be used with caution with pa-
tients with pre-existing hearing, vestibular and renal
impairment.2
Toxicity
The significant clinical toxicities of aminoglycosides are
ototoxicity, nephrotoxicity and less often neuromuscular
toxicity. There is no definitive evidence of differences in
the degree of toxicity among the three commonly used
agents (gentamicin, tobramycin and amikacin).5,6 Patient
factors that vary the risk of toxicity include pre-existing
disease, severity of illness, concomitant drugs adminis-
tered and genetic predisposition.5,6 In addition, prolonged
therapy of aminoglycosides has shown to be an indepen-
dent risk factor for toxicity.7
Nephrotoxicity occurs after glomerular filtration of
the agent in the proximal convoluted tubule. Ototoxicity,
including vestibular and cochlear toxicity, occurs from
damage to the sensory hair cells of these organs. The
exact pathophysiological mechanism at both sites is
incompletely understood. Neuromuscular blockade after
Table 1 Indications for parenteral aminoglycosides2
Surgical prophylaxis (preventive)
Duration: single dose only
Agent: gentamicin used in combination or alone
Procedures
Urological surgery
Selected abdominal surgery (excluding hernia repair)
Vascular surgery
Cardiac surgery
Empirical therapy (pathogen unknown)
Patient illness: severe
Duration: <48 h
Agent: gentamicin always used in combination
Intra-abdominal and surgical infection
Cholangitis
Acute cholecystitis
Diverticulitis
Perforated viscus
Surgical site infection
Genito-urinary infection
Pyelonephritis
Epididymo-orchitis (from a suspected urinary source)
Pelvic inflammatory disease (non-sexually acquired)
Respiratory tract infection
Community acquired pneumonia in tropical regions
Hospital acquired pneumonia
Infective endocarditis
Central nervous system
Epidural abscess
Endophthalmitis
Sepsis
Intravascular line-related
Adult with an unknown source or suspected Gram-negative bacteraemia
Children less than 4 months if age (including neonates) with an unknown
source
Febrile neutropenia†
Directed therapy (pathogen known)
Duration: prolonged, often weeks
Agent: see below, almost always used in combination
Gentamicin
Brucellosis
Infective endocarditis‡ (pathogen): Enterococcus spp., Streptococcus
spp. and Bartonella spp.
Infective endocarditis‡ (device): infection associated with a prosthetic
valve or intra-cardiac device
Enteric organism bacteraemia: Campylobacter spp. and Yersinia spp.
Pseudomonas aeruginosa infection‡
Severe listeria†‡
Treatment of biological warfare agents: pneumonic plague and
tularaemia
Tobramycin
Pseudomonas aeruginosa infection in cystic fibrosis
Amikacin
Highly drug-resistant Gram-negative organisms, for example, metallo
ß-lactamase producing bacteria;
Central nervous system Nocardia spp. infection;
(Resistant) mycobacterial infection including M. tuberculosis, M.
abscessus, M. avium complex§
†Indication not in TG14: Antibiotic. ‡Synergistic use. §In the setting of
drug-resistant tuberculosis amikacin is used at a low dose often for pro-
longed periods (>6 months).
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administration is described, usually in conjunction with
other diseases or drugs that affect the neuromuscular
junction, for example, patients with myasthenia gravis.5
Although a genetic susceptibility mutation has been
reported (mitochondrial 1555A→G) in patients with kin-
dreds with an inherited susceptibility to hearing loss,8 the
population prevalence of these mutations (1:500) is prob-
ably too infrequent to account for most cases of ototox-
icity. The incidence of vestibular or cochlear toxicity
varies in studies with the definition used, and most were
performed before the era of high-dose-extended interval
regimens. However, most reviews have reported rates
of approximately 5–10% for hearing impairment and
approximately 3% for vestibular toxicity.9 The rate of
ototoxicity with durations of treatment less than 48 h is
not known; however, ototoxicity following single doses
has been described.10,11
Monitoring for toxicity can be through three mecha-
nisms; quantitative testing of end-organ effects (monitor-
ing serum creatinine and audiometry), active bedside
testing and passive reporting by the patient. There is no
definitive evidence to inform optimal techniques for
monitoring of toxicity.5 As a minimum standard, before
the commencement of aminoglycoside therapy patients
should be informed about the possible adverse effects and
asked to report if they develop subjective hearing loss,
tinnitus or oscillopsia, and serum creatinine should be
monitored in all patients. Where the expected duration
of therapy is more than 5 days, bedside tests should be
performed for cochlear and vestibular function (Table 2).
The ‘whisper test’ has been shown to have a high
sensitivity for hearing impairment within the clinically
relevant frequency range,12 but does not detect
high-frequency hearing loss that often occurs earlier.
Additionally, hearing loss may occur after cessation of
the antibiotic course. Where available, serial audiometry
(pure tone audiometry  otoacoustic emissions) may
be considered; the development of high-tone hearing
impairment and impaired outer cell function is charac-
teristic of drug-induced damage. Diagnosis is most accu-
rate if a baseline result is available for comparison, as
similar changes may be found in patients with hearing
loss because of other causes, including presbycusis (age-
related hearing loss). There is no definitive evidence that
ceasing aminoglycosides when ototoxicity is detected
minimizes further damage, but it would seem prudent to
weigh up the benefits of continuing with the significant
risk of ototoxicity in this situation.
Aminoglycoside resistance
Aminoglycoside resistance in Gram-negative bacteria can
be endogenous or acquired. Examples of clinically
encountered bacteria exhibiting endogenous resistance
include Stenotrophomonas maltophilia and Burkholderia
cepacia.
Acquired resistance can occur in almost all Gram-
negative organisms, including commonly encountered
bacteria, such as Escherichia coli, Klebsiella pneumoniae and
P. aeruginosa. Acquired resistance is frequently encoded
Table 2 Clinical screening tests for ototoxicity
Whispered voice test
Performance
The examiner stands arm’s length (0.6 m) behind the seated
patient and whispers a combination of numbers and letters (e.g.
4-K-2) and then asks the patient to repeat the sequence.
The examiner should quietly exhale before whispering to ensure
as quiet a voice as possible.
The examiner always stands behind the patient to prevent lip
reading.
Each ear is tested individually, starting with the ear with better
hearing, and during testing the non-test ear is masked by gently
occluding the auditory canal with a finger and rubbing the tragus in
a circular motion.
The other ear is assessed similarly with a different combination of
numbers and letters.
Interpretation
If the patient responds correctly, hearing is considered normal; if
the patient responds incorrectly, the test is repeated using a
different number/letter combination.
The patient is considered to have passed the screening test if
they repeat at least three out of a possible six numbers or letters
correctly.
Action
Patients with impaired hearing should be referred for audiometry.
Dynamic visual acuity testing
Performance
With the patient seated and with the head kept still at 6 metres
from the Snellen chart determine their best visual acuity with both
eyes open.
Then do the same with examiner standing behind the patient and
rotating the patient’s head smoothly from side to side at a rate of
approximately two cycles per second in a continuous, sinusoidal
fashion (i.e. with no stationary periods to allow fixation).
Interpretation
A normal person will lose less than or equal to two rows on the
Snellen chart.
Anything greater than this indicates an abnormality of the
vestibulo-ocular reflex (i.e. in the case of gentamicin or amikacin
because of bilateral vestibular injury).
Record both baseline and during rotation results to compare with
prior and future tests.
Action
If there is evidence of vestibular toxicity, aminoglyoside antibiotic
should be ceased where possible.
Patients should be assessed by physiotherapy and occupational
therapy.
A neurological opinion should be sought if there is evidence of
functional impairment.
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by genes located on a transferrable plasmid, increasing
the likelihood of horizontal spread to other bacteria. It is
frequently associated with other resistance genes, such as
those encoding extended spectrum b-lactamases,13 ren-
dering bacteria resistant to multiple classes of antibiotics.
There is a wide variety of mechanisms of aminoglyco-
side resistance. The most common is enzymatic inactiva-
tion of the aminoglycoside through adenylation,
acetylation or phosphorylation. Other less frequent
mechanisms include decreased antimicrobial permeabil-
ity, active efflux pumps and various changes in the
ribosomal target site.14 A newly described mechanism of
resistance is methylation of 16S ribosomal RNA. This
mechanism results in high level resistance to gentamicin,
tobramycin and amikacin.15
In the drug development pipeline are next-generation
aminoglycosides or ‘neoglycosides’, synthesized by
extensive modification of current agents. They have
demonstrated promising in vitro activity against bacteria
resistant to currently available aminoglycosides.16
However, they are unlikely to be active against strains
which produce 16S ribosomal RNA methylases.
Pharmacokinetic consideration for
Gram-negative infection
Traditionally, gentamicin was administered as multiple
daily doses until the introduction of once-daily aminogly-
coside dosing in the early 1990s. Following increased
evidence from clinical studies,17–22 it is now widely
accepted that once-daily dosing is as effective and
probably less nephrotoxic than conventional multiple-
daily dosing regimens. The advantages of once-daily
dosing include: optimization of the maximum con-
centration (Cmax) : minimum inhibitory concentration
(MIC) ratio,23,24 area under the curve (AUC), post-
antibiotic effect25 and reduction in costs of medication
administration (Fig. 1).26–28
There are two pharmacodynamic predictors of efficacy
for aminoglycosides namely AUC0–24 : MIC and the
Cmax : MIC ratio and dosing should aim to optimize these
parameters. Target AUC values of 80 to 100 and Cmax 8 to
10, respectively, are reasonable based on animal and
human pharmacodynamic studies.6 In clinical practice
either or both of these parameters could be used, even
though they are influenced differently by host factors.
Cmax : MIC ratio is related most exclusively to volume of
distribution, whereas the AUC0–24 : MIC ratio is influ-
enced by both volume of distribution and clearance. It
has been argued that getting high peaks to achieve satis-
factory Cmax : MIC ratios against P. aeruginosa should be
the main aim of therapy, because susceptible members
of this species have median MIC values of <2 mg/L.6
However, for organisms with a MIC of 2 mg/L, such as P.
aeruginosa, high Cmax of at least 20 mg/L (10 times MIC of
2 mg/L) would thus be required.23,24 In theory, constant
exposure to aminoglycosides is required where it is
being used in synergy with beta-lactams for endocarditis,
and this is the basis for the recommendation for multiple
daily dosing in many guidelines.2,29 However, clinical
trials have demonstrated the efficacy of single daily doses
for at least some pathogens.30 Based on these studies,
international guidelines recommend these regimens
routinely.31
Therapeutic drug monitoring
Therapeutic drug monitoring is frequently used to
confirm serum concentrations of aminoglycosides and to
make required dosage adjustments. However, it is impor-
tant to record accurate data, such as the dose, time of
sample and time of start and of infusion, in order to
correctly interpret serum concentrations and make the
correct dosage adjustments.
When patient individualization dosing strategies are
used based on the subject’s weight and aimed at a thera-
peutic range to optimize clinical outcomes, a greater
percentage of patients will achieve the targeted concen-
tration as compared with patients who receive a fixed
dose strategy.32 Patients who attained targeted therapeu-
tic serum concentrations of aminoglycosides early in their
treatment course have shown an improved clinical
outcomes.5
Some centres measure ‘peak’ and ‘trough’ concentra-
tions and make empiric dosage adjustments, which was
commonly performed in the era when multiple daily
dosing regimens were common. These empiric adjust-
ments result in a ‘trial and error period’ with different
dosage regimens until optimal serum concentrations are
Figure 1 Pharmacokinetic parameters. AUC0–24, area under the curve
(24-h dosing interval); Cmax, maximum concentration; Cmin, minimum con-
centration; MIC, minimum inhibitory concentration (of the organism the
antibiotic is targeting).
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achieved. This approach potentially results in incorrect
dosage adjustments, prolonged periods to obtain targeted
concentrations and unnecessary healthcare costs.5 To
optimize the use of serum concentrations and make the
interpretation of pharmacokinetic data more meaningful
the second level should not be a trough concentration,
but a measurable random concentration (above the limit
of detection of the assay normally at or above 0.5 mg/L).
If an undetectable level is reported, that is <0.5 mg/L, and
one substitutes a level of 0.5 mg/L when calculating a
patient’s pharmacokinetic parameters, several assump-
tions are made which can result in inaccurate dosage
regimens.
Aminoglycoside monitoring
Several nomograms and algorithms have been developed
to individualize pharmacokinetic monitoring for gen-
tamicin. Three major methods of dose individualization
commonly used to target specific pharmacokinetic
parameters are: (i) linear regression analysis (one com-
partment model), (ii) population methods and (iii)
Bayesian estimation procedures.33 Currently available
algorithms and computer programs are summarized in
Table 3.
Australian guidelines for monitoring
For many years, the ‘Therapeutic Guidelines’ has recom-
mended several methods for monitoring gentamicin.
Although their recommended method for monitoring
aminoglycosides was a computerized method with a
dosage adjustment to achieve a target AUC they also
realized that not all hospitals would have access to
these computer programs so nomograms were included.
However, the new Therapeutic Guidelines have now
been released and they have made several new recom-
mendations, including the deletion of the nomograms
and recommendation to only use AUC-based computer-
ized methods.
Linear regression analysis
The first method used to fit serum concentrations
to individual patient models was the Sawchuk-Zaske
method using linear regression analysis. The Aminogly-
coside Levels and Daily Dose Indicator (ALADDIN) is also
another example of this method. These methods use an a
posteriori drug dosing calculations where the patient’s
pharmacokinetic parameters are calculated from at least
two measured serum concentrations and assume a
one compartment model.5 These methods require health-
care practitioners who have specialized pharmacokinetic
knowledge (clinical pharmacologist/pharmacist) and
patient information, such as value and timing of dose and
level and duration of infusion, in order to interpret accu-
rately the pharmacokinetic results (AUC, Cmax, Cmin, Cl
and Vd). Based on the pharmacokinetic results the pro-
grams then determine the most appropriate dose and
dosing interval adjustments for the patient. They also
require additional resources, such as access to computers
at the point of patient care.
Although these methods are simple they do make
several assumptions: they only use serum concentration
data around the dosing interval where the levels were
obtained and therefore there is a loss of continuity of
data; they assume that the assay error is a constant per-
centage which means lower serum concentrations can be
overestimated.5 The lack of population data, and hence
the necessity to have two levels presents a limitation in
some settings, such as paediatrics.
Population methods
A population method, alternatively called an a priori
dosing method, determines aminoglycoside dosage based
on population pharmacokinetic parameters, without
using the patient’s individual pharmacokinetic results.5
Nomograms such as the Therapeutic Guidelines: Antibi-
otic Dose Adjustment Nomogram (TG Nomogram), the
Hartford Nomogram and the Begg Nomogram, use esti-
mates of pharmacokinetic parameters such as volume of
distribution in order to estimate dosage recommenda-
tions. The nomograms have proved popular as they are
easy to interpret, require no specialized pharmacokinetic
knowledge for the interpretation of the results and
limited use of resources (personnel and/or computers). In
addition, the patient information required to interpret
the nomogram is minimal and they only require infor-
mation, such as value and timing of dose and level.
Although the TG Nomogram and the Hartford Nomo-
gram have been widely used, it is important to ensure the
individual patient matches the population for which the
nomogram has been developed. In addition all nomo-
grams assume stability of pharmacokinetic parameters,
such as creatinine clearance, which may not occur in a
sick patient. The TG Nomogram has only been validated
in a small number of patients with a normal renal func-
tion and may not be suitable in patients with a creatinine
clearance less than 90 mL/min,34 whereas the Hartford
Nomogram has not been validated in patients that may
have altered kinetic parameters, such as, burns, preg-
nancy, ascites, dialysis.24 In addition, several studies
have found a lack of agreement in dose recommenda-
tions made by the population–nomogram methods.34,36
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Unfortunately the patients’ pharmacokinetic parameters
were not described in these studies.
Bayesian estimation procedures
The Bayesian approach offers the advantage that it makes
optimal use of all information contained in the popula-
tion model (a priori) combined with the most current
pharmacokinetic information from the patient (a poste-
riori) to develop the patient’s most precise regimen.5,33
Examples are the Sequential Bayesian Algorithm for
Gentamicin (SeBA-GEN, The University of Queensland,
Australia and the University of Otago, New Zealand)
program, Target Intervention Software program (TCI
works, The University of Queensland, Australia, and the
University of Otago, New Zealand) and MM-USCPACK
(Laboratory of Applied Pharmacokinetics, School of
Medicine, University of Southern California, Los Angeles,
CA, USA), which have been developed for dose adjust-
ment of once-daily dosing of aminoglycosides.5,33
Although these methods calculate the most precise
regimen, they require healthcare practitioners (clinical
pharmacologist/pharmacist) who have specialized phar-
macokinetic knowledge and ready access to resources,
such as computers. In addition, patient information such
as the patient’s sex, height, weight, age, serum creati-
nine, value and timing of dose and level, duration of
infusion in order to accurately compute pharmacokinetic
parameters (AUC, Cmax, Cmin, Cl and Vd). An advantage of
the Bayesian estimation procedures is that they can cal-
culate doses based on a single serum concentration and
can also predict an appropriate starting dose providing
some patient information has been entered into the
program.
Conclusion
The aminoglycosides remain an important antibiotic
class in our current therapeutic armamentarium. They
continue to be recommended for short-term and pro-
longed therapy in selected situations. Their use can be
associated with significant toxicity. A key strategy in
minimizing toxicity and optimizing therapy is therapeu-
tic drug monitoring. All of the methods for dose indi-
vidualization described above have been used by
hospitals and each is associated with advantages and dis-
advantages. The ideal method is one that predicts an
accurate, clinically appropriate dose, requires minimal
resources and is easy to use. The linear regression
methods, that is, Sawchuk-Zaske and ALADDIN, require
two serum concentrations after a dose of aminoglycoside
whereas the Bayesian estimation procedures can calcu-
late doses based on one serum concentration. However,
both the linear regression and the Bayesian estimation
procedures require skilled personnel, usually clinical
pharmacists and or clinical pharmacologists, with an
understanding of pharmacokinetics to use and interpret
the information. As not all clinicians have access to these
specialized pharmacy services this limits their applica-
tion. Additionally, it should be stressed the software is
only as good as the data entered – if the time of admin-
istration of the drug or specimen collection is inaccurate,
then erroneous results may occur. The once–daily ami-
noglycoside nomograms (i.e. TG Nomogram and Hart-
ford Nomogram) require only one serum concentration,
are easy to interpret and require no specialized pharma-
cokinetic knowledge. Nevertheless, concerns have been
raised about their reliability as they make the assump-
tion that all patients have the same constant pharmaco-
kinetic parameters, which means they are not valid in
patients that do not meet these criteria, such as special
population groups, for example, renal impairment.
Therefore, given the large interpatient variability in ami-
noglycoside pharmacokinetic parameters there are many
clinical situations where it is inappropriate to use nomo-
grams. We recommend the Bayesian estimation proce-
dures be used, wherever feasible.
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Abstract: Urinary tract infection (UTI) is among the most common infectious diseases of humans and is the most com-
mon nosocomial infection in the developed world. They cause significant morbidity and mortality, with approximately 
150 million cases globally per year. It is estimated that 40-50% of women and 5% of men will develop a UTI in their life-
time, and UTI accounts for more than 1 million hospitalizations and $1.6 billion in medical expenses each year in the 
USA. Uropathogenic E. coli (UPEC) is the primary cause of UTI. This review presents an overview of the primary viru-
lence factors of UPEC, the major host responses to infection of the urinary tract, the emergence of specific multidrug re-
sistant clones of UPEC, antibiotic treatment options for UPEC-mediated UTI and the current state of vaccine strategies as 
well as other novel anti-adhesive and prophylactic approaches to prevent UTI. New and emerging themes in UPEC re-
search are also discussed in the context of future outlooks. 
Keywords: Antibiotic resistance, uropathogenic Escherichia coli, vaccine, virulence. 
INTRODUCTION 
 Urinary tract infections (UTI) are among the most fre-
quent human bacterial infections, with an estimated 40-50% 
of women experiencing at least one cystitis episode in their 
lifetime [1, 2]. UTI usually starts as a bladder infection (cys-
titis), but can develop to acute kidney infection (pyelonephri-
tis), ultimately resulting in scaring and renal failure. UTI is 
also a major cause of sepsis, which has a mortality rate of 
25% and results in more than 36,000 deaths per year in the 
USA [3]. Almost all patients with an indwelling urinary 
catheter for 30 days or longer develop catheter-associated 
UTI, which accounts for approximately 40% of all hospital-
acquired infections [1]. Common Gram-negative and Gram-
positive bacterial pathogens that cause UTI include Es-
cherichia coli, Pseudomonas aeruginosa, Klebsiella pneu-
moniae, Proteus mirabilis, Enterobacter cloacae, Acineto-
bacter baumannii, Morganella morgannii, Staphylococcus 
saprophyticus and Enterococcus spp.  
UROPATHOGENIC ESCHERICHIA COLI AND MA-
JOR VIRULENCE FACTORS 
 Uropathogenic E. coli (UPEC) is the most common etio-
logical agent of UTI, causing more than 80% of infections. 
UPEC strains are often classified on the basis of O (somatic), 
K (capsular polysaccharide), and H (flagellar) antigens. 
There is a high frequency of the antigens O1, O2, O4, O6, 
O7, O8, O16, O18, O25, and O75 among UPEC strains, 
while specific K and H antigens display a less distinct pat-
tern [4]. UPEC strains possess an arsenal of virulence factors 
*Address correspondence to this author at the School of Chemistry and 
Molecular Biosciences, Building 76, University of Queensland, Brisbane 
QLD 4072, Australia; Tel: +617 33653306; Fax: +617 33654699; 
E-mail: m.schembri@uq.edu.au
Fig. (1) that contribute to their ability to cause disease, in-
cluding adhesins (e.g. type 1 and P fimbriae), toxins (e.g. 
hemolysin) and iron-acquisition systems that utilise sidero-
phores (e.g. enterobactin, salmochelin, aerobactin) [5-7]. 
Several studies have also implicated UPEC flagella as a viru-
lence factor that contributes to UTI [8-11]. Undoubtedly, 
adherence to the urinary tract epithelium is a critical step in 
the initiation of disease; it enables UPEC to resist the hydro-
dynamic forces of urine flow and triggers host and bacterial 
cell-signalling pathways that result in inflammation and 
colonization, respectively.  
Fimbrial Adhesins 
 Fimbrial adhesins of UPEC are characterised by a con-
served chaperone-usher pathway that underpins their assem-
bly [12]. Fimbriae (or pili) assembled by the chaperone-
usher pathway are typically encoded by gene clusters that in 
addition to the chaperone- and usher-encoding genes also 
include genes encoding the major and minor pilin subunits. P 
and type 1 fimbriae are the best-characterised chaperone-
usher class of fimbriae produced by UPEC. P fimbriae are 
strongly associated with acute pyelonephritis; they contribute 
to the establishment of UTI by binding to the -D-
galactopyranosyl-(1-4)--D-galactopyranoside receptor epi-
tope in the globoseries of glycolipids and activate innate 
immune responses in animal models and in human infection 
[13-16]. Type 1 fimbriae enhance colonization and host re-
sponse induction in the murine UTI model, and promote 
biofilm formation and host cell invasion [17-19]. Type 1 
fimbriae confer binding to -D-mannosylated proteins such 
as uroplakins, which are abundant in the bladder [17, 20]. 
Both P- and type 1 fimbriae recognise their receptor targets 
by virtue of organelle tip-located adhesins, namely PapG and 
FimH, respectively [21-23]. 
1873-5592/12 $58.00+.00 © 2012 Bentham Science Publishers
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 Genome sequencing of a number of UPEC strains has 
revealed they contain multiple fimbrial gene clusters; for 
example the well-defined CFT073 strain contains ten puta-
tive chaperone-usher gene clusters [24]. Some of these other 
chaperone-usher fimbriae have also been associated with the 
ability of UPEC to cause UTI. F1C fimbriae resemble type 1 
fimbriae in their genetic organisation and organelle structure 
[25-27], however differ in their adhesin specificity. F1C 
fimbriae mediate binding to galactosylceramide targets pre-
sent on epithelial cells in the bladder and kidneys as well as 
globotriaosylceramide present exclusively in the kidneys [28, 
29]. Other fimbriae of the chaperone-usher family that have 
been characterised from UPEC include S fimbriae (which 
mediate adherence to sialic acid glycolipids or glycoproteins) 
[30], Afa/Dr fimbriae (which mediate adherence to decay-
accelerating factor, collagen IV and carcinoembryonic anti-
gen-related cell adhesion molecules) [31], F9 fimbriae [32], 
type 3 fimbriae [33-35] and Auf fimbriae [36]. 
Autotransporter Adhesins 
 Another class of adhesins strongly associated with UPEC 
virulence is represented by the autotransporter (AT) proteins. 
AT proteins represent the largest group of bacterial type V 
secreted proteins and share several common features: an N-
terminal signal sequence, a passenger () domain that is ei-
ther anchored to the cell surface or released into the external 
milieu, and a translocation () domain that resides in the 
outer membrane [37, 38]. In general, AT proteins differ sub-
stantially in their passenger domain sequence, which deter-
mines the unique functional characteristics of the protein and 
is often associated with virulence [39]. Similar to chaperone-
usher fimbrial genes, UPEC contain multiple different AT-
encoding genes; CFT073 strain contains eleven putative AT 
genes [40, 41]. Characterised UPEC AT proteins include the 
secreted toxin Sat (see below), the phase variable outer 
membrane protein antigen 43 (Ag43) [42], the trimeric AT 
protein UpaG [43, 44] and the surface-located UpaB, UpaC 
and UpaH proteins [40, 45]. AT proteins of UPEC possess a 
diverse range of functions including adhesion, aggregation, 
biofilm formation and cytotoxicity. The Ag43, UpaB and 
UpaH AT proteins contribute to colonization of the mouse 
bladder [40, 42, 45] and Ag43 expression is associated with 
intracellular biofilm formation [46]. The secretion of AT 
proteins is assisted by accessory factors such as the Bam 
complex (also known as the YaeT or Omp85 complex), as 
well as periplasmic chaperones such as SurA, Skp and DegP 
[47-53]. Most recently, a new translocation and assembly 
module (TAM) that promotes efficient secretion of AT pro-
teins in proteobacteria has been described [54]. 
Toxins 
 UPEC also secrete a range of toxins that damage host 
epithelial cells. Approximately 50 % of UPEC strains pro-
duce -hemolysin and its expression correlates strongly 
with symptomatic UTI [55]. The secretion of -hemolysin 
causes host cell lysis and results in the release of nutrients 
Fig. (1). Major virulence factors of UPEC. Schematic diagram of a UPEC bacterium showing examples of the major virulence factors 
present on the cell surface or secreted. Fimbrial and autotransporter adhesins mediate attachment and colonization of multiple host tissues. 
Flagella mediate motility and chemotaxis and contribute to bacterial dissemination to new sites in the urinary tract. Iron uptake systems scav-
enge iron from the host and facilitate its uptake into UPEC, thus promoting bacterial fitness in the iron-limiting urinary tract. Secreted toxins 
induce host cell lysis and can disrupt inflammatory signaling cascades in the host. Capsule and O-antigen mediate serum resistance and pro-
mote host evasion. Expression of each factor is tightly regulated by UPEC and coordinated to prevent co-expression of virulence factors with 
competing functions. UPEC organelles and virulence factors are not drawn to scale. 
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and other growth factors such as iron that can be utilized by 
the infecting bacteria. Sublytic concentrations of hemolysin 
may also contribute to virulence by inactivating the ser-
ine/threonine kinase Akt, which plays a central role in host 
cell cycle progression, metabolism, vesicular trafficking, 
survival, and inflammatory signaling pathways [56]. An-
other toxin, cytonecrotizing factor 1 (CNF1) is secreted by 
approximately one third of UPEC strains. CNF1 activates 
the small GTP-binding proteins of the Rho family by in-
ducing glutamine deamination, resulting in the disruption 
of normal eukaryotic cell function [57, 58]. The serine pro-
tease autotransporter toxins Sat and Vat are also produced 
by some UPEC strains. Sat is a 107 kDa protein that in-
duces a variety of cytopathic effects on bladder and kidney 
cells and elicits glomerular damage in the mouse UTI 
model [59, 60]. Vat has been best characterized from avian 
pathogenic E. coli, which is closely related to UPEC at the 
genomic level, and also induces cytopathic effects in 
epithelial cells [61]. A hybrid nonribosomal peptide-
polyketide colibactin that induces cytopathic effects on 
epithelial cells has been described [62]. However, the genes 
encoding this toxin are also found in many commensal E.
coli strains and thus a specific role in UTI has not been 
determined. 
Iron Acquisition Systems 
 Iron is essential for bacterial growth and is limited in 
the urinary tract. Therefore, iron acquisition systems are 
important colonization factors for UPEC. An efficient 
method for the sequestration of iron is through the produc-
tion of siderophores, which are low molecular weight Fe3+-
chelating compounds, and subsequent uptake via their as-
sociated membrane receptors [63, 64]. Four different si-
derophore systems have been identified and characterised 
in UPEC, namely enterobactin [65, 66], the glucosylated 
enterobactin derivative salmochelin [67], yersiniabactin 
[68-70] and aerobactin [71]. These siderophore systems are 
negatively regulated by ferrous iron and the ferric uptake 
regulator Fur, and are expressed under low iron conditions 
[72, 73]. UPEC strains encode and express different com-
binations of these siderophores [66, 74], with some strains 
such as the asymptomatic bacteriuria strain 83972 able to 
express all four siderophores [75]. In the UPEC strains 
CFT073 and 536, aerobactin, yersiniabactin and the heme 
receptors (ChuA and Hma) contribute to virulence in a 
mouse UTI model [76]. 
Outlook 
 Recent advances in DNA sequencing technologies have 
demonstrated that the E. coli pan-genome is open, with some 
studies estimating a gene pool of 13,000 genes [77]. There 
are currently 61 complete and 246 draft E. coli genomes 
available on the NCBI database. New E. coli genes continue 
to be identified with every new genome sequence. The ma-
jority of these new genes are carried on mobile DNA ele-
ments (plasmids, prophages, pathogenicity islands) and are 
of unknown function. Therefore, the full virulence gene rep-
ertoire of E. coli remains to be determined, and continued 
sequencing efforts, together with detailed molecular studies 
of putative virulence factors, are needed.  
HOST-UPEC INTERACTIONS DURING UTI 
Early Innate Responses Triggered Upon UPEC Entry 
and Attachment to Urothelium 
 The host response to UTI includes antimicrobial pep-
tides, cytokine production, neutrophil influx, inflammation, 
apoptosis and exfoliation of host cells. Urothelial cells en-
sure sterility in the urinary tract by release of proteins, such 
as the Tamm-Horsfall protein that blocks bacterial adhesion, 
and lipocalin and lactoferrin, which dramatically limit the 
free iron present in the urinary tract. In addition, a first-line 
defense mechanism by urothelial cells against invading 
pathogens includes the synthesis and secretion of antimicro-
bial peptides, known as defensins, including alpha- and beta-
defensins and cathelicidin. For example, the human 
cathelicidin antimicrobial peptide LL-37 protects the urinary 
tract from UPEC infection and its production by infected 
urothelial cells was recently shown to be enhanced by vita-
min D supplementation [78, 79]. However, some UPEC 
strains have evolved strategies to subvert these first-line de-
fenses and colonise the urothelium. Upon adhesion to man-
nosylated glycoproteins in the urothelium, UPEC trigger a 
cascade of Toll-like receptor mediated responses [80]. TLRs 
are a family of pathogen recognition receptors (PRRs) [81, 
82], which are membrane-bound sensors that recognize 
pathogen associated molecular patterns (PAMPs) in the ex-
tracellular compartment and endosomes [83]. TLR4 is a key 
factor mediating mucosal immunity of the urinary tract 
against UPEC, as C3H/HeJ mice bearing a mutation in the 
Toll/interleukin-1 receptor (TIR) domain of TLR4 are poor
at resolving experimental UTI [84]. Furthermore, tlr4 -/- mice 
have a significantly higher bacterial burden in their bladder, 
compared to wild-type mice [85]. The poor ability to resolve 
UTI in these mice is a result of impaired cytokine and 
chemokine production and neutrophil recruitment. The TLR4 
response initiated by UPEC is triggered by LPS, which acts 
in concert with P [86-88] and type 1 fimbriae [89, 90], upon 
initial attachment of bacteria to the urinary epithelium. Other 
TLRs that recognise UPEC flagellin were also shown to be 
involved in the host defence against UPEC. tlr11-/- and tlr5-/-
mice display increased susceptibility to UPEC infection in 
the kidney and bladder, respectively [91, 92]. Downstream 
TLR adaptor molecules such as myeloid differentiation pri-
mary response protein 8 (MyD88), TIR domain-containing 
adaptor inducing beta interferon (TRIF), and TRIF-related 
adaptor molecule (TRAM) are also essential in signalling 
and activate the canonical NF-kB transcription factor to in-
duce pro-inflammatory gene expression [93]. UPEC have 
also adapted mechanisms to evade and counter host recogni-
tion and signalling. Some UPEC strains produce the 
Toll/interleukin-1 receptor domain-containing protein TcpC, 
which has a similar structure to the TIR domain of human 
TLR1 and can interfere with MyD88 via direct binding [94]. 
TcpC disrupts TLR and non-TLR signalling pathways, 
thereby dampening innate immune responses.  
UPEC Invasion of Host Cells and Intracellular Survival 
 In the mouse UTI model, adherence of some UPEC 
strains to the bladder surface results in the invasion of super-
ficial facet cells in a type 1 pilus-dependent manner [18, 95]. 
Studies using the reference cystitis UPEC strain UTI89, have 
revealed a series of cellular events post-invasion that lead to 
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the rapid replication of UPEC in the cell cytoplasm and the 
formation of aggregates referred to as intracellular bacterial 
communities (IBCs) [46]. The end-point of the IBC cycle is 
characterised by UPEC fluxing out of superficial facet cells 
as long filamentous bacteria [96]. IBCs may enable UPEC 
evasion of the host immune response, permit re-infection and 
contribute to chronicity [97]. Evidence for the presence of 
IBCs in human UTI has also been provided; IBCs and fila-
mentous bacteria have been observed in urine from women 
suffering acute cystitis [98]. The ability of UPEC to survive 
intracellularly is not limited to epithelial cells. Some UPEC 
strains were shown to survive in primary mouse and human 
macrophages within late endosome LAMP1 positive vesicles 
[99]. Another study reported that FimH-expressing UPEC 
are taken up into a membrane bound vesicle containing gly-
colipid proteins and caveolin [100]. The ability of UPEC to 
reside inside epithelial cells and macrophages invokes the 
idea that autophagy might be implicated in targeting intracel-
lular UPEC during early or late bacterial entry. Classically a 
non-selective degradation system for proteins and organelles, 
there is mounting evidence that autophagy can indeed target 
intracellular pathogens [101]. The role of autophagy as an 
important innate immune response mechanism has been 
demonstrated against intracellular pathogens such as Myco-
bacterium tuberculosis [102], Salmonella enterica serovar 
Typhimurium [103] and Francisella tularensis [93]. Auto-
phagy can either result in pathogen elimination, as in the 
case of M. tuberculosis [102], or enable pathogen survival 
(e.g. Coxiella burnetti [104, 105]). The role of autophagy in 
UTI remains unclear. UPEC toxins such as hemolysin [106] 
and Sat [107] were recently shown to induce the onset of 
autophagy. Work from Amer et al., [108] suggests that auto-
phagy serves a protective function in macrophages infected 
with the UPEC strain CFT073. Chemically inhibition of 
CFT073-mediated autophagy in macrophages using 3-
methyladenine (3-MA) increased macrophage killing of in-
tracellular CFT073. However, CFT073 survives poorly in 
macrophages [99], suggesting that different UPEC strains 
may be affected by autophagy in different ways.  
Outlook 
 While the mechanisms of UPEC intracellular survival are 
not well understood, it is clear that this opportunistic intra-
cellular lifestyle offers UPEC a significant advantage; bacte-
ria are protected from the immune response or from antibiot-
ics sufficiently to be able to replicate and establish acute 
infection, while some bacteria may also remain quiescent for 
long periods contributing to persistent and chronic infec-
tions. The mouse model of experimental UTI has been an 
invaluable tool in understanding host-UPEC interactions 
during acute infection. Recent work describing how this 
model can be used to study chronic infection [109], is offer-
ing unique insight into how early host-pathogen interactions 
determine the outcome of disease and will greatly facilitate 
the identification of UPEC and host factors that are impor-
tant in different stages of UTI. 
EMERGING ANTIBIOTIC RESISTANT CLONES OF 
E. COLI
 Since their discovery, antibiotics have revolutionised the 
treatment and prevention of bacterial infections. For the ma-
jority of community-acquired UTI, conventional antimicro-
bial therapy still provides effective treatment. However, the 
recent emergence and increasing prevalence of antibiotic 
resistant uropathogens has complicated the management of 
UTI. Antibiotic resistance genes are often carried on plas-
mids and mobile DNA elements that can spread rapidly and 
efficiently among bacterial populations. In addition, increas-
ing human migration and travel, as well as the emergence of 
medical tourism (referring to the rapidly-growing phenome-
non of international travel to obtain health care) are also con-
tributing to the rapid spread of some resistant strains across 
the globe [110]. Many multidrug resistant E. coli strains are 
now recognized as belonging to specific clones that are 
commonly isolated from UTI cases originating in a specific 
locale, country or even globally.  
E. coli Clonal Group A 
 First reported a decade ago, E. coli strains belonging to 
clonal group A (CGA) commonly exhibit resistance to mul-
tiple antibiotics, predominantly trimethoprim/sulfamethoxa-
zole (TMP/SMZ) [111, 112]. While TMP/SMZ-resistant 
CGA strains are particularly prominent across the United 
States [113], they are now recognized to belong to a broadly 
disseminated multidrug resistant clone that is endemic 
worldwide [114].  
E. coli ST131 
 Another more recent example of an emerging multidrug 
resistant E. coli clonal group is the O25b:H4-ST131 group of 
extraintestinal pathogens. Reports within the last five years 
have demonstrated the global distribution of this lineage in-
dicating that it constitutes a major threat to public health 
worldwide. E. coli ST131 are commonly associated with 
production of the CTX-M-15 enzyme, currently the most 
widespread extended spectrum -lactamase (ESBL) of its 
type in the world [115, 116]. Apart from oxyimino-
cephalosporins (i.e cefotaxime, ceftazidime), and monobac-
tams, E. coli ST131 strains are often co-resistant to fluoro-
quinolones (i.e ciprofloxacin) [117-119], thus limiting fur-
ther the treatment options that are currently available against 
this clone.  
Virulence of Multidrug Resistant E. coli Clones 
 The successful dissemination of both E. coli CGA and 
ST131 clones is thought to be due to their resistance to mul-
tiple antibiotic classes as well as their virulence capacity. E. 
coli CGA strains belong to phylogenetic group D and cluster 
within clonal complex 69 by MLST analysis [120, 121]. The 
typical virulence genotype of CGA strains includes several 
genes commonly associated with UPEC, including genes 
encoding P fimbriae, group 2 capsule, and the aerobactin and 
yersiniabactin iron-acquisition systems [113]. In contrast, E. 
coli ST131 strains are derived from phylogenetic group B2, 
which also includes other recognised pathogenic E. coli
clonal groups, and only a few virulence genes appear to be 
uniformly encoded in all E. coli ST131 strains - i.e. the fimH
adhesin of type 1 fimbriae, the secreted autotransporter toxin 
(sat), the aerobactin receptor (iutA), the uropathogenic-
specific protein (usp), and the pathogenicity island marker 
(malX) [116-118, 122]. The absence of hallmark UPEC viru-
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lence factors among E. coli ST131, such as P or S fimbriae 
and toxins, is intriguing considering the widely successful 
emergence of the ST131 clone as a major cause of urinary 
tract and bloodstream infections in the community and 
healthcare facilities across Europe, Asia, Africa, North 
America and Australia [116, 118, 123-126]. In the first com-
prehensive analysis of a genome sequence from an E. coli
ST131 isolate, we demonstrated the presence of unique ge-
nomic regions that encode several putative virulence factors 
and are absent from other characterised UPEC isolates [127]. 
These genomic regions are prevalent among E. coli ST131 
(Totsika, Beatson and Schembri, unpublished data) and 
likely contribute to the fitness of this globally disseminated 
multi-resistant E. coli clone. In a mouse model of acute UTI, 
E. coli ST131 isolates from the United Kingdom and Austra-
lia were shown to colonise the bladder robustly and this de-
pended on their ability to express type 1 fimbriae [127]. 
Type 1 fimbriae expression in E. coli ST131 is affected by a 
null mutation identified in the regulator-encoding gene fimB
and shown to be prevalent among geographically diverse E. 
coli ST131 isolates [127]. While fimB inactivation resulted in 
altered phase-on switching of type 1 fimbriae in the majority 
of E. coli ST131, we showed that these isolates were still 
able to express type 1 fimbriae at a level that could mediate 
enhanced adherence, invasion of and intracellular survival in 
bladder epithelial cells in vitro, as well as increased coloni-
zation of the mouse bladder during acute infection in vivo
[127]. Our study highlighted some unique genomic and viru-
lence attributes of E. coli ST131, underlying the need for 
more studies looking into the virulence mechanisms em-
ployed by this widespread clone of multidrug resistant 
pathogens.  
Outlook 
 The need to understand how different multidrug resistant 
E. coli clonal groups cause disease has become even more 
urgent in the face of emerging types of bacterial enzymes 
that confer multi- or even extensive-drug resistant pheno-
types and thus restrict our already limited options for antibi-
otic therapy. In 2008, a new type of metallo-beta-lactamase, 
termed New Delhi metallo--lactamase-1 (NDM-1), was 
identified in a uropathogenic strain of K. pneumoniae [128]. 
NDM-1 can hydrolyse penicillins, cephalosporins and car-
bapenems and the blaNDM-1 gene has been found in different 
plasmid types that co-harbor other resistance genes [129]. 
Since first reported, NDM-1 has spread among Enterobacte-
riaceae (and other bacteria) rapidly and widely [130]. Re-
cently, there have been several studies reporting the acquisi-
tion of the blaNDM-1 gene by E. coli ST131 strains [131, 132]. 
The presence of the blaNDM-1 gene and other carbapenem-
hydrolyzing -lactamase genes, including blaKPC-2 [133], in a 
widely disseminated and virulent E. coli clone is of great 
concern to public health. In addition, novel NDM-1 variants 
with enhanced carbapenamase activity, such as NDM-4 and 
NDM-5, have been very recently identified in E. coli [134, 
135], suggesting that these enzymes are continuously and 
rapidly evolving. With carbapenem antibiotics considered 
our ‘last-line’ of therapy against multidrug resistant Gram-
negative pathogens, the need for the development of alterna-
tive anti-infective strategies is extremely urgent. 
TREATMENT OF UTI 
Treatment Strategy 
 For clinical purposes UTI can be divided in a number of 
ways. They may be divided into ‘lower tract’ and ‘upper 
tract’ infection referring to cystitis and pyelonephritis respec-
tively. Alternatively they may be classified as ‘uncompli-
cated’ which generally refers to non-pregnant women with 
cystitis in a structurally and functionally normal renal tract; 
or ‘complicated’ which refers to pyelonephritis in non-
pregnant women, or any UTI in other patient groups includ-
ing men, children and those with structurally or functionally 
abnormal renal tracts (including an indwelling catheter) 
[136]. This clinical division facilitates the selection of an 
appropriate treatment strategy. Uncomplicated infection can 
be treated with a short course of therapy (<5 days, depending 
on the susceptibility and regimen). Complicated infections 
may require prolonged antimicrobial therapy and/or other 
non-pharmacological interventions including removal of in-
dwelling devices. 
 The traditional strategy for treating uncomplicated UTI is 
with empiric orally administered antimicrobials, commenc-
ing after a urine sample has been submitted for culture (but 
prior to identification and susceptibility testing of the impli-
cated bacteria). Other strategies have also been investigated. 
Clinical studies of uncomplicated cystitis have observed 
natural resolution of symptoms in most untreated women in 
approximately 5 days, albeit delayed when compared with 
treatment with active antimicrobial therapy [137]. A com-
parison of multiple strategies including empiric therapy 
without culture, delayed therapy commenced for ongoing 
symptoms at 48 hours, and delayed therapy based on urine 
culture results demonstrated the efficacy of all strategies. 
Targeting therapy based on dipstick, urine culture, or delay-
ing therapy for 48 hours, lead to a decrease on the overall use 
of antimicrobials [138]. Non-culture strategies rely on the 
high susceptibility of local bacteria to empiric antimicrobial 
therapy and have not been trialled in settings of high rates of 
multidrug resistant organisms. The treatment of complicated 
infection is more specifically tailored to the patient and site 
of infection. For the most common complication, pye-
lonephritis, most national guidelines recommend between 7 
and 14 days intravenous and/or oral therapy depending on 
the agent selected [139, 140]. 
Antimicrobial Therapy 
 Over the last forty years, antimicrobial treatment of un-
complicated UTI has evolved in response to the prevalence 
of antibiotic resistance in E. coli in the community. Thus, for 
example, orally administered amoxicillin was superseded by 
non-beta-lactam antibiotics or beta-lactam antibiotics stable 
to the TEM-1 beta-lactamase, which became the prevalent 
cause of amoxicillin resistance [141]. For many years, amox-
icillin/clavulanate, cephalexin, trimethoprim/ sulfamethoxa-
zole or fluoroquinolones (for example, ciprofloxacin) were 
used as first line treatment of uncomplicated UTI. However, 
resistance of E. coli to each of these antibiotics is now sub-
stantial and in many parts of the world these drugs can no 
longer be used as empiric therapy [139]. The dissemination 
of specific clonal groups has contributed to this spread of 
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resistance via CGA harbouring trimethoprim/ sulfamethoxa-
zole resistance [112] and ST131 strains harbouring fluoro-
quinolone resistance [142]. 
Oral Therapy 
 In most parts of the world, nitrofurantoin, fosfomycin 
and pivmecillinam remain active against the majority of E. 
coli strains causing uncomplicated UTI [123, 143-146]. 
However, in nations where there has been heavy use of these 
agents, resistance has emerged [147]. Whilst useful for un-
complicated lower tract infection, these agents have draw-
backs. Orally administered nitrofurantoin has low efficacy 
for pyelonephritis due to poor tissue penetration and should 
not be administered to patients with impaired renal function. 
Fosfomycin has good penetration of renal tissue, [148] how-
ever there have been few clinical studies on its use in pye-
lonephritis; hence it is of uncertain efficacy in the treatment 
of pyelonephritis [149]. Furthermore, fosfomycin and 
pivmecillinam are not readily available or licenced for use in 
a number of countries [150]. Another potential option is the 
beta-lactam/beta-lactamase inhibitor combination of amox-
icillin/clavulanate. It has proved successful in the treatment 
of lower urinary tract infection caused by ESBL producing 
organisms where in vitro activity is confirmed (MIC 
8g/ml) [151]. It has also been used for step-down therapy 
after intravenous treatment of pyelonephritis in similar iso-
lates [152]. 
Parenteral Therapy 
 The extent of resistance to orally administered antibiot-
ics, coupled with issues of drug availability and suitability, 
means that some patients with uncomplicated UTI or early 
pyelonephritis, who would previously have been treated with 
oral therapy, now need intravenous therapy. The common 
phenotype causing this clinical scenario is an isolate har-
bouring fluoroquinolone, trimethoprim/sulfamethoxazole 
resistance and an ESBL enzyme, usually of CTX-M type. 
These isolates also frequently co-produce enzymes that con-
fer aminoglycoside resistance [153]. Patients with severe 
infection causing sepsis also require parenteral therapy, re-
gardless of the antimicrobial resistance phenotype. 
 For suspected or proven resistant infection, intravenous 
carbapenem antimicrobials have become the treatment of 
choice. Whilst all the commonly available carbapenems 
(meropenem, imipenem, doripenem and ertapenem) are ac-
tive against ESBL producing E. coli, intravenous ertapenem 
has found favour. Its prolonged half-life allows once daily 
administration for ambulatory intravenous therapy [154]. In 
addition, its narrower spectrum (without activity against P. 
aeruginosa) may decrease risk of further potentiating further 
resistance within the healthcare environment [155]. Other 
parenteral treatment options for ESBL E. coli include the 
intravenous beta-lactam/beta-lactamase inhibitor combina-
tion, Piperacillin/Tazobactam, if in vitro activity is present 
[152]. The aminoglycoside amikacin is also frequently active 
against CTX-M harbouring E. coli, even in the presence of 
resistance to other drugs from this class (gentamicin and 
tobramycin) due to the stability of amikacin against degrada-
tion by the predominant aminoglycoside resistance mecha-
nism (aac(6’)-1b). As with all aminoglycosides, toxicity 
including ototoxicity and nephrotoxicity is problematic with 
prolonged amikacin administration [156]. 
 Unfortunately, the dissemination of beta-lactamases that 
inactivate carbapenems (“carbapenemases”) amongst E. coli,
has further complicated management of UTI. E. coli may 
now produce blaKPC or blaNDM type beta-lactamases which 
confer resistance to all penicillins, cephalosporins and car-
bapenems, without any useful inhibition by currently avail-
able beta-lactamase inhibitors [157, 158]. These organisms 
are also typically resistant to fluoroquinolones and amino-
glycosides. In this setting of extensive drug resistance there 
are few options for treatment. The legacy agent colistin 
maintains activity [159], however its use comes with a sig-
nificant risk of nephrotoxicity. The relatively novel glycyl-
cycline, tigecycline, is also frequently active in vitro [158, 
159], although its efficacy in renal tract infection is uncertain 
[160]. 
Outlook 
 To address the challenge of rising drug resistance among 
bacteria, the Infectious Diseases Society of America (IDSA) 
in collaboration with the European Society for Clinical Mi-
crobiology and Infectious Diseases (ESCMID), have recently 
updated their guidelines for the treatment of uncomplicated 
cystitis and pyelonephritis among women [139]. The pro-
posed changes aim to provide recommendations on optimal 
treatment options for uncomplicated UTI taking into account 
the increased rates of antimicrobial resistance, among other 
factors. Despite the increasing trend in antibiotic resistance 
among uropathogenic E. coli seen worldwide, regional resis-
tance rates and patterns can vary considerably [161, 162]. 
This variation represents an additional challenge for clini-
cians when choosing effective treatments for UTI in different 
countries and highlights the need for continuous active sur-
veillance of antibiotic resistance patterns at the insti-
tute/regional level. The outlook for management of antimi-
crobial resistant UTI in the future is guarded. While some 
new antibiotics are relatively advanced in development, such 
as the novel aminoglycoside ACHN-490, they are not likely 
to be active against metallo-beta-lactamase producers (eg. 
blaNDM) which also harbour emerging aminoglycoside resis-
tance mechanisms (16S rRNA methylases) [163]. Priorities 
for drug discovery for UTI include orally administered anti-
biotics active against ESBL producers and intravenously 
administered antibiotics active against producers of both 
carbapenemases and 16S rRNA methylases. As a temporis-
ing measure, improving global access and further clinical 
trials of existing agents such as fosfomycin and temocillin 
should also be a priority. 
VACCINATION APPROACHES FOR THE PREVEN-
TION OF UTI 
 The need for vaccines to prevent UTI has increased as 
fast as antibiotic resistance among UPEC strains. The com-
bination of successful antibiotic treatments and the versatility 
of UPEC strains on evading the immune system imposed 
economic and immunological obstacles that reduced the in-
terest on vaccination and delayed its research and develop-
ment for several years. Now that the scenario has completely 
changed and antibiotic treatment has struggled to catch up 
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with the evolving mechanisms of drug resistance, novel vac-
cinology approaches have been proposed to overcome old 
pitfalls and deliver a safe and broadly protective vaccine Fig. 
(2). 
Conventional Vaccinology Approaches 
 Initial vaccinology approaches for ExPEC followed the 
same conventional rules that led to the decrease and even 
eradication of several diseases for more than a century. Ini-
tial attempts involved the use of capsular polysaccharides 
[164] and O-antigen [165] in immunotherapies, but high 
diversity and the limited immunogenicity and immunological 
memory towards polysaccharides if not protein-conjugated 
made the development of a polysaccharide-based vaccine 
extremely challenging. In an attempt to partially overcome 
capsular diversity, six UPEC strains representing the most 
important serotypes involved in UTI were combined in a 
heat-killed multi-microbial vaccine (SolcoUrovac), and used 
for the vaginal immunization of women suffering from re-
current UTIs during a phase II clinical trial. Vaccination pre-
vented re-infection in 50% of women during the 24-week 
trial and significantly delayed the re-infection interval com-
pared to the placebo-treated group. Mucosal vaccination was 
shown to be safe and efficient, but efficacy against heterolo-
gous strains and long-lasting mucosal immune responses was 
not demonstrated [166]. 
 Conventional vaccinology approaches have led to the 
development of most of the vaccines that are currently li-
censed. None of these approaches, however, have success-
fully overcome the problem of high antigenic variability and 
the diverse virulence mechanisms of UPEC. This led to their 
gradual replacement with functional vaccinology approaches 
focused on common mechanisms in UTI pathogenesis and 
targeting bacterial components directly involved in viru-
lence. Functional vaccinology approaches have attempted to 
block the interaction between UPEC and the host or neutral-
ize UPEC secreted components responsible for tissue dam-
age and/or nutrient scavenging. Hemolysin [167], type 1 
[168] and P [169] fimbriae subunits, and siderophore recep-
tors [170, 171] have been targeted by this approach. How-
ever, despite promising results obstacles including low 
prevalence, poor solubility and high variability have ham-
pered progress. 
 Despite the diversity and low immunogenicity of the E.
coli capsule, the potential of whole-cell formulations is high, 
since whole cells could display multiple antigens, may pos-
sess natural adjuvants and should allow the production of 
antibodies against conformational epitopes. As an alternative 
to whole-cell vaccines, proteomic vaccinology approaches 
have exploited the ability of E. coli to form and release outer 
membrane vesicles, in order to define the composition of the 
outer membrane and to use outer membrane vesicles as a 
natural vehicle to deliver a multi-component vaccine against 
UPEC and other extra-intestinal pathogenic E. coli strains 
through a high-yield system [172].  
New Vaccinology Approaches 
 Iron receptors show promise as targets for vaccine formu-
lations against UTI. Iron is essential for bacterial growth, 
therefore UPEC strains have evolved several highly special-
ized iron scavenging systems for survival in limited iron 
environments (e.g. urine). All iron receptors have a beta-
barrel structure that spans the outer membrane and contains 
external loops that interact with the siderophore substrates to 
promote iron internalization. UPEC strains have a vast reper-
toire of iron scavenging systems and some strains can harbor 
multiple systems with functional redundancy [75]. Low 
solubility and functional redundancy are the two major ob-
stacles in successfully using iron receptors in vaccine formu-
lations. As a means to overcome this, structural vaccinology 
Fig. (2). Vaccinology approaches against UPEC. Several vaccinology approaches have been applied for the delivery of vaccines against 
UPEC strains: Conventional approaches, providing protection through the delivery of whole inactivated bacteria or major surface compo-
nents, like lipopolysaccharides or capsular polysaccharides; Functional approaches, targeting mechanisms involved in the interaction to the 
host and pathogenesis, like fimbrial components and toxins; Structural approaches, taking advantage of structural analysis of outer membrane 
antigens for the identification of surface-exposed epitopes, like iron and siderophore receptors; Proteomic approaches, using OMVs for the 
identification of novel surface-exposed antigens or as vehicles for multi-component vaccines; Reverse vaccinology approaches, mining ge-
nome sequences for the identification of surface-exposed or secreted antigens.
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approaches that use protein crystal structures and structural 
modeling have identified the external loops of different iron 
receptors, which were successfully targeted as fused recom-
binant antigens and conferred protection with increased cov-
erage and prevented bacterial survival due to functional re-
dundancy in iron receptors [173]. 
 Although several vaccinology approaches have identified 
promising candidates, antigen solubility and diversity remain 
important obstacles in delivering a broadly protective vac-
cine against UTI. For these reasons, a multi-component vac-
cine approach seems like the most promising alternative. The 
genome sequence of bacteria can be viewed as the most 
comprehensive library for the identification of multiple vac-
cine candidates. It provides information on all of the proteins 
that can be encoded by any bacterial strain without having to 
rely on in vitro or in vivo culture conditions. The reverse 
vaccinology approach uses genomic information for the 
identification of immunogenic and protective vaccine candi-
dates and has been successful in providing protective anti-
gens against several pathogens [174, 175]. Using a novel 
genomic analysis approach to compare UPEC and neonatal 
meningitis-associated E. coli with and non-pathogenic E. coli
strains, (called subtractive reverse vaccinology), nine protec-
tive antigens were identified, most of them with improved 
solubility, cross-protection and high prevalence among a 
collection of extra-intestinal pathogenic E. coli strains (in-
cluding UPEC), indicating that their combination in a multi-
component formulation could lead to the development of a 
novel recombinant vaccine [176]. 
Outlook 
 Now that several vaccine candidates have been identified 
and the feasibility of a vaccine against UPEC strains has 
been demonstrated, our attention has slightly shifted to the 
host. Research in mucosal immune responses will allow the 
improvement of existing or development of novel adjuvants 
and alternative routes of administration to facilitate delivery 
and boost the immune response to target antigens in the uri-
nary tract. 
ALTERNATIVE APPROACHES TO PREVENT UTI 
Anti-Adhesion Strategies 
 Over the last decade several alternative approaches have 
been investigated for the treatment and prevention of UPEC-
mediated UTI. Given the critical role of adhesion in coloni-
zation of the urinary tract, a number of methods aimed at 
preventing adhesion have been investigated; for example, 
anti-adhesion methods that target specific interactions be-
tween fimbrial adhesins and their cognate receptor. In this 
respect, the greatest progress has been made with molecules 
that prevent binding mediated by the tip-located FimH adhe-
sin of type 1 fimbriae. FimH binds to a wide range of glyco-
proteins containing one or more N-linked high-mannose 
structures, and this binding can be inhibited by D-mannose 
[177] as well as a variety of natural and synthetic saccharides 
containing terminal mannose residues [178-184]. Other 
mannose derivates with higher FimH binding affinity have 
also been identified [185, 186]. Most recently, a series of 
small-molecular weight compounds (mannosides) optimized 
for oral administration were shown to block UPEC FimH-
receptor binding to the bladder uroepithelium and subsequent 
colonization in the mouse UTI model [187]. An exciting 
aspect of this work was the observation that these man-
nosides enhanced the activity of trimethoprim-
sulfamethoxazole against a resistant UPEC strain. The ability 
of mannosides to inhibit colonization by globally dissemi-
nated multidrug resistant UPEC clones, such as E. coli
ST131, remains to be examined. 
Pilicides 
 Pilicides are a class of synthetic molecules that prevent 
the synthesis of UPEC chaperone-usher fimbriae by inhibit-
ing the function of the chaperone protein [188]. Pilicides 
have been designed that target the specific site of the chaper-
one that interacts with its cognate usher protein, the outer-
membrane assembly platform that facilitates fimbrial assem-
bly [188, 189]. An attractive feature of pilicides is the poten-
tial to target multiple different chaperone-usher fimbrial 
types. Thus, it may be possible to inhibit the biosynthesis of 
multiple different chaperone usher fimbriae from UPEC, or 
even other Gram-negative bacterial pathogens, simultane-
ously. More recently, new pilicide derivatives with improved 
efficacy or altered specificity have been described [190, 
191].  
Prophylactic Strategies Using Asymptomatic E. coli
Strain 83972 
 Another approach aimed at the prevention of UTI in-
volves the use of the prophylactic asymptomatic bacteriuria 
(ABU) E. coli strain 83972. E. coli 83972 is a B2 clinical 
isolate capable of long-term bladder colonization that has 
been effectively employed as a prophylactic agent for the 
prevention of UTI in human inoculation studies [192-199]. 
E. coli 83972 was originally isolated from a young Swedish 
girl with ABU who had carried it for at least three years 
without symptoms [192, 194]. It is well adapted for growth 
in the urinary tract where it establishes long-term bacteriuria 
[196]. E. coli 83972 lacks defined O and K surface antigens, 
is non-motile and does not produce a capsule [192, 200, 
201]. In addition, it is attenuated in a number of virulence 
determinants, including type 1, P and F1C fimbriae [200, 
202, 203]. E. coli 83972 has been used for prophylactic pur-
poses in patients with chronic and recurrent UTI. In these 
studies the bladders of patients were deliberately colonized 
with E. coli 83972 in order to prevent the establishment of 
UPEC and other uropathogens. E. coli 83972 has been suc-
cessfully used in several studies and can establish bacteriuria 
without jeopardizing the health of the patient. In one study, 
women with chronic symptomatic UTI were eradicated of 
their infection and then deliberately colonized with E. coli
83972. Stable bacteriuria was established for more than 30 
days in seven of the twelve individuals [192]. In another 
study, a group of patients with recurrent symptomatic UTI 
had their bladders deliberately colonized with E. coli 83972. 
Successful long-term colonization (5 months to 3 years) was 
achieved in 6/12 patients with neurogenic bladder disorder 
[196]. Deliberate colonization with E. coli 83972 can reduce 
the frequency of UTI in patients with neurogenic bladder 
secondary to spinal cord injury [193, 195] and prevent cathe-
ter colonization by bacterial and fungal uropathogens [197, 
199, 204]. E. coli 83972 is well maintained in the bladder, 
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does not adhere to uroepithelial cells or induce a proinflam-
matory cytokine response, and can outcompete other UPEC 
strains during growth in human urine – possibly due to its 
ability to produce multiple siderophores [75, 205-207]. 
Clinical trials using E. coli 83972 to pre-coat urinary cathe-
ters have been carried out in Sweden and the USA and show 
promising results, with these trials currently being extended 
[192, 193, 195, 208]. Other complementary approaches 
aimed at altering the adherence capacity of E. coli 83972 are 
also being investigated [209]. 
Outlook 
 The recent rapid emergence of multidrug resistant UPEC 
strains has necessitated the need to develop new approaches 
to treat UTI and other infections caused by these organisms. 
The prevention of UPEC adhesion can be achieved by anti-
adhesive molecules that mimic human receptor targets and 
by compounds that disrupt adhesin assembly (i.e. pilicides). 
Prophylactic approaches based on the asymptomatic bacteri-
uria strain 83972 also show promise. A comprehensive 
evaluation of these approaches in defined animal infection 
models and human clinical trials is now required. 
CONCLUSIONS 
 Several new and emerging themes in UPEC research 
should influence future directions in the field. Although tra-
ditionally regarded as an extracellular pathogen, recent work 
has shown that some UPEC strains can survive and replicate 
intracellularly within epithelial cells and macrophages. Thus, 
it appears that there are two types of UPEC strains that cause 
symptomatic UTI: (i) those represented by the prototype 
strain CFT073 that produce toxins and cause severe damage 
to the uroepithelium and (ii) those represented by the proto-
type strain UTI89 that can invade epithelial cells, form IBCs 
and survive intracellularly. The emergence of dominant 
UPEC clones such as ST131 suggests that these phenotypes 
can now be coupled with antibiotic resistance, making the 
overall picture of UPEC virulence even more diverse. The 
challenge over the next decade will be to understand the mo-
lecular mechanisms by which different UPEC strains colo-
nise the urinary tract, dissect the corresponding host re-
sponses to infection and then exploit this knowledge in the 
development of new approaches to treat and prevent UTI. 
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1. The paradox of Japanese antimicrobials
A 3-year-old infant presents to a Tokyo hospital emergency
clinic with acute otitis media. The experienced physician notes the
severe pain and fever. She chooses to prescribe antimicrobial
therapy. The doctor is aware that Japanese children do not receive
protection against Haemophilus influenzae type B (Hib) through the
national vaccine schedule, Hib being a common, albeit prevent-
able, cause of otitis media and severe complications including
mastoiditis and meningitis. She is also aware that Japan has the
world’s highest rate of BLNAR (beta-lactamase-negative ampicil-
lin-resistant) H. influenzae, rendering most commonly used oral
antimicrobials ineffective in approximately 30% of such infections
in Japan.1 Fortunately, since 2009, Japan is the only country in the
world with an oral carbapenem available to combat such
infections.2 Therapy is successful.
In the neurology ward of the same hospital a patient is
diagnosed with neurosyphilis. Until August 2011, the clinician
would have been unable to follow almost universal treatment
recommendations suggesting intravenous benzylpenicillin, as this
agent was not approved for intravenous use.3 Likewise, a patient
suffering from Clostridium difficile diarrhea has only had access to
metronidazole for this indication since February 2012.4 Even now,
a patient diagnosed with methicillin-sensitive Staphylococcus
aureus endocarditis would not be able to receive the ‘gold
standard’ treatment of an anti-staphylococcal penicillin, as a
suitable agent is completely unavailable.
The vignettes above highlight some of the profound contrasts of
Japanese antimicrobial use and development, and the impact these
contrasts have on medical practice and ultimately on patients. In
essence, the current commercial and regulatory environment has
led to a nation of polar opposites.
On the positive side, a tightly held domestic pharmaceutical
industry with major regulatory and financial hurdles to the
importation and use of foreign antimicrobial agents has spurred
significant local antimicrobial drug development,5 defying the
recent global trend away from new antimicrobial development.6
Japan is the birthplace of many agents, including broad-spectrum
antimicrobials used regularly by infectious disease physicians and
other practitioners to treat critically ill patients the world over
(Table 1). These agents include the carbapenems such as
meropenem and doripenem, used to treat the emerging global
epidemic of multi-resistant organisms, including those harboring
extended-spectrum beta-lactamase enzymes.
Of less clear benefit, the protection afforded to the domestic
industry has also facilitated the development of a large number of
‘domestic’ antimicrobials. Usually derivatives of existing classes,
many of these agents are not used widely in other nations (Table 1).
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Whilst the situation has not been thoroughly explored for
antimicrobials, in other medical disciplines, particularly oncology,
the standards by which the efficacy of ‘domestic’ agents has been
measured have been brought into question.5
This environment has a clear negative aspect, however, as
Japanese clinicians have not had access to a number of everyday
narrow-spectrum antimicrobials (Table 1). Clinicians in most other
nations use these ‘workhorse’ agents on a daily basis for a vast
range of conditions, ranging from minor to life-threatening. Local
experience in Japan shows that clinicians now substitute broad-
spectrum antimicrobial therapies for the absent narrow-spectrum
agents.7 These ‘substitutions’ offer no additional therapeutic
benefit for the patient, and come with the additional risk of
potentiating antimicrobial resistance.
The evolution of this situation is illustrated by the case of the
narrow-spectrum penicillins, benzylpenicillin and cloxacillin.
Until the recent change to the regulatory approval, benzylpenicillin
was approved in Japan only for intramuscular use at a very low
dose (600 000 units every 6 h). Although discrepancies between
approved and real-life indications exist in many nations, Japanese
prescribers are reluctant to use therapies ‘off-label’ even when the
indication is based on the best clinical evidence.
This reluctance stems from the existence of two conflicting sets
of laws governing doctor’s pharmaceutical prescribing practices.
Clause 21 of the Japanese Medical Practitioners Law advises
doctors of their duty to prescribe appropriate drugs as required for
the clinical situation. Potentially conflicting this, Japan’s Pharma-
ceutical Affairs Law restricts prescribing only to agents approved
by these laws.8 Consequently, off-label use of antimicrobials (or
other agents), would potentially expose the doctor and hospital to
financial penalties and medico-legal sanction. The health practi-
tioner may be refused reimbursement from the national health
insurance scheme for the therapy and the patient will be excluded
from coverage by the universally available compensation scheme
for medical adverse events.9
The competitive nature of the Japanese market has posed a
predicament to Japanese pharmaceutical companies regarding the
supply of older and cheaper antimicrobial agents. By way of
example, the cost of the benzylpenicillin in Japan is low (1 million
units = 213 JPY = 3 USD), rendering a costly application for
expanded indication non-viable on purely financial terms. The
negative financial impact could potentially be compounded if the
change in licensure led to diminished use of newer domestically
developed agents. The possibility of domestic (or foreign) third
parties establishing themselves in the market to supply low-cost
narrow-spectrum agents seems slim. In addition to the cost, it
would involve navigating of the regulatory authorities, which have
been described as opaque in their decision-making process,
making any application a financially risky process.5 This predica-
ment is in contrast to newer, high-cost agents such as linezolid,
tigecycline, and daptomycin, all of which have been successfully
licensed in the previous decade.
The least desirable outcome of this financial and regulatory
environment is illustrated by the anti-staphylococcal penicillin,
cloxacillin. In 1998 the Japanese producer discontinued local
manufacture of this parenteral agent. With importation an
unrealistic option, for reasons outlined above, this crucial class
of antimicrobial was rendered effectively unavailable in the nation.
The only remaining agent is an infrequently utilized co-formula-
tion of cloxacillin and ampicillin, licensed at a very low dose
(cloxacillin total dose = 2000 mg/day).10 Clinicians now rely
primarily on cephalosporins, at times even using fourth-genera-
tion cephalosporins, carbapenems, or fluoroquinolones when
treating susceptible staphylococcal infections. Many of these
substitute antimicrobials have neither been formally studied nor
have ‘time-tested’ experience in this indication.
The heavy use of broad-spectrum agents is one of the likely
contributors to the high rates of antimicrobial resistance in
particular organisms in Japan. Whilst such agents are invaluable in
empiric therapy and the treatment of resistant infection, their
indiscriminate use increases the risk of emergence of resistance via
‘collateral damage’.11 The first ever description of a mobile
metallo-beta-lactamase (MBL) enzyme (blaIMP-1), originated from
Japan during the 1980s.12 These MBLs confer resistance to vitally
important carbapenem antimicrobials and remain endemic in
Japan today.13,14 The authors of the original description directly
attributed the emergence of this enzyme to the heavy use of
carbapenem agents in Japan.12
In addition, as noted earlier, there is also extreme resistance in
H. influenzae to beta-lactams,1 a phenomenon potentiated by
antimicrobial overuse and poor access to the Hib vaccine.
Regulation and licensing of vaccines in Japan remains in a similar
bind to that outlined herein for antimicrobials. A complex political
and regulatory environment has limited the availability and
uptake of a number of vaccines that are routine in almost all other
nations. Vaccines affording protection for bacterial pathogens
including Hib and Streptococcus pneumoniae are classified as
‘elective’ rather than ‘scheduled’. The consequence of this second
tier classification is that there is no specific inclusion in national
vaccination schedules, nor any obligation for public funding of
these agents. The mechanism by which vaccines are classified into
these tiers has been described as ‘not fully transparent’ and is
discussed further in the reference provided.15 The current lay of the
land also demonstrates high rates of antimicrobial resistance in
Table 1
Antimicrobial development and availability in Japan
Japanese developed antimicrobials with
a global market
Domestic Japanese antimicrobials
(without a major global market)
Agents difficult to access in Japan
Carbapenems Carbapenems Agents with very recent approval
Meropenem, doripenem Biapenem, panipenem, tebipenem (oral) Oral metronidazole: approved for
Clostridium difficile 2012
Quinolones Quinolones Intravenous benzylpenicillin: approved 2011
Levofloxacin, norfloxacin, gatifloxacin Pazufloxacin, enoxacin, nadifloxacin,
lomefloxacin, tosufloxacin, fleroxacin,
garenoxacin, sitafloxacin, prulifloxacin
TMP–SMX: approved for Pneumocystis jiroveci
pneumonia in 2012; use for other indications is
allowed ‘‘only when other agents cannot be used’’
Other Other Agents that remain unavailable
Cefazolin Ceftaroline Arbekacin (anti-MRSA aminoglycoside) Anti-staphylococcal penicillins, e.g. nafcillin,
oxacillin, cloxacillin, flucloxacillin
Colistin Ceftarolinea Faropenem (oral ‘penem’ antimicrobial) Intravenous metronidazole
Kanamycin Ceftaroline Benzathine penicillin
Polymyxins, e.g. colistin,a polymyxin B
MRSA, methicillin-resistant Staphylococcus aureus; TMP–SMX, trimethoprim–sulfamethoxazole.
a Although colistin was developed in Japan, the agent is no longer available in this nation.
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other common pathogens. This includes endemic methicillin-
resistant S. aureus16 and some of the world’s highest rates of
macrolide resistance in respiratory pathogens including S.
pneumoniae and Mycoplasma pneumoniae.17
The licensing of intravenous benzylpenicillin is an encouraging
step for a number of reasons. Firstly, it represents the use of an
alternative pathway to expanded licensing indications in Japan.
Since 2010 Japanese medical specialist societies have been able to
directly apply for licensing of new agents or indications,
circumventing some of the issues highlighted above. If similar
approval has previously been granted in other nations (USA, UK,
France, or Germany), then approval may be granted in Japan
without further domestic trials. Furthermore, in addition to
licensing, the regulator may request and incentivize a supplier
in the local market to produce or import the drug if supply is not
readily available.8
Secondly, this process was initiated by IDATEN, Japan’s nascent
community of infectious disease specialists.18 By global standards
this community is small. Despite an otherwise highly developed
medical workforce, Infectious Disease has not traditionally been a
recognized specialty. Few hospitals in Japan have access to a
trained Infectious Diseases specialist, let alone a department with
other roles including antimicrobial management and stewardship,
now emerging as the standard of care in other nations.19 The
expanded licensing of benzylpenicillin (and other antimicrobials)
highlights what may be a major task for this society in the future.
There are now generations of clinicians in Japan who have little
experience treating patients with such traditional and narrow-
spectrum agents. These clinicians will require considerable
encouragement, education, and support in order to begin utilizing
them to their full potential.
Like many other nations and the global community as a whole,
Japan faces significant challenges balancing antimicrobial devel-
opment and use. The first difficulty lies in uncoupling the supply
and use of off-patent and commercially unprofitable narrow-
spectrum antimicrobials from purely commercial imperatives that
may lead to their demise.20 The second challenge is in creating an
environment that fosters the continued development of new
antimicrobial agents, although not by simply encouraging their
overuse in order to provide a financial return. We hope that the
recent expanded licensing of intravenous benzylpenicillin, and
other agents, prompted by the emergence of a new voice from the
infectious disease community in Japan, is a first step in rebalancing
the nation’s formulary. Enhancing Japanese clinicians’ access to
important narrow-spectrum antimicrobials will greatly benefit
patients in Japan. Continued good work by the Japanese
pharmaceutical industry in the development of new antimicrobial
agents benefits the global community as a whole.
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EPIDEMIOLOGY
Treatment Options for New Delhi Metallo-Beta-Lactamase-
Harboring Enterobacteriaceae
Benjamin A. Rogers,1 Hanna E. Sidjabat,1 Anna Silvey,1 Tara L. Anderson,2
Shalini Perera,3 Jian Li,4 and David L. Paterson1
The New Delhi metallo-b-lactamase gene (blaNDM-1) has emerged as a worldwide concern among isolates of
Enterobacteriaceae. Its epidemiology is been strongly associated with travel and healthcare on the Indian
Subcontinent. We report two cases of urinary tract infection with Enterobacteriaceae harboring a blaNDM-1. Both
cases presented as infection in community-dwelling individuals in Australia and were associated with travel to
the Indian Subcontinent. One isolate of Escherichia coli harbored the previously undescribed enzyme variant
blaNDM-3, differing from blaNDM-1 by a single nonsynonymous SNP conferring a putative peptide sequence
change at the 95th position (ASP/ASN). The second was an Enterobacter cloacae harboring blaNDM-1. Further
genetic characterization included identification of additional b-lactamase and aminoglycoside resistance genes.
Legacy antimicrobials were used for treatment. Oral therapy with nitrofurantoin was successful in one case,
while combination of colistin and rifampicin was required in the second patient. Such infection, due to exten-
sively drug-resistant pathogens, poses significant challenges in balancing the efficacy and toxicity of potential
antimicrobial therapies.
Introduction
THE NEW DELHI METALLO-b-lactamase gene (blaNDM-1) hasrecently been described as disseminated on the Indian
Subcontinent and in the United Kingdom.7,22 A number of
blaNDM variants have subsequently been reported.
4,5 These
plasmid-borne genes code for an ambler class B, zinc-
dependent b-lactamase enzyme that confers resistance to
penicillin, cephalosporins, and carbapenems. Organisms
harboring the blaNDM-1 gene invariably carry resistance to
other classes of antimicrobials, including fluoroquinolones,
trimethoprim/sulfamethoxazole, and aminoglycosides.
Some blaNDM-1-harboring isolates have been described as
pan-resistant with demonstrable resistance to all currently
available antimicrobials.7 The gene has been associated with
community-onset and healthcare-associated or acquired in-
fection and colonization, by a range of common Entero-
bacteriaceae and other gram-negative pathogens. Due to
the extensive antimicrobial resistance of blaNDM-harboring
isolates, treatment options are very limited.
Case Histories
We report two contrasting cases of successful treatment of
blaNDM-harboring Enterobacteriaceae causing urinary tract
infection (UTI), illustrative of a spectrum of complexities in
acquisition and management.
Case 1: Community-acquired uncomplicated cystitis
In December 2010, a 28-year-old previously well woman
presented to her local doctor in Queensland, Australia,
7 days after return from travel to India. She reported
symptoms of cystitis, including urinary frequency and dys-
uria. She had no history of UTI, renal tract abnormality, or
significant medical illness. She was of Indian descent, and
resided in Australia. The patient travelled in India for 2
months to visit friends and relatives. The majority of the trip
was spent in metropolitan areas in the states of Gujarat
and Madhya Pradesh. While in India, the patient under-
went tooth extractions with a local dentist, including
prescription of an unknown oral antimicrobial. She had no
other healthcare contact, except a brief visit to a relative in
hospital.
On presentation, she had no fever or suggestion of upper
renal tract involvement. Midstream urine culture was sent to
a private diagnostic laboratory. The urine yielded a pure
growth of Escherichia coli (> 108 organisms/L) on culture.
Antimicrobial susceptibility testing by the private diagnostic
This study was presented in part at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, 2011.
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laboratory indicated resistance to all agents tested (ampi-
cillin, amoxicillin/clavulanate, piperacillin/tazobactam, ceph-
alexin, ceftriaxone, ceftazidime, meropenem ciprofloxacin,
trimethoprim, gentamicin, amikacin), with the exception of
nitrofurantoin. The isolate was referred to our research labo-
ratory for further investigation. The patient was treated with a
7-day course of nitrofurantoin with rapid resolution of all
clinical symptoms.
Case 2: Complicated healthcare-associated cystitis
In January 2011, a 78-year-old man presented to a physi-
cian in Tasmania, Australia, with several weeks of mild
dysuria and urinary frequency. Approximately 12 weeks
earlier, he had been discharged from a hospital in Calcutta,
West Bengal, India, after a 10-day stay for management of
hematuria. During this admission, he underwent surgical
management, including urethrotomy, transurethral resection
of residual prostatic tissue, and evacuation of intravesical
thrombus. After discharge from hospital, an in-dwelling
catheter remained in situ for a further 14 days.
The patient was of Indian descent. He spends 5 months each
year in India and the remaining 7 months of the year in Aus-
tralia, residing with family in each location. He had returned to
Australia *6 weeks before this presentation. Relevant history
included a previous transurethral resection of prostate, hyper-
tension, and cardiovascular and peripheral vascular disease.
On presentation in Australia, he was systemically well
without signs of upper UTI or sepsis. A mid-stream urine
culture demonstrated 1,000 · 106/L leukocytes and growth of
both E. cloacae >108 CFU/L and Pseudomonas aeruginosa
> 108/L. An ultrasonography of the renal tract showed no
abnormality. Both organisms were noted to be antimicro-
bial resistant. In particular, the E. cloacae was resistant to
carbapenems. After confirmation of antimicrobial suscepti-
bilities, the patient was admitted to hospital and treated with
intravenous colistin methanesulfonate (and oral rifampicin),
as no oral agents were available. Colistin methanesulfonate
was commenced at a dose of 100mg colistin base activity 12
hourly and oral rifampicin 300mg 12 hourly. Therapy was
complicated by deterioration in renal function on day 4, with
serum creatinine rising from 77 to 146mmol/L (reference
range, 60–120mmol/L).The colistin methane sulfonate dose
was reduced to 75mg colistin base activity 12 hourly in ad-
dition to increased hydration and withholding his regular
angiotensin II receptor antagonist. He completed 14 days of
combined therapy with resolution of all symptoms and dem-
onstration of a negative urine culture 3 months after therapy.
Methods and Results
Phenotypic analysis
Phenotypic antimicrobial susceptibility was undertaken
by disc diffusion as per CLSI methods2 and Etest minimum
inhibitory concentration (MIC) (bioMe´rieux, Marcy l’Etoile,
France). Results for E. coli and E. cloacae are listed in Table 1.
Phenotypic MBL activity was confirmed with the use of
EDTA inhibition in both isolates.3 Neither demonstrated
synergy with clavulanic acid. The P. aeruginosa was suscepti-
ble to meropenem and colistin, while resistant to ceftazidime,
piperacillin/tazobactam, ciprofloxacin, and gentamicin. No
phenotypic MBL activity was detected.
Genotypic analysis
Antimicrobial resistance genes were investigated by PCR
as described previously.20 Genes investigated included b-
lactamases and aminoglycoside resistance genes; Ambler
Table 1. Antimicrobial Susceptibility and Resistance Genes in the NDM-Producing Isolates
Escherichia coli Enterobacter cloacae
Phenotypic antimicrobial susceptibilitya
Imipenem Resistant (12mcg/ml) Resistant (> 32mcg/ml)
Meropenem Resistant (4mcg/ml) Resistant (> 32mcg/ml)
Doripenem Resistant (12mcg/ml) Resistant (> 32mcg/ml)
Piperacillin + tazobactam Resistant (> 256mcg/ml) Resistant (> 256mcg/ml)
Cefoxitin Resistant Resistant
Cefotaxime Resistant Resistant
Ceftazidime Resistant Resistant
Aztreonam Resistant Resistant
Ciprofloxacin Resistant Resistant
Trimethoprim/sulfamethoxazole Resistant Resistant
Gentamicin Resistant Resistant
Amikacin Resistant Resistant
Tigecycline 0.19mcg/ml 3.0mcg/ml
Colistin 0.5mcg/ml < 0.125mcg/ml
Nitrofurantoin Susceptible (16mcg/ml) Resistant ( > 512mcg/ml)
Fosfomycin Susceptible (3mcg/ml) Resistant (256mcg/ml)
Chloramphenicol Susceptible Resistant
Genetic characterization
NDM genes blaNDM-3 blaNDM-1
Other extended-spectrum b-lactamase genes blaCMY-6, blaCTX-M15 Nil
Aminoglycoside resistance genes aac-6¢-Ib and rmtC aac-6¢-Ib and rmtC
aPerformed by disk as per CLSI standards or Etest, where an MIC is listed. Where no break point has been established for a given agent,
only the MIC is provided.
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class A ESBLs (blaCTX-M, blaTEM and blaSHV); class B metallo-
b-lactamases (blaNDM, blaVIM, and blaIMP); class C extended-
spectrum cephalosporinases (blaDHA and blaCMY); and the
aminoglycoside resistance genes aac-6¢-Ib and methylase
genes. Results are in Table 1. The presence of blaNDM was
detected using forward primer (5¢-GGGCCGTATGAGTG
ATTGC-3¢) and reverse primer (5¢-GAAGCTGAGCACCG
CATTAG-3¢), producing a 758-bp product in E. coli and
E. cloacae. In addition, a pair of flanking primers was
used to amplify and sequence the entire gene, NDM F (5¢-
CTGGGTCGAGGTCAGGATAG-3¢) and NDM R (5¢-TCGCC
CCATATTTTTGCTAC-3¢). Amplicons were sequenced in
forward and reverse direction using an Applied Biosystems
3730xl platform and compared to published sequences in
GenBank (www.ncbi.nlm.nih.gov/genbank). P. aeruginosa
did not harbor a detectable blaNDM or other MBL genes, and
is not discussed further.
The E. coli blaNDM sequence contained a nonsynonymous
single-nucleotide polymorphism at the 283rd position (G/
A), conferring a putative peptide sequence change at the 95th
position (ASP/ASN). Plasmid transformation studies re-
ported elsewhere show similar carbapenem MICs in the
parent and transformant, confirming the carbapenemase
activity of this variant.21 This variant has been designated
blaNDM-3 (www.lahey.org/Studies/) and submitted to Gen-
bank (accession: NDM-3 JQ734687). Further characterization
is ongoing. The sequence obtained from E. cloacae demon-
strated 100% concordance with the previously published
sequences of blaNDM-1.
Discussion
We present two cases of travel-associated UTI with highly
resistant organisms harboring the New Delhi metallo-b-
lactamase enzyme.
The first case demonstrates importation of community-
acquired blaNDM harboring E. coli. While less common than
healthcare-associated infection, such acquisition has been
reported in several other countries,1,7 although not Australia.
Key epidemiological factors in this case include travel and
antimicrobial use.6 Travel per se is associated with UTI in
females.18 Travel to countries with a high incidence of anti-
microbial resistance, in particular the Indian Subcontinent, is
associated with gastrointestinal carriage of antimicrobial-
resistant organisms on return. Antimicrobial use while
travelling was an independent risk for acquisition and pro-
longed carriage of such organisms.6,17
The second case highlights the increasing frequency and
complexity of the intercountry patient. This patient could be
described as an informal medical tourist seeking healthcare
in multiple nations for social and familial reasons.16 While
we cannot determine the exact timing of infection, the clinical
picture is likely of healthcare associated if not nosocomial
infection. The organism was most likely acquired in a hos-
pital in Calcutta or after discharge while catheterized in the
community.
In infection due to highly resistant pathogens, antimicro-
bial choice is limited, and requires a considered analysis of
risk and benefit of available agents. The case reports de-
scribed illustrate an unusual clinical situation, as the patients
were systemically well, at most requiring oral therapy.
However, the extreme resistance of the isolates dictated that
the only options for therapy were limited to infrequently
used and legacy antimicrobials.
Clinical studies of cystitis have observed natural resolu-
tion in most women, although delayed when compared with
susceptible antimicrobial therapy.10 In this setting of a highly
resistant pathogen, however, withholding therapy must be
weighed against a potential risk of upper UTI and subse-
quent sepsis with difficult to treat organism. In the second
case, additional factors, including a concern about infection
of the prostatic surgical bed, the patient’s surgically altered
urinary tract, and his underlying multiple medical co-
morbidities, also influenced the decision to treat and the
duration of therapy.
As yet, there have been few descriptions in the literature
and no prospective studies of oral therapy for blaNDM-
harboring organisms. Virtually, all described isolates are
resistant in vitro to commonly used non-b-lactams, such as
trimethoprim/sulfamethoxazole and fluoroquinolones. Sus-
ceptibility testing to legacy oral antimicrobials such as
nitrofurantoin, fosfomycin, and chloramphenicol is not in-
cluded in all reports of blaNDM-harboring isolates. In a single
study, one-third of urinary tract E. coli harboring blaNDM-1
remained nitrofurantoin susceptible.19 Due to poor tissue
penetration, this agent only has utility in cystitis, however.
Fosfomycin has been used successfully in the therapy of
cystitis of other resistance phenotypes, including extended-
spectrum b-lactamases, and has good reported penetration
into prostate tissue.11 Susceptibility of NDM-harboring
Enterobacteriaceae to fosfomycin has been reported,12–15 al-
though with no clear denominator of isolates to determine a
true rate of resistance. It may have been a suitable alternative
in the first case presented, although unfortunately is not
easily available in Australia. Susceptibility to other poten-
tially useful legacy oral agents, including chloramphenicol8,9
and tetracycline,15 is also occasionally reported, again with-
out a clear denominator.
Conclusion
We present two cases of multidrug-resistant New Delhi
metallo-b-lactamase-producing Enterobacteriaceae illustrat-
ing a spectrum of acquisition and treatment complexity. Both
were treated with legacy antimicrobials, one case with sig-
nificant complications. While such agents have gone out of
favor due to potential side effects, tolerability issues, or ab-
sence of availability (in the case of fosfomycin in Australia),
at times they may be the best option available. In the setting
where an isolate can be confirmed as susceptible and the
clinical scenario is appropriate, such as cystitis, we suggest
consideration of oral legacy antimicrobials to treat NDM-1-
harboring infections.
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Escherichia coli is part of our normal intestinal flora and a
ubiquitous human pathogen. It causes a wide range of disease,
including intestinal infection (from diarrhea to hemolytic
uremic syndrome) and extraintestinal infection (from un-
complicated urinary tract infection to bacteremia and men-
ingitis). Although wild-type E. coli is intrinsically susceptible
to most antimicrobials, extraintestinal E. coli strains have
shown the ability to develop resistance to every class of agents
introduced for human use. This trend goes back to the de-
velopment of sulfonamide and ampicillin resistance in the
mid-twentieth century and seems unlikely to abate in the
foreseeable future.1,2
The previous decade has heralded some changes in the
dynamics of resistance in E. coli. Resistance to sulfameth-
oxazole-trimethoprim and fluoroquinolones has skyrocketed
worldwide, which is a significant trend, because it compro-
mises 2 valuable oral treatment options for infections caused
by E. coli. Equally alarming has been a rapid increase in the
incidence of E. coli–producing extended-spectrum b-lacta-
mase enzymes (ESBL-EC), and the expansion of ESBL-EC
from nosocomial to community acquisition that has occurred
in many regions.
A breakthrough in understanding these epidemiologic
shifts in resistance came in the mid-2000s, when researchers
used multilocus sequence typing (MLST) to identify the dom-
inance of a particular bacterial clone, sequence type (ST) 131,
among ESBL-EC strains.3,4 Subsequently, ST131 E. coli has
been shown to have worldwide distribution. It spans not only
clinical strains of ESBL-EC, in which ST131 frequently ac-
counts for greater than 25% of those isolates recovered, but
also a significant proportion of fluoroquinolone-resistant
strains and even asymptomatic carriage of ciprofloxacin-
resistant ST131 E. coli among healthy individuals.5 Overall,
ST131 is now regarded as the single most important clone
driving multidrug resistance in the community setting.
With this in mind, the work by Banerjee et al6 reported in
this issue of Infection Control and Hospital Epidemiology urges
us to redefine the epidemiology of E. coli ST131. Here, the
authors conducted a population-based, molecular epidemi-
ologic analysis of 299 consecutive clinical isolates of extra-
intestinal E. coli identified in Olmstead County, Minnesota.
Because of this study design, the isolates represented a rel-
atively unbiased sample of community-associated, healthcare-
associated, and hospital-acquired infections without regard
to antimicrobial susceptibility. It should be pointed out that
39% of the isolates were from individuals with healthcare-
associated or hospital-acquired infections; thus, the sample
represented a relatively “medicalized” population.
In this context, ST131 accounted for 27% of the isolates.
The most intriguing finding was that ST131 accounted for a
much greater proportion of healthcare-associated than com-
munity-associated isolates (49% vs 15%). A whopping 76%
of the isolates from long-term care facility (LTCF) residents
were ST131. As expected, ST131 accounted for a much bigger
share of antimicrobial-resistant isolates, including over 80%
of isolates that were nonsusceptible to fluoroquinolones and
approximately half of isolates resistant to trimethoprim-sul-
famethoxazole; however, only 11% of the ST131 isolates were
nonsusceptible to ceftriaxone, which is most commonly due
to production of ESBL. The independent predictors for ST131
included residence in a LTCF, urinary tract infection in the
previous month, complex infection due to E. coli, and pre-
vious antimicrobial exposure (extended-spectrum cephalo-
sporin, macrolides, and fluoroquinolones). These predictors
could all be considered potential markers of healthcare-
associated infection, although only residence in a LTCF is
included in the most commonly adopted definition.7
In summary, the data presented by Banerjee et al6 yield
compelling odds ratios for these medical risk factors that are
in favor of ST131, not against it. Although these findings
seemingly contradict the largest body of work on this clone,
which strongly delineates its community-associated nature,5
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table 1. Key Information on Molecular Epidemiology Methods Used in Characterizing Sequence Type (ST) 131 Escherichia coli
Method Typing targets Resolution for ST131 Key characteristics
Multilocus sequence typing Genomic sequence of 7 con-
served housekeeping genes
present in all E. coli. Gene
functions are unrelated to
bacterial virulence and
pathogenesis.
First identified ST131 as a
global epidemic clone.3,4
By definition, all strains
type as ST131 under the
Achtman scheme (http://
mlst.ucc.ie/mlst/dbs/
Ecoli).
Provides very broad molecu-
lar epidemiological char-
acterization. Given STs
may contain a large range
of bacteria of quite diverse
genetic makeup.
Pulsed-field gel electrophoresis DNA restriction sites (arbi-
trary sequences of 4–8
base-pairs of DNA) scat-
tered throughout the E.
coli genome.
Types ST131 into a variety
of pulsotypes (subclones).
Distinguishes human and
animal clones and demon-
strates geographical varia-
tion in circulating ST131
clones.16
Highly discriminatory typing
method often used for
spatially and temporally
related outbreaks (eg,
within a given healthcare
network). May fail to
identify spread of less
closely related strains
when used alone (eg,
ST131 separates into a
large number of
pulsotypes).
fimH typing17 Genomic sequence of a 469-
base-pair fragment of the
gene encoding a subunit
of the type 1 fimbriae,
which is used by E. coli to
adhere to urothelium (the
gene is occasionally absent
in nonuropathogenic
strains).
ST131 show a variety of
fimH types. Some of these
correlate closely with
other characteristics, in-
cluding fluoroquinolone
resistance.18
Given the functional nature
of this gene, potentially
identifies genetic traits
that play a role in bacte-
rial pathogenesis.
a number of historical8,9 and contemporary10,11 studies have
also demonstrated high rates of healthcare-associated and
hospital-acquired ST131. However, none demonstrate these
findings with the weight of the study by Banerjee et al.6
This contrast in epidemiology warrants further consider-
ation. Simple explanations may be geographical and meth-
odological. First, the epidemiology of this clone undoubtedly
varies by location.5 Second, the methodology of published
studies varies. Many investigators set out to find ST131 in
the context of community-associated ESBL-EC infection and
carefully surveyed this particular group.12 Others have not
stratified community-onset infections by healthcare associa-
tion at all. In retrospect, these studies may have been ex-
amining only the tip of the iceberg (ie, community-associated,
ESBL-producing E. coli ST131) while largely ignoring the
much more substantial remainder under the water (ie, health-
care-associated, fluoroquinolone-resistant E. coli ST131). An-
other possibility is also in play. We may be seeing a change
in the epidemiology of ST131, with this unwanted resident
increasingly moving from the community into acute care set-
tings, which is a path already travelled by predecessors such
as community-associated methicillin-resistant Staphylococcus
aureus.13
Regardless of the “when” and “where,” the question of
“why” ST131 has become a resident of our healthcare system
is important. Some portals of entry are clear. Banerjee et al6
and a number of other researchers have identified LTCFs as
a reservoir of ST131. Two-way traffic of patients and resistant
organisms between LTCFs and acute care facilities is almost
invariable, with the term “revolving door” used by some to
characterize this.11 Heavy use of fluoroquinolones should
likely shoulder some blame, although the true nature of their
effect is not defined. Other than correlating individuals’ pre-
vious fluoroquinolone exposure to infection with fluoro-
quinolone-resistant ST131 clones, we have no information
on the broader ecological impact of fluoroquinolone use on
the spread of ST131. We do know from other settings that
overall population fluoroquinolone use closely correlates with
rates of resistance amongst all E. coli14 and that, once estab-
lished, gastrointestinal carriage of fluoroquinolone resistance
is prolonged compared with the carriage of resistance to other
agents, such as ESBLs.15 It is also increasingly clear among
ST131 that animals and human clones are genetically dis-
tinct.16 This suggests that problematic fluoroquinolone use
driving this particular epidemic could be in the human pop-
ulation rather than the result of often-cited veterinary use
and food contamination.
The most elusive component of “why” relates to the mo-
lecular characteristics of the clone. Although not extensively
discussed in this study, Baterjee et al6 offer some intriguing
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data. Although ST131 was originally identified as an epidemic
clone using MLST, the molecular-epidemiological equivalent
of a 40,000-foot view, drilling down on ST131s with the other
methods gives interesting insights (Table 1). Pulsed-field gel
electrophoresis (PFGE), which is traditionally used within a
defined spatial and temporal context, demonstrates that ap-
proximately half of the ST131 fluoroquinolone-resistant iso-
lates in the Banterjee et al6 study belonged to 2 specific PFGE
pulsotypes. However, the more specific method to define the
core subclone of fluoroquinolone-resistant ST131 appeared
to be fimH typing, which is a recently defined single-locus
sequence typing method that uses a section of the fimH gene.17
Unlike the benign housekeeping genes of MLST, fimH is a
virulence gene that codes for a subunit of type I fimbriae
crucial for bacterial adhesion to urotheleium. Here, 99% of
the fluoroquinolone-resistant ST131 isolates shared a specific
allele, fimH30, whereas this allele was absent from any of the
fluoroquinolone-susceptible ST131 isolates. This allele is
likely more than just an epidemiological marker. In-depth
examination of fimH30-carrying strains by other investigators
has suggested a positively selected patho-adaptive trait. These
strains appear to have augmented urovirulence via an en-
hanced ability to bind to urothelium.18 In essence, this flu-
oroquinolone-resistant ST131 fimH30 subclone is now fine-
tuned for its host and environment and appears to be
out-competing other ST131 subclones and non-ST131
strains.
The study was performed in a rather rural county in North
America, and the generalizability of the authors’ findings re-
mains to be seen. However, they will prompt us to redefine
the way we think about this emerging and expanding epi-
demic, which has the potential to deprive us of most oral
treatment options for infections due to this exceedingly com-
mon bacteria in the near future.
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Transrectal ultrasound (TRUS)–guided prostate biopsy is currently considered the standard technique for
obtaining tissue to make a histological diagnosis of prostatic carcinoma. Infectious complications following
TRUS-guided prostate biopsy are well described, and are reportedly increasing in incidence. The role of antibiotic
prophylaxis in reducing post–TRUS biopsy infections is now established, and many guidelines suggest that fluoro-
quinolone antimicrobials are the prophylactic agents of choice. Of note, however, recent reports suggest an emerg-
ing association between TRUS biopsy and subsequent infection with fluoroquinolone-resistant Escherichia coli.
Against this background, we provide an overview of the epidemiology, prevention, and treatment of infectious
complications following TRUS biopsy, in the wider context of increasing global antimicrobial resistance.
Keywords. prostate biopsy; Escherichia coli; fluoroquinolones; ESBL.
Transrectal ultrasound (TRUS)–guided prostate biopsy
is the standard technique for obtaining a histological
diagnosis of prostatic carcinoma [1]. The commonest
indications for TRUS biopsy are a raised prostate-
specific antigen (PSA) level and/or an abnormal digital
rectal examination. According to recent estimates, ap-
proximately 1 million TRUS biopsies are performed
annually in the United States [2].
TRUS biopsy is generally performed under local anes-
thetic in the outpatient setting. The patient is placed in the
lateral decubitus position with both hips and knees flexed.
An ultrasound probe is inserted into the rectum, to enable
visualization of the prostate gland anatomy (Figure 1).
A spring-loaded device is used to collect core biopsies,
sampling tissue systematically from both sides of the
gland. The optimum number of biopsies is controversial,
although data suggest that an extended regimen (≥10
cores) detects more cancers than previously used sextant
techniques [3]. If histopathology fails to reveal malignan-
cy, repeat biopsies are often performed as a second proce-
dure may detect carcinoma in around 20% of cases [3].
Although generally considered a safe and well-tolerated
procedure, postbiopsy complications are reported in up to
50% of cases, and include pain, hematuria, hematosper-
mia, urinary retention, and infection [4]. In the following
review, we provide an overview of the published literature
relating to infectious complications of TRUS biopsy, with
a specific focus on antimicrobial-resistant Escherichia coli.
INCIDENCE ANDMORBIDITY OF
INFECTIOUS COMPLICATIONS AFTER
TRUS BIOPSY
A variety of infectious complications may occur follow-
ing TRUS biopsy, ranging from asymptomatic bacteriuria
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or urinary tract infection (UTI) through to prostatitis, bactere-
mia, and severe sepsis [5, 6]. The reported incidence of UTI after
TRUS biopsy typically ranges between 2% and 6% with approxi-
mately 30%–50% of these patients having accompanying bactere-
mia [7, 8]. Bacteremia is frequently accompanied by severe sepsis,
which has an overall incidence of 0.1%–2.2% following TRUS
biopsy [7]. One recent study reported that among post–TRUS
biopsy patients hospitalized with E. coli bacteremia, 25% had
severe sepsis requiring intensive care unit (ICU) admission [9].
Despite relatively high rates of ICU admission in that study, men
with E. coli bacteremia after TRUS biopsy had significantly lower
30-day mortality than other men with community-onset E. coli
bacteremia during the same time period (0% vs 9.9%; P = .017).
Similar findings are reported in another retrospective observa-
tional study where lower 30-day mortality was observed among
men after TRUS biopsy compared to men who did not have a
preceding TRUS biopsy (0.31% vs 1.09%; P < .0001). The
authors of that study postulated that the lower mortality rate was
a reflection of less comorbidity in the TRUS biopsy group [2].
For the less severe infectious complications of TRUS biopsy,
it is likely that the true incidence is underestimated, as reported
rates of infectious complications usually only include patients
requiring hospitalization [2, 10]. The suggestion that many
infectious complications are managed in the community is
supported by a recent large prospective European study where,
in the 2 weeks following prostate biopsy, fever was reported
in 4.2% of patients whereas hospitalization occurred in only
0.8% [11]. Similarly, a retrospective observational study from
Scotland reported that the majority of post–TRUS biopsy
infectious complications were managed by primary care practi-
tioners [12].
Interestingly, several recent reports suggest that the incidence
of infectious complications after TRUS biopsy is increasing.
One study from Ontario, Canada [10], reported increasing rates
of hospitalizations within the 30-day period following TRUS
biopsy, from 1.0% in 1996 to 4.1% in 2005 (P < .0001). Of note,
more than two-thirds of postbiopsy hospitalizations were for
infection-related causes. Similarly, using data derived from
Medicare records [2], researchers from the United States also
described an increasing frequency of infectious complications
following TRUS biopsy, increasing from 0.4% in 1991 to 1.1%
in 2007 (P < .0001). The reasons for these reported increases in
postbiopsy infections are unclear, but suggested contributory
factors include rising rates of antimicrobial resistance and
changes in biopsy technique [2, 10].
PATHOPHYSIOLOGYANDCAUSATIVE
PATHOGENS OF POST–TRUS BIOPSY
INFECTIONS
Although no studies have clearly defined the pathophysiology
of post–TRUS biopsy sepsis, the primary mechanism is likely
to be direct inoculation of bacteria from the rectal mucosa
by the biopsy needle into the prostate, blood vessels, or urinary
tract. This is supported by high reported rates of bacteremia
(16%–75%) and bacteriuria (36%–53%) immediately postpro-
cedure in the absence of prophylactic antibiotics and the fact
that most infections manifest clinically within 3 days of TRUS
biopsy [13]. In addition, preexisting infection or inflammation
may also contribute to postbiopsy infections, although the
value of routine urine culture and prebiopsy treatment of
asymptomatic bacteriuria remains controversial. One study
Figure 1. A, Anatomy of the male genitourinary tract in relation to transrectal ultrasound–guided prostate biopsy. Graphic used with permission of
Terese Winslow. B, Typical biopsy apparatus consisting of ultrasound probe with a protective condom (gray handle) and spring-loaded sampling device
(beige handle).
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demonstrated a rate of febrile genitourinary infections of 27%
(3/11) among patients with asymptomatic bacteriuria pre-
biopsy compared to a rate of 0.9% (12/1322) among those with
negative prebiopsy urine cultures [14]. In another study,
however, none of 12 patients with asymptomatic bacteriuria
prebiopsy had infectious complications compared to 4 of 341
(1.2%) of those with negative urine prebiopsy cultures [15]. A
similar study also reported no infectious complications among
7 patients with prebiopsy asymptomatic bacteriuria compared
to infectious complications in 2 of 46 men (4.3%) with negative
prebiopsy urine cultures [16].
Causative Pathogens and Antimicrobial Resistance Profiles
The commonest pathogen implicated in post–TRUS biopsy
sepsis is E. coli, accounting for approximately 75%–90% of in-
fectious complications in published series (Table 1).
Over the past decade, antimicrobial-resistant E. coli has been
increasingly described in the setting of postbiopsy sepsis
(Table 1). To date, the most clinically significant resistance phe-
notypes described in E. coli following TRUS biopsy are fluoro-
quinolone resistance and/or production of an extended
spectrum β-lactamase (ESBL) (Table 1). Recent studies indicate
that approximately 11%–22% of men undergoing prostate bio-
psy harbor fluoroquinolone-resistant organisms within the rec-
tum prior to the administration of antimicrobials [13, 24–26].
In addition, a recent study found that the rate of fluoroquino-
lone-resistant E. coli in postbiopsy bloodstream infections was
62% [9], compared to 14% in nonbiopsy E. coli bloodstream
isolates from males in the same geographic setting (P < .001). A
strong association has been described between fluoroquino-
lone-resistant E. coli and sequence type (ST) 131 E. coli, a rela-
tively recently described lineage of phylogenetic group B2 [27].
This globally spread “pandemic” clone is notable for its ability
to harbor numerous genes associated with both antimicrobial
resistance and virulence [28]. Contemporary studies have indi-
cated that E. coli ST131 frequently makes up >50% of all fluoro-
quinolone-resistant E. coli isolated from UTIs [27]. Of note, a
recent study also found that ST131 E. coli accounted for 40% of
all E. coli bloodstream isolates after TRUS biopsy [9]. Similarly,
another study reported that 70% of fluoroquinolone-resistant
E. coli isolated from rectal swabs taken from men prior to pros-
tate biopsy belonged to the ST131 clone [24]. Given the report-
ed spread of this clone [27], it is likely that increasing
community transmission and resultant fecal carriage has con-
tributed to these reports of postbiopsy infections with ST131
E. coli.
ESBL-producing E. coli has also been increasingly identified
in case series of postbiopsy infections [18, 21, 29]. Of impor-
tance in the setting of postbiopsy sepsis is the strong association
between ESBL production and fluoroquinolone resistance in
E. coli. The rate of coresistance to fluoroquinolones among
ESBL-producing E. coli ranges from 50% to 100% [30]. Conse-
quently, the preceding use of fluoroquinolone antimicrobials is
a significant risk factor for subsequent ESBL-producing E. coli
infection [31, 32]. This is relevant when considering the current
recommendations to use fluoroquinolones as prophylactic
agents prior to TRUS biopsy [33]. In addition to selecting for
fluoroquinolone-resistant E. coli that may be harbored in the
gastrointestinal tract prebiopsy, the use of prophylactic fluoro-
quinolones may also coselect for ESBL-producing E. coli.
Aminoglycoside resistance is another important resistance phe-
notype, commonly encountered alongside fluoroquinolone
resistance and ESBL production [27]. Awareness of aminogly-
coside resistance is important when considering the appropri-
ate choice of empiric treatment for patients presenting to
hospital with post–TRUS biopsy infections, particularly given
that some recent guidelines advocate aminoglycosides for the
empiric treatment of urosepsis [34, 35].
POTENTIAL RISK FACTORS FOR POST–TRUS
BIOPSY INFECTIONS
In view of the increasing burden on healthcare services result-
ing from post–TRUS biopsy infections [36], several recent
studies have attempted to identify both patient and procedural
factors that may predict which men are at greatest risk of infec-
tious complications [2, 11, 20, 22]. Patient-specific risk factors
identified include underlying medical comorbidities, particu-
larly diabetes mellitus, and recent hospitalization [2, 22]. For
example, one recent study [22] observed that patients who had
been hospitalized in the month preceding TRUS biopsy were
significantly more likely to be hospitalized with urosepsis post-
biopsy than those without a history of hospitalization (odds
ratio, 8.63; 95% confidence interval [CI], 1.48–50.4; P = .02).
Preexisting urological pathology may also increase the risk of
postbiopsy infections. One study noted that patients with long-
term urethral catheters were significantly more likely to develop
an infectious complication postbiopsy compared to patients
without catheters (19.2% vs 3.06%; P < .0001) [20]. However,
data regarding the role of other urological abnormalities in pre-
disposing to infections are conflicting and reports of associations
with prebiopsy prostate size and preexisting prostatic malignan-
cy have been inconsistent in their findings [11, 22, 37]. Similar-
ly, no procedural factors have been specifically identified as risk
factors for post–TRUS biopsy infections. Although one study
found that an increased number of cores taken during the
biopsy procedure was associated with postbiopsy infection [20],
other studies have not confirmed this association [22, 37]. In
addition, having a second TRUS biopsy procedure has not been
associated with an increased risk of postbiopsy infection [20].
In one instance, contamination of equipment used to perform
TRUS biopsy was implicated as a causal factor in an outbreak
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of postbiopsy infections, although in this case, the causative
pathogen was Pseudomonas aeruginosa [38].
Several studies have also attempted to assess possible risk
factors specifically for post–TRUS biopsy infection with anti-
microbial-resistant E. coli. Although only reported from
smaller cohorts to date, evidence supports the link between
postbiopsy sepsis with a fluoroquinolone-resistant E. coli and
receipt of a fluoroquinolone antimicrobial in the months
preceding biopsy [17, 21]. Moreover, the link between prior
fluoroquinolone exposure, colonization with fluoroquinolone-
resistant E. coli, and subsequent postbiopsy infection with
fluoroquinolone-resistant E. coli has also recently been
demonstrated [25]. In addition, travel to areas with a high prev-
alence of resistant pathogens has also recently been associ-
ated with post–TRUS biopsy sepsis due to ESBL-producing
E. coli [21, 29].
Table 1. Published Series of Microbiologically Confirmed Post–Transrectal Ultrasound-Guided Prostate Biopsy Infections Since 2009
Study Location
TRUS
Biopsies,
No.
Confirmed
Infections,a
No. (%)
Organisms Isolated on
Culture, No.
Fluoroquinolone-Resistant
Organisms, No. (%)
Additional Susceptibility
Data, No. (%)
Young et al [17] US 1423 5 (0.4) Escherichia coli: 5/5 5/5 (100) ESBL: 3/5 (60)
Gentamicin resistant:
1/5 (20)
Hadway et al [16] UK 256 7 (2.7) E. coli: 5/7
Citrobacter freundii:
1/7 Proteus spp: 1/7
7/7 (100) ESBL E. coli: 3/5 (60)
ESBL C. freundii:
1/1 (100)
Horcajada et al
[18]
Spain 411 11 (2.7) E. coli: 8/11
Klebsiella pneumoniae:
2/11
Morganella morganii:
1/11
6/11 (55)
(all organisms collated)
4/11 ESBL (36)
(all organisms collated)
Lange et al [19] Canada 4749 16 (0.3) E. coli: 16/16 16/16 (100) 3rd-generation
cephalosporin resistant:
2/16 (13)
Gentamicin resistant:
3/16 (19)
Simsir et al [20] Turkey 2033 62 (3.0) E. coli: 46/62
K. pneumoniae: 9/62
Psuedomonas
aeruginosa: 6/62
CoNS 1/62
E. coli: 3/46 (7)
K. pneumoniae: 3/9 (33)
P. aeruginosa: 2/6 (33)
Not reported
Zaytoun et al [8] US 1446 9 (0.6) E. coli: 7/9
Micrococcus spp: 1/9
Staphylococcus
aureus: 1/9
E. coli: 4/7 (57) ESBL E. coli: 0/7 (0)
Gentamicin resistant:
1/7 (14)
Patel et al [21] UK 316 10 (3.2) E. coli: 10/10 E. coli: 10/10 (100) Gentamicin resistant:
3/9 (33)
(1 isolate not tested)
Loeb et al [11] Netherlands 10 474 72 (0.7) E. coli: 63/72
P. aeruginosa:
6/72 Klebsiella
oxytoca: 2/72
Enterococcus faecalis:
1/72
14% blood isolates
6% urine isolates
(all organisms collated)
Not reported
Carignan et al
[22]
Canada 5798 48 (0.8) E. coli: 36/48
Enterobacter spp:
3/48
Citrobacter spp: 3/48
GPC: 6/48
For all Enterobacteriaceae
tested:
20/42 (48)
For all Enterobacteriaceae
tested:
Gentamicin resistant:
9/41 (22)
3rd-generation
cephalosporin resistant:
2/28 (7)
Carmignani et al
[23]
Italy 447 9 (2.0) E. coli: 8/9
Aeromonas spp: 1/9
E. coli: 7/8 (88) ESBL: 6/8 (75)
Abbreviations: CoNS, coagulase-negative staphylococci; ESBL, extended-spectrum β-lactamase; GPC, gram-positive cocci; TRUS, transrectal ultrasound.
a Definition of confirmed infection is positive bacterial growth from urine or blood with accompanying clinical symptoms.
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PREVENTION OF INFECTIOUS COMPLICATIONS
AFTER TRUS BIOPSY
Antimicrobial Prophylaxis
Strong evidence exists to support the use of antimicrobial pro-
phylaxis prior to TRUS biopsy [4–6]. However, wide variability
in practice with respect to both the choice and duration of pro-
phylaxis has been reported [39]. A recent systematic review of
relevant studies concluded that antimicrobial prophylaxis was
effective in preventing infectious complications following pros-
tate biopsy, with risk ratios (RRs) favoring prophylaxis for bac-
teriuria (RR, 0.25; 95% CI, .15–.42), bacteremia (RR, 0.67; 95%
CI, .49–.92), fever (RR, 0.39; 95% CI, .23–.64), UTI (RR, 0.37;
95% CI, .22–.62), and hospitalization (RR, 0.13; 95% CI,
.03–.55) [40]. Data were analyzed separately for fluoroquino-
lones, sulphonamides, and other antibiotic classes. All agents
were effective vs placebo, but most data supported the use of
fluoroquinolones [40]. Fluoroquinolones are particularly useful
in this setting due to their broad spectrum of activity against in-
testinal flora and high prostatic tissue levels obtained after oral
administration [41]. In addition, fluoroquinolones are recom-
mended as first-line prophylactic agents prior to TRUS biopsy
in current guidelines [33–35]. No conclusive data have been
found to support either the use of long-course (3 days) over
short (1 day) fluoroquinolone regimens, or multiple vs single-
dose schedules [40]. The equivalence of single-dose ciprofloxa-
cin to that of longer regimens has also been more recently
reported in a large US study [42].
Role of Targeted Antimicrobial Prophylaxis
In view of increasing rates of fluoroquinolone resistance in E.
coli in many countries and the frequent isolation of such organ-
isms in cases of postbiopsy sepsis, a key question is whether
universal use of prophylactic fluoroquinolones will remain an
appropriate recommendation. Rather than a “one size fits all”
model, recent data suggest that a tailored approach to prophy-
laxis may be more clinically useful and cost-effective. The role
of prebiopsy screening for resistant pathogens, followed by
culture-directed antimicrobial prophylaxis, has been assessed
in several recent studies [25, 43]. In particular, it is suggested
that prebiopsy screening for fluoroquinolone-resistant E. coli
may allow identification of those men harboring such organ-
isms in their endogenous gastrointestinal flora prebiopsy, and
for whom fluoroquinolone prophylaxis may not be appropriate
[44]. One recent prospective study observed infectious compli-
cations in 9 of 345 (2.6%) men who received empiric fluoro-
quinolone prophylaxis prebiopsy, compared to 0 of 112 men
who underwent prebiopsy screening for fluoroquinolone-resis-
tant pathogens and “directed” prophylaxis with alternative
agents such as cephalosporins or trimethoprim-sulfamethoxa-
zole [43]. Of note, these authors suggested that this targeted
approach to prophylaxis resulted in a cost benefit to their insti-
tution [43].
Adjunctive Measures to Antimicrobial Prophylaxis
The role of adjunct measures in preventing postbiopsy
infections remains controversial. In particular, the role of pre-
biopsy rectal cleansing enemas has been recently assessed [40].
The rationale for enema use is to reduce the rectal microbial
burden prebiopsy and hence lessen the bacterial inoculum in-
troduced during the biopsy procedure. To date, however, no
significant differences have been found between “antibiotic”
and “antibiotic + enema” groups [40]. Currently, enema use in
this context is not routinely recommended in European guide-
lines, but use of this practice may be more common in the
United States, where American Urological Association guide-
lines advise “physician discretion” in their use [33]. In addition,
rectal disinfection with agents such as chlorhexidine or povi-
done-iodine has been proposed as another potential adjunct to
antibiotic prophylaxis, although data supporting the efficacy of
such approaches are currently limited [13]. It is possible that in
the face of the increasing antimicrobial resistance, more re-
search into this intervention may prove worthwhile.
MANAGEMENTOF INFECTIOUS
COMPLICATIONS AFTER TRUS BIOPSY
At present, there are no published guidelines for the manage-
ment of post–TRUS biopsy infections. However, in addition to
patient-specific prophylactic regimens, consideration should be
given to tailored empiric antimicrobial therapy if a patient pre-
sents with postbiopsy sepsis. Previous studies have demonstrat-
ed that inappropriate empiric therapy of E. coli bloodstream
infections is associated with an increased risk of mortality [32].
Of note, a recent study suggested that receipt of inappropriate
empiric therapy in the setting of post–TRUS biopsy sepsis is
not uncommon. In this study, among 47 men presenting with
postbiopsy E. coli bacteremia, approximately one-third received
inappropriate empiric therapy, including 12 men who required
admission to the ICU [9]. These authors suggested that
in their setting, recent TRUS biopsy was actually a risk factor for
bacteremia with multidrug-resistant E. coli. Therefore, broader-
spectrum empiric antimicrobial coverage should be con-
sidered for post–TRUS biopsy sepsis compared to that given
for other causes of community-onset urosepsis. Moreover, as
discussed above, other individual risk factors that should be
considered when choosing appropriate empiric therapy
include prior exposure to fluoroquinolones and a history of
recent travel to areas with high endemicity for resistant organ-
isms [21, 29].
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FUTURE RESEARCHDIRECTIONS
Several issues remain unresolved in the prevention and treat-
ment of post–TRUS biopsy infections. Although initial
studies indicate the possible clinical and economic benefits
of a tailored approach to prophylaxis, a number of methodo-
logical, logistical, and pharmacological questions remain
unclear. The optimal laboratory screening methodology for
detecting clinically meaningful populations of resistant path-
ogens is not yet established, with published studies utilizing
a variety of methods [43, 45]. In addition, the optimal dura-
tion between prebiopsy screening and biopsy is uncertain,
but in order to be clinically useful, a prebiopsy screen must
be taken at a sufficient time beforehand to allow culture and
susceptibility results to become available. Furthermore, the
most appropriate choice of alternative prophylactic agent(s)
should be considered, and must take into account relevant
pharmacokinetic and pharmacodynamic parameters, particu-
larly penetration into prostatic tissue and postantibiotic
effect. At present, data are lacking to guide choice of alterna-
tive agents to fluoroquinolones, although some data suggest that
agents such as amikacin [46] and piperacillin/tazobactam [47]
may have utility. In addition, preliminary data suggest that fos-
fomycin may be of benefit in preventing postbiopsy infections,
particularly in patients who harbor fluoroquinolone-resistant
E. coli [48].
Apart from antimicrobial prophylaxis strategies, another
potentially useful strategy to decrease post–TRUS biopsy in-
fections may be to increase utilization of the transperineal
route, whereby tissue is sampled transcutaneously across the
perineal skin, rather than the rectal mucosa. Currently, this
approach is used primarily for men with >1 previous nega-
tive TRUS biopsy in the context of a persistently elevated
PSA [49]. Recent data suggest that efficacy of cancer detec-
tion is equivalent to that of TRUS biopsy and, importantly,
that infectious complications are no higher than with TRUS
biopsy, even in the absence of prophylactic antimicrobi-
als [49, 50]. Given that the risk of TRUS-biopsy sepsis is un-
likely to be completely ameliorated, the overall risks and
benefits to each individual patient prior to performing a
TRUS biopsy should also be assessed. Important factors to
consider include concomitant comorbid conditions, antici-
pated life expectancy, and suitability for subsequent treat-
ment of any underlying malignancy. Furthermore, as
illustrated by the recent debate about the overall impact of
PSA screening on clinical outcomes and survival in asymp-
tomatic men [51], optimization of the use of biomarkers in
identifying those men at greatest risk of morbidity and mor-
tality from prostate malignancy is required. Potentially newer
biomarkers may allow better prediction of men who may
receive the greatest potential benefit from TRUS biopsy [52].
CONCLUSIONS
Although infrequent, infectious complications following
TRUS-guided prostate biopsy can result in potentially life-
threatening complications. Given the large number of biopsies
performed annually, the population and economic burden of
postbiopsy sepsis is substantial, and is underestimated by
studies assessing only hospitalized patients. Post–TRUS biopsy
infections caused by resistant E. coli are an increasingly en-
countered clinical problem that pose a practical challenge to cli-
nicians attempting to determine the most appropriate
prophylactic and empiric therapy regimens. As multidrug-re-
sistant E. coli increases in prevalence globally, further studies
are required to investigate the utility of prebiopsy screening for
resistant E. coli and the role of individualized decision making
in the prevention and treatment of postbiopsy infections.
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Sir,
The global spread of New Delhi metallo-b-lactamase (NDM)-
producing Enterobacteriaceae is of significant public health
concern.1 To date, NDM-producing Enterobacteriaceae have been
isolated from numerous geographical regions, including Europe,
North America, Australia and New Zealand.1 In addition to hydro-
lysing carbapenems, NDM-producing organisms display resistance
to a broad range of antimicrobial classes, primarily due to the pres-
ence of additional acquired plasmid-associated resistance genes.2
As a result, infections caused by these organisms pose a consider-
able therapeutic challenge.
Transrectal ultrasound (TRUS)-guided prostate biopsy is a
commonly performed urological outpatient procedure, with
1000000 biopsies performed annually in the USA.3 A variety
of infectious complications have been reported following TRUS
biopsy, ranging from urinary tract infection through to bacter-
aemia and sepsis.3,4Of note, the incidence of infectious complica-
tions following TRUS biopsy is reportedly increasing, with clinical
and economic consequences.3,5 The most common pathogen in
the setting of post-biopsy sepsis is Escherichia coli, with causative
strains probably originating from the patient’s own endogenous
flora. Over the past decade, the prevention and management of
TRUS-biopsy infections due to E. coli has become more compli-
cated due to increasing antimicrobial resistance in this organism.
Currently, the most common resistance profiles encountered in
this setting are fluoroquinolone resistance and/or extended-
spectrum b-lactamase (ESBL) production.3,6 Recent studies
suggest that pre-biopsy screening for such resistant pathogens
with subsequent ‘tailored’ prophylaxis based on antimicrobial sus-
ceptibility results may be an effective way to reduce infectious
complications.3,7 To date, however, there are no reports describing
pre-TRUS biopsy isolation of carbapenemase-producing E. coli.
Here, we describe the isolation of NDM-1-producing E. coli from a
patient undergoing rectal screening prior to TRUS biopsy.
In early 2013, an elderly New Zealand male attended the
urology outpatient clinic for a pre-biopsy rectal screen. A TRUS
biopsy 15 months earlier had demonstrated the presence of low-
grade prostatic carcinoma, and the patient was being monitored
by regular measurement of prostate-specific antigen (PSA) levels
and outpatient clinic assessments. In order to assess possible pro-
gression of his carcinoma, a repeat biopsy was recommended. In
the month before attending for pre-biopsy rectal screening, the
patient had returned from visiting relatives in India. He had no
known healthcare contact during this trip.
Rectal screening for pre-TRUS biopsy carriage of fluoroqui-
nolone-resistant E. coli was introduced in Auckland City Hospital,
NewZealand inMarch2012.Wherepossible, rectal swabsobtained
from patients pre-TRUS biopsy are incubated aerobically overnight
in MacConkey broth containing 1 mg/L ciprofloxacin. Isolates
growing in this broth are then subcultured onto MacConkey agar
containing 1 mg/L ciprofloxacin. Any E. coli isolates growing after
24 h are identified using the Bruker MALDI-TOF system, and anti-
microbial susceptibility testing is performed using agar dilution
according to CLSI guidelines.8
The patient’s pre-biopsy rectal swab grew a fluoroquinolone-
resistant E. coli that was also resistant to penicillins, extended-
spectrum cephalosporins, carbapenems, piperacillin/tazobactam,
aztreonam, aminoglycosides and trimethoprim/sulfamethoxazole.
The isolate tested susceptible to fosfomycin and nitrofurantoin.
Double-disc synergy testing using meropenem or ertapenem with
either EDTA or dipicolinic acid as inhibitors was positive, but the
modified Hodge test was negative. PCR analysis and DNA sequen-
cing demonstrated the presence of the blaNDM-1 and blaCTX-M-15
genes. In addition, the isolate was also found to harbour the
aac-6′-Ib and rmtC genes. Multilocus sequence typing (MLST) ana-
lysis was performed as previously described (http://mlst.ucc.ie/
mlst/dbs/Ecoli), and revealed sequence type (ST) 101.
Given the risk of a post-biopsy infection with extremely limited
treatment options, along with the patient’s advanced age and
the low-grade nature of his carcinoma, a decision was made not
to proceed with biopsy.
This case illustrates the increasinglycomplexchallenges caused
byantimicrobial resistance in the context of TRUS biopsy. Although
for many patients colonized with fluoroquinolone-resistant E. coli,
pre-biopsy screening and ‘targeted’ prophylaxis may be a useful
preventative strategy,7,9 for patients colonized with extremely
resistant organisms such as NDM-producing E. coli, options for
targeted prophylaxis and potential treatment may be so limited
that the benefit of proceeding with biopsy may itself need to be
called into question. Although fosfomycin has shown initial efficacy
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in preventing post-TRUS biopsy infections with antimicrobial-
resistant pathogens, susceptibility of NDM-producing Entero-
bacteriaceae to fosfomycin remains variable.10 Given the global
dissemination of blaNDM-producing Enterobacteriaceae, coupled
with the large number of TRUS biopsies performed inmany regions,
it seems inevitable that these organismswill continue tobe isolated
inthesettingofTRUSbiopsy-relatedsepsis.Accordingly,apragmatic
approachtoundertakingTRUSbiopsyseems indicated, includingnot
only a tailoring of prophylaxis based on the patient’s colonization
status, but also a careful reassessment of the overall net benefit
and clinical utility of the procedure itself, particularly in patients
found to be colonized with highly resistant pathogens such as
NDM-producing E. coli.
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Australia has never permitted fluoroquinolone use in food-producing animals. We examined local
retail poultry for contamination with fluoroquinolone non-susceptible Escherichia coli, then
explored the hypothesis that their presence may be due to co-selection of resistance
determinants. Between August and November 2010, samples from 30 locally produced,
uncooked retail poultry carcasses from four different processing centres underwent selective
enrichment culture for ciprofloxacin non-susceptible E. coli. Their chromosomal- and plasmid-
mediated resistance determinants were characterized, and phylogenetic analysis and
transformation experiments were performed. Unexpectedly, we found nine (30%) of our small
collection of poultry samples carried fluoroquinolone non-susceptible E. coli of which nearly half
possessed aac(6’)-Ib-cr, a novel plasmid-mediated gene encoding an aminoglycoside acetylating
enzyme that also confers fluoroquinolone resistance. All nine isolates were co-resistant to
amoxicillin, gentamicin, tetracycline and trimethoprim/sulfamethoxazole – all antibiotic classes that
are registered for use in poultry reared for food production within Australia. Their unique
phylogenetic relatedness suggested clonal dissemination driven by non-fluoroquinolone selective
pressures. aac(6’)-Ib-cr was successfully transformed and selected for using non-fluoroquinolone
antibiotic pressure. Vertical and perhaps horizontal co-selection may be contributing to the
emergence of fluoroquinolone resistance in poultry and could play a similar role in the human
setting. This suggests that preservation of the usefulness of fluoroquinolones may require more
than just restriction of their use in isolation from other interventions.
INTRODUCTION
Antimicrobial use in food-producing animals combined
with faecal contamination from animals during processing
of carcasses may contribute to transmission of resistant
pathogens and/or resistance determinants from animals to
humans (Cheng et al., 2012; JETACAR, 2009). This is of
particular concern for fluoroquinolones, which are critical
to human health yet are one of the classes of antimicrobial
most commonly used in veterinary medicine (Forcella
et al., 2010). Australia is in the unique position of never
having permitted fluoroquinolone use in food-producing
animals (JETACAR, 2009). Preliminary findings from
our group suggested the prevalence of fluoroquinolone
non-susceptible Escherichia coli in Western Australian retail
poultry samples was significantly higher than the 0%
previously reported in 2007 (Barlow & Gobius, 2008). In
the absence of selective pressure due to fluoroquinolone
use, we explored the hypothesis that this may be due to co-
selection of resistance determinants.
METHODS
Between August and November 2010, 30 locally produced, uncooked
retail poultry carcasses were obtained from four Western Australian
processing centres and rinsed with 500 ml peptone water. Fifty
millilitres of rinse fluid was added to 50 ml double-strength E. coli
broth and incubated at 44 uC overnight. A 500 ml sample of this broth
was spread evenly onto MacConkey agar containing 1 mg ciproflox-
acin ml21 and incubated overnight at 37 uC. Presumptive E. coli wereAbbreviation: rep-PCR, repetitive element palindromic-PCR.
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randomly selected and then identified using standard methods. MIC
values were determined by Etest (AB Biodisk; bioMe´rieux) and
interpreted using Clinical and Laboratory Standards Institute criteria
(CLSI, 2010). For all ciprofloxacin non-susceptible isolates, PCR and
sequencing of gyrA, gyrB, parC and parE genes were performed as
described previously (Komp Lindgren et al., 2003). A multiplex PCR
was used to screen for isolates with qnrA, qnrB and qnrS (Robicsek
et al., 2006b). PCR was used to detect isolates containing qepA1,
qepA2 and aac(6’)-Ib (Wang et al., 2003). The aac(6’)-Ib-cr variant (a
novel plasmid-mediated gene encoding an aminoglycoside acetylating
enzyme that also confers fluoroquinolone resistance) was detected by
sequencing the aac(6’)-Ib gene (Park et al., 2006). Phylogenetic
grouping was determined with multiplex PCR (Clermont et al., 2000).
Genetic relatedness was investigated using repetitive element
palindromic-PCR (rep-PCR) (DiversiLab; bioMe´rieux). Plasmid
mobility was determined by transformation. Plasmids purified by
alkaline lysis were electroporated into E. coli DH10B using a
previously described method, modified by use of selective medium
containing 4 mg gentamicin l21 (Sidjabat et al., 2009).
RESULTS AND DISCUSSION
Ciprofloxacin non-susceptible E. coli were isolated from
nine (30%) of the 30 poultry carcasses (originating from
three of the four processing plants). The ciprofloxacin MIC
for all nine isolates was .32 mg l21. Each isolate
demonstrated an identical susceptibility profile, namely
non-susceptibility to amoxicillin, tetracycline, trimetho-
prim/sulfamethoxazole and gentamicin, but susceptibility
to ceftriaxone and ceftazidime. All the isolates had the same
chromosomal mutations known to be associated with
fluoroquinolone non-susceptibility including those within
gyrA (S83L, D83N) and parC (S80I, E84G), but not gyrB or
parE. Four isolates possessed the aac(6’)-Ib-cr variant. No
qnr or qepA plasmid-mediated quinolone resistance was
detected. Two ciprofloxacin non-susceptible isolates (WA
CH1, WA CH2) were selected for transformation experi-
ments (Table 1). These results demonstrated that genes
encoding amoxicillin, tetracycline and trimethoprim/
sulfamethoxazole resistance were co-located on the same
plasmid as genes encoding aminoglycoside resistance; these
genes could be passed horizontally between E. coli strains
and then be selected out in the presence of an aminoglyco-
side. When present, the aac(6’)-Ib-cr variant was also
shown to be co-located on the same plasmid. This variant
was subject to the same horizontal transfer and selection
processes in the absence of a fluoroquinolone. All nine
isolates belonged to phylogenetic group D and showed a
high degree of genetic relatedness (Fig. 1). All nine
appeared unrelated to four ciprofloxacin-susceptible iso-
lates from the same cohort of retail poultry samples.
Fluoroquinolone non-susceptible E. coli have been detected
from poultry in countries in which fluoroquinolone use is
currently, or has previously been permitted in the rearing
of food-producing animals. This includes the USA
(Johnson et al., 2007), Europe (0–4% of isolates) (Gyles,
2008), Iran (42%) (Moniri & Dastehgoli, 2005) and
Nigeria (55%) (Fortini et al., 2011), although, to our
knowledge, aac(6’)-Ib-cr has only ever been detected in
retail poultry from China (Huang et al., 2009). Thus, our
finding of a comparatively high rate (30%) of ciproflox-
acin non-susceptible E. coli [nearly half of which possessed
the aac(6’)-Ib-cr gene] in poultry without prior fluoroquin-
olone exposure was unexpected.
Contamination of carcasses with human faecal flora from
poultry processors is unlikely since all nine isolates had a
unique antibiotic susceptibility profile that is dissimilar to
isolates causing community-onset E. coli human infections
in Australia (Pearson et al., 2007). All nine were genetically
closely related and hence unlikely to have resulted from
contamination at three separate poultry processing centres.
Surreptitious veterinary use of fluoroquinolones is unlikely
because Australia has strict regulatory control over antibiotic
use in animals (JETACAR, 2009). A national study of antibiotic
consumption demonstrated no evidence of quinolone use in
stock feed between 1992 and 1997 (JETACAR, 2009).
A more plausible explanation for our findings is co-selection
due to the use of non-fluoroquinolone antimicrobials in
Table 1. Antimicrobial MIC testing and molecular characterization of quinolone resistance determinants in the parent and
transformant isolate
Study isolate WA CH2 WA CH1
Parent Transformant Parent Transformant
Phenotype (MIC, mg l21)
Gentamicin .16 .16 .16 .16
Amoxicillin .256 .256 .256 .256
Tetracycline .256 .256 .256 .256
Trimethoprim/sulfamethoxazole .32 .32 .32 .32
Ciprofloxacin .32 ,0.002 .32 0.047
Genotype
gyrA (S83L, D83N), parC (S80I, E84G) Yes No Yes No
aac(6’)-Ib Yes Yes Yes Yes
aac(6’)-Ib-cr No No Yes Yes
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food-producing animals (Fortini et al., 2011; Gyles, 2008).
All nine isolates demonstrated co-resistance to antibiotic
classes that are registered for therapeutic or prophylactic
use in poultry reared for food production within Australia
(JETACAR, 2009). Co-selection may be driven by one of
twomechanisms. Firstly, a single resistancemechanism [e.g.
aac(6’)-Ib-cr or a multi-drug efflux pump] may confer
resistance to multiple antibiotic classes concurrently.
Secondly, two different antibiotic resistance determinants
(usually co-located) may be vertically or horizontally
passed between bacterial isolates. The unique genetic
relatedness of all nine isolates suggests that dissemination
of chromosomal quinolone resistance determinants is a
clonal phenomenon (vertical co-selection), although the
origins of this clone are unknown. Our transformation
experiments demonstrate that dissemination of plasmid-
mediated quinolone resistance determinants such as
aac(6’)-Ib-cr may also occur in the context of non-
fluoroquinolone selective pressure (horizontal co-selec-
tion). Although acquisition of aac(6’)-Ib-cr confers only a
minor rise in fluoroquinolone MIC, it may promote
subsequent mutations that confer high-level resistance
(Robicsek et al., 2006a). Plasmid heterozygosity may
explain why only some isolates appeared to carry the
aac(6’)-Ib-cr variant (Novick & Richmond, 1965).
Co-selection has been proposed as an explanation for the
emergence of fluoroquinolone resistance in Gram-nega-
tive bacteria in both humans (Park et al., 2006) and
animals (Gyles, 2008). However, in these studies, the
relative contribution of co-selection versus direct selective
pressure has been difficult to discern in the context of
active fluoroquinolone use. As our study was performed
in a country that has never permitted fluoroquinolone use
in food-producing animals, our results suggest that
vertical and perhaps horizontal co-selection may be
contributory forces behind the emergence of fluoroqui-
nolone resistance. This necessitates a re-evaluation of the
mechanisms contributing to this problem, and our
attempts to address it. If co-selection does explain our
findings, then efforts to preserve the long-term future of
fluoroquinolones, whether in animals or humans, may
require more than just restriction of their use in isolation
from other interventions.
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Fig. 1. Dendrogram showing results of rep-PCR typing of the nine ciprofloxacin non-susceptible E. coli isolates (WA CH1, -2,
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Escherichia coli sequence type 131 (ST131) is a globally dissemi-
nated, multidrug resistant (MDR) clone responsible for a high pro-
portion of urinary tract and bloodstream infections. The rapid
emergence and successful spread of E. coli ST131 is strongly asso-
ciated with several factors, including resistance to fluoroquino-
lones, high virulence gene content, the possession of the type 1
fimbriae FimH30 allele, and the production of the CTX-M-15 ex-
tended spectrum β-lactamase (ESBL). Here, we used genome se-
quencing to examine the molecular epidemiology of a collection of
E. coli ST131 strains isolated from six distinct geographical loca-
tions across the world spanning 2000–2011. The global phylogeny
of E. coli ST131, determined from whole-genome sequence data,
revealed a single lineage of E. coli ST131 distinct from other extra-
intestinal E. coli strains within the B2 phylogroup. Three closely
related E. coli ST131 sublineages were identified, with little as-
sociation to geographic origin. The majority of single-nucleotide
variants associated with each of the sublineages were due to
recombination in regions adjacent to mobile genetic elements
(MGEs). The most prevalent sublineage of ST131 strains was char-
acterized by fluoroquinolone resistance, and a distinct virulence
factor and MGE profile. Four different variants of the CTX-M
ESBL–resistance gene were identified in our ST131 strains, with
acquisition of CTX-M-15 representing a defining feature of a dis-
crete but geographically dispersed ST131 sublineage. This study
confirms the global dispersal of a single E. coli ST131 clone and
demonstrates the role of MGEs and recombination in the evolution
of this important MDR pathogen.
bacterial evolution | genomics | phylogeography | genomic epidemiology
Many multidrug-resistant (MDR) bacterial strains are nowrecognized as belonging to clones that originate in a spe-
cific locale, country, or even globally. Escherichia coli sequence
type 131 (ST131) is one such recently emerged and globally
disseminated MDR pandemic clone responsible for community
and hospital-acquired urinary tract and bloodstream infections.
E. coli ST131 was identified in 2008 as a major clone linked
to the spread of the CTX-M-15 extended-spectrum β-lactamase
(ESBL) resistance (1–3). Since then, E. coli ST131 has also been
strongly associated with fluoroquinolone resistance, and core-
sistance to aminoglycosides and trimethoprim-sulfamethoxazole
(4–6). Alarmingly, strains of E. coli ST131 resistant to carbape-
nems have also been reported (7, 8), further limiting treatment
options for this clone.
E. coli ST131 belongs to the B2 phylogenetic subgroup I, with
most isolates characterized as serotype O25b:H4 (1). Epidemi-
ology studies using pulse-field gel electrophoresis (PFGE) have
demonstrated that E. coli ST131 strains exhibit diversity, with
some dominant PFGE pulsotypes including the UK epidemic
strain A (9) and pulsotype 968 (10, 11) widely distributed across
the globe. More recently, a typing scheme using the type 1 fim-
briae fimH adhesin gene revealed that a large subclonal lineage
of E. coli ST131 strains possess the FimH30 allele, which is also
associated with specific mutations in the gyrA and parC genes
that confer resistance to fluoroquinolones (12).
Several whole genome (13–16) and PCR (1, 17–20) studies
have revealed that E. coli ST131 strains possess a variable
complement of genes encoding established virulence factors
commonly associated with extraintestinal pathogenic E. coli
(ExPEC). Indeed, few virulence genes appear to be uniformly
present in E. coli ST131 and, thus, it is likely that differences
in virulence gene content contribute to the variable virulence
potential that has been reported. For example, although some
ST131 strains cause rapid death in a mouse sepsis infection
model (21), this phenotype is not consistent among all strains
(22). The E. coli ST131 strain EC958, which is a representative
of the FimH30-fluoroquinolone resistant subgroup, has been
characterized at the molecular level (15). E. coli EC958 contains
an insertion in the type 1 fimbriae regulator gene fimB (15) that
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is also common to other strains in the FimH30 subgroup (23)
and colonizes the mouse bladder in a type 1 fimbriae-dependent
manner (15). In mice, E. coli EC958 establishes acute and chronic
urinary tract infection (UTI), forms intracellular bacterial com-
munities in the bladder (24), and causes impairment of ureter
contractility (25). E. coli EC958 is also resistant to the bactericidal
action of human serum (26).
The rapid global dissemination of E. coli ST131, combined
with its MDR phenotype and the lack of new antimicrobial drugs
in the developmental pipeline, highlights the urgent need to un-
derstand this pathogen and combat its spread. Here, we sequenced
the genomes of 95 E. coli ST131 strains from six geographical
regions (isolated from 2000 to 2011) to examine the spatial and
temporal relationships of E. coli ST131. Our data supports the rapid
and recent global dispersal of E. coli ST131 as a single clone.
Results and Discussion
A Global Collection of E. coli ST131 Strains. A collection of 99 E. coli
strains defined as ST131, using a described PCR test specific
for the O25b rfb gene and allele 3 of the pabB gene (27), were
isolated between 2000 and 2011 from six countries (Australia,
Canada, India, Spain, United Kingdom, New Zealand) (Dataset
S1). The strains were obtained from several clinical sources and
included isolates from urine (n = 53), blood (n = 21), peritoneal
fluid (n = 1), abdominal abscess (n = 1), surgical wound (n = 2),
and rectal swabs (n = 11). The strains were selected with an
endeavor to encompass diversity with respect to geographic or-
igin, date of isolation, and clinical source. The strains possessed
a range of antibiograms, including variable resistance to ami-
noglycosides, second and third generation cephalosporins, fluo-
roquinolones, penicillins, and sulfonamides (Dataset S1). All
strains were sequenced by using the Illumina HiSeq, assembled
using Velvet, and in silico multilocus sequence typing (MLST)
was performed to confirm the sequenced strains were ST131.
Four strains originally defined as ST131 by rfb and pabB PCR
actually belonged to ST95 (Dataset S1), thus reducing the final
number of ST131 strains examined to 95.
Rapid Global Dispersal of E. coli ST131 as a Single Clone. Phylo-
genetic analysis of the 95 E. coli ST131 strains was carried out
by using whole genome alignment and single-nucleotide poly-
morphism (SNP) analysis using the completely sequenced ST131
representative strain SE15 (13). A maximum likelihood (ML)
tree built using all 142,750 SNPs confirmed that all ST131 strains
belonged to phylogroup B2, subgroup I and showed that ST131
clustered into three well-supported clades that we refer to as
A, B, and C (SI Appendix, Fig. S1A). ML trees based on the
3,186,979-bp core alignment of the assembled sequence data
supported this topology (SI Appendix, Fig. S2A). Recombination
is the primary contributor to interclade diversity with only 70
nucleotide substitutions found to distinguish clades B and C
after removal of recombinant regions (Fig. 1A and Dataset S2).
Neither temporal nor geographical clustering between the major
clades could be observed (Fig. 1A); however, each clade is
comprised of at least two well-supported sublineages and smaller
clusters of closely-related strains that exhibit some geographical
association (Fig. 1B and Dataset S2). This data suggested an
evolutionary history more complex than a standard geographical
clonal expansion, as exemplified by many occurrences of nearly
identical strains isolated in different countries and continents
and over different periods of time. Similar phylogeographic
patterns have been observed for other successful MDR global
lineages such as Staphylococcus aureus ST239 and the PMEN1
pneumococcal lineages (28, 29), whereas a contrasting exam-
ple of clonal expansion with more defined geographical clus-
tering has been reported for Shigella sonnei (30).
ST131 clade A contains the previously-sequenced SE15 strain
and is the most divergent clade (∼7,000 and ∼8,900 SNPs from
clades B and C, respectively) characterized by the fimH41 allele
and different gyrA and parC variants. ST131 clade B is very similar
to clade C (distinguished by ∼2,900 SNPs) and is characterized by
an intact fimB, the fimH22 allele, and gyrA and parC variants that
are consistent with their fluoroquinolone sensitivity (Fig. 1A and
Dataset S1). ST131 clade C strains make up 79% of the ST131
strains sequenced in this study and are distinguished by possession
of the fimH30 allele and the fluoroquinolone resistance alleles
gyrA1AB and parC1aAB (Fig. 1A). All but one of the clade C
strains contained an insertion within the fimB gene as we originally
observed in the clade C strain EC958 (15). These isolates were
collected in six countries from 2000 to 2011, indicating that the
dominant clade C ST131 lineage originated from a single clone
before the year 2000 (Fig. 1A). Although we cannot rule out the
possibility of a bias in our strain collection, we note that the
dominant group among another large collection of ST131 strains
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Fig. 1. Phylogenetic relationship of ST131 strains. (A) ML phylogram with
triangles indicating bootstrap support of >90% from 1,000 replicates. The
tree is rooted by using the outgroup phylogroup D strain UMN026; branch
lengths correspond to the number of SNPs difference (scale bar bottom left).
The phylogram was built from 119,514 substitution-only SNPs determined by
read-mapping using E. coli SE15 as reference excluding recombinant regions,
as defined by BRATNextGen analysis (34). The taxa labels for sequenced
ST131 strains are colored red (clade A), orange (clade B) and green (clade C).
Previously sequenced reference strains are colored black. Colored circles next
to each strain correspond to country and year of isolation (see key). Squares
indicate allelic profiling for fimH, parC, gyrA, and CTX-M (see key). A missing
square indicates the gene is absent. (B) Several well-supported subclades are
evident in the ST131 phylogeny, with the CTX-M-15 gene confined to the
second subclade of clade C. The topology-only cladogram (not to scale)
corresponding to the phylogram in A is shown in gray, with node support
of >90% depicted as gray diamonds. The number of SNPs that define clade
C and sublineages C1 (Upper) and C2 (Lower) are shown below relevant
branches (nonsynonymous, synonymous, intergenic); refer to Dataset S2 for
full list of SNPs and consequences.
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was also found to share the same fimH30-gyrA1AB-parC1aAB
allelic profile (12).
Analysis of the density of all SNPs along the SE15 reference
chromosome revealed a nonhomogeneous distribution, with
many core-genome regions associated with a density ∼8.5-fold
higher than the expected average (Fig. 2). Because discrete
regions with a high-density of SNPs may be the result of re-
combination events, as opposed to mutational hotspots (31, 32),
we inferred the recombination across ST131 genomes by using
a Bayesian clustering approach that was previously successfully
applied to S. aureus and Streptococcus pneumoniae (33, 34). We
found that recombination has introduced 76.6% of the 16,424
SNPs and 2,050 small indels that differentiate the strains within
the ST131 lineage (SI Appendix, Fig. S3 and Dataset S3). Phylo-
genetic analysis using only SNPs found in recombinant regions
also clustered the ST131 strains into the same three-clades
structure (SI Appendix, Figs. S1B and S2B). Overall these results
reflect the significant role that recombination has played in
shaping the three major ST131 lineages with subsequent point
mutations driving the fine-scale diversity within each clade.
Antibiotic Resistance Is Associated with ST131 Clade C. Besides the
major contribution of recombination events to the between-clade
diversity of ST131, we also observed differences in the distribu-
tion of SNPs between recombinant and nonrecombinant regions
(Fig. 2). SNP density across all strains combined was higher in
recombinant regions with an estimated 1.19 × 10−2 SNPs per site
compared with 1.39 × 10−3 SNPs per site in nonrecombinant
regions. Despite the lower density of SNPs, nonrecombinant
regions were characterized by a relatively higher ratio of non-
synonymous to synonymous SNPs (0.05 and 0.07 SNPs per ki-
lobase, respectively) compared with recombinant regions (0.2
and 0.89 SNPs per kilobase, respectively). This difference was
significant (χ2 = 1,045.8, P < 0.00001) and is consistent with a
pairwise comparison of ST131 clade A and clade C strains (23).
Fluoroquinolone resistance is one of the major determining
features of the ST131 clone and is associated with point muta-
tions in the gyrA and parC genes (12) (Fig. 1). The three major
gyrA alleles found in our ST131 dataset were attributed to ver-
tically transmitted point mutations, with unique gyrA mutations
also found in clade A strain S5EC (A669T) and clade C strain
B36EC (Q453R), respectively. In contrast, the parC1aAB allele
was introduced into clade C via recombination, replacing the
parC1 allele and surrounding Rec_089 region that is conserved in
most clade A and B strains (Dataset S3). Multiple, overlapping
recombination events continue to shape the ST131 lineage as
evidenced by two independent replacements of Rec_089 in
subgroups of clade A (encompassing parC2) and clade B (parC3A),
with a further two partial replacements of a 1.8-kb Rec_089
subfragment immediately upstream of parC in two clade C
strains (S101EC and S113EC). Among the 34 nonsynonymous
and nonrecombinant substitutions that define clade C, we could
map nine to crystal structures of homologs, several of which
encode amino acid changes that may impact their function (SI
Appendix, Fig. S5 and Dataset S2). For example, there is a
mutation in the gene encoding the MukB chromosome partition
protein, a known interacting partner of ParC (35). In addition to
established fimH, parC and gyrA mutations in clade C strains, our
identification of further genes with clade C-specific mutations
paves the way for more targeted investigations to identify key
evolutionary events that underpin the success of E. coli ST131.
Among the SNPs that have arisen in individual ST131 clade C
strains or subgroups, there are a number within potential anti-
biotic resistance genes that may have been selected in response
to antibiotic treatment (Dataset S2). Each ST131 clade C strain
(minus NA114) has between 0 and 50 (mean = 13, SD = 11)
unique, nonrecombinant SNPs, 49% of which are nonsyno-
nymous. There are numerous examples of nonsynonymous SNPs
within genes that encode homologs of multidrug resistance
proteins or other putative transporters that may affect antimi-
crobial uptake or efflux (Dataset S2). There are also several SNPs
in genes encoding penicillin-binding proteins (e.g., ECSF_2363/
PBP1C, ECSF_0094/PBP3), other cell wall modifying enzymes
(e.g., ECSF_2495 lytic murein transglycosylase B) and examples of
cell division genes (e.g., ECSF_2198), or essential genes that may
be important for intrinsic resistance development. Although the
majority of ST131 clade C SNPs are unique to the strain in
which they are found, or exhibit patterns of descent consistent
with the inferred phylogeny, we identified genes in which the
same mutation appeared to have been acquired independently
(Dataset S2). For example, the dihydrofolate reductase gene
(ESCF_0053) acquired the trimethoprim resistance L28R
mutation in two phylogenetically separated clade C strains (S116EC
and S11EC), with several other nonsynonymous mutations in
this gene present in different strains.
The majority of clade C strains also possess the CTX-M-15
gene (36 of 42 strains in sublineage C2), with seven other clade C
strains containing different CTX-M alleles (3, 14, or 27) (Fig. 1A
and Dataset S1). The CTX-M-15–positive strains cluster
within a discrete, but temporally and geographically dispersed,
sublineage within clade C (Fig. 1B). Although the pattern of
CTX-M-15 distribution within this sublineage is suggestive of
an ancestral acquisition of the CTX-M-15 gene and subsequent
loss by some individual strains, this allele does not associate
with any particular plasmid incompatibility group defined by
sequence-based typing (SI Appendix, Fig. S4). Furthermore, the
CTX-M-15 gene is found on assembled contiguous fragments
(contigs) ranging in size from 1.4 kb to 10 kb with variable
adjacent gene content (many of which have been previously
identified on plasmids), suggesting that the CTX-M-15 gene has
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Fig. 2. Distribution of ST131-only core SNPs in recombinant versus nonrecombinant regions. (A) Comparison of the linear genome arrangement of the clade
C strain EC958 (Upper) and the clade A strain SE15 (Lower). Solid dark-blue lines between EC958 and SE15 indicate BLAST match of ≥99% nucleotide identity
between the two genomes. Genomic features of interest are highlighted for both strains as follows: prophages (pink); ST131 characteristic ROD1, ROD2, and
ROD3 (yellow); previously characterized genomic islands (blue); and other regions of interest (turquoise). Labels refer to the ST131-characteristic regions
defined in the genome of EC958 (15). (B) Heatmap showing the density of 16,424 ST131-only core SNPs along the SE15 chromosome: Syn_NR (synonymous,
nonrecombinant); NSyn_NR (nonsynonymous, nonrecombinant); Syn_R (synonymous, recombinant); and NSyn_R (nonsynonymous, recombinant). ST131-only
core SNPs were defined as bases called from the mapping data in all strains of the dataset with polymorphisms specific to the ST131 lineage. Recombinant
region coordinates were delineated by using BratNextGen. The SNP density heatmap with (number of SNPs per 1 kbp nonoverlapping bin) is indicated by the
color key. The x axis at the bottom of the figure represents the SE15 reference chromosome coordinates.
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been independently acquired several times or that it has trans-
located between different plasmids or the chromosome. Both
scenarios are consistent with previous reports of different
types of ST131 plasmids that harbor CTX-M-15 (37).
E. coli ST131 Contains Many ExPEC-Associated Genes. The comple-
ment of virulence-associated genes was determined in the 95
E. coli ST131 strains by examining for the presence of genes
encoding chaperone-usher (CU) fimbriae (38), autotransporter
(AT) proteins (39), siderophore receptors (40), toxins, colicins
(41), and other genes often assessed by PCR in ExPEC (1) (SI
Appendix, Fig. S6). The E. coli ST131 strains contained genes
encoding type 1, Mat (ECP), Yde, ECSF_0166, EC958_4610,
and Yeh fimbriae; other CU fimbriae genes including Afa and P
fimbriae were variable. The complement of AT-encoding genes
was highly conserved, with most strains containing genes encoding
antigen 43, UpaB, UpaC, YfaL, and Sat. The ECSF_4014 AT
gene was uniquely present in E. coli ST131 strains. Most E. coli
ST131 strains contained a number of genes associated with iron
acquisition; of note, the Yersiniabactin receptor (ECSF_1835)
was found to be widely prevalent but highly diverse with 17
independent substitutions (14 nonsynonymous) confined to
clade B and C strains, strongly suggesting that, like fimH, this
gene may be under positive selection. Approximately 15% of
E. coli ST131 strains contained genes encoding the HlyA and
Cnf1 toxins. In all but clade C strain S115EC, these genes were
colocated on the chromosome, which is consistent with their
presence on the same genomic island in other ExPEC strains
such as CFT073. In general, 131 UPEC-specific genes present
in CFT073, UTI89, 536, and F11 (42) were also conserved, with
only the gene encoding the putative regulator c0765 absent from
all ST131 strains.
Diversity Within the ST131 Lineage Is Primarily due to Mobile Genetic
Elements and Recombination of Associated Regions. E. coli ST131
strain EC958 contains several mobile genetic elements (MGEs)
and other genomic regions not found in completely sequenced
non-ST131 UPEC strains (i.e., CFT073, 536, UTI89, UMN026,
IAI39), including seven prophage elements (Phi1-7), the Flag-2
lateral flagellar locus, the O-antigen loci, the ratA-like toxin
encoding gene, the type VI secretion locus, the capsular locus,
and four genomic islands (GI) in chromosomal integration hot-
spots (GI-pheV, GI-selC, GI-leuX, and GI-thrW) (15). The ma-
jority of these regions were highly conserved in strains from clade
C but were fully or partly absent in strains from clades A and B
(Fig. 3 and SI Appendix, Fig. S6). Exceptions included the Phi6,
GI-selC, and capsular loci regions, which were not exclusively
associated with a particular clade, suggesting a more complex
evolutionary history. The Flag-2 locus was completely absent in
strains from clade A and in four Spanish strains of clade B
(HVM277, HVM52, HVM2044, HVM2289), replaced by the
fhiA-mbhA scar found in E. coli K12 strains (43). Interestingly,
these four Spanish strains form a discrete sublineage (Fig. 1B)
and also lack prophage and genomic islands that are present in
other clade B strains. In contrast to the O25b serotype of most
clade B and C strains, the LPS core biosynthesis region (spe-
cifically wbbJ-rfbE) of clade A strains was the same as in SE15,
which has been reported as serotype O150 (13). Three regions of
difference (ROD) > 10 kb in length were shown to be unique in
ST131 strains EC958 and SE15 (15). Although the functions of
genes encoded by ROD1 are unclear, ROD1 is conserved in all
ST131 strains. Similarly, ROD2 (which contains several sugar
metabolism genes) was also ubiquitous but contained deletions
in at least three ST131 strains (SI Appendix, Fig. S7). ROD3 is
also conserved across all ST131 strains except for clade A. The
absence of several regions within the NA114 genome that are
otherwise present in closely related clade C strains such as S97EC
(Fig. 3) is consistent with the assembly of this genome, which was
performed by concatenating ordered contigs to produce a single
pseudomolecule without gap closure and finishing (14).
A total of 137 regions were defined as recombinant within the
ST131 lineage (Dataset S3), with a clear propensity to be located
adjacent to predicted MGEs (SI Appendix, Fig. S3). These
recombinant regions totalled 0.94 Mb, or nearly one-fifth of the
entire E. coli SE15 genome and include the aforementioned
fimH and parC genes, which are found on recombinant regions
Rec_137 (92.3 kb) and Rec_089 (18.5 kb), respectively. Although
the majority of regions are less than 1,000 bp in length, ∼80% of
the recombinant bases are contained within 24 large recombi-
nant regions that range in size from 10.2 kb to 166.2 kb. We
could define the lineage on which the recombination event oc-
curred in the majority of cases; however, the larger fragments,
such as Rec_088, Rec_089, and Rec_137, have a more complex
evolutionary history with evidence for multiple blocks of different
origin, reflecting sequential, overlapping recombination events
within the same region (SI Appendix, Fig. S3 and Dataset S3).
When considering the repertoire of recombinant regions that
distinguish each clade, clade A was the most distant, with a total
of 0.52 and 0.6 Mb differing from clade B and C, respectively.
Fig. 3. Selected regions of interest in ST131 strains. ST131-characteristic
regions previously defined in the genome of EC958 (15) are shown along the
x axis with strain identifiers listed on the y axis according to the phylogenetic
tree order displayed in Fig. 1A. Regions A–M are shown to scale in order of
their location relative to the SE15 chromosome (Fig. 2) and correspond to: A,
flag2 flagellar region (38.1 kb); B, GI-ThrW genomic island; C, ROD1; D, Phi1
prophage; E, Phi2 prophage; F, Phi3 prophage; G, ROD2; H, Phi4 prophage; I,
Phi5 prophage; J, Phi6 prophage; K, High-Pathogenicity Island; L, cryptic
prophage; M, O-antigen 1 region (wbbJ-rfbE); N, Phi7 prophage; O, RatA-like
region; P, T6SS region; Q, GI-PheV genomic island; R, capsule region;
S, O-antigen2 region; T, GI-SelC genomic island; U, ROD3; V, GI-LeuX. Black
shading indicates a match of ≥95% nucleotide identity in a minimum window
of 200 bp calculated by comparing the query sequence to the assembled
contigs or the consensus from mapped reads for each strain, as implemented
in seqfindr (http://github.com/mscook/seqfindr).
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Fewer recombinant regions distinguish clade B from clade C,
with the majority of differences contained in regions upstream
of Phi3, and upstream and downstream of GI-pheV and GI-leuX,
respectively (Dataset S3).
A striking feature of the recombination distribution along the
chromosome is that the majority of large recombinant regions
were associated with the sites of insertion of prophage and ge-
nomic island MGEs (SI Appendix, Fig. S3). Statistical evaluation
of 10,000 replicates of the Kolmogorov–Smirnov test confirmed
that the distribution of the observed distances between recom-
binant regions and MGEs was significantly negatively skewed
compared with randomly selected regions (K–S test, mean D =
0.370, SD = 0.049, mean P = 6.082 × 10−6, SD = 8.004 × 10−5)
(SI Appendix, Fig. S8). This phenomenon has been observed in
a comparison using the E. coli ST131 SE15 and NA114 genomes,
for which our analysis agrees with 20 of 22 recombination regions
(23), and in other comparisons of closely related E. coli genomes
(44). In contrast, a reduced role for recombination was reported
in a study comparing 12 ST131 genomes and 50 publicly available
E. coli reference genomes (45).
Recombinant Regions Have Shaped the ST131 Lineage. Fimbrial
adhesins and bacterial motility genes were significantly over-
represented in recombinant fragments (SI Appendix, Fig. S9).
A prime example was the fliC-fliY flagellar locus encoded on the
recombinant fragment Rec_051 (ECSF_1762 to ECSF_1776). In
SE15 and other ST131 clade A strains, the fliC allele corresponds
to the H5 serogroup. In contrast, clade B and C strains possess
an H4 fliC allele within Rec_051, a 12.6-kb recombinant frag-
ment that is adjacent to the Phi5 insertion in EC958. The fim
operon containing the type 1 fimbrial fimH gene resides within
Rec_137, which at 92.6 kb is one of the largest and most complex
recombinant fragments within the ST131 lineage (Dataset S3).
The subfragment of Rec_137 that encodes the region fimC to uxuR
displayed characteristic recombination patterns, introducing a
clade-specific fimH allele (fimH41 in clade A, fimH22 in clade B,
and fimH30 in clade C). Interestingly, these three fimH alleles
were also identified as the major signatures in a small collection
of mainly American isolates, and the same recombinant region
was deduced from the comparison of SE15 and NA114 (23). As
observed in EC958 (15), an insertion within fimB was found in
clade C strains, although it is not clear if this insertion was ac-
quired by homologous recombination concomitant with the ac-
quisition of the fimH30 subfragment, or subsequent to this event.
The only exception in our collection was the ST131 clade C
strain S77EC, which contained a large deletion encompassing
part of the 3′ end of the adjacent GI-leuX island (Fig. 3) and the
fim locus.
Several regions containing putative virulence genes, namely
Rec_087 (ECSF_2626 to ECSF_2634) and part of Rec_088
(ECSF_2784 to ECSF_2804), which contain genes related to
a Type 6 Secretion System (T6SS) and a Type 2 Secretion System
(T2SS), respectively, have also undergone gene conversion.
Clade B and C strains carry T6SS alleles that are distinct from
clade A strains. In contrast, the T2SS locus in clade C strains
appears to have been subjected to several independent recom-
bination events, consistent with its location in a recombination
hotspot downstream of the GI-pheV island (SI Appendix, Fig. S3).
Between the T2SS region and GI-pheV, the Rec_088 recombi-
nant fragment also encodes the group II capsule synthesis locus
(ECSF_2771 to ECSF_2783). Several variant region 2 gene
clusters were observed between region 1 (kpsFEDUCS) and
region 3 (kpsTM) of ST131 genomes, consistent with multiple
instances of replacement since divergence of ST131 clades A and
C with corresponding differences in K-antigen serotype (46). As
described above, differences in the LPS core biosynthesis locus
within the 70.3-kb Rec_069 recombinant fragment suggest that
the O25b serotype is also associated with divergence of clades B
and C from clade A (13).
Several less-well characterized genomic regions that could
differentiate clade C strains from other ST131 strains were also
identified. Two regions with the most distinctive recombination
profiles that clearly distinguished all three clades were Rec_131
(ECSF_4099 to ECSF_4159) upstream of GI-leuX, and part
of Rec_137 (ECSF_4277 to ECSF_4338). The Rec_131 region
contains the tamAB genes, which encode a recently described
translocation and assembly module that contributes to the se-
cretion of some AT proteins (47), whereas the Rec_137 region
contains genes associated with salt resistance (osmY), siderophore-
based iron transport (fhuF), and regulation (creBC). When the
impact of recombination on major gene functions independent
of virulence was considered, significant differences were observed
in genes encoding transporters, fructose-mannose metabolism,
histidine metabolism, and the pentose-phosphate pathway (SI
Appendix, Fig. S9). The impact of these sequence changes remains
to be determined.
Conclusion
Our whole-genome phylogenetic analysis indicates that ST131
has arisen from a single progenitor E. coli that diverged into
three sublineages some time before the year 2000 with acquisition
of multiple mobile genetic elements, associated recombination
events, and point-mutations jointly responsible for the emer-
gence of the most prevalent clade C strains. In addition to the
known fimH, fimB, parC, and gyrA alleles that characterize ST131
clade C, we have defined several additional genes and regions
that may be important for adaptive diversification in response to
host or antibiotic resistance pressures. These results also provide
a framework for future PCR-based assays to rapidly classify ST131
strains and monitor their evolution. Further molecular analysis
of the clade defining variants and MGEs identified in this study
will help to elucidate the mechanisms that have led to ST131
colonization of the urinary tract and other clinical sites, and the
rapid global dispersal of this important group of ExPEC.
Materials and Methods
Genome Sequencing and Assembly. Draft genomes were generated by using
100-bp paired-end Illumina HiSeq 2000 reads and assembled with Velvet (48).
Contigs ≥200 bp were ordered against the EC958 draft genome (BioProject:
PRJEA61443) by using Mauve (49). Sequencing reads are available at the
European Nucleotide Archive under study number ERP001354, accessions
in Study ERP001354 (ERS126551–ERS126646) (see Dataset S1 for accession
numbers) with draft genomes available at http://github.com/BeatsonLab-
MicrobialGenomics/ST131_99. See also SI Appendix, SI Materials and Methods.
Genome Analysis. Alignment of the ST131 draft genome assemblies and three
ST131 reference genomes (SE15, NA114, and EC958), plus completely se-
quenced non-ST131 genomes belonging to the E. coli B2 phylogenetic group
(CFT073, UTI89, E2348/69, ED1a, 536, S88, APEC O1), was performed by using
Mugsy (50) and GBLOCKS (51) with a minimum syntenic block of 5 kbp.
Recombination in the ST131 sequences was estimated by using BratNextGen,
which implements a Bayesian clustering algorithm for detection of recom-
binant fragments in closely related sequences (34). See also SI Appendix, SI
Materials and Methods.
Read Mapping and SNP Analysis. Reads from each ST131 isolate and reads
simulated in silico for the 10 complete genomes used in this study were
mapped onto the reference genome SE15 (16) by using SHRIMP 2.0 (52).
Nesoni (www.vicbioinformatics.com/software.nesoni.shtml) was used to
perform SNP calling (conservative default parameters), small indel pre-
diction, and coding effect SNP annotation. In addition, the Nesoni n-way
pairwise comparison method was used to establish the list of all polymorphic
positions conserved in all strains of the dataset. Polymorphic substitution-
only sites were concatenated to produce an alignment that was used for
phylogenetic tree construction. Analysis and visualization of SNP distribution
across the collection were performed by using custom R scripts. See also SI
Appendix, SI Materials and Methods.
Phylogeny. ML phylogenetic trees were estimated by using RAxML 7.2.8 (53)
for the inferred core genome and the SNP alignments (prerecombination
and postrecombination filtering) under the GTR nucleotide substitution
model with a gamma correction for ASRV. Recombination filtering was per-
formed by collapsing the recombinant segment boundaries predicted for each
strain into a unique list of 137 nonoverlapping segments and subsequently
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masking these regions from the alignment (Dataset S3). Support for nodes
was assessed by using 1,000 random bootstrap replicates. See also SI Ap-
pendix, SI Materials and Methods.
Comparative Genomics. Virulence factor profiles, and the presence of other
regions in the draft genomes, were visualized by using seqfindr (http://
github.com/mscook/seqfindr). Query sequences and their source are listed
in Dataset S1 and with sequences available at http://github.com/BeatsonLab-
MicrobialGenomics/ST131_99/. Comparisons between individual genomes
and verification of seqfindr results were performed by using BLAST (54),
Artemis Comparison Tool (55), Easyfig (56), and BRIG (57). See also SI
Appendix, SI Materials and Methods.
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